"AHC","PY","nTotDoc","meanAUPerArt","meanAU_IN_PerArt","meanArtWith_AU_IN_FIRST","meanArtWith_AU_IN_LAST","meanArtWith_AU_IN_CORR","mean_articles_per_internal_author","mean_articles_per_internal_first_author","mean_articles_per_internal_last_author","mean_articles_per_internal_corresponding_author","ArtOA","singleAuArt","Q1_nSJR","Q2_nSJR","Q3_nSJR","Q4_nSJR","Q1_percSJR","Q2_percSJR","Q3_percSJR","Q4_percSJR","meanTCperArt","mean_NTC","meanCitationTrend","InternCoauthorship","AffCoauthorship","GC_AUIN_wFractional","GC_AUIN_FIRSTname","GC_AUIN_LASTname","GC_AUIN_CORRESP","top_AU","top_AU_freq","top_AU_wFract","top_AU_freq_wFract","top_AUIN","top_AUIN_freq","top_AUIN_wFract","top_AUIN_freq_wFract","topAUbyCit","topAUbyCit_TC","topAUINbyCit","topAUINbyCit_TC","topAUINbyCit_norm_byYear","topAUINbyCit_TC_norm_byYear","topConcept_L0","topFreq_L0","topConcept_L1","topFreq_L1","topConcept_L2","topFreq_L2","topConcept_L3","topFreq_L3","topConcept_L4","topFreq_L4","topMESH","topMESH_n","topprimary_topic.display_name","topprimary_topic.display_name_n","topDE","topDE_n","topTI_TM","topTI_TM_n","topAB_TM","topAB_TM_n","nDoc_wALTM","percDoc_wALTM","altmetric_score_thirdQu","cited_by_accounts_count_thirdQu","cited_by_fbwalls_count_thirdQu","cited_by_feeds_count_thirdQu","cited_by_gplus_count_thirdQu","cited_by_msm_count_thirdQu","cited_by_patents_count_thirdQu","cited_by_peer_review_sites_count_thirdQu","cited_by_policies_count_thirdQu","cited_by_posts_count_thirdQu","cited_by_rdts_count_thirdQu","cited_by_rh_count_thirdQu","cited_by_tweeters_count_thirdQu","cited_by_videos_count_thirdQu","cited_by_wikipedia_count_thirdQu","cohorts.com_thirdQu","cohorts.doc_thirdQu","cohorts.pub_thirdQu","cohorts.sci_thirdQu","readers.citeulike_thirdQu","readers.connotea_thirdQu","readers.mendeley_thirdQu","readers_count_thirdQu","n_patentsDistinct","nPatentStatus_Abandoned","nPatentStatus_Granted","nPatentStatus_N/A","nPatentStatus_Pending","nPatentStatus_Active","nPatentStatus_Not-in-force","nPatentStatus_Expired - Fee Related","nPatentStatus_Withdrawn","nPatentStatus_Ceased","nPatentStatus_Revoked","nPatentStatus_Expired - Lifetime","nPatentPubType_Application","nPatentPubType_Grant","nPatentPubType_N/A","avg_citations_Patent","avg_Inventors_Patent","inventor_per_AUIN_100","avg_InstitutesInvolved_Patent","nPatent_singleInventor","n_Patents_CoAff","n_Jurisdiction_distinct","nJurisd_AU","nJurisd_CA","nJurisd_EP","nJurisd_IN","nJurisd_CN","nJurisd_US","nJurisd_DE","nJurisd_ES","nJurisd_IT","nJurisd_AT","nJurisd_BR","nJurisd_WO","nJurisd_JP","nJurisd_DK","nJurisd_IL","nJurisd_PT","nJurisd_PL","nJurisd_FR","nJurisd_SA","nJurisd_MY","nJurisd_KR","nJurisd_NL","nJurisd_CO","nJurisd_SM","nJurisd_SI","nJurisd_HR","nJurisd_RU","nJurisd_EA","nJurisd_MX","nJurisd_HK","nPatentKC_A1","nPatentKC_A","nPatentKC_A2","nPatentKC_B1","nPatentKC_D1","nPatentKC_T3","nPatentKC_B2","nPatentKC_T1","nPatentKC_A3","nPatentKC_C","nPatentKC_B","nPatentKC_C2","nPatentKC_C0","nPatentKC_A8","nPatentKC_E","nPatentKC_T4","nPatentKC_D0","nPatentKC_T2","nPatentKC_A0","nPatentKC_B8","nPatentKC_A4","nPatentKC_T8","nPatentKC_C1","nPatentKC_U1","nPatentKC_T5","nPatentKC_B3","nPatentKC_T7","nPatentKC_A9","top_Inventor names_Patent","top_Inventor names_Patent_n","top_Original assignee names_Patent","top_Original assignee names_Patent_n","top_Fields of Research (ANZSRC 2020)_Patent","top_Fields of Research (ANZSRC 2020)_Patent_n","top_RCDC Categories_Patent","top_RCDC Categories_Patent_n","top_HRCS RAC Categories_Patent","top_HRCS RAC Categories_Patent_n","top_IPCR_Patent","top_IPCR_Patent_n","top_CPC_Patent","top_CPC_Patent_n","n_clTrial","avg_durationYear_clTrial","avg_participants_clTrial","clTrial_perAUIN_100","nClTrial_w_AltmScore","cl_AltmS_rel","avg_sponsor_clTrial","nclTrialPhase_Phase 1","nclTrialPhase_Phase 1/2","nclTrialPhase_Phase 2","nclTrialPhase_Phase 2/3","nclTrialPhase_Phase 3","nclTrialPhase_Phase 3/4","nclTrialPhase_Phase 4","nclTrialPhase_N/A","nclTrialPhase_Post Authorisation Studies","nclTrial_StudyType_Interventional","nclTrial_StudyType_Observational","nclTrial_StudyType_Other","nclTrial_StudyType_Expanded access","nclTrial_StudyType_Active surveillance","nclTrial_StudyType_Non-interventional","nclTrial_StudyType_RCT","nclTrial_StudyType_CCT","nclTrial_Gender_All","nclTrial_Gender_Female","nclTrial_Gender_Male","nclTrial_Registry_ClinicalTrials.gov","nclTrial_Registry_EU-CTR","nclTrial_Registry_ENCePP","nclTrial_Registry_ISRCTN","nclTrial_Registry_ANZCTR","nclTrial_Registry_GCTR","nclTrial_Registry_PACTR","nclTrial_Registry_CTRI","nclTrial_Registry_ReBEC","nclTrial_Registry_UMIN-CTR","top_funder_country","top_funder_country_n","top_Fields of Research (ANZSRC 2020)_clTrial","top_Fields of Research (ANZSRC 2020)_clTrial_n","top_RCDC Categories_clTrial","top_RCDC Categories_clTrial_n","top_HRCS HC Categories_clTrial","top_HRCS HC Categories_clTrial_n","top_HRCS RAC Categories_clTrial","top_HRCS RAC Categories_clTrial_n","top_Cancer Types_clTrial","top_Cancer Types_clTrial_n","top_CSO Categories_clTrial","top_CSO Categories_clTrial_n","n_grants","avg_funding_EUR","avg_funding_EUR_perOrganization","avg_durationYear_grant","avg_Organization_per_grant","avg_countries_per_grant","perc_grant_internationalColl","avg_ResultingPublications_per_grant","totFundingOrgbyActivedGrant","avgPubByActivedFundingGrant_1000","top_Research Organization - standardized_Grants","top_Research Organization - standardized_n_Grants","top_Funder_Grants","top_Funder_n_Grants","top_Funder Group_Grants","top_Funder Group_n_Grants","top_Program_Grants","top_Program_n_Grants","top_Fields of Research (ANZSRC 2020)_Grants","top_Fields of Research (ANZSRC 2020)_n_Grants","top_RCDC Categories_Grants","top_RCDC Categories_n_Grants","top_HRCS HC Categories_Grants","top_HRCS HC Categories_n_Grants","top_HRCS RAC Categories_Grants","top_HRCS RAC Categories_n_Grants","top_Cancer Types_Grants","top_Cancer Types_n_Grants","top_CSO Categories_Grants","top_CSO Categories_n_Grants","top_Units of Assessment_Grants","top_Units of Assessment_n_Grants","top_Sustainable Development Goals_Grants","top_Sustainable Development Goals_n_Grants","n_dataset","top_Repository_Dataset","top_Repository_Dataset_n","top_Fields of Research (ANZSRC 2020)_Dataset","top_Fields of Research (ANZSRC 2020)_Dataset_n","top_RCDC Categories_Dataset","top_RCDC Categories_Dataset_n","top_HRCS HC Categories_Dataset","top_HRCS HC Categories_Dataset_n","top_HRCS RAC Categories_Dataset","top_HRCS RAC Categories_Dataset_n","top_Health Research Areas_Dataset","top_Health Research Areas_Dataset_n","top_Broad Research Areas_Dataset","top_Broad Research Areas_Dataset_n","top_Cancer Types_Dataset","top_Cancer Types_Dataset_n","top_Sustainable Development Goals_Dataset","top_Sustainable Development Goals_Dataset_n"
"IRCCS_SANTORSOLA",2000,104,6.65384615384615,1.97115384615385,0.548076923076923,0.211538461538462,0.576923076923077,1.1551724137931,1.14,1.05,1.15686274509804,0.259615384615385,9,47,16,5,30,0.45,0.15,0.05,0.29,71.2,1.57071227699183,NA,0.182692307692308,0.711538461538462,0.445,0.224,0.222,0.228,"GIAMPAOLO GAVELLI;L. SAVARINO;L BASTAGLI;DOMENICO CUCINOTTA;VITTORIO PENGO;P ZUCCHELLI;PAOLA FORTI;GIOVANNI RAVAGLIA;VALENTINA VICENNATI;GIULIO MARCHESINI;MAURIZIO ZOMPATORI;MARCO PIOLANTI;R. PASQUALI;GIAN LUCA GRAZI;F. GRUPPIONI;FRANCESCA CAVALCANTI;MICHELA VERSARI;UTE LATZA;LUCIA CONTICINI;M SCHIAVINA","4;4;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2","VALENTINA VICENNATI;PAOLO G. MORSELLI;G FINZI;RICCARDO CASADEI;R. PASQUALI;G. RAVAGLIA;LUIGI MURATORI;ADA DORMI;ROBERTO MANFREDI;GIAMPAOLO GAVELLI;MAURIZIO ZOMPATORI;P ZUCCHELLI;DANIELA COTA;L CERONI;L. SAVARINO;R BERGONZINI;LIBERO BAROZZI;A ZUCCALÀ;RITA GOLFIERI;AUDE AMATO","2;2;1.25;1.2;1.17;1;1;1;1;0.95;0.7;0.67;0.67;0.67;0.56;0.53;0.53;0.5;0.5;0.5","L BASTAGLI;DOMENICO CUCINOTTA;P ZUCCHELLI;PAOLA FORTI;GIOVANNI RAVAGLIA;VALENTINA VICENNATI;GIULIO MARCHESINI;MAURIZIO ZOMPATORI;R. PASQUALI;GIAN LUCA GRAZI;F. GRUPPIONI;ALESSANDRO DI LEO;PASQUALE CHIECO;ELEONORA PORCU;GIANANDREA PASQUINELLI;MARA BRIZI;LUCIA TARTUFERI;A. TUCCI;FRANCESCO RESTA;LORIS POLI","3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2","VALENTINA VICENNATI;PAOLO G. MORSELLI;G FINZI;RICCARDO CASADEI;R. PASQUALI;G. RAVAGLIA;LUIGI MURATORI;ADA DORMI;ROBERTO MANFREDI;MAURIZIO ZOMPATORI;P ZUCCHELLI;DANIELA COTA;L CERONI;LIBERO BAROZZI;RITA GOLFIERI;G BUZZI;DE FABRITIIS A;RENATO PASQUALI;GIULIO MARCHESINI;A. MARTONI","2;2;1.25;1.2;1.17;1;1;1;1;0.7;0.67;0.67;0.67;0.53;0.5;0.5;0.5;0.5;0.49;0.48","ALFREDO LLOVET;ANDREW G. MOORE;ARTURO EVANGELISTA;CHARLENE GACA;CHRISTOPH A. NIENABER;DAN GILON;DAVID BRUCKMAN;DEAN KARAVITE;ERIC M. ISSELBACHER;G. MICHAEL DEEB;HANS JOSEF DEUTSCH;HOLGER DIEDRICHS;JAE K. OH;JOSE MARCOS Y ROBLES;JOSEPH F. MALOUF;KIM A. EAGLE;LINDA PAPE;P. RUSSMAN;PETER HAGAN;ROSSELLA FATTORI","3312;3312;3312;3312;3312;3312;3312;3312;3312;3312;3312;3312;3312;3312;3312;3312;3312;3312;3312;3312","ROSSELLA FATTORI;GIOVANNI M. FRASCÀ;VALENTINA VICENNATI;ANNA JANUSZKIEWICZ;L. LINDGREN;THEO H.N. GROENLAND;PASQUALE CHIECO;GIOVANNI RAVAGLIA;G PALARETI;STEFANO PILERI;ANDREA FACCHINI;ANGELA MARIA GRAZIA PACILLI;COLIN D. BINGLE;F GIOVINE;GORDON W. DUFF;IAN JOHNSTON;IAN P. HALL;J. M. TIMMS;JOHN BRITTON;MARIO FABBRI","3312;330;310;309;309;309;277;273;223;203;186;186;186;186;186;186;186;186;186;186","GIULIO MARCHESINI;MAURIZIO ZOMPATORI;STEFANO PILERI;VALENTINA VICENNATI;A. GADDI;ALESSANDRO DI LEO;BENILDE COSMI;DOMENICO CUCINOTTA;ELEONORA PORCU;F FONTANA;G CAVALLI;G FINZI;G PALARETI;GIANANDREA PASQUINELLI;GIORGIO BALLARDINI;GIOVANNI M. FRASCÀ;GIOVANNI RAVAGLIA;LUCIA TARTUFERI;P BERNARDI;P BONI","3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;COMPUTER SCIENCE;MATHEMATICS;ECONOMICS;ENGINEERING;MATERIALS SCIENCE;POLITICAL SCIENCE;PSYCHOLOGY;BUSINESS;SOCIOLOGY","95;33;15;7;5;3;2;2;2;2;2;1;1","INTERNAL MEDICINE;SURGERY;PATHOLOGY;ENDOCRINOLOGY;IMMUNOLOGY;GASTROENTEROLOGY;BIOCHEMISTRY;GENETICS;RADIOLOGY;PSYCHIATRY;ENVIRONMENTAL HEALTH;CARDIOLOGY;PEDIATRICS;FAMILY MEDICINE;INTENSIVE CARE MEDICINE;MOLECULAR BIOLOGY;ORGANIC CHEMISTRY;ANESTHESIA;GENERAL SURGERY;ONCOLOGY;VIROLOGY","69;29;28;22;20;17;16;16;14;11;10;9;8;6;6;6;6;5;5;5;5","DISEASE;GENE;POPULATION;CANCER;HORMONE;ANTIBODY;BLOOD PRESSURE;DIABETES MELLITUS;IMMUNOHISTOCHEMISTRY;CHEMOTHERAPY;ENZYME;KIDNEY;TRANSPLANTATION;ALTERNATIVE MEDICINE;ANTIGEN;CHOLESTEROL;CIRRHOSIS;CYTOKINE;IN VITRO;INTERVENTIONAL RADIOLOGY;LUNG;MAGNETIC RESONANCE IMAGING;NEUROLOGY;OBESITY;RANDOMIZED CONTROLLED TRIAL;VIRUS;VITAMIN","12;10;10;9;8;7;7;7;6;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4;4;4;4","VIRAL DISEASE;BREAST CANCER;HYPOTHALAMIC–PITUITARY–ADRENAL AXIS;NEPHROPATHY;RETINOL;CD30;LIVER TRANSPLANTATION;METABOLIC SYNDROME;NEURORADIOLOGY;PHENOTYPE;ALLELE;AMENORRHEA;ANAPLASTIC LARGE-CELL LYMPHOMA;ANGIOTENSIN-CONVERTING ENZYME;CISPLATIN;ENDOCRINE SYSTEM;GASTRITIS;GENE EXPRESSION;GENOTYPE;GLOMERULONEPHRITIS;INSULIN RESISTANCE;LIPOPROTEIN;MONOCLONAL ANTIBODY;NUCLEOLUS;PLACEBO;POSTPRANDIAL;PRAVASTATIN;THYROID FUNCTION;THYROID FUNCTION TESTS;TOPOTECAN;VASCULITIS;VENOUS THROMBOSIS;WARFARIN","5;4;4;4;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","ABDOMINAL OBESITY;ADJUVANT CHEMOTHERAPY;CARBOPLATIN;NUCLEOLUS ORGANIZER REGION;ORAL ANTICOAGULANT;SIDA;VERY LOW-DENSITY LIPOPROTEIN;VITAMIN A DEFICIENCY;ZIDOVUDINE;(+)-NALOXONE;ACE INHIBITOR;ACENOCOUMAROL;ALLELE FREQUENCY;ALPORT SYNDROME;ANAPLASTIC LYMPHOMA KINASE;ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY;ANTIFIBRINOLYTIC;ANTIRETROVIRAL THERAPY;ATROPHIC GASTRITIS;AUTOIMMUNE THYROIDITIS;CAGA;CERIVASTATIN;COMPARATIVE GENOMIC HYBRIDIZATION;CYSTATHIONINE BETA SYNTHASE;DEHYDROEPIANDROSTERONE SULFATE;DIFFUSING CAPACITY;DUCTAL CARCINOMA;EMOTIONAL EATING;ENALAPRIL;ENDOGENOUS OPIOID;ESOPHAGEAL CANDIDIASIS;EXCESSIVE DAYTIME SLEEPINESS;FOSINOPRIL;GENE PRODUCT;GENOTYPE-PHENOTYPE DISTINCTION;GIANT CELL ARTERITIS;GLOMERULAR BASEMENT MEMBRANE;HBSAG;HERPESVIRIDAE;HYPERTENSIVE NEPHROPATHY;HYPOCAPNIA;IMMUNOCONJUGATE;INFLAMMATORY BOWEL DISEASES;INTERLEUKIN 1Β;LARGE CELL;LENTIVIRUS;LISINOPRIL;MAMMARY GLAND;MITOCHONDRIAL ENCEPHALOMYOPATHY;MORNING STIFFNESS;NATURAL KILLER CELL;NEURAL CELL ADHESION MOLECULE;NORMOCAPNIA;OPIOID PEPTIDE;OPPORTUNISTIC INFECTION;PLATELETPHERESIS;PNEUMOCYSTIS CARINII;RECEPTOR ANTAGONIST;RENAL TUMOR;SOMATOSTATIN RECEPTOR 2;SPIRILLACEAE;STERILIZATION (ECONOMICS);TYPE IV COLLAGEN;VIRAL ENTRY;VITAMIN E DEFICIENCY","3;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;MALE;ADULT;FEMALE;MIDDLE AGED;AGED;;LIVER;ANTICOAGULANTS;ADOLESCENT;HIV INFECTIONS;TOMOGRAPHY, X-RAY COMPUTED;AGED, 80 AND OVER;ITALY;KIDNEY FAILURE, CHRONIC;BILE DUCT DISEASES;CYTOMEGALOVIRUS INFECTIONS;HYDROCORTISONE;LUNG DISEASES;OBESITY","83;44;37;37;32;28;21;15;13;12;12;11;9;9;9;8;8;8;8;8","ATRIAL FIBRILLATION;CHOLESTEROL-LOWERING TREATMENT;CHRONIC KIDNEY DISEASE AND DIALYSIS TREATMENT;DIAGNOSIS AND MANAGEMENT OF GASTROESOPHAGEAL REFLUX DISEASE;DIAGNOSIS AND MANAGEMENT OF PANCREATITIS;EFFECTS OF STRESS ON BRAIN FUNCTION AND HEALTH;EFFICACY AND SAFETY OF ANTIRETROVIRAL THERAPY FOR HIV;EPIDEMIOLOGY AND MANAGEMENT OF CYTOMEGALOVIRUS INFECTION;EPIDEMIOLOGY AND MANAGEMENT OF NEUROENDOCRINE TUMORS;EPIDEMIOLOGY AND TREATMENT OF HEAD AND NECK CANCER;GENETIC DISORDERS CAUSING TISSUE MINERALIZATION ABNORMALITIES;HELICOBACTER PYLORI INFECTION AND GASTRIC CANCER;HIP ARTHROPLASTY TECHNIQUES AND MATERIALS;INFECTIONS RELATED TO ENDOSCOPIC PROCEDURES;LYMPHOID NEOPLASMS;PATHOPHYSIOLOGY OF GLOMERULAR DISEASES AND NEPHROTIC SYNDROMES;PREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM;SARCOMA RESEARCH AND TREATMENT;THYROID DISEASE AND HORMONE REGULATION;","3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1","ANTICOAGULANT THERAPY;HYPOTHALAMIC–PITUITARY–ADRENAL AXIS;INTERVENTIONAL RADIOLOGY;ABDOMINAL OBESITY;ANTIRETROVIRAL THERAPY;HIV;HPA AXIS;NEURORADIOLOGY;PROTHROMBIN TIME;SEVERITY ASSESSMENT;TREATMENT;ACUTE PANCREATITIS;ADJUVANT CHEMOTHERAPY;ANAPLASTIC LARGE-CELL LYMPHOMA;BICARBONATE;CARBOPLATIN;CHYLOMICRON;DIAGNOSIS;DISINFECTION;ESOPHAGEAL MOTILITY DISORDERS","4;4;4;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2","LIVER TRANSPLANTATION;ABDOMINAL OBESITY;ACUTE PANCREATITIS;ANTIRETROVIRAL THERAPY;BLOOD MICRONUTRIENT;CD ANTIGEN;CHYLOMICRON RETENTION;CULTURED HUMAN;DEFICIENCY DUE;ENDOTHELIAL CELLS;FEMALE PATIENTS;HORMONE CONCENTRATIONS;HUMAN ENDOTHELIAL;HYPOTHALAMIC-PITUITARY-ADRENAL AXIS;INSULIN RESISTANCE;LOCALIZED OSTEOSARCOMA;MONITOR COAGUCHECK;NEOADJUVANT CHEMOTHERAPY;NONDEPRESSED WOMEN;ORAL ANTICOAGULANT;PATIENTS TREATED;PERIPHERAL ALTERATION;POLYETHYLENE TEREPHTHALATE;PORTABLE PROTHROMBIN;PROTHROMBIN TIME;PYROLYTIC CARBON;REPRODUCTIVE FUNCTIONS;RESECTION MARGIN;RESISTANCE EVIDENCE;RETENTION DISEASE","3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","PUBMED SCOPUS;CROSSREF PUBMED;PUBMED GOOGLE;DUCTAL PLATE;DUCTULAR CELLS;CELL ADHESION;REACTIVE DUCTULES;EPITHELIAL CELLS;ACUTE PANCREATITIS;BILIARY EPITHELIAL;DESMET VJ;HPA AXIS;NEURAL CELL;ADHESION MOLECULE;BILE DUCTULES;FETAL LIVERS;GML PERCOLL;PATHOL -PUBMED;AGE RANGE;BILE DUCTS;OLDEST-OLD SUBJECTS;PLASMA MEMBRANE;PRIMARY ANTIBODIES;PRIMARY CHOLANGIOPATHIES;ACUTE AORTIC;ANAPLASTIC LARGECELL;BREAST CANCER;CHOLESTATIC LIVER;CHRONIC LIVER;DUCTULAR REACTION","29;28;19;15;13;11;10;9;8;8;8;8;8;7;7;7;7;7;6;6;6;6;6;6;5;5;5;5;5;5",15,0.14,3.5,3,0,5,0,0,5,0,1,3,0,0,19,1,1.5,0,10,10,4,0,0,51.5,51.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2,8,329,1.25,0,0,2,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,2,0,0,2,0,0,0,0,0,0,0,0,0,"Italy;Switzerland","2;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS","2;2;1","CLINICAL RESEARCH;ASSISTIVE TECHNOLOGY;BIOENGINEERING;CANCER;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;HEMATOLOGY;RARE DISEASES","2;1;1;1;1;1;1",NA,NA,"6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES","1;1","LEUKEMIA / LEUKAEMIA","1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS","1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_SANTORSOLA",2001,115,6.84347826086957,2.55652173913044,0.660869565217391,0.269565217391304,0.678260869565217,1.26724137931034,1.11764705882353,1.14814814814815,1.14705882352941,0.191304347826087,10,44,26,10,28,0.38,0.23,0.09,0.24,39.26,0.859242338511782,NA,0.147826086956522,0.765217391304348,0.439,0.309,0.3,0.309,"ROBERTO MANFREDI;PIER LUIGI TAZZARI;ANTONINO CAVALLARI;PAOLA FORTI;GIOVANNI RAVAGLIA;LEONARDO CALZA;ANDREA MARTONI;ANGELO BRANZI;DONATELLA SANTINI;MASSIMO CAMPIERI;FRANCESCO B. BIANCHI;FRANCESCO CHIODO;ROBERTO CONTE;LUIGI BOLONDI;GAETANO GARGIULO;ALESSANDRO DI LEO;BRUNA ANGELELLI;F CHIODO;ALESSANDRO GRANITO;UMBERTO VOLTA","5;5;5;4;4;4;4;4;4;4;4;4;4;4;3;3;3;3;3;3","E AMBROSIONI;LUIGI BOLONDI;BENILDE COSMI;ROBERTO MANFREDI;GUIDO BIASCO;LEONARDO CALZA;F CHIODO;SIMONE PISCAGLIA;P PAVLICA;C FLAMIGNI;M MARTORELLI;ALESSANDRO ZUCCALAGRAVE;FRANCESCO CHIODO;GAETANO GARGIULO;ANTONINO CAVALLARI;MASSIMO CAMPIERI;GIAMPAOLO GAVELLI;ROBERTO MANFREDI;CRISTINA ROSSI;PAOLO GIONCHETTI","2;1.62;1.5;1.43;1.08;1.06;1.03;1;1;1;1;1;0.98;0.81;0.65;0.62;0.62;0.58;0.56;0.56","ROBERTO MANFREDI;PIER LUIGI TAZZARI;ANTONINO CAVALLARI;PAOLA FORTI;GIOVANNI RAVAGLIA;LEONARDO CALZA;ANDREA MARTONI;DONATELLA SANTINI;MASSIMO CAMPIERI;FRANCESCO B. BIANCHI;FRANCESCO CHIODO;ROBERTO CONTE;LUIGI BOLONDI;GAETANO GARGIULO;ALESSANDRO DI LEO;BRUNA ANGELELLI;ALESSANDRO GRANITO;UMBERTO VOLTA;MARIA PIA PISTILLO;PAOLO CAPANNI","5;5;5;4;4;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3","E AMBROSIONI;LUIGI BOLONDI;BENILDE COSMI;ROBERTO MANFREDI;GUIDO BIASCO;LEONARDO CALZA;SIMONE PISCAGLIA;P PAVLICA;C FLAMIGNI;M MARTORELLI;ALESSANDRO ZUCCALAGRAVE;FRANCESCO CHIODO;GAETANO GARGIULO;ANTONINO CAVALLARI;MASSIMO CAMPIERI;ROBERTO MANFREDI;CRISTINA ROSSI;PAOLO GIONCHETTI;FERNANDO RIZZELLO;GUALTIERO PALARETI","2;1.62;1.5;1.43;1.08;1.06;1;1;1;1;1;0.98;0.81;0.65;0.62;0.58;0.56;0.56;0.56;0.53","LUIGI BOLONDI;A VACCARINO;ADRIANO ALATRI;ADRIANO BERTOLDI;ALESSANDRA ASCANI;ALFONSO IORIO;ANGELO GHIRARDUZZI;ANTONIO GIROLAMI;CRISTINA TOMASI;FABIO AMBROSINI;GIANCARLO AGNELLI;GIANLUIGI SCANNAPIECO;GIOVANNI B. AMBROSIO;GIULIANA GUAZZALOCA;GUALTIERO PALARETI;IDO IORI;LAURA MOSENA;LUIGI STEIDL;MARCO MOIA;MARIA GABRIELLA SANTAMARIA","705;586;586;586;586;586;586;586;586;586;586;586;586;586;586;586;586;586;586;586","LUIGI BOLONDI;GIULIANA GUAZZALOCA;ANTONINO CAVALLARI;ALIGHIERI MAZZIOTTI;FILIPPO PIERANGELI;GIAN LUCA GRAZI;GIORGIO ERCOLANI;MASSIMO DEL GAUDIO;MATTEO CESCON;ALESSANDRO GRANITO;UMBERTO VOLTA;FRANCESCO B. BIANCHI;LUCIA DE FRANCESCHI;A CAVALLI;ANNA MARIA FERRETTI;PIETRO ANDREONÉ;ANDREA PESSION;DONATELLA SANTINI;N. PETROLINI;CESARE PEROTTI","672;586;430;340;340;340;340;340;340;302;302;279;216;203;203;165;156;150;147;142","ROBERTO MANFREDI;PIER LUIGI TAZZARI;ANDREA MARTONI;DONATELLA SANTINI;MASSIMO CAMPIERI;ROBERTO CONTE;FRANCESCO B. BIANCHI;ALESSANDRO BOVICELLI;ALESSANDRO DI LEO;ALESSANDRO GRANITO;ANTONINO CAVALLARI;BRUNA ANGELELLI;CLAUDIO CECCARELLI;LEONARDO CALZA;PATRIZIA TERZANO;SILVANO COSTA;UMBERTO VOLTA;MAURIZIO ZOMPATORI;A. BARGOSSI;ADA DORMI","6;5;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;2;2","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;MATERIALS SCIENCE;COMPUTER SCIENCE;ECONOMICS;ENGINEERING;SOCIOLOGY;POLITICAL SCIENCE;MATHEMATICS;PSYCHOLOGY;BUSINESS;HISTORY","108;29;15;10;6;4;4;4;4;3;2;2;1;1","INTERNAL MEDICINE;SURGERY;GASTROENTEROLOGY;IMMUNOLOGY;BIOCHEMISTRY;PATHOLOGY;CARDIOLOGY;ENDOCRINOLOGY;GENETICS;RADIOLOGY;ENVIRONMENTAL HEALTH;PSYCHIATRY;INTENSIVE CARE MEDICINE;ANESTHESIA;PEDIATRICS;COMPOSITE MATERIAL;MICROBIOLOGY;OPTICS;ONCOLOGY;UROLOGY","85;35;24;22;20;17;15;13;13;13;10;9;8;7;7;6;6;6;5;4","DISEASE;GENE;ANTIBODY;TRANSPLANTATION;CANCER;POPULATION;BLOOD PRESSURE;CLINICAL TRIAL;ENZYME;CHEMOTHERAPY;CIRRHOSIS;EPIDEMIOLOGY;LUNG;RANDOMIZED CONTROLLED TRIAL;ANTIBIOTICS;IMMUNOHISTOCHEMISTRY;IN VITRO;INCIDENCE (GEOMETRY);NEUROLOGY;THROMBOSIS","22;11;10;10;9;9;8;7;7;6;6;6;6;6;5;5;5;5;5;5","NEURORADIOLOGY;COELIAC DISEASE;LIVER TRANSPLANTATION;AUTOANTIBODY;DEMENTIA;NEUTROPENIA;ULCERATIVE COLITIS;ADENOCARCINOMA;ALPHA INTERFERON;AMBULATORY BLOOD PRESSURE;ANDROGEN;AUTOIMMUNE DISEASE;AUTOIMMUNITY;BACTEREMIA;BONE MINERAL;CARDIAC OUTPUT;CHRONIC HEPATITIS;ENDOVASCULAR TREATMENT;ENTEROPATHY;EXON;FETUS;GESTATIONAL AGE;HEART RATE;HEPATIC ENCEPHALOPATHY;HEPATIC FIBROSIS;HYPERHOMOCYSTEINEMIA;INFLAMMATORY BOWEL DISEASE;KIDNEY TRANSPLANTATION;LIVER BIOPSY;LUNG VOLUMES;MONOCLONAL ANTIBODY;PHASES OF CLINICAL RESEARCH;PORTAL HYPERTENSION;PORTAL VEIN THROMBOSIS;PROBIOTIC;PROSTATE;REPERFUSION INJURY;RESEARCH METHODOLOGY;SEROLOGY;THORACIC AORTA;TISSUE TRANSGLUTAMINASE;TOLERABILITY;UMBILICAL VEIN;UNIVARIATE ANALYSIS;VASCULAR RESISTANCE;VENOUS THROMBOEMBOLISM;VENOUS THROMBOSIS;WARFARIN","5;4;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","DEHYDROEPIANDROSTERONE SULFATE;ESOPHAGEAL VARICES;FAMILY PLANNING;INTRAEPITHELIAL NEOPLASIA;PORTOSYSTEMIC SHUNT;11Β-HYDROXYSTEROID DEHYDROGENASE TYPE 1;ABDOMINAL OBESITY;ACENOCOUMAROL;ACINETOBACTER CALCOACETICUS;ADENOSQUAMOUS CARCINOMA;ANNEXIN A5;ANTI-NUCLEAR ANTIBODY;ANTI-THYROID AUTOANTIBODIES;ANTIRETROVIRAL THERAPY;AROMATASE;ATROPHIC GASTRITIS;AUTOIMMUNE THYROIDITIS;BECLOMETASONE DIPROPIONATE;BILIARY CIRRHOSIS;BOVINE SPONGIFORM ENCEPHALOPATHY;BRAIN METASTASIS;CARDIAC INDEX;CLINICAL DEMENTIA RATING;CONDOM;CREUTZFELDT-JAKOB SYNDROME;CTLA-4;DABIGATRAN;DIFFUSING CAPACITY;DISTORTION (MUSIC);ENDOMYSIUM;ENDOVASCULAR ANEURYSM REPAIR;EPIRUBICIN;ESOPHAGEAL MOTILITY DISORDER;ESOPHAGEAL SPASM;EXCESSIVE DAYTIME SLEEPINESS;EXTRACORPOREAL PHOTOPHERESIS;FABRY'S DISEASE;FACTOR V LEIDEN;FEBRILE NEUTROPENIA;FUNCTIONAL RESIDUAL CAPACITY;GASTRIC VARICES;GERIATRIC DEPRESSION SCALE;GQ ALPHA SUBUNIT;IMMUNOGLOBULIN A;IMMUNOTOXIN;IN SITU HYBRIDIZATION;IN UTERO;INFLAMMATORY BOWEL DISEASES;INTERFERON ALFA;INTERMEDIATE FILAMENT;LAMIVUDINE;MEAN ARTERIAL PRESSURE;METHYLENETETRAHYDROFOLATE REDUCTASE;MICROVESICLES;MYOEPITHELIOMA;OPIOID PEPTIDE;ORAL ANTICOAGULANT;OSTEOPOROTIC FRACTURE;OXALIPLATIN;PHOSPHOINOSITIDE PHOSPHOLIPASE C;PHOSPHOLIPASE A;PORTAL VENOUS PRESSURE;POUCHITIS;PRENATAL DIAGNOSIS;SCRAPIE;SEXUALLY TRANSMITTED DISEASE;SINGLE-CHAIN VARIABLE FRAGMENT;SKIN INFECTION;SOLID-PHASE MICROEXTRACTION;SPLENIC VEIN;STREPTOCOCCUS PYOGENES;STROKE VOLUME;STYRENE;THORACIC AORTIC ANEURYSM;TICLOPIDINE;TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT;TROCHANTER;TRYPSINOGEN;UREA CYCLE;VINORELBINE;VITRONECTIN","2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;MALE;FEMALE;MIDDLE AGED;ADULT;AGED;ADOLESCENT;;ITALY;LIVER;AGED, 80 AND OVER;LIVER CIRRHOSIS;LIVER TRANSPLANTATION;CELIAC DISEASE;HIV INFECTIONS;ANTIBODIES;CARCINOMA, HEPATOCELLULAR;HEPATITIS C, CHRONIC;HYPERTENSION;LIVER NEOPLASMS","92;62;58;54;43;41;18;15;15;14;13;13;12;11;11;10;10;10;10;10","LIVER TRANSPLANTATION AND GRAFT SURVIVAL ANALYSIS;DIAGNOSIS AND MANAGEMENT OF CELIAC DISEASE;GENETICS AND TREATMENT OF INFLAMMATORY BOWEL DISEASE;HIP ARTHROPLASTY TECHNIQUES AND MATERIALS;STANDARDISATION AND MANAGEMENT OF COPD;ACUTE MYELOID LEUKEMIA;CONGENITAL CORONARY ARTERY ANOMALIES AND THEIR MANAGEMENT;DIAGNOSIS AND MANAGEMENT OF GASTROESOPHAGEAL REFLUX DISEASE;DIAGNOSIS AND MANAGEMENT OF LIVER DISEASES;DIAGNOSIS AND MANAGEMENT OF PANCREATITIS;EPIDEMIOLOGY AND MANAGEMENT OF NAFLD;GYNECOLOGIC ONCOLOGY;HEPATOCELLULAR CARCINOMA;LIVER CIRRHOSIS AND ASSOCIATED COMPLICATIONS;LONG-TERM EFFECTS OF TESTOSTERONE ON HEALTH;MANAGEMENT OF HYPERTENSION AND CARDIOVASCULAR RISK FACTORS;MANAGEMENT OF PRIMARY ALDOSTERONISM;OSTEOPOROSIS;PREVENTION AND TREATMENT OF HIV/AIDS INFECTION;PREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM","5;4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","NEURORADIOLOGY;TREATMENT;DISCONTINUATION;GLUTEN SENSITIVITY;HIGH-FLOW OXYGEN THERAPY;HYPERTENSION;INTERVENTIONAL RADIOLOGY;LIVER BIOPSY;ACUTE PANCREATITIS;AGING MEN;ANEURYSM RUPTURE;ANEURYSM SCREENING;ANTITHROMBOTIC THERAPY;APROTININ;BACTEREMIA;BONE MINERAL DENSITY;CARDIAC ELECTROPHYSIOLOGY;CERVICAL CANCER;COMBINATION THERAPY;CT SCREENING","5;5;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2","LIVER TRANSPLANTATION;CHRONIC HEPATITIS;COELIAC DISEASE;ACRYLIC BONE;ACUTE MYELOID;ACUTE PANCREATITIS;ARTERY DOPPLER;ATRIAL FIBRILLATION;BLOOD PRESSURE;BONE CEMENTS;BONE MINERAL;BOWEL DISEASE;CELLS INCUBATED;CERVICAL CARCINOMA;CLINICAL FEATURES;COMPUTED TOMOGRAPHY;DOPPLER RESISTANCE;ENDOTHELIAL CELLS;HEPATIC ARTERY;HEPATOCELLULAR CARCINOMA;HIV DISEASE;HIV INFECTION;HUMAN ENDOTHELIAL;INFLAMMATORY BOWEL;LIVER FIBROSIS;LUNG CANCER;MINERAL DENSITY;MULTICENTER RANDOMIZED;MYELOID LEUKEMIA;NATURAL HISTORY","4;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","BLOOD PRESSURE;FEMORAL NECK;HEPATOCELLULAR CARCINOMA;SURVIVAL RATE;ANTILACTOFERRIN ANTIBODIES;FU MGM;OHP MGM;RISK FACTORS;SURVEILLANCE PROGRAMME;VENOUS THROMBOEMBOLISM;MGM -FU;NECK BMD;TREATED PATIENTS;AUTOIMMUNE CHOLANGITIS;AUTOIMMUNE HEPATITIS;BILIARY CIRRHOSIS;CARDIOVASCULAR RISK;CELSIOR SOLUTION;FRACTURE RISK;HEALTHY WOMEN;HIV DISEASE;LIVER DISEASE;LIVER TRANSPLANTATION;MGM PATIENTS;MICROG NA;MULTIVARIATE ANALYSIS;ORAL CONTRACEPTIVES;ORTHOTOPIC LIVER;PATIENTS OHP;PNS LS","7;6;6;6;5;5;5;5;5;5;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3",13,0.11,6,2,0,1,0,1,1.5,0,1.75,4,0,0,2.5,0,3,0,0,2.5,0,0,0,49,49,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,5,4,10830,2.37,0,0,210.2,0,0,0,0,4,0,1,0,0,5,0,0,0,0,0,0,0,5,0,0,5,0,0,0,0,0,0,0,0,0,"United States;Germany;Italy","2;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS","5;3;2","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;PATIENT SAFETY;AGING;CARDIOVASCULAR;COLO-RECTAL CANCER;DIGESTIVE DISEASES;HEART DISEASE;HEART DISEASE - CORONARY HEART DISEASE;HIV/AIDS;ORPHAN DRUG;RARE DISEASES;UROLOGIC DISEASES","5;5;2;2;1;1;1;1;1;1;1;1;1;1","CANCER;CARDIOVASCULAR;INFECTION","2;1;1","6.1 PHARMACEUTICALS","5","BLADDER CANCER;COLON AND RECTAL CANCER","1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS","2",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_SANTORSOLA",2002,148,6.32432432432432,2.39189189189189,0.702702702702703,0.358108108108108,0.702702702702703,1.3003663003663,1.2093023255814,1.2,1.20689655172414,0.222972972972973,16,70,15,8,44,0.47,0.1,0.05,0.3,47.1,0.853769299850372,NA,0.148648648648649,0.662162162162162,0.443,0.324,0.345,0.314,"PIER LUIGI TAZZARI;MAURIZIO ZOMPATORI;ROBERTO MANFREDI;ANGELO BRANZI;LEONARDO CALZA;S COCCHERI;ROBERTO CONTE;NICOLA SCIASCIA;FRANCESCO GRIGIONI;MAURO BIFFI;MARIA LETIZIA BACCHI REGGIANI;CRISTINA LEGNANI;ANTONIO SANTORO;ROSSELLA FATTORI;FRANCESCO CHIODO;GIUSEPPE BORIANI;GIAN LUCA GRAZI;R VALENTINI;GUALTIERO PALARETI;LUCIANO POTENA","7;6;6;6;5;5;5;4;4;4;4;4;4;4;4;4;3;3;3;3","ROBERTO MANFREDI;ANDREA BELLUZZI;ANTONIO SANTORO;S COCCHERI;MAURO BIFFI;CRISTINA LEGNANI;VALENTINA VICENNATI;F. BALDI;LEONARDO CALZA;MARIA PIA PISTILLO;MAURIZIO ZOMPATORI;FRANCESCO CHIODO;FABRIZIO BONANNO;ALESSANDRO SANTORO;SERGIO SABBATANI;P AUREA;ALESSANDRO PULSONI;G. M. FRASCA;PIER LUIGI TAZZARI;ANGELO BRANZI","2.21;2;1.83;1.64;1.59;1.48;1.37;1.25;1.21;1.11;1.09;1.01;1;1;1;1;1;1;0.98;0.9","PIER LUIGI TAZZARI;MAURIZIO ZOMPATORI;ROBERTO MANFREDI;ANGELO BRANZI;S COCCHERI;ROBERTO CONTE;NICOLA SCIASCIA;FRANCESCO GRIGIONI;MAURO BIFFI;MARIA LETIZIA BACCHI REGGIANI;CRISTINA LEGNANI;ANTONIO SANTORO;ROSSELLA FATTORI;GIUSEPPE BORIANI;GIAN LUCA GRAZI;GUALTIERO PALARETI;LUCIANO POTENA;FRANCESCO SAVERIO VIOLANTE;VALENTINA VICENNATI;GIULIO MARCHESINI","7;6;6;6;5;5;4;4;4;4;4;4;4;4;3;3;3;3;3;3","ROBERTO MANFREDI;ANDREA BELLUZZI;ANTONIO SANTORO;S COCCHERI;MAURO BIFFI;CRISTINA LEGNANI;VALENTINA VICENNATI;F. BALDI;MARIA PIA PISTILLO;MAURIZIO ZOMPATORI;FABRIZIO BONANNO;ALESSANDRO SANTORO;SERGIO SABBATANI;P AUREA;ALESSANDRO PULSONI;PIER LUIGI TAZZARI;ANGELO BRANZI;ALESSANDRA GAMBINERI;RENATO PASQUALI;FAUSTO CATENA","2.21;2;1.83;1.64;1.59;1.48;1.37;1.25;1.11;1.09;1;1;1;1;1;0.98;0.9;0.87;0.87;0.73","GIULIO MARCHESINI;ALESSANDRO MUSSO;ELISABETTA BUGIANESI;ESTER VANNI;F. BRUNELLO;LORENZO CAPUSSOTTI;MARIO RIZZETTO;MAURO SALIZZONI;NICOLA LEONE;P. CARUCCI;PAOLO DE PAOLIS;ROSSELLA FATTORI;ANDREW G. MOORE;ARTURO EVANGELISTA;CHRISTOPH NIENABER;DAN GILON;DAVID BRUCKMAN;ERIC M. ISSELBACHER;JAE K. OH;KIM A. EAGLE","1472;1435;1435;1435;1435;1435;1435;1435;1435;1435;1435;895;496;496;496;496;496;496;496;496","MAURO SALIZZONI;ROSSELLA FATTORI;S COCCHERI;G. PILU;JOSEPH F. MALOUF;GUALTIERO PALARETI;P. FALCO;SARA ZAGONARI;VALENTINA VICENNATI;ALESSANDRA GAMBINERI;RENATO PASQUALI;A. VISENTIN;KENNETH B. MARCU;UBERTO PAGOTTO;GABRIELE GROSSI;ANGELO PIERANGELI;PAOLO GIONCHETTI;A. VENTURI;FERNANDO RIZZELLO;KAREN M. LAMMERS","1435;496;446;359;301;296;286;286;284;283;283;242;219;199;176;169;169;149;149;149","PIER LUIGI TAZZARI;ROBERTO MANFREDI;ANTONIO SANTORO;ROBERTO CONTE;ANGELO BRANZI;FAUSTO CATENA;GIUSEPPE BORIANI;S COCCHERI;ALESSANDRA GAMBINERI;ANGELO PIERANGELI;FEDERICO CONTEDINI;FRANCESCO GRIGIONI;FRANCESCO SAVERIO VIOLANTE;G. PILU;MARIA LETIZIA BACCHI REGGIANI;MAURO BIFFI;RENATO PASQUALI;RICCARDO CIPRIANI;VALENTINA VICENNATI;VILMA MANTOVANI","7;6;5;5;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3","MEDICINE;BIOLOGY;CHEMISTRY;MATHEMATICS;PHYSICS;COMPUTER SCIENCE;PSYCHOLOGY;MATERIALS SCIENCE;SOCIOLOGY;ENGINEERING;GEOGRAPHY;PHILOSOPHY;ECONOMICS;HISTORY;POLITICAL SCIENCE","137;55;13;13;11;7;5;4;4;2;2;2;1;1;1","INTERNAL MEDICINE;SURGERY;BIOCHEMISTRY;IMMUNOLOGY;GENETICS;CARDIOLOGY;ENDOCRINOLOGY;GASTROENTEROLOGY;RADIOLOGY;PATHOLOGY;INTENSIVE CARE MEDICINE;ENVIRONMENTAL HEALTH;MOLECULAR BIOLOGY;MICROBIOLOGY;PSYCHIATRY;VIROLOGY;ANESTHESIA;GENERAL SURGERY;CANCER RESEARCH;ONCOLOGY;UROLOGY","102;44;25;24;22;20;19;18;17;16;13;11;11;10;10;9;8;7;6;6;6","GENE;DISEASE;POPULATION;CANCER;ANTIBODY;BLOOD PRESSURE;ENZYME;LUNG;TRANSPLANTATION;VIRUS;ANTIBIOTICS;AORTA;CHEMOTHERAPY;INSULIN;OBESITY;PREGNANCY;ANTIGEN;BACTERIA;BIOPSY;CIRRHOSIS;DIABETES MELLITUS;NEUROLOGY;PLATELET;RESPIRATORY SYSTEM;URINARY SYSTEM","16;14;12;11;9;7;7;7;7;7;6;6;6;6;6;6;5;5;5;5;5;5;5;5;5","VIRAL DISEASE;INSULIN RESISTANCE;NEURORADIOLOGY;AORTIC ANEURYSM;AORTIC DISSECTION;CERVICAL CANCER;COLORECTAL CANCER;CROHN'S DISEASE;FETUS;GENOTYPE;GESTATIONAL AGE;HEART RATE;HEPATITIS C VIRUS;IMMUNOASSAY;LIVER TRANSPLANTATION;MUTATION;PLACEBO;STAPHYLOCOCCUS AUREUS;WAIST;ALLELE;ANTIBIOTIC RESISTANCE;BASAL (MEDICINE);BREATH TEST;BRONCHIOLITIS;CHRONIC COUGH;CYTOTOXIC T CELL;EJECTION FRACTION;ENTEROCOCCUS;GENE EXPRESSION;GESTATION;HEART TRANSPLANTATION;HEMATOPOIETIC STEM CELL TRANSPLANTATION;INFLAMMATORY BOWEL DISEASE;INFLIXIMAB;LYMPHOBLASTIC LEUKEMIA;POLYMERASE CHAIN REACTION;PROBIOTIC;RECOMBINANT DNA;RESPIRATORY DISEASE;RESPIRATORY TRACT;RETINOIC ACID;RNA;SERINE;SOTALOL;T CELL;TOLERABILITY;TYPE 2 DIABETES;VENOUS THROMBOEMBOLISM;VENOUS THROMBOSIS;VIRAL LOAD","5;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","ABDOMINAL OBESITY;ACUTE LYMPHOCYTIC LEUKEMIA;ANTIRETROVIRAL THERAPY;ENTEROCOCCUS FAECALIS;MICROARRAY;PAPILLOMAVIRIDAE;POLYCYSTIC OVARY;RIBOSOME;SIDA;(+)-NALOXONE;ABCIXIMAB;ABSOLUTE NEUTROPHIL COUNT;ACUTE PROMYELOCYTIC LEUKEMIA;AKT1;AL AMYLOIDOSIS;ALLELE FREQUENCY;ANGIOTENSIN RECEPTOR;ANTIBIOTIC-ASSOCIATED DIARRHEA;AORTIC RUPTURE;BDNA TEST;BILIARY CIRRHOSIS;BREAST RECONSTRUCTION;BRONCHIAL HYPERREACTIVITY;BRONCHIOLITIS OBLITERANS;CALPROTECTIN;CARBOPLATIN;CARDIAC RESYNCHRONIZATION THERAPY;CATAPLEXY;CD28;CD40;CD86;CERVICAL INTRAEPITHELIAL NEOPLASIA;CHEMILUMINESCENT IMMUNOASSAY;CHYMOTRYPSIN;CLAUDICATION;COENZYME Q – CYTOCHROME C REDUCTASE;COLPOSCOPY;CTLA-4;CYSTECTOMY;DOUBLE BLIND;DYSKERATOSIS CONGENITA;ENTHESITIS;ESOPHAGITIS;FACTOR V LEIDEN;FETAL DISTRESS;FUNCTIONAL RESIDUAL CAPACITY;GESTATIONAL SAC;GLUCOSE HOMEOSTASIS;GLUCOSE TOLERANCE TEST;HAPLOTYPE;HEARTBURN;HETEROZYGOTE ADVANTAGE;HISTOCOMPATIBILITY;HOLOPROSENCEPHALY;HYPERINSULINEMIA;IMPAIRED GLUCOSE TOLERANCE;INFLAMMATORY BOWEL DISEASES;INTERMITTENT CLAUDICATION;IΚB KINASE;LAMIVUDINE;LENTIVIRUS;LOSARTAN;LOWER RESPIRATORY TRACT INFECTION;MEAN ARTERIAL PRESSURE;METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS;METHYLENETETRAHYDROFOLATE REDUCTASE;MISOPROSTOL;MISSENSE MUTATION;NFKB1;NITROFURANTOIN;NONALCOHOLIC FATTY LIVER DISEASE;NORETHISTERONE;OPIOID PEPTIDE;OTOTOXICITY;OXALIPLATIN;PARAMYXOVIRIDAE;PEAK INSPIRATORY PRESSURE;PIPERACILLIN;PLACEBO GROUP;POINT MUTATION;PRENATAL DIAGNOSIS;PRESSOR RESPONSE;PRODUCTS OF CONCEPTION;PROSTATE BIOPSY;PROSTATE-SPECIFIC ANTIGEN;PROSTATECTOMY;RAPID UREASE TEST;REFLUX ESOPHAGITIS;RENAL ARTERY STENOSIS;RENAL ISCHEMIA;SEX HORMONE-BINDING GLOBULIN;SMALL FOR GESTATIONAL AGE;SPIRILLACEAE;STEATOHEPATITIS;THORACIC AORTIC ANEURYSM;THREONINE;THROMBOMODULIN;THYMIDYLATE SYNTHASE;TRAF2;UMBILICAL ARTERY;UREA BREATH TEST;UTERINE ARTERY","2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MALE;MIDDLE AGED;ADULT;AGED;ITALY;;AGED, 80 AND OVER;RISK FACTORS;TIME FACTORS;ADOLESCENT;RETROSPECTIVE STUDIES;TREATMENT OUTCOME;COLORECTAL NEOPLASMS;LIVER CIRRHOSIS;LIVER NEOPLASMS;SENSITIVITY AND SPECIFICITY;CHILD;VENOUS THROMBOSIS","126;83;79;63;53;47;24;19;19;17;17;16;15;15;12;12;12;12;11;11","DIAGNOSIS AND MANAGEMENT OF AORTIC DISEASES;MICROSURGICAL RECONSTRUCTION TECHNIQUES;DIAGNOSIS AND MANAGEMENT OF CHRONIC COUGH;DIAGNOSIS AND MANAGEMENT OF PANCREATITIS;DIAGNOSIS AND TREATMENT OF RENAL ARTERY STENOSIS;GENETICS AND TREATMENT OF INFLAMMATORY BOWEL DISEASE;GENOTOXICITY AND CARCINOGENESIS MECHANISMS;HELICOBACTER PYLORI INFECTION AND GASTRIC CANCER;HUMAN PAPILLOMAVIRUS AND CERVICAL CANCER EPIDEMIOLOGY;THROMBOSIS AND COAGULATION DISORDERS;ANALYSIS AND APPLICATIONS OF HEART RATE VARIABILITY;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;COLORECTAL CANCER RESEARCH AND TREATMENT;DIAGNOSIS AND MANAGEMENT OF LIVER DISEASES;DIAGNOSIS AND TREATMENT OF HEART FAILURE;DUAL-ENERGY COMPUTED TOMOGRAPHY;FUNCTIONAL BOWEL DISORDERS AND GASTROINTESTINAL HEALTH;GENETIC AND ENVIRONMENTAL INFLUENCES ON CLEFT LIP AND PALATE;HEMATOPOIETIC STEM CELL BIOLOGY;HEPATITIS C INFECTION AND TREATMENT","4;4;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2","TREATMENT;AORTIC DISSECTION;NEURORADIOLOGY;ANTIRETROVIRAL THERAPY;EWING'S SARCOMA;GOLD STANDARD (TEST);INTERVENTIONAL RADIOLOGY;MANDIBULAR RECONSTRUCTION;MICROSURGICAL RECONSTRUCTION;PERFORATOR FLAP;VENOUS THROMBOEMBOLISM;ABDOMINAL OBESITY;ACUTE LYMPHOCYTIC LEUKEMIA;ACUTE PANCREATITIS;AORTIC ROOT REPLACEMENT;BASAL (MEDICINE);BASE (TOPOLOGY);CARDIAC SURGERY RISK MODELS;CHRONIC COUGH;CONCOMITANT","7;4;4;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2","RISK FACTORS;AORTIC DISSECTION;HEART FAILURE;VENOUS THROMBOEMBOLISM;VIRUS INFECTION;ACUTE AORTIC;ANTIBIOTIC RESISTANCE;ANTIRETROVIRAL THERAPY;ATRIAL FIBRILLATION;BASE RECONSTRUCTION;COLORECTAL CANCER;COMPUTED TOMOGRAPHY;CONGESTIVE HEART;DNA MICROARRAY;EMERGENCY SURGERY;ENZYME IMMUNOASSAY;FACTOR VII;GPD MUTATIONS;HEART TRANSPLANTATION;HEPATOCELLULAR CARCINOMA;HIGH-CARBOHYDRATE MEALS;HIV DISEASE;HUMAN PAPILLOMAVIRUS;HYPOTHALAMIC-PITUITARY-ADRENOCORTICAL AXIS;INCREASES RESPONSE;INFLIXIMAB INCREASES;LIVER DISEASE;LIVER TRANSPLANTATION;NORTHERN ITALY;OBESITY PHENOTYPES","5;4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","CELL LINES;PUBMED SCOPUS;CELL LINE;CROSSREF PUBMED;DYSKERATOSIS CONGENITA;CONTROL CELL;DKC CELL;RIBOSOMAL BIOGENESIS;SIGNIFICANT DIFFERENCE;VERSUS CONTROL;LINE GMC;CONTROL LINE;CELL PROLIFERATION;HPA AXIS;AL DERENZINI;TRYPAN BLUE;ARTERIAL PRESSURE;FLOW CYTOMETRY;GMC SIGNIFICANT;DKC CELLS;MORTALITY RATE;BONE MARROW;KNIGHT SW;NUCLEOLAR SIZE;PRESSURE RESPONSE;VULLIAMY TJ;X-LINKED DYSKERATOSIS;AL KNIGHT;CELL DEATH;CONTROL CELLS","44;29;28;25;25;23;21;18;16;16;12;11;10;10;9;9;8;8;8;7;7;6;6;6;6;6;6;5;5;5",21,0.14,6,3,1,1,0,3.5,3,0,2,4,0,0,2,0,1.75,0,0,2,0,0,0,66,66,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,4,10.75,2836.75,1.61,1,0.25,122.25,0,0,0,0,3,0,1,0,0,4,0,0,0,0,0,0,0,4,0,0,4,0,0,0,0,0,0,0,0,0,"Belgium;Italy","1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3202 CLINICAL SCIENCES","4;2;2;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;HEMATOLOGY;RARE DISEASES;CARDIOVASCULAR;HEART DISEASE;LUNG;NEUROBLASTOMA;NEUROSCIENCES;NUTRITION;ORPHAN DRUG;PEDIATRIC;PREVENTION","4;3;2;2;2;1;1;1;1;1;1;1;1;1","CANCER;CARDIOVASCULAR","2;2","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;6.4 SURGERY;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES","2;1;1;1","LEUKEMIA / LEUKAEMIA;NEUROBLASTOMA","1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS","2",1,3485992,348599.2,3,10,5,1,0,116199.733333333,1.27366901587841,"ALMAVIVA (ITALY);ASOCIACIÓN DE INVESTIGACIÓN DE LA INDUSTRIA AGROALIMENTARIA;CAS SOFTWARE (GERMANY);INTERNATIONAL CENTER FOR NUMERICAL METHODS IN ENGINEERING;KU LEUVEN;NATIONAL AGENCY FOR NEW TECHNOLOGIES, ENERGY AND SUSTAINABLE ECONOMIC DEVELOPMENT;POLICLINICO S.ORSOLA-MALPIGHI;SCIENTIFIC AND TECHNICAL CENTER FOR BUILDING;SPANISH NATIONAL RESEARCH COUNCIL;UNIVERSITY OF STUTTGART","1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION","1","COALITION S;EC & ERC - EUROPEAN UNION","1;1","ACM - PREPARATORY, ACCOMPANYING AND SUPPORT MEASURES (FUNDING SCHEME);FP5-IST - PROGRAMME FOR RESEARCH, TECHNOLOGICAL DEVELOPMENT AND DEMONSTRATION ON A ""USER-FRIENDLY INFORMATION SOCIETY, 1998-2002"" (PROGRAMME)","1;1","33 BUILT ENVIRONMENT AND DESIGN;3301 ARCHITECTURE;46 INFORMATION AND COMPUTING SCIENCES","1;1;1",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"B11 COMPUTER SCIENCE AND INFORMATICS","1",NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_SANTORSOLA",2003,192,7.046875,2.75,0.640625,0.307291666666667,0.671875,1.47486033519553,1.41379310344828,1.22916666666667,1.38709677419355,0.25,18,74,45,14,47,0.39,0.23,0.07,0.24,58.42,1.10370267430638,NA,0.171875,0.744791666666667,0.462,0.378,0.338,0.381,"GIUSEPPE BORIANI;GIAN LUCA GRAZI;ANDREA PESSION;SERGIO SABBATANI;PIER LUIGI TAZZARI;ANTONINO CAVALLARI;GUALTIERO PALARETI;GIORGIO ERCOLANI;MATTEO CESCON;MICHELE BACCARANI;ANGELO BRANZI;UBERTO PAGOTTO;CRISTINA LEGNANI;FRANCO LOCATELLI;BRUNO CHIAPPINI;PIER PAOLO PICCALUGA;ROBERTO DI BARTOLOMEO;RAFFAELE PEZZILLI;GIOVANNI MARTINELLI;GIOVANNI RAVAGLIA","12;7;7;7;7;7;6;6;6;6;6;6;6;5;5;5;5;5;5;4","SERGIO SABBATANI;BRUNO CHIAPPINI;GIUSEPPE BORIANI;O. TRIOSSI;ETTORE AMBROSIONI;GIOVANNI RAVAGLIA;T. GHI;LUIGI BOLONDI;GIAMPAOLO BIANCHI;CLAUDIO RAPEZZI;MARCO ZECCA;PIER PAOLO PICCALUGA;CRISTINA LEGNANI;R DÒMINI;COSTANZA MAZZEO;ROBERTO MANFREDI;A. MARTONI;PAOLOG. MORSELLI;MARINA MARTORELLI;GUALTIERO PALARETI","4.42;1.65;1.59;1.5;1.5;1.31;1.25;1.14;1.1;1.08;1.07;1.05;1.03;1;1;1;1;1;1;0.96","GIUSEPPE BORIANI;GIAN LUCA GRAZI;ANDREA PESSION;SERGIO SABBATANI;PIER LUIGI TAZZARI;ANTONINO CAVALLARI;GUALTIERO PALARETI;GIORGIO ERCOLANI;MATTEO CESCON;MICHELE BACCARANI;ANGELO BRANZI;UBERTO PAGOTTO;CRISTINA LEGNANI;FRANCO LOCATELLI;BRUNO CHIAPPINI;PIER PAOLO PICCALUGA;ROBERTO DI BARTOLOMEO;RAFFAELE PEZZILLI;GIOVANNI RAVAGLIA;ALESSANDRA LONGHI","12;7;7;7;7;7;6;6;6;6;6;6;6;5;5;5;5;5;4;4","SERGIO SABBATANI;BRUNO CHIAPPINI;GIUSEPPE BORIANI;O. TRIOSSI;ETTORE AMBROSIONI;GIOVANNI RAVAGLIA;T. GHI;LUIGI BOLONDI;GIAMPAOLO BIANCHI;CLAUDIO RAPEZZI;MARCO ZECCA;PIER PAOLO PICCALUGA;CRISTINA LEGNANI;R DÒMINI;COSTANZA MAZZEO;ROBERTO MANFREDI;A. MARTONI;PAOLOG. MORSELLI;MARINA MARTORELLI;GUALTIERO PALARETI","4.42;1.65;1.59;1.5;1.5;1.31;1.25;1.14;1.1;1.08;1.07;1.05;1.03;1;1;1;1;1;1;0.96","MICHELE BACCARANI;GIUSEPPE SAGLIO;ALOÏS GRATWOHL;ANDREAS HOCHHAUS;ANN E. BOLTON;BENGT SIMONSSON;BRIAN J. DRUKER;FRANCISCO CERVANTES;FRANÇOIS GUILHOT;GREGOR VERHOEF;HAGOP M. KANTARJIAN;INSA GATHMANN;JAN J. CORNELISSEN;JOHAN LANNG NIELSEN;JOHN D. SHEPHERD;JOHN M. GOLDMAN;JOSY REIFFERS;KERRY TAYLOR;KLAUS LECHNER;PHILIPPE ROUSSELOT","3588;3535;3505;3505;3505;3505;3505;3505;3505;3505;3505;3505;3505;3505;3505;3505;3505;3505;3505;3505","MICHELE BACCARANI;UBERTO PAGOTTO;RENATO PASQUALI;CRISTINA CERVINO;FEDERICA TOMASSONI;PIER LUIGI TAZZARI;ANGELO BRANZI;FERNANDO RIZZELLO;KAREN M. LAMMERS;MASSIMO CAMPIERI;PAOLO GIONCHETTI;MARCO ZECCA;GIUSEPPE BORIANI;ROBERTO DI BARTOLOMEO;ANGELO PIERANGELI;ANDREA PESSION;ROBERTO CONTE;CRISTIAN MARTIGNANI;GIAMPAOLO BIANCHI;MAURO BIFFI","3505;1424;1340;1223;1223;405;336;287;287;287;287;285;282;238;232;230;222;218;214;208","GIUSEPPE BORIANI;ANDREA PESSION;PIER LUIGI TAZZARI;SERGIO SABBATANI;UBERTO PAGOTTO;ANTONINO CAVALLARI;GIAN LUCA GRAZI;GIORGIO ERCOLANI;MATTEO CESCON;PIER PAOLO PICCALUGA;RAFFAELE PEZZILLI;ROBERTO DI BARTOLOMEO;ANGELO BRANZI;BRUNO CHIAPPINI;CRISTINA LEGNANI;GIOVANNI RAVAGLIA;GUALTIERO PALARETI;VILMA MANTOVANI;ANGELO PIERANGELI;ROBERTO CONTE","11;7;7;7;6;6;5;5;5;5;5;5;5;5;5;4;4;4;4;4","MEDICINE;BIOLOGY;PHYSICS;CHEMISTRY;ECONOMICS;PSYCHOLOGY;COMPUTER SCIENCE;GEOGRAPHY;MATHEMATICS;POLITICAL SCIENCE;ENGINEERING;HISTORY;SOCIOLOGY;PHILOSOPHY;BUSINESS;MATERIALS SCIENCE;GEOLOGY","179;61;16;11;8;7;6;6;6;5;4;4;4;3;2;2;1","INTERNAL MEDICINE;SURGERY;PATHOLOGY;GASTROENTEROLOGY;IMMUNOLOGY;CARDIOLOGY;GENETICS;RADIOLOGY;BIOCHEMISTRY;ENDOCRINOLOGY;ENVIRONMENTAL HEALTH;PSYCHIATRY;ANESTHESIA;CANCER RESEARCH;ONCOLOGY;OPTICS;INTENSIVE CARE MEDICINE;GENERAL SURGERY;MICROBIOLOGY;MOLECULAR BIOLOGY;PEDIATRICS;PHARMACOLOGY","128;59;40;34;33;32;30;24;23;20;19;17;12;12;11;11;10;9;9;8;8;8","DISEASE;GENE;POPULATION;TRANSPLANTATION;ANTIBODY;CHEMOTHERAPY;CANCER;INCIDENCE (GEOMETRY);PREGNANCY;RECEPTOR;ATRIAL FIBRILLATION;HEART FAILURE;ADVERSE EFFECT;BLOOD PRESSURE;EPIDEMIOLOGY;HORMONE;VIRUS;LESION;MYELOID LEUKEMIA;NEUROLOGY;PANCREATITIS;RADIATION THERAPY;RISK FACTOR;THROMBOSIS","22;18;18;15;12;12;11;10;9;9;8;8;7;7;7;7;7;6;6;6;6;6;6;6","LIVER TRANSPLANTATION;MUTATION;VENOUS THROMBOSIS;AORTIC VALVE REPLACEMENT;C-REACTIVE PROTEIN;EJECTION FRACTION;ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY;NEURORADIOLOGY;ALLELE;ANTAGONIST;AUTOIMMUNE DISEASE;CANNABINOID;CATHETER ABLATION;DEMENTIA;ENDOCANNABINOID SYSTEM;FETUS;GENOTYPE;HEART TRANSPLANTATION;HEPATITIS C VIRUS;IMATINIB;INFERTILITY;INSULIN RESISTANCE;INTERLEUKIN;KIDNEY TRANSPLANTATION;POLYMERASE CHAIN REACTION;THROMBOPHILIA;TOLERABILITY;VIRAL DISEASE;VIRAL LOAD","6;6;5;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3","CANNABINOID RECEPTOR;FACTOR V LEIDEN;IMATINIB MESYLATE;ALLELE FREQUENCY;ATRIAL TACHYCARDIA;AZOOSPERMIA;CARDIAC RESYNCHRONIZATION THERAPY;COGNITIVE DECLINE;CORONAVIRUS DISEASE 2019 (COVID-19);EMBRYONAL RHABDOMYOSARCOMA;FIRST TRIMESTER;GENE MUTATION;HAPLOTYPE;MELANIN-CONCENTRATING HORMONE;NEUROPEPTIDE Y RECEPTOR;POLYCYSTIC OVARY;PRENATAL DIAGNOSIS;REVERSE TRANSCRIPTASE;THREATENED ABORTION;TREPONEMA","3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","HUMANS;MALE;FEMALE;MIDDLE AGED;ADULT;AGED;ITALY;;ADOLESCENT;CHILD;AGED, 80 AND OVER;TREATMENT OUTCOME;FOLLOW-UP STUDIES;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;POSTOPERATIVE COMPLICATIONS;CHILD, PRESCHOOL;TIME FACTORS;BONE NEOPLASMS;RETROSPECTIVE STUDIES;HEART FAILURE","163;105;102;73;67;56;33;26;25;25;24;24;20;19;17;16;16;15;15;14","CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;DIAGNOSIS AND MANAGEMENT OF PANCREATITIS;SARCOMA RESEARCH AND TREATMENT;ACUTE MYELOID LEUKEMIA;MANAGEMENT OF HYPERTENSION AND CARDIOVASCULAR RISK FACTORS;DIAGNOSIS AND MANAGEMENT OF AORTIC DISEASES;ENDOCANNABINOID SYSTEM AND ITS EFFECTS ON HEALTH;EPIDEMIOLOGY AND MANAGEMENT OF CONGENITAL HEART DISEASE;EPIDEMIOLOGY AND MANAGEMENT OF NAFLD;EPIDEMIOLOGY AND MANAGEMENT OF NEUROENDOCRINE TUMORS;HEMATOPOIETIC STEM CELL BIOLOGY;HEPATITIS C INFECTION AND TREATMENT;KIDNEY TRANSPLANTATION;PREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM;THROMBOSIS AND COAGULATION DISORDERS;ATRIAL FIBRILLATION;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;DIAGNOSIS AND MANAGEMENT OF ALZHEIMER'S DISEASE;DIAGNOSIS AND MANAGEMENT OF CELIAC DISEASE;DIAGNOSIS AND MANAGEMENT OF GASTROINTESTINAL BLEEDING","7;5;5;4;4;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2","TREATMENT;AORTIC ROOT REPLACEMENT;ACUTE PANCREATITIS;EWING'S SARCOMA;REGIMEN;AORTIC DISSECTION;CARDIAC RESYNCHRONIZATION THERAPY;DEEP VEIN THROMBOSIS;HEPATITIS C;HYPERTENSION;IMMUNOSUPPRESSION;NEURORADIOLOGY;VENOUS THROMBOEMBOLISM;APOPTOSIS;CANNABINOID RECEPTORS;CB1 AND CB2 RECEPTORS;D-DIMER;DEPRESSION (ECONOMICS);ENDOCANNABINOID SYSTEM;GROUP B","10;6;5;5;5;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3","PATIENTS TREATED;HEART FAILURE;RISK FACTORS;ACUTE MYELOID;AORTIC VALVE;IMPLANTABLE CARDIOVERTER;LEUKEMIA CELLS;LIVER TRANSPLANTATION;MYELOID LEUKEMIA;PEPTIC ULCER;TRANSPLANT RECIPIENT;VALVE REPLACEMENT;VENOUS THROMBOEMBOLISM;ACUTE LYMPHOBLASTIC;ACUTE PANCREATITIS;ACUTE PHASE;AFFECTS ENERGY;ANTEGRADE SELECTIVE;ATRIAL TACHYARRHYTHMIA;BILIARY PANCREATITIS;BLEEDING PEPTIC;BONE MARROW;CANNABINOID SYSTEM;CARDIAC RESYNCHRONIZATION;CARDIOVASCULAR RISK;CARDIOVERTER DEFIBRILLATOR;CENTRAL OREXIGENIC;CEREBRAL PERFUSION;CHRONIC HEPATITIS;CHRONIC MYELOID","5;4;4;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","CMV INFECTION;VENOUS THROMBOEMBOLISM;PROTHROMBIN LEVELS;RISK FACTORS;FAMILY HISTORY;AKT INHIBITOR;NEWLY DIAGNOSED;PATIENTS TREATED;PROTHROMBIN MUTATION;VALVE REPLACEMENT;ATRIAL FIBRILLATION;CROHNS DISEASE;CTL LINES;THROMBOPHILIC DEFECTS;ULCERATIVE COLITIS;AORTIC VALVE;ATRIAL FIBRILLATIONFLUTTER;CALORIC INTAKE;DE NOVO;EWINGS SARCOMA;FOOD INTAKE;GHRELIN LEVELS;GRAFT FUNCTION;HOSPITAL STAY;IDIOPATHIC VENOUS;LEAN PHENOTYPE;MEDIAN FOLLOW-UP;MRNA LEVELS;RESONANCE IMAGING;THROMBOEMBOLISM VTE","10;10;9;9;7;6;6;6;6;6;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4",25,0.13,6,4,1,2.5,0,46.5,5,1,1,4,0,0,11,0,4,0,4,6.5,2.75,0,0,48,48,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,8,5.14,322.57,2.44,0,0,52.38,0,0,1,0,4,0,2,1,0,7,0,0,0,0,0,0,0,7,0,1,6,1,0,1,0,0,0,0,0,0,"United States;Italy;Germany","4;2;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;49 MATHEMATICAL SCIENCES;4901 APPLIED MATHEMATICS;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY","8;4;2;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;HEMATOLOGY;RARE DISEASES;CARDIOVASCULAR;CHRONIC PAIN;COMPARATIVE EFFECTIVENESS RESEARCH;DENTAL/ORAL AND CRANIOFACIAL DISEASE;DIABETES;DIGESTIVE DISEASES;KIDNEY DISEASE;LYMPHOMA;ORPHAN DRUG;PAIN RESEARCH;PATIENT SAFETY;PEDIATRIC;PEDIATRIC CANCER;PREVENTION","6;5;4;3;3;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CANCER;GENERIC HEALTH RELEVANCE;METABOLIC AND ENDOCRINE","2;1;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES","4;1;1","LEUKEMIA / LEUKAEMIA;COLON AND RECTAL CANCER;MYELOMA","2;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;5.1 LOCALIZED THERAPIES - DISCOVERY AND DEVELOPMENT;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","3;1;1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_SANTORSOLA",2004,224,7.70535714285714,3.54017857142857,0.625,0.424107142857143,0.633928571428571,1.64315352697095,1.44329896907216,1.43939393939394,1.3921568627451,0.321428571428571,15,102,63,26,28,0.46,0.28,0.12,0.12,36.4,0.773528727477317,NA,0.21875,0.758928571428571,0.446,0.348,0.364,0.359,"GIORGIO ERCOLANI;MATTEO CESCON;GIOVANNI MARTINELLI;GIAN LUCA GRAZI;MICHELE BACCARANI;MARIO TAFFURELLI;MATTEO RAVAIOLI;PIER LUIGI TAZZARI;GUALTIERO PALARETI;FRANCESCO SAVERIO VIOLANTE;ANGELO BRANZI;UBERTO PAGOTTO;FRANCESCO CHIODO;GAETANO VETRONE;LUCA ANSALONI;FRANCESCO GRIGIONI;BENILDE COSMI;ANTONIO DANIELE PINNA;ANDREA MARTONI;FAUSTO CATENA","9;9;9;8;8;8;8;8;7;7;6;6;6;5;5;5;5;5;5;5","SERGIO SABBATANI;CLAUDIO BORGHI;GUIDO OPPIDO;BRUNO CHIAPPINI;LEONARDO CALZA;GUALTIERO PALARETI;FRANCESCO CHIODO;DONATELLA MAGALOTTI;BENILDE COSMI;LORIS PIRONI;VINCENZO STANGHELLINI;ALESSANDRO GRANITO;MARIO TAFFURELLI;FRANCESCO SAVERIO VIOLANTE;F FONTANA;GABRIELE DONATI;GIORGIO ERCOLANI;MATTEO CESCON;GIOVANNI MARTINELLI;ROBERTO MANFREDI","2.37;2;1.56;1.51;1.5;1.49;1.47;1.43;1.33;1.27;1.27;1.23;1.19;1.15;1.12;1.1;1.07;1.06;1.01;1","GIORGIO ERCOLANI;MATTEO CESCON;GIOVANNI MARTINELLI;GIAN LUCA GRAZI;MICHELE BACCARANI;MARIO TAFFURELLI;MATTEO RAVAIOLI;PIER LUIGI TAZZARI;GUALTIERO PALARETI;FRANCESCO SAVERIO VIOLANTE;ANGELO BRANZI;UBERTO PAGOTTO;FRANCESCO CHIODO;GAETANO VETRONE;LUCA ANSALONI;FRANCESCO GRIGIONI;BENILDE COSMI;ANTONIO DANIELE PINNA;ANDREA MARTONI;FAUSTO CATENA","9;9;9;8;8;8;8;8;7;7;6;6;6;5;5;5;5;5;5;5","SERGIO SABBATANI;CLAUDIO BORGHI;GUIDO OPPIDO;BRUNO CHIAPPINI;GUALTIERO PALARETI;FRANCESCO CHIODO;DONATELLA MAGALOTTI;BENILDE COSMI;LORIS PIRONI;VINCENZO STANGHELLINI;ALESSANDRO GRANITO;MARIO TAFFURELLI;FRANCESCO SAVERIO VIOLANTE;F FONTANA;GABRIELE DONATI;GIORGIO ERCOLANI;MATTEO CESCON;GIOVANNI MARTINELLI;ROBERTO MANFREDI;A BINI","2.37;2;1.56;1.51;1.49;1.47;1.43;1.33;1.27;1.27;1.23;1.19;1.15;1.12;1.1;1.07;1.06;1.01;1;1","FRANCESCO B. BIANCHI;UBERTO PAGOTTO;ANTONIO MARIA MORSELLI‐LABATE;ROSSELLA FATTORI;CHRISTOPH NIENABER;DEAN E. SMITH;ERIC M. ISSELBACHER;JAMES L. JANUZZI;JEANNA V. COOPER;JIANMING FANG;KIM A. EAGLE;LINDA PAPE;RAJENDRA H. MEHTA;ALESSANDRA GAMBINERI;DIEGO VERGANI;EDUARDO LUIZ RACHID CANÇADO;EDWARD PENNER;FERNANDO ÁLVAREZ;IAN R. MACKAY;MICHAEL P. MANNS","592;526;508;482;477;477;477;477;477;477;477;477;477;427;417;417;417;417;417;417","FRANCESCO B. BIANCHI;ROSSELLA FATTORI;ANTONIO MARIA MORSELLI‐LABATE;ALESSANDRA GAMBINERI;ROBERTO DI BARTOLOMEO;FRANCESCO SAVERIO VIOLANTE;GABRIELE DONATI;GIAN LUCA GRAZI;GUALTIERO PALARETI;UBERTO PAGOTTO;BRUNO CHIAPPINI;GIUSEPPE MARINELLI;MAURO BERNARDI;PAOLO CARACENI;PIER LUIGI TAZZARI;ANTONINO CAVALLARI;GIORGIO ERCOLANI;MATTEO CESCON;LUIGI BOLONDI;FRANCESCO GRIGIONI","506;477;423;385;370;364;321;317;313;312;301;301;289;289;268;245;230;227;226;225","GIORGIO ERCOLANI;MATTEO CESCON;PIER LUIGI TAZZARI;MARIO TAFFURELLI;FRANCESCO SAVERIO VIOLANTE;FAUSTO CATENA;MATTEO RAVAIOLI;GIAN LUCA GRAZI;MICHELE BACCARANI;UBERTO PAGOTTO;ANGELO BRANZI;ANTONINO CAVALLARI;ANTONIO DANIELE PINNA;FRANCESCO GRIGIONI;GAETANO VETRONE;GUALTIERO PALARETI;LUCA ANSALONI;LUIGI BOLONDI;GIOVANNI MARTINELLI;ROBERTO CONTE","9;8;8;8;7;7;7;7;6;5;5;5;5;5;5;5;5;5;5;5","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;COMPUTER SCIENCE;PSYCHOLOGY;POLITICAL SCIENCE;ENGINEERING;PHILOSOPHY;SOCIOLOGY;HISTORY;ECONOMICS;MATHEMATICS;ART;GEOLOGY;MATERIALS SCIENCE","210;65;22;16;12;10;6;4;4;4;3;2;2;1;1;1","INTERNAL MEDICINE;SURGERY;GASTROENTEROLOGY;PATHOLOGY;GENETICS;IMMUNOLOGY;CARDIOLOGY;BIOCHEMISTRY;ENDOCRINOLOGY;ENVIRONMENTAL HEALTH;RADIOLOGY;PEDIATRICS;CANCER RESEARCH;PSYCHIATRY;ANATOMY;PHYSICAL THERAPY;OBSTETRICS;ANESTHESIA;INTENSIVE CARE MEDICINE;UROLOGY","152;79;43;42;31;30;28;24;24;23;20;16;14;14;12;12;11;10;10;10","DISEASE;POPULATION;TRANSPLANTATION;CANCER;ANTIBODY;CHEMOTHERAPY;GENE;PREGNANCY;BLOOD PRESSURE;BIOPSY;THROMBOSIS;ALTERNATIVE MEDICINE;AORTA;CIRRHOSIS;CONFIDENCE INTERVAL;BODY MASS INDEX;DIABETES MELLITUS;ENZYME;EPIDEMIOLOGY;INCIDENCE (GEOMETRY);MYELOID LEUKEMIA;QUALITY OF LIFE (HEALTHCARE);RECEPTOR;REGIMEN;RISK FACTOR","28;23;20;16;15;15;14;14;12;9;9;8;8;8;8;7;7;7;7;7;7;7;7;7;7","LIVER TRANSPLANTATION;SEROLOGY;ADENOCARCINOMA;REFLUX;BREAST CANCER;FATTY LIVER;MUTATION;THROMBOPHILIA;VENOUS THROMBOSIS;AORTIC ARCH;AUTOIMMUNE HEPATITIS;COLORECTAL CANCER;FETUS;IMATINIB;INSULIN RESISTANCE;LIVER BIOPSY;ALLELE;ANTITHROMBIN;AORTIC DISSECTION;CD34;COGNITIVE IMPAIRMENT;EJECTION FRACTION;GENOTYPE;GESTATION;GESTATIONAL AGE;INGUINAL HERNIA;METFORMIN;MONOCLONAL ANTIBODY;PI3K/AKT/MTOR PATHWAY;PROSTATE CANCER;PROTEIN KINASE B;RESTENOSIS;RITUXIMAB;TACROLIMUS;VENOUS THROMBOEMBOLISM;WEIGHT LOSS;WHITE MATTER","14;8;6;6;5;5;5;5;5;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3","FACTOR V LEIDEN;GERD;IMATINIB MESYLATE;MILAN CRITERIA;POLYCYSTIC OVARY;ABDOMINOPERINEAL RESECTION;ABL;BASILIXIMAB;CD33;COMPOUND HETEROZYGOSITY;IMMUNOTOXIN;IMPAIRED GLUCOSE TOLERANCE;LOSS OF HETEROZYGOSITY;MINI–MENTAL STATE EXAMINATION;NEOADJUVANT THERAPY;NILOTINIB;OPIOID PEPTIDE;OXALIPLATIN;PHOSPHOINOSITIDE 3-KINASE;PROTEIN S DEFICIENCY;SINGLE-NUCLEOTIDE POLYMORPHISM;SOMATOSTATIN RECEPTOR 2;VINORELBINE","5;4;4;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","HUMANS;FEMALE;MALE;MIDDLE AGED;ADULT;AGED;;ITALY;TREATMENT OUTCOME;AGED, 80 AND OVER;ADOLESCENT;FOLLOW-UP STUDIES;LIVER NEOPLASMS;ANTIBODIES, MONOCLONAL;LIVER TRANSPLANTATION;RISK FACTORS;CHILD;GASTROESOPHAGEAL REFLUX;HIV INFECTIONS;POSTOPERATIVE COMPLICATIONS","164;114;110;81;71;57;50;31;26;24;22;21;21;18;18;18;16;15;15;15","MANAGEMENT OF HYPERTENSION AND CARDIOVASCULAR RISK FACTORS;LIVER TRANSPLANTATION AND GRAFT SURVIVAL ANALYSIS;THROMBOSIS AND COAGULATION DISORDERS;DIAGNOSIS AND MANAGEMENT OF AORTIC DISEASES;DIAGNOSIS AND MANAGEMENT OF GASTROESOPHAGEAL REFLUX DISEASE;HEPATOCELLULAR CARCINOMA;ATRIAL FIBRILLATION;COLORECTAL CANCER RESEARCH AND TREATMENT;EFFICACY AND RESISTANCE IN CML TREATMENT;EPIDEMIOLOGY AND MANAGEMENT OF CONGENITAL HEART DISEASE;EPIDEMIOLOGY AND MANAGEMENT OF NAFLD;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;DIAGNOSIS AND MANAGEMENT OF LIVER DISEASES;DIAGNOSIS AND MANAGEMENT OF PANCREATITIS;DIAGNOSIS AND MANAGEMENT OF POLYCYSTIC OVARY SYNDROME;GENOTOXICITY AND CARCINOGENESIS MECHANISMS;HEPATITIS C INFECTION AND TREATMENT;HERNIA REPAIR TECHNIQUES AND MATERIALS;LIVER CIRRHOSIS AND ASSOCIATED COMPLICATIONS;LYMPHOID NEOPLASMS","9;6;6;5;5;5;4;4;4;4;4;3;3;3;3;3;3;3;3;3","HYPERTENSION;REGIMEN;TREATMENT;VENOUS THROMBOEMBOLISM;AORTIC DISSECTION;BLOOD PRESSURE;GASTROESOPHAGEAL REFLUX DISEASE;HEPATITIS C;LIVER TRANSPLANTATION;STEATOSIS;AORTIC ROOT REPLACEMENT;ATRIAL FIBRILLATION;AUTOIMMUNE HEPATITIS;ETIOLOGY;HEPATOCELLULAR CARCINOMA;IMATINIB;IMATINIB MESYLATE;LIVER DISEASE;LIVING DONOR LIVER TRANSPLANTATION;ANTICOAGULANT THERAPY","12;7;6;6;5;5;5;5;5;5;4;4;4;4;4;4;4;4;4;3","BLOOD PRESSURE;LIVER TRANSPLANTATION;FATTY LIVER;PRESSURE CONTROL;ATRIAL FIBRILLATION;AUTOIMMUNE HEPATITIS;HEPATOCELLULAR CARCINOMA;INGUINAL HERNIA;ACUTE MYELOID;AORTIC DISSECTION;CONTINUOUS INFUSION;FLOW CYTOMETRY;HELICOBACTER PYLORI;HIV INFECTION;LIVER DISEASE;OVARY SYNDROME;POLYCYSTIC OVARY;VENOUS THROMBOEMBOLISM;ACUTE LYMPHOBLASTIC;ACUTE TYPE;ADULT PATIENTS;AMINO ACID;ANALYSIS NIRA;ANTIHYPERTENSIVE DRUGS;ANTIRETROVIRAL THERAPY;AORTIC ARCH;ASSOCIAZIONE ITALIANA;AUTOIMMUNE SEROLOGY;BOLOGNA PHASE;BREAST CANCER","9;9;5;5;4;4;4;4;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2","LIVER TRANSPLANTATION;AORTIC ARCH;NECROTIZING MEDIASTINITIS;PUBMED SCOPUS;RISK FACTORS;DESCENDING NECROTIZING;SURGICAL TREATMENT;TRACHEAL AGENESIS;INSULIN RESISTANCE;AMINO ACID;CHRONIC PANCREATITIS;FATTY LIVER;HA GRAFT;PATIENT SURVIVAL;PITUITARY ADENOMAS;AORTIC DISSECTION;BODY MASS;CROSSREF PUBMED;FETAL LOSS;LIVER FUNCTION;MASS INDEX;MEDIASTINAL DRAINAGE;PARTIAL NECROSIS;REGRESSION ANALYSIS;TRACHEOESOPHAGEAL FISTULA;TUMOR RECURRENCE;BASILIXIMAB PLACEBO;BASILIXIMAB STEROIDS;BLOOD PRESSURE;BP CONTROL","12;11;10;10;10;9;9;9;8;7;7;7;7;7;7;6;6;6;6;6;6;6;6;6;6;6;5;5;5;5",36,0.16,6,3.25,1,1,1,1,8,0,1,4,0,0,2,0,2,0,0,2,0,0,0,51.5,51.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,22,3.67,1203.17,5.03,2,0.09,44,0,0,11,0,7,0,2,2,0,11,1,0,0,0,0,0,0,22,0,0,11,10,0,1,0,0,0,0,0,0,"Italy;United States","3;2","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3202 CLINICAL SCIENCES;3212 OPHTHALMOLOGY AND OPTOMETRY;40 ENGINEERING;4003 BIOMEDICAL ENGINEERING;42 HEALTH SCIENCES;43 HISTORY, HERITAGE AND ARCHAEOLOGY;50 PHILOSOPHY AND RELIGIOUS STUDIES;5002 HISTORY AND PHILOSOPHY OF SPECIFIC FIELDS","19;9;7;7;1;1;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;HEMATOLOGY;RARE DISEASES;CANCER;CARDIOVASCULAR;LYMPHOMA;HEART DISEASE;ORPHAN DRUG;BIOMEDICAL IMAGING;HEART DISEASE - CORONARY HEART DISEASE;LUNG;ATHEROSCLEROSIS;DIGESTIVE DISEASES;HEPATITIS;INFECTIOUS DISEASES;LIVER DISEASE;PEDIATRIC;PREVENTION;BIOENGINEERING","11;7;7;7;6;5;5;4;4;3;3;3;2;2;2;2;2;2;2;1","CANCER;CARDIOVASCULAR;EYE;INFECTION","8;6;1;1","6.1 PHARMACEUTICALS;5.1 PHARMACEUTICALS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.2 CELLULAR AND GENE THERAPIES","12;2;1;1","NON-HODGKIN'S LYMPHOMA;HODGKIN'S DISEASE;LEUKEMIA / LEUKAEMIA;BLOOD CANCER;ESOPHAGEAL / OESOPHAGEAL CANCER;STOMACH CANCER","7;3;2;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY","7;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_SANTORSOLA",2005,258,7.97286821705426,3.14728682170543,0.60077519379845,0.410852713178295,0.612403100775194,1.63709677419355,1.3135593220339,1.35897435897436,1.28455284552846,0.25968992248062,14,128,52,22,39,0.5,0.2,0.09,0.15,48.84,0.922436151763111,NA,0.236434108527132,0.798449612403101,0.457,0.395,0.416,0.403,"ANTONIO DANIELE PINNA;GIAN LUCA GRAZI;GIUSEPPE BORIANI;GUALTIERO PALARETI;STEFANO FANTI;PIER LUIGI TAZZARI;PAOLA FORTI;GIOVANNI RAVAGLIA;GIORGIO ERCOLANI;MICHELE BACCARANI;ANGELO BRANZI;CRISTINA NANNI;MOHSEN FARSAD;MAURO BIFFI;GIOVANNI RAMACCIATO;ROBERTO FRANCHI;AUGUSTO LAURO;GIOVANNI MARTINELLI;MATTEO RAVAIOLI;MABEL MARTELLI","12;11;11;9;9;9;8;8;8;8;8;8;8;8;7;7;7;7;7;6","SERGIO SABBATANI;GUALTIERO PALARETI;CARLO CALABRESE;ELENA BIAGINI;BENILDE COSMI;PAOLO MURATORI;FRANCESCO CHIODO;G. COMPAGNONE;ANTONIO SANTORO;GIUSEPPE BORIANI;BRUNO CHIAPPINI;LUIGI GATTA;MAURO BIFFI;PIER LUIGI TAZZARI;GIAN LUCA GRAZI;ANTONIO DANIELE PINNA;UBERTO PAGOTTO;L. PAGAN;CARLO PACE NAPOLEONE;MARCO BORDERI","3.58;2.51;2;1.52;1.48;1.26;1.25;1.25;1.24;1.2;1.2;1.14;1.12;1.11;1.1;1.09;1.05;1;1;1","ANTONIO DANIELE PINNA;GIAN LUCA GRAZI;GIUSEPPE BORIANI;GUALTIERO PALARETI;STEFANO FANTI;PIER LUIGI TAZZARI;PAOLA FORTI;GIOVANNI RAVAGLIA;GIORGIO ERCOLANI;MICHELE BACCARANI;ANGELO BRANZI;CRISTINA NANNI;MOHSEN FARSAD;MAURO BIFFI;GIOVANNI RAMACCIATO;ROBERTO FRANCHI;AUGUSTO LAURO;GIOVANNI MARTINELLI;MATTEO RAVAIOLI;MABEL MARTELLI","12;11;11;9;9;9;8;8;8;8;8;8;8;8;7;7;7;7;7;6","SERGIO SABBATANI;GUALTIERO PALARETI;CARLO CALABRESE;ELENA BIAGINI;BENILDE COSMI;PAOLO MURATORI;FRANCESCO CHIODO;G. COMPAGNONE;ANTONIO SANTORO;GIUSEPPE BORIANI;BRUNO CHIAPPINI;LUIGI GATTA;MAURO BIFFI;PIER LUIGI TAZZARI;GIAN LUCA GRAZI;ANTONIO DANIELE PINNA;UBERTO PAGOTTO;L. PAGAN;CARLO PACE NAPOLEONE;MARCO BORDERI","3.58;2.51;2;1.52;1.48;1.26;1.25;1.25;1.24;1.2;1.2;1.14;1.12;1.11;1.1;1.09;1.05;1;1;1","ENRICA PERUGINI;MOHSEN FARSAD;GIOVANNI RAVAGLIA;PAOLA FORTI;LUCIA SERVADEI;CINZIA PETTINATO;FABIOLA MAIOLI;MABEL MARTELLI;NICOLETTA BRUNETTI;ANGELO BRANZI;ALICIA M. MACEIRA;DUDLEY J. PENNELL;IDRIS HARDING;JAMES MOON;JAYSHREE JOSHI;MARY N. SHEPPARD;PHILIP A. POOLE‐WILSON;PHILIP N. HAWKINS;SANJAY PRASAD;MARIA LETIZIA BACCHI REGGIANI","1762;1454;1208;1208;1158;1137;1136;1136;1108;983;924;924;924;924;924;924;924;924;924;906","MOHSEN FARSAD;GIOVANNI RAVAGLIA;PAOLA FORTI;ENRICA PERUGINI;ALICIA M. MACEIRA;DUDLEY J. PENNELL;IDRIS HARDING;JAMES MOON;JAYSHREE JOSHI;MARY N. SHEPPARD;PHILIP A. POOLE‐WILSON;PHILIP N. HAWKINS;SANJAY PRASAD;LUCIA SERVADEI;FABIOLA MAIOLI;MABEL MARTELLI;CINZIA PETTINATO;NICOLETTA BRUNETTI;ELISA PORCELLINI;FEDERICO LICASTRO","1297;1208;966;965;924;924;924;924;924;924;924;924;924;916;894;894;893;866;816;816","ANTONIO DANIELE PINNA;GIUSEPPE BORIANI;GIAN LUCA GRAZI;GIOVANNI RAVAGLIA;PIER LUIGI TAZZARI;GIORGIO ERCOLANI;GUALTIERO PALARETI;AUGUSTO LAURO;MATTEO RAVAIOLI;MAURO BIFFI;MASSIMO DEL GAUDIO;ANGELO BRANZI;ELENA BIAGINI;PAOLA FORTI;STEFANO FANTI;MICHELE BACCARANI;MOHSEN FARSAD;ANTONIO SANTORO;BENILDE COSMI;GIOVANNI RAMACCIATO","11;10;9;8;8;8;8;7;7;7;6;6;6;6;6;5;5;5;5;5","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;COMPUTER SCIENCE;PSYCHOLOGY;MATERIALS SCIENCE;ENGINEERING;MATHEMATICS;ECONOMICS;GEOGRAPHY;POLITICAL SCIENCE;SOCIOLOGY;ART;HISTORY;ENVIRONMENTAL SCIENCE;GEOLOGY","238;64;24;23;22;10;6;5;5;3;3;3;3;2;2;1;1","INTERNAL MEDICINE;SURGERY;PATHOLOGY;CARDIOLOGY;GASTROENTEROLOGY;IMMUNOLOGY;BIOCHEMISTRY;RADIOLOGY;GENETICS;ENDOCRINOLOGY;CANCER RESEARCH;ENVIRONMENTAL HEALTH;NUCLEAR MEDICINE;INTENSIVE CARE MEDICINE;ANESTHESIA;MOLECULAR BIOLOGY;PEDIATRICS;CELL BIOLOGY;VIROLOGY;OPTICS","181;62;55;47;44;44;35;31;27;23;18;18;16;14;12;12;12;11;11;10","DISEASE;TRANSPLANTATION;CANCER;GENE;ANTIBODY;CHEMOTHERAPY;BLOOD PRESSURE;IMMUNE SYSTEM;POPULATION;ALTERNATIVE MEDICINE;ANTIGEN;CONFIDENCE INTERVAL;RISK FACTOR;DIABETES MELLITUS;MYOCARDIAL INFARCTION;THROMBOSIS;HEART FAILURE;HORMONE;IN VITRO;MAGNETIC RESONANCE IMAGING;POSITRON EMISSION TOMOGRAPHY;PROSPECTIVE COHORT STUDY;RECEPTOR","38;23;22;20;15;15;13;13;13;11;10;10;10;9;9;9;8;8;8;8;8;8;8","LIVER TRANSPLANTATION;PLACEBO;ULCERATIVE COLITIS;DEMENTIA;HAZARD RATIO;PROSTATE;T CELL;EJECTION FRACTION;HAEMATOPOIESIS;HEART RATE;REFLUX;TACROLIMUS;VENOUS THROMBOEMBOLISM;ALLELE;AORTIC DISSECTION;AUTOANTIBODY;CD8;COLORECTAL CANCER;CROHN'S DISEASE;GENE EXPRESSION;HUMAN FACTORS AND ERGONOMICS;HYPERHOMOCYSTEINEMIA;INSULIN RESISTANCE;PI3K/AKT/MTOR PATHWAY;PROTEIN KINASE B;VENOUS THROMBOSIS;VIRAL DISEASE","11;8;7;6;6;6;6;5;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4;4;4;4","GERD;POLYCYSTIC OVARY;SINGLE-NUCLEOTIDE POLYMORPHISM;ACUTE PROMYELOCYTIC LEUKEMIA;ANTIRETROVIRAL THERAPY;ATRIAL TACHYCARDIA;AUTOPHOSPHORYLATION;BRADYCARDIA;CARDIAC RESYNCHRONIZATION THERAPY;CELL CYCLE CHECKPOINT;DNA MISMATCH REPAIR;ESOPHAGITIS;HERPESVIRIDAE;IMMUNOGLOBULIN A;INTRAEPITHELIAL NEOPLASIA;IONIZATION CHAMBER;JURKAT CELLS;NEOADJUVANT THERAPY;POUCHITIS;PROSTATE BIOPSY;RAPID UREASE TEST;RIBAVIRIN;THYMOGLOBULIN;VASCULAR DEMENTIA;WORTMANNIN","3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","HUMANS;FEMALE;MALE;MIDDLE AGED;ADULT;AGED;;ITALY;TREATMENT OUTCOME;ADOLESCENT;AGED, 80 AND OVER;RETROSPECTIVE STUDIES;FOLLOW-UP STUDIES;RISK FACTORS;LIVER TRANSPLANTATION;PROSPECTIVE STUDIES;CHILD;LIVER NEOPLASMS;POSTOPERATIVE COMPLICATIONS;VENOUS THROMBOSIS","210;139;131;121;100;89;42;38;35;32;32;31;29;28;24;24;23;22;22;22","ATRIAL FIBRILLATION;PREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM;ACUTE MYELOID LEUKEMIA;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;GENETICS AND TREATMENT OF INFLAMMATORY BOWEL DISEASE;DIAGNOSIS AND MANAGEMENT OF AORTIC DISEASES;LIVER TRANSPLANTATION AND GRAFT SURVIVAL ANALYSIS;ROLE OF HOMOCYSTEINE IN HEALTH AND DISEASE;ADVANCED CARDIAC IMAGING TECHNIQUES AND DIAGNOSTICS;CHRONIC KIDNEY DISEASE AND DIALYSIS TREATMENT;DIAGNOSIS AND MANAGEMENT OF GASTROESOPHAGEAL REFLUX DISEASE;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;DIAGNOSIS AND MANAGEMENT OF ALZHEIMER'S DISEASE;DIAGNOSIS AND MANAGEMENT OF CELIAC DISEASE;DIAGNOSIS AND MANAGEMENT OF PANCREATITIS;DIAGNOSIS AND MANAGEMENT OF POLYCYSTIC OVARY SYNDROME;HEALTH RISKS OF MEDICAL IMAGING RADIATION EXPOSURE;HELICOBACTER PYLORI INFECTION AND GASTRIC CANCER;HEPATITIS C INFECTION AND TREATMENT;KIDNEY TRANSPLANTATION","8;8;6;6;6;5;5;5;4;4;4;3;3;3;3;3;3;3;3;3","DIAGNOSIS;DEEP VEIN THROMBOSIS;TREATMENT;VENOUS THROMBOEMBOLISM;AORTIC DISSECTION;LIVER TRANSPLANTATION;ANTICOAGULANT THERAPY;CARDIAC IMAGING;CARDIAC RESYNCHRONIZATION THERAPY;ECHOCARDIOGRAPHY;PACEMAKER THERAPY;CARDIOVASCULAR RISK ASSESSMENT;D-DIMER;ETIOLOGY;HEPATITIS C;HYPERHOMOCYSTEINEMIA;LIVING DONOR LIVER TRANSPLANTATION;PET/CT;REGIMEN;TYPE B AORTIC DISSECTION","8;7;7;7;6;6;5;5;5;5;5;4;4;4;4;4;4;4;4;4","LIVER TRANSPLANTATION;RISK FACTORS;VENOUS THROMBOEMBOLISM;AORTIC DISSECTION;CARDIOVASCULAR RISK;COGNITIVE IMPAIRMENT;ACUTE AORTIC;AUTOMATIC CAPTURE;AUTOMATIC THRESHOLD;BOWEL TRANSPLANTATION;CLINICAL PERFORMANCE;COLORECTAL CANCER;CORONARY ARTERY;CROHNS DISEASE;GROWTH FACTOR;HEPATOCELLULAR CARCINOMA;MAGNETIC RESONANCE;MILD COGNITIVE;MONONUCLEAR CELLS;OVARY SYNDROME;PERIPHERAL BLOOD;POLYCYSTIC OVARY;PRELIMINARY RESULTS;RISK FACTOR;STRESS ECHOCARDIOGRAPHY;THYROID CARCINOMA;VENTRICULAR AUTOMATIC;X-RAY EXAMINATIONS;ABDOMINAL OBESITY;ACUTE MYELOID","9;7;5;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;2;2","PUBMED SCOPUS;CROSSREF PUBMED;RISK FACTORS;IMMUNOL -CROSSREF;DNA BINDING;REV IMMUNOL;RISK FACTOR;ANNU REV;GENE EXPRESSION;IKKΑ-- MEFS;LIVER TRANSPLANTATION;MATHEMATICAL MODEL;MOL CELL;MYOCARDIAL INFARCTION;WT IKKΑ;CARDIAC DEATH;NATURE -CROSSREF;NF-ΚB ACTIVATION;NF-ΚB-DEPENDENT GENES;CANONICAL NF-ΚB;CELL -ABSTRACT;CONFIDENCE INTERVAL;GAYNOR RB;IMMUNOL -ABSTRACT;KINASE ACTIVITY;MARCU KB;NUCLEAR LOCALIZATION;TRENDS IMMUNOL;TRIPLE THERAPY;TYPE AIH","72;42;26;16;11;11;11;10;9;9;9;9;9;9;9;8;8;8;8;7;7;7;7;7;7;7;7;7;7;7",31,0.12,6,4,0,1.75,0,0,2,0,1,4,0,0,5,0,2,1,0,5.25,1,0,0,61.5,61.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,20,4.7,351.4,4.57,2,0.1,11.05,0,0,2,0,13,0,2,3,0,7,3,0,0,0,0,0,0,17,3,0,10,10,0,0,0,0,0,0,0,0,"Italy;United States","4;3","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;30 AGRICULTURAL, VETERINARY AND FOOD SCIENCES;3009 VETERINARY SCIENCES;3207 MEDICAL MICROBIOLOGY;3211 ONCOLOGY AND CARCINOGENESIS;3213 PAEDIATRICS;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;44 HUMAN SOCIETY;4405 GENDER STUDIES","19;9;5;1;1;1;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;LUNG;RARE DISEASES;PEDIATRIC;HEMATOLOGY;AGING;AUTOIMMUNE DISEASE;BIOMEDICAL IMAGING;BRAIN DISORDERS;CANCER;CHRONIC LIVER DISEASE AND CIRRHOSIS;CONTRACEPTION/REPRODUCTION;DIGESTIVE DISEASES;EMERGING INFECTIOUS DISEASES;HEPATITIS;HEPATITIS - C;INFANT MORTALITY;INFECTIOUS DISEASES;LIVER DISEASE","12;4;4;4;3;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CARDIOVASCULAR;CANCER;INFECTION;RESPIRATORY;NEUROLOGICAL;ORAL AND GASTROINTESTINAL;REPRODUCTIVE HEALTH AND CHILDBIRTH","5;3;2;2;1;1;1","6.1 PHARMACEUTICALS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS;6.3 MEDICAL DEVICES;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES","6;1;1;1;1","LIVER CANCER;STOMACH CANCER;COLON AND RECTAL CANCER;MYELOMA","3;2;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;2.1 EXOGENOUS FACTORS IN THE ORIGIN AND CAUSE OF CANCER;5.5 COMBINATIONS OF LOCALIZED AND SYSTEMIC THERAPIES","4;2;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_SANTORSOLA",2006,320,8.490625,4.259375,0.66875,0.490625,0.85,1.9036312849162,1.43624161073825,1.70652173913043,1.51111111111111,0.296875,16,169,55,31,45,0.53,0.17,0.1,0.14,57.55,1.12676478241891,NA,0.234375,0.790625,0.49,0.438,0.455,0.467,"STEFANO FANTI;CRISTINA NANNI;MICHELE BACCARANI;MOHSEN FARSAD;PAOLO CASTELLUCCI;ANTONIO DANIELE PINNA;ROBERTO FRANCHI;GIAN LUCA GRAZI;VALENTINA AMBROSINI;DOMENICO RUBELLO;GIORGIO ERCOLANI;ANDREA MARTONI;ANGELO BRANZI;DONATELLA SANTINI;PASQUALE CHIECO;RAFFAELE PEZZILLI;MARCO LENZI;ALESSANDRO GRANITO;UBERTO PAGOTTO;AUGUSTO LAURO","29;20;19;19;18;15;14;13;13;11;10;10;10;10;9;9;8;8;8;8","SERGIO SABBATANI;STEFANO FANTI;NULL AUTHOR_ID;ANTONELLA MARANGONI;RAFFAELE PEZZILLI;CLAUDIO BORGHI;GIAN LUCA GRAZI;CRISTINA NANNI;MOHSEN FARSAD;PAOLO CASTELLUCCI;LORENZO FANTINI;ANTONIO DANIELE PINNA;ANTONIO SANTORO;ROBERTO FRANCHI;MICHELE BACCARANI;LIBERO BAROZZI;ANDREA MARTONI;ROBERTO DI BARTOLOMEO;VALENTINA AMBROSINI;DONATELLA SANTINI","3.33;3.03;3;2.45;2.24;2.08;2.04;2.02;1.85;1.72;1.62;1.6;1.57;1.49;1.46;1.46;1.43;1.35;1.32;1.31","STEFANO FANTI;CRISTINA NANNI;MICHELE BACCARANI;MOHSEN FARSAD;PAOLO CASTELLUCCI;ANTONIO DANIELE PINNA;ROBERTO FRANCHI;GIAN LUCA GRAZI;VALENTINA AMBROSINI;GIORGIO ERCOLANI;ANDREA MARTONI;ANGELO BRANZI;DONATELLA SANTINI;PASQUALE CHIECO;RAFFAELE PEZZILLI;MARCO LENZI;ALESSANDRO GRANITO;UBERTO PAGOTTO;AUGUSTO LAURO;GIOVANNI MARTINELLI","29;20;19;19;18;15;14;13;13;10;10;10;10;9;9;8;8;8;8;8","SERGIO SABBATANI;STEFANO FANTI;NULL AUTHOR_ID;ANTONELLA MARANGONI;RAFFAELE PEZZILLI;CLAUDIO BORGHI;GIAN LUCA GRAZI;CRISTINA NANNI;MOHSEN FARSAD;PAOLO CASTELLUCCI;LORENZO FANTINI;ANTONIO DANIELE PINNA;ANTONIO SANTORO;ROBERTO FRANCHI;MICHELE BACCARANI;LIBERO BAROZZI;ANDREA MARTONI;ROBERTO DI BARTOLOMEO;VALENTINA AMBROSINI;DONATELLA SANTINI","3.33;3.03;3;2.45;2.24;2.08;2.04;2.02;1.85;1.72;1.62;1.6;1.57;1.49;1.46;1.46;1.43;1.35;1.32;1.31","MICHELE BACCARANI;HAGOP M. KANTARJIAN;ANDREAS HOCHHAUS;BRIAN J. DRUKER;FRANCISCO CERVANTES;RICHARD M. STONE;RICHARD T. SILVER;TIMOTHY P. HUGHES;RICHARD A. LARSON;NORBERT GATTERMANN;GIUSEPPE SAGLIO;ALOÏS GRATWOHL;BAYARD L. POWELL;BENGT SIMONSSON;CHARLENE SO;FRANÇOIS GUILHOT;GREGOR VERHOEF;HERMINE AGIS;INSA GATHMANN;JAN J. CORNELISSEN","4815;4054;4043;4034;4034;4034;4034;4034;3440;3429;3424;3420;3420;3420;3420;3420;3420;3420;3420;3420","MICHELE BACCARANI;UBERTO PAGOTTO;RENATO PASQUALI;A. GADDI;SIMONA NASCETTI;CRISTINA CERVINO;ANTONIO DANIELE PINNA;CRISTINA LEGNANI;H. KIESEWETTER;HANS BÄUMLER;HANS‐JOACHIM F. ZUNFT;HENRIK E. POULSEN;JAAKKO MURSU;JARI KAIKKONEN;JAUME MARRUGAT;JUKKA T. SALONEN;JYRKI K. VIRTANEN;KRISTIINA NYYSSÖNEN;MARÍA‐ISABEL COVAS;MONTSERRAT FITÓ","4644;1505;1112;883;883;828;768;723;716;716;716;716;716;716;716;716;716;716;716;716","STEFANO FANTI;CRISTINA NANNI;MOHSEN FARSAD;ANTONIO DANIELE PINNA;PAOLO CASTELLUCCI;MICHELE BACCARANI;VALENTINA AMBROSINI;ROBERTO FRANCHI;GIAN LUCA GRAZI;ALESSANDRO GRANITO;ANDREA MARTONI;AUGUSTO LAURO;GIOVANNI MARTINELLI;PASQUALE CHIECO;UBERTO PAGOTTO;GIORGIO ERCOLANI;GIUSEPPE BORIANI;M. GUIDI;MATTEO RAVAIOLI;MARCO LENZI","26;18;16;15;15;15;13;11;9;8;8;8;8;8;8;7;7;7;7;7","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;COMPUTER SCIENCE;MATHEMATICS;POLITICAL SCIENCE;PHILOSOPHY;ENGINEERING;MATERIALS SCIENCE;ECONOMICS;HISTORY;SOCIOLOGY;GEOGRAPHY;PSYCHOLOGY;ART;BUSINESS;ENVIRONMENTAL SCIENCE;GEOLOGY","290;117;36;20;16;11;10;9;7;6;5;4;4;3;3;2;1;1;1","INTERNAL MEDICINE;SURGERY;GASTROENTEROLOGY;PATHOLOGY;IMMUNOLOGY;GENETICS;RADIOLOGY;BIOCHEMISTRY;CARDIOLOGY;NUCLEAR MEDICINE;ENDOCRINOLOGY;ONCOLOGY;ENVIRONMENTAL HEALTH;CELL BIOLOGY;CANCER RESEARCH;INTENSIVE CARE MEDICINE;PALEONTOLOGY;PEDIATRICS;PSYCHIATRY;MICROBIOLOGY;MOLECULAR BIOLOGY","214;82;71;56;50;46;46;44;42;35;28;28;27;24;22;21;20;17;15;11;11","CANCER;GENE;DISEASE;TRANSPLANTATION;CHEMOTHERAPY;POPULATION;POSITRON EMISSION TOMOGRAPHY;ANTIBODY;HEART FAILURE;HORMONE;MYELOID LEUKEMIA;RECEPTOR;STAGE (STRATIGRAPHY);ADVERSE EFFECT;CIRRHOSIS;ALTERNATIVE MEDICINE;HEPATOCELLULAR CARCINOMA;IN VITRO;BLOOD PRESSURE;PREGNANCY;RANDOMIZED CONTROLLED TRIAL","48;37;35;30;26;23;20;19;14;13;13;12;12;11;11;10;10;10;9;9;9","LIVER TRANSPLANTATION;COLORECTAL CANCER;BREAST CANCER;IMATINIB;AUTOANTIBODY;MUTATION;EJECTION FRACTION;CARDIOMYOPATHY;HEPATOCYTE;PET-CT;PLACEBO;REFLUX;AUTOIMMUNE HEPATITIS;CHROMOSOMAL TRANSLOCATION;FETUS;HEART TRANSPLANTATION;HEPATITIS C VIRUS;INSULIN RESISTANCE;PHASES OF CLINICAL RESEARCH;PROGRESSIVE DISEASE;PROSTATE CANCER;THYROID CARCINOMA","18;12;11;10;8;8;7;6;6;6;6;6;5;5;5;5;5;5;5;5;5;5","IMATINIB MESYLATE;IRINOTECAN;GASTRO-;GERD;PHILADELPHIA CHROMOSOME;CARDIAC RESYNCHRONIZATION THERAPY;CETUXIMAB;CITRULLINE;CROSSOVER STUDY;MODEL FOR END-STAGE LIVER DISEASE;NEOADJUVANT THERAPY;NILOTINIB;ORTHOTOPIC LIVER TRANSPLANTATION;OXALIPLATIN;PRIMARY TUMOR;TAMOXIFEN;ADIPONECTIN;ANDROGEN RECEPTOR;ANTI-NUCLEAR ANTIBODY;ANTIRETROVIRAL THERAPY;ASIALOGLYCOPROTEIN RECEPTOR;BIOARTIFICIAL LIVER DEVICE;CAPECITABINE;CARBOPLATIN;CORONAVIRUS DISEASE 2019 (COVID-19);CYTOGENETICS;FERTILITY PRESERVATION;FMS-LIKE TYROSINE KINASE 3;FOCUSED ASSESSMENT WITH SONOGRAPHY FOR TRAUMA;HORMONAL THERAPY;HYPERINSULINEMIA;IIF;INTERRUPTED AORTIC ARCH;KARYOTYPE;LEFT VENTRICULAR NONCOMPACTION;LEVOMEPROMAZINE;MACE;METASTATIC BREAST CANCER;MUCOSA-ASSOCIATED LYMPHOID TISSUE;PAPILLARY THYROID CANCER;PARATHYROIDECTOMY;PLACENTA;POLYCYSTIC OVARY;PROCESSIVITY;RADIOIMMUNOTHERAPY;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;THYMOGLOBULIN;TRANSACTIVATION;TRASTUZUMAB","10;5;4;4;4;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","HUMANS;FEMALE;MALE;ADULT;MIDDLE AGED;;AGED;TREATMENT OUTCOME;ANIMALS;CARCINOMA, HEPATOCELLULAR;LIVER NEOPLASMS;AGED, 80 AND OVER;ADOLESCENT;ITALY;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;LIVER TRANSPLANTATION;LIVER CIRRHOSIS;LIVER DISEASES;TOMOGRAPHY, X-RAY COMPUTED;PROSPECTIVE STUDIES","216;136;133;104;93;87;74;41;31;30;30;29;28;28;27;26;22;22;22;21","POSITRON EMISSION TOMOGRAPHY IMAGING IN ONCOLOGY;DIAGNOSIS AND MANAGEMENT OF LIVER DISEASES;EFFICACY AND RESISTANCE IN CML TREATMENT;LIVER CIRRHOSIS AND ASSOCIATED COMPLICATIONS;LIVER TRANSPLANTATION AND GRAFT SURVIVAL ANALYSIS;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;ORGAN TRANSPLANTATION AND REJECTION;DIAGNOSIS AND MANAGEMENT OF PANCREATITIS;HEPATOCELLULAR CARCINOMA;LYMPHOID NEOPLASMS;DIAGNOSIS AND MANAGEMENT OF AORTIC DISEASES;DIAGNOSIS AND MANAGEMENT OF GASTROESOPHAGEAL REFLUX DISEASE;DIAGNOSIS AND MANAGEMENT OF HYPERTROPHIC CARDIOMYOPATHY;EPIDEMIOLOGY AND MANAGEMENT OF CONGENITAL HEART DISEASE;EPIDEMIOLOGY AND MANAGEMENT OF NEUROENDOCRINE TUMORS;PROVISION AND ASSESSMENT OF NUTRITION SUPPORT THERAPY;ACUTE MYELOID LEUKEMIA;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA","11;9;9;9;7;6;6;5;5;5;4;4;4;4;4;4;3;3;3;3","PET/CT;IMATINIB MESYLATE;LIVER TRANSPLANTATION;TRANSPLANTATION;CARDIAC IMAGING;IMATINIB;CANCER IMAGING;PET IMAGING;PET-CT;ACUTE PANCREATITIS;AUTOIMMUNE HEPATITIS;ETIOLOGY;LIVER BIOPSY;LIVER CANCER;LIVER CIRRHOSIS;LIVER DISEASE;LIVING DONOR LIVER TRANSPLANTATION;REGIMEN;TREATMENT;AORTIC ROOT REPLACEMENT","11;10;10;8;7;7;6;6;6;5;5;5;5;5;5;5;5;5;5;4","LIVER TRANSPLANTATION;PHASE II;BREAST CANCER;CANCER PATIENTS;LIVER FAILURE;MYELOID LEUKEMIA;HEPATOCELLULAR CARCINOMA;II STUDY;PROSTATE CANCER;ANIMAL PET;CHRONIC MYELOID;CHRONIC PHASE;LEFT VENTRICULAR;NEOADJUVANT CHEMOTHERAPY;ACUTE LIVER;ACUTE PANCREATITIS;AUTOIMMUNE HEPATITIS;BILIARY CIRRHOSIS;C-CHOLINE PETCT;CLINICAL PRACTICE;CORONARY ARTERY;DIAGNOSTIC ACCURACY;END-STAGE LIVER;F-FDG PET;F-FDG PETCT;FOLCETUX STUDY;GASTRO-OESOPHAGEAL REFLUX;GASTROESOPHAGEAL JUNCTION;HEART TRANSPLANT;INTERVENTIONAL RADIOLOGY","9;8;7;7;6;6;5;5;5;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3","PUBMED SCOPUS;CROSSREF PUBMED;ABDOMINAL AORTA;CORONARY ARTERY;NPHS PROMOTER;VKA WITHDRAWAL;NEPHROTIC SYNDROME;ARTERY CALCIUM;CONFIDENCE INTERVAL;KUPFFER CELLS;END-STAGE RENAL;HEMODIALYSIS PATIENTS;CIRRHOTIC PATIENTS;IGA NEPHROPATHY;KIDNEY DIS;LIVER DISEASE;LIVER TRANSPLANTATION;NEGATIVE PREDICTIVE;NEPHROL -CROSSREF;BONE MARROW;CELL DEBRIS;COMPUTED TOMOGRAPHY;DIS -ABSTRACT;ODDS RATIO;RENAL DISEASE;RISK FACTOR;RISK FACTORS;STATISTICALLY SIGNIFICANT;VENOUS THROMBOEMBOLISM;ABNORMAL DD","79;47;22;18;18;18;16;14;12;12;11;11;10;10;10;10;10;10;10;9;9;9;9;9;9;9;9;9;9;8",48,0.15,6,4,2,2,1,20.5,3.5,0,2,4.25,1,1,12.5,1,4,1,2.5,9.5,2,0,0,77.25,77.25,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,44,3.57,400.68,6.73,0,0,20.86,1,0,14,2,14,0,9,4,0,17,2,0,0,0,0,0,0,39,5,0,17,25,0,2,0,0,0,0,0,0,"Italy;Germany;United States;Switzerland","6;2;2;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;31 BIOLOGICAL SCIENCES;3204 IMMUNOLOGY;3212 OPHTHALMOLOGY AND OPTOMETRY;35 COMMERCE, MANAGEMENT, TOURISM AND SERVICES;3505 HUMAN RESOURCES AND INDUSTRIAL RELATIONS;42 HEALTH SCIENCES;3101 BIOCHEMISTRY AND CELL BIOLOGY;3103 ECOLOGY;3207 MEDICAL MICROBIOLOGY;3213 PAEDIATRICS;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;3215 REPRODUCTIVE MEDICINE;33 BUILT ENVIRONMENT AND DESIGN;4203 HEALTH SERVICES AND SYSTEMS;4204 MIDWIFERY;43 HISTORY, HERITAGE AND ARCHAEOLOGY","38;16;14;10;4;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;RARE DISEASES;HEMATOLOGY;DIGESTIVE DISEASES;LYMPHOMA;KIDNEY DISEASE;NUTRITION;STEM CELL RESEARCH;AUTOIMMUNE DISEASE;CARDIOVASCULAR;INFLAMMATORY BOWEL DISEASE;LIVER DISEASE;PATIENT SAFETY;PREVENTION;STEM CELL RESEARCH - NONEMBRYONIC - HUMAN;TRANSPLANTATION;BIOMEDICAL IMAGING;CHILDHOOD LEUKEMIA","17;14;11;10;7;5;5;3;3;3;2;2;2;2;2;2;2;2;1;1","CANCER;CARDIOVASCULAR;RENAL AND UROGENITAL;ORAL AND GASTROINTESTINAL;BLOOD;INFECTION;INFLAMMATORY AND IMMUNE SYSTEM;METABOLIC AND ENDOCRINE","15;5;3;2;1;1;1;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS;6.3 MEDICAL DEVICES;6.4 SURGERY","20;9;2;1;1;1;1","NON-HODGKIN'S LYMPHOMA;COLON AND RECTAL CANCER;MYELOMA;STOMACH CANCER;LEUKEMIA / LEUKAEMIA;NERVOUS SYSTEM;OVARIAN CANCER;BREAST CANCER;GASTROINTESTINAL TRACT;HODGKIN'S DISEASE;KIDNEY CANCER;LIVER CANCER;MELANOMA;NEUROBLASTOMA;PANCREATIC CANCER;THYROID CANCER","8;3;3;3;2;2;2;1;1;1;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;1.4 CANCER PROGRESSION AND METASTASIS;3.2 NUTRITIONAL SCIENCE IN CANCER PREVENTION;4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY;4.2 TECHNOLOGY AND/OR MARKER EVALUATION WITH RESPECT TO FUNDAMENTAL PARAMETERS OF METHOD;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","10;2;1;1;1;1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_SANTORSOLA",2007,311,9.42122186495177,4.11575562700964,0.581993569131833,0.430868167202572,0.64951768488746,1.61548223350254,1.25874125874126,1.47777777777778,1.27215189873418,0.347266881028939,10,150,83,35,24,0.48,0.27,0.11,0.08,48.71,0.922969139279166,NA,0.308681672025723,0.778135048231511,0.535,0.435,0.451,0.425,"MICHELE BACCARANI;STEFANO FANTI;ANTONIO DANIELE PINNA;CRISTINA NANNI;ANDREA MARTONI;GIOVANNI MARTINELLI;RAFFAELE PEZZILLI;GIAN LUCA GRAZI;ANGELO BRANZI;MATTEO RAVAIOLI;DONATELLA SANTINI;ROBERTO DI BARTOLOMEO;PIER LUIGI TAZZARI;DOMENICO RUBELLO;AUGUSTO LAURO;CLAUDIO CECCARELLI;GIUSEPPE BORIANI;PAOLO CASTELLUCCI;EMANUELA OTTAVIANI;ALBERTO M. MARTELLI","17;16;15;14;13;13;12;11;11;11;10;9;9;9;8;8;8;7;7;7","RAFFAELE PEZZILLI;ROBERTO MANFREDI;GIAN LUCA GRAZI;STEFANO FANTI;GUALTIERO PALARETI;CRISTINA NANNI;ANDREA MARTONI;DOMENICO CUCINOTTA;MICHELE BACCARANI;ANGELO BRANZI;DONATELLA SANTINI;LORENZO FANTINI;ANTONIO DANIELE PINNA;ROBERTO DI BARTOLOMEO;DOMENICO RUBELLO;ELENA MANCINI;EMILIANO SPEZI;ANDREA DELL’AMORE;LUCA BOTTA;ANDREA FERRI","2.15;2;1.82;1.79;1.73;1.62;1.59;1.45;1.41;1.37;1.36;1.31;1.3;1.22;1.21;1.17;1.12;1.12;1.12;1.03","MICHELE BACCARANI;STEFANO FANTI;ANTONIO DANIELE PINNA;CRISTINA NANNI;ANDREA MARTONI;GIOVANNI MARTINELLI;RAFFAELE PEZZILLI;GIAN LUCA GRAZI;ANGELO BRANZI;MATTEO RAVAIOLI;DONATELLA SANTINI;ROBERTO DI BARTOLOMEO;PIER LUIGI TAZZARI;AUGUSTO LAURO;CLAUDIO CECCARELLI;GIUSEPPE BORIANI;PAOLO CASTELLUCCI;EMANUELA OTTAVIANI;CARMINE PINTO;LORENZO FANTINI","17;16;15;14;13;13;12;11;11;11;10;9;9;8;8;8;7;7;7;7","RAFFAELE PEZZILLI;ROBERTO MANFREDI;GIAN LUCA GRAZI;STEFANO FANTI;GUALTIERO PALARETI;CRISTINA NANNI;ANDREA MARTONI;DOMENICO CUCINOTTA;MICHELE BACCARANI;ANGELO BRANZI;DONATELLA SANTINI;LORENZO FANTINI;ANTONIO DANIELE PINNA;ROBERTO DI BARTOLOMEO;ELENA MANCINI;EMILIANO SPEZI;ANDREA DELL’AMORE;LUCA BOTTA;ANDREA FERRI;GIOVANNI MARTINELLI","2.15;2;1.82;1.79;1.73;1.62;1.59;1.45;1.41;1.37;1.36;1.31;1.3;1.22;1.17;1.12;1.12;1.12;1.03;1.03","MICHELE BACCARANI;DONATELLA SANTINI;CLAUDIO CECCARELLI;MASSIMILIANO BONAFÉ;CRISTINA NANNI;HAGOP M. KANTARJIAN;STEFANO FANTI;PASQUALE CHIECO;ANDREAS HOCHHAUS;GIANLUCA STORCI;PHILIPP LE COUTRE;FRANCIS J. GILES;NORBERT GATTERMANN;STEPHEN G. O’BRIEN;YAPING SHOU;SIMONA TAVOLARI;TIZIANA GUARNIERI;KENNETH B. MARCU;GIOVANNI MARTINELLI;MARIO TAFFURELLI","1734;1339;1186;1157;1086;1079;1076;1066;1063;1062;1054;1038;1038;1038;1038;1009;1009;999;950;945","CLAUDIO CECCARELLI;MASSIMILIANO BONAFÉ;PASQUALE CHIECO;GIANLUCA STORCI;KENNETH B. MARCU;MICHELE BACCARANI;FRANCESCA PALANDRI;CATIA GIOVANNINI;CESARE ROSSI;PIER PAOLO PICCALUGA;GIOVANNI MARTINELLI;ROSSELLA FATTORI;ANDREA MARTONI;LAURA MAZZANTI;PIER LUIGI TAZZARI;DONATELLA SANTINI;RAFFAELE PEZZILLI;CRISTINA NANNI;STEFANO FANTI;ELENA ZAMAGNI","1186;1136;1066;1062;999;983;927;859;797;759;749;708;668;657;589;585;539;523;513;451","ANTONIO DANIELE PINNA;ANDREA MARTONI;MICHELE BACCARANI;STEFANO FANTI;DONATELLA SANTINI;GIAN LUCA GRAZI;RAFFAELE PEZZILLI;PIER LUIGI TAZZARI;GIOVANNI MARTINELLI;ANGELO BRANZI;CRISTINA NANNI;ROBERTO DI BARTOLOMEO;AUGUSTO LAURO;CLAUDIO CECCARELLI;MATTEO RAVAIOLI;LUCA BOTTA;GIUSEPPE BORIANI;LUIGI BOLONDI;ORNELLA LEONE;CARMINE PINTO","15;13;12;10;9;9;9;9;9;8;8;8;8;8;8;6;6;6;6;6","MEDICINE;BIOLOGY;PHYSICS;CHEMISTRY;COMPUTER SCIENCE;ENGINEERING;MATHEMATICS;PSYCHOLOGY;MATERIALS SCIENCE;ECONOMICS;POLITICAL SCIENCE;PHILOSOPHY;SOCIOLOGY;ART;BUSINESS;ENVIRONMENTAL SCIENCE;GEOGRAPHY;GEOLOGY;HISTORY","278;104;31;28;21;12;12;12;8;6;5;3;2;1;1;1;1;1;1","INTERNAL MEDICINE;SURGERY;GASTROENTEROLOGY;CARDIOLOGY;GENETICS;PATHOLOGY;RADIOLOGY;IMMUNOLOGY;BIOCHEMISTRY;CANCER RESEARCH;ENDOCRINOLOGY;ONCOLOGY;ENVIRONMENTAL HEALTH;NUCLEAR MEDICINE;CELL BIOLOGY;INTENSIVE CARE MEDICINE;PHARMACOLOGY;PSYCHIATRY;OPTICS;ANESTHESIA;PALEONTOLOGY","203;79;64;52;50;49;46;40;34;30;23;22;21;21;20;20;20;18;16;15;15","CANCER;GENE;DISEASE;TRANSPLANTATION;CHEMOTHERAPY;POPULATION;BLOOD PRESSURE;MYELOID LEUKEMIA;HEART FAILURE;ANTIBODY;POSITRON EMISSION TOMOGRAPHY;IMMUNE SYSTEM;RADIATION THERAPY;RECEPTOR;STEM CELL;AORTA;BIOPSY;INCIDENCE (GEOMETRY);ALTERNATIVE MEDICINE;LEUKEMIA;PANCREATITIS;SIGNAL TRANSDUCTION;STAGE (STRATIGRAPHY)","44;38;36;29;23;20;19;17;14;13;12;11;11;11;11;10;10;10;9;9;9;9;9","COLORECTAL CANCER;IMATINIB;LIVER TRANSPLANTATION;MUTATION;BREAST CANCER;REFLUX;GENE EXPRESSION;GENOTYPE;T CELL;ADENOCARCINOMA;CHROMOSOMAL TRANSLOCATION;DEMENTIA;METASTASIS;NEUTROPENIA;PLACEBO;AORTIC DISSECTION;CARDIOMYOPATHY;DIASTOLE;GEMCITABINE;HEART TRANSPLANTATION;PHENOTYPE;PI3K/AKT/MTOR PATHWAY;PROTEIN KINASE B;TYROSINE KINASE","14;12;10;10;9;9;8;8;8;6;6;6;6;6;6;5;5;5;5;5;5;5;5;5","IMATINIB MESYLATE;DASATINIB;GERD;MISSENSE MUTATION;PHILADELPHIA CHROMOSOME;BRADYCARDIA;NILOTINIB;OXALIPLATIN;CARBOPLATIN;CARDIAC RESYNCHRONIZATION THERAPY;GASTRO-;VASCULAR DEMENTIA;ABL;ANTI-NUCLEAR ANTIBODY;BRUTON'S TYROSINE KINASE;CALPROTECTIN;CAPECITABINE;CETUXIMAB;COGNITIVE DECLINE;COLPOSCOPY;CROSSOVER STUDY;EXCESSIVE DAYTIME SLEEPINESS;FRAMESHIFT MUTATION;GERMLINE MUTATION;IL-2 RECEPTOR;INDOLEAMINE 2,3-DIOXYGENASE;INSULIN-LIKE GROWTH FACTOR;IRINOTECAN;MODEL FOR END-STAGE LIVER DISEASE;NEOADJUVANT THERAPY;PENETRANCE;POLYCYSTIC OVARY;PORTOSYSTEMIC SHUNT;SINGLE-NUCLEOTIDE POLYMORPHISM;TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT;TUMOR SUPPRESSOR GENE;VANCOMYCIN","10;7;6;6;5;4;4;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","HUMANS;FEMALE;MALE;;MIDDLE AGED;ADULT;AGED;TREATMENT OUTCOME;ANIMALS;AGED, 80 AND OVER;ITALY;RENAL DIALYSIS;FOLLOW-UP STUDIES;BONE NEOPLASMS;PROSPECTIVE STUDIES;POSITRON-EMISSION TOMOGRAPHY;ANTINEOPLASTIC AGENTS;KIDNEY FAILURE, CHRONIC;TOMOGRAPHY, X-RAY COMPUTED;BREAST NEOPLASMS","201;147;136;93;92;82;76;46;28;26;26;25;24;23;23;22;21;21;21;20","DIAGNOSIS AND MANAGEMENT OF GASTROESOPHAGEAL REFLUX DISEASE;EFFICACY AND RESISTANCE IN CML TREATMENT;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;POSITRON EMISSION TOMOGRAPHY IMAGING IN ONCOLOGY;DIAGNOSIS AND MANAGEMENT OF AORTIC DISEASES;DIAGNOSIS AND MANAGEMENT OF PANCREATITIS;HEPATOCELLULAR CARCINOMA;LIVER CIRRHOSIS AND ASSOCIATED COMPLICATIONS;PROVISION AND ASSESSMENT OF NUTRITION SUPPORT THERAPY;ATRIAL FIBRILLATION;GENETICS AND TREATMENT OF INFLAMMATORY BOWEL DISEASE;HEPATITIS B INFECTION AND TREATMENT;PANCREATIC CANCER RESEARCH AND TREATMENT;SCHIZOPHRENIA RESEARCH AND TREATMENT;CANCER STEM CELLS AND TUMOR METASTASIS;DIAGNOSIS AND MANAGEMENT OF CARDIAC TUMORS;DIAGNOSIS AND MANAGEMENT OF HYPERTROPHIC CARDIOMYOPATHY;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;DUAL-ENERGY COMPUTED TOMOGRAPHY;EPIDEMIOLOGY AND MANAGEMENT OF CONGENITAL HEART DISEASE","10;9;7;6;5;5;5;5;5;4;4;4;4;4;3;3;3;3;3;3","IMATINIB MESYLATE;LIVER TRANSPLANTATION;GASTROESOPHAGEAL REFLUX DISEASE;IMATINIB;PET/CT;TREATMENT;CANCER IMAGING;LIVER DISEASE;LIVING DONOR LIVER TRANSPLANTATION;PET IMAGING;ANEURYSM SCREENING;DASATINIB;IMAGING;LIVER BIOPSY;PHILADELPHIA CHROMOSOME;AORTIC DISSECTION;AORTIC ROOT REPLACEMENT;CANCER CELL METABOLISM;CARDIAC IMAGING;CARDIAC RESYNCHRONIZATION THERAPY","11;10;8;7;7;7;6;6;6;6;5;5;5;5;5;4;4;4;4;4","MYELOGENOUS LEUKEMIA;ATRIAL FIBRILLATION;CORONARY ARTERY;GENE EXPRESSION;LIVER TRANSPLANTATION;CHRONIC MYELOGENOUS;LEUKEMIA CELLS;MYELOID LEUKEMIA;ACUTE LYMPHOBLASTIC;CANCER PATIENTS;CELL CYCLE;FOLLOW-UP DATA;HEART TRANSPLANTATION;HEPATOCELLULAR CARCINOMA;IMATINIB -YEAR;KINASE INHIBITOR;LIVER DISEASE;MULTIPLE MYELOMA;PRELIMINARY RESULTS;ACUTE MYELOGENOUS;ACUTE MYELOID;AKT INHIBITOR;BREAST CANCER;BREAST CARCINOMA;DE NOVO;EXPRESSION PROFILE;F-FDG PETCT;GASTRO-OESOPHAGEAL REFLUX;GROWTH FACTOR-I;HEART FAILURE","8;6;6;6;6;5;5;5;4;4;4;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3","PUBMED SCOPUS;CROSSREF PUBMED;IBD PATIENTS;DEGLI STUDI;DIPARTIMENTO DI;STUDI DI;UNIVERSITÀ DEGLI;BOLOGNA ITALYSEARCH;DI BOLOGNA;BOLOGNA BOLOGNA;ORTHOGONAL PLANES;FETAL BRAIN;INFLAMMATORY BOWEL;CORONARY ARTERY;CORPUS CALLOSUM;CEREBELLAR VERMIS;RS RS;UO DI;BLOOD PRESSURE;ULTRASOUND EXAMINATION;VENA CAVA;C-REACTIVE PROTEIN;CARDIOANGIOLOGIA ED;DI MEDICINA;ED EPATOLOGIA;ELEPHANT TRUNK;EPATOLOGIA UNIVERSITÀ;GENETICA MEDICA;INTERNA CARDIOANGIOLOGIA;MEDICA DIPARTIMENTO","44;31;23;22;22;22;22;18;18;16;16;14;14;13;13;12;12;12;11;11;11;10;10;10;10;10;10;10;10;10",62,0.2,6,5,5,1,0,1,7,1,1,5.75,0,1,2,1.75,3.25,0,1.5,2,1,0,0,76.25,83.75,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,39,6,721.43,5.53,7,0.18,32.62,0,1,12,0,9,0,12,5,0,18,3,0,0,0,0,0,0,36,3,0,19,18,0,2,0,0,0,0,0,0,"Italy;United States;Germany;France;Japan;United Kingdom","5;4;2;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;42 HEALTH SCIENCES;31 BIOLOGICAL SCIENCES;40 ENGINEERING;3107 MICROBIOLOGY;4003 BIOMEDICAL ENGINEERING;3103 ECOLOGY;3207 MEDICAL MICROBIOLOGY;3212 OPHTHALMOLOGY AND OPTOMETRY;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;3215 REPRODUCTIVE MEDICINE;4008 ELECTRICAL ENGINEERING;4201 ALLIED HEALTH AND REHABILITATION SCIENCE;4202 EPIDEMIOLOGY;4204 MIDWIFERY;4206 PUBLIC HEALTH;47 LANGUAGE, COMMUNICATION AND CULTURE","36;22;11;5;4;3;3;2;2;1;1;1;1;1;1;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;RARE DISEASES;HEMATOLOGY;CARDIOVASCULAR;ORPHAN DRUG;DIGESTIVE DISEASES;HEART DISEASE;ASSISTIVE TECHNOLOGY;BIOENGINEERING;INFECTIOUS DISEASES;ATHEROSCLEROSIS;CHILDHOOD LEUKEMIA;HEART DISEASE - CORONARY HEART DISEASE;KIDNEY DISEASE;LUNG;LYMPHOMA;PATIENT SAFETY;PEDIATRIC","21;19;10;9;8;5;5;4;4;3;3;3;2;2;2;2;2;2;2;2","CANCER;CARDIOVASCULAR;INFECTION;ORAL AND GASTROINTESTINAL;EYE;METABOLIC AND ENDOCRINE;MUSCULOSKELETAL","13;5;2;2;1;1;1","6.1 PHARMACEUTICALS;6.4 SURGERY;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES;6.7 PHYSICAL;7.2 END OF LIFE CARE","15;3;2;2;2;1;1;1;1","COLON AND RECTAL CANCER;LEUKEMIA / LEUKAEMIA;NON-HODGKIN'S LYMPHOMA;PANCREATIC CANCER;SARCOMA;BREAST CANCER;ESOPHAGEAL / OESOPHAGEAL CANCER;GASTROINTESTINAL TRACT;KIDNEY CANCER;LUNG CANCER;MYELOMA;SMALL INTESTINE CANCER;STOMACH CANCER","4;3;2;2;2;1;1;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;5.5 COMBINATIONS OF LOCALIZED AND SYSTEMIC THERAPIES;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING","12;2;2;2;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_SANTORSOLA",2008,368,9.04076086956522,3.69021739130435,0.548913043478261,0.41304347826087,0.567934782608696,1.71898734177215,1.36486486486486,1.61702127659574,1.34838709677419,0.328804347826087,10,182,74,36,44,0.49,0.2,0.1,0.12,47.72,0.869713853175252,NA,0.266304347826087,0.823369565217391,0.498,0.455,0.464,0.453,"STEFANO FANTI;ANTONIO DANIELE PINNA;CRISTINA NANNI;GIACOMO FALDELLA;DOMENICO RUBELLO;PAOLO CASTELLUCCI;ROBERTO FRANCHI;VALENTINA AMBROSINI;AUGUSTO LAURO;PIER LUIGI ZINZANI;MARIO MARENGO;GIAN LUCA GRAZI;GIORGIO ERCOLANI;RAFFAELE PEZZILLI;PIER LUIGI TAZZARI;FRANCESCA RICCI;MATTEO CESCON;LUCA BOTTA;MAURO BERNARDI;LUIGI BOLONDI","22;20;17;17;16;14;14;13;12;12;11;10;10;10;10;9;9;9;9;9","SERGIO SABBATANI;GIACOMO FALDELLA;RAFFAELE PEZZILLI;STEFANO FANTI;ROBERTO MANFREDI;ANTONIO DANIELE PINNA;LUCA BOTTA;CRISTINA NANNI;DOMENICO RUBELLO;ROBERTO FRANCHI;ANTONIO SANTORO;PAOLO CASTELLUCCI;VALENTINA AMBROSINI;MARIO MARENGO;RENATO PASQUALI;UMBERTO VOLTA;LUIGI CORVAGLIA;STEFANO ZUCCHINI;CLAUDIO BORGHI;STEFANO VENTUROLI","4.03;2.6;2.54;2.14;2;1.92;1.82;1.79;1.74;1.64;1.57;1.54;1.54;1.42;1.37;1.34;1.28;1.27;1.17;1.11","STEFANO FANTI;ANTONIO DANIELE PINNA;CRISTINA NANNI;GIACOMO FALDELLA;DOMENICO RUBELLO;PAOLO CASTELLUCCI;ROBERTO FRANCHI;VALENTINA AMBROSINI;AUGUSTO LAURO;PIER LUIGI ZINZANI;MARIO MARENGO;GIAN LUCA GRAZI;GIORGIO ERCOLANI;RAFFAELE PEZZILLI;PIER LUIGI TAZZARI;FRANCESCA RICCI;MATTEO CESCON;LUCA BOTTA;MAURO BERNARDI;LUIGI BOLONDI","22;20;17;17;16;14;14;13;12;12;11;10;10;10;10;9;9;9;9;9","SERGIO SABBATANI;GIACOMO FALDELLA;RAFFAELE PEZZILLI;STEFANO FANTI;ROBERTO MANFREDI;ANTONIO DANIELE PINNA;LUCA BOTTA;CRISTINA NANNI;DOMENICO RUBELLO;ROBERTO FRANCHI;ANTONIO SANTORO;PAOLO CASTELLUCCI;VALENTINA AMBROSINI;MARIO MARENGO;RENATO PASQUALI;UMBERTO VOLTA;LUIGI CORVAGLIA;STEFANO ZUCCHINI;CLAUDIO BORGHI;STEFANO VENTUROLI","4.03;2.6;2.54;2.14;2;1.92;1.82;1.79;1.74;1.64;1.57;1.54;1.54;1.42;1.37;1.34;1.28;1.27;1.17;1.11","GUALTIERO PALARETI;ALAN K. JACOBSON;ELAINE M. HYLEK;JACK ANSELL;JACK HIRSH;MARK CROWTHER;GIAN LUCA GRAZI;GIORGIO ENRICO GERUNDA;ALEJANDRO FORNER;ANDREW K. BURROUGHS;BART VAN HOEK;FEDJA A. ROCHLING;I. BOIN;JACQUES BELGHITI;JAN LERUT;JEAN GUGENHEIM;JORDI BRUIX;JOSEP M. LLOVET;LUCIANO DE CARLIS;LUIGI MARIANI","2312;2075;2075;2075;2075;2075;1962;1920;1817;1817;1817;1817;1817;1817;1817;1817;1817;1817;1817;1817","GUALTIERO PALARETI;GIAN LUCA GRAZI;STEFANO FANTI;PAOLO CASTELLUCCI;STEFANO VENTUROLI;ROSSELLA FATTORI;RENATO PASQUALI;PASQUALE SANSONE;CRISTINA NANNI;MICHELE BACCARANI;ROCCO MAURIZIO ZAGARI;LUIGI LOVATO;TIZIANA LAZZAROTTO;MOHAMED MABROUK;RENATO SERACCHIOLI;VALENTINA AMBROSINI;FEDERICO PERNA;FERNANDO RIZZELLO;MASSIMO CAMPIERI;PAOLO GIONCHETTI","2312;1871;872;809;594;576;547;500;499;463;454;436;426;397;397;381;375;375;375;375","ANTONIO DANIELE PINNA;GIACOMO FALDELLA;STEFANO FANTI;CRISTINA NANNI;ROBERTO FRANCHI;MARIO MARENGO;VALENTINA AMBROSINI;PAOLO CASTELLUCCI;PIER LUIGI TAZZARI;AUGUSTO LAURO;LUCA BOTTA;STEFANO VENTUROLI;FRANCESCA RICCI;ARIANNA ACETI;GIORGIO ERCOLANI;GIUSEPPE BORIANI;LUIGI CORVAGLIA;TIZIANA LAZZAROTTO;ANDREA BONTADINI;ANTONÍO MARZOCCHI","16;15;14;12;11;10;10;9;9;9;8;8;8;7;7;7;7;7;7;7","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;COMPUTER SCIENCE;MATHEMATICS;PSYCHOLOGY;ENGINEERING;ECONOMICS;POLITICAL SCIENCE;SOCIOLOGY;MATERIALS SCIENCE;HISTORY;PHILOSOPHY;GEOGRAPHY;BUSINESS;GEOLOGY","336;114;36;36;24;15;11;10;9;8;7;5;3;3;2;1;1","INTERNAL MEDICINE;SURGERY;GASTROENTEROLOGY;IMMUNOLOGY;CARDIOLOGY;GENETICS;PATHOLOGY;RADIOLOGY;BIOCHEMISTRY;ENDOCRINOLOGY;NUCLEAR MEDICINE;INTENSIVE CARE MEDICINE;CANCER RESEARCH;PEDIATRICS;ENVIRONMENTAL HEALTH;ONCOLOGY;PSYCHIATRY;ANESTHESIA;OPTICS;PHARMACOLOGY","253;82;65;54;53;52;50;50;35;32;30;29;28;26;24;20;20;19;18;18","DISEASE;TRANSPLANTATION;GENE;CANCER;POPULATION;HEART FAILURE;MYOCARDIAL INFARCTION;VIRUS;ANTIBODY;PREGNANCY;CONFIDENCE INTERVAL;RANDOMIZED CONTROLLED TRIAL;CHEMOTHERAPY;POSITRON EMISSION TOMOGRAPHY;HEPATOCELLULAR CARCINOMA;INCIDENCE (GEOMETRY);DIABETES MELLITUS;IMMUNE SYSTEM;LYMPHOMA;RECEPTOR","42;42;36;30;21;20;20;19;18;18;17;17;16;15;14;14;13;13;13;12","LIVER TRANSPLANTATION;PERCUTANEOUS CORONARY INTERVENTION;HEART TRANSPLANTATION;REFLUX;T CELL;HAZARD RATIO;VIRAL DISEASE;CHROMOSOME;GENE EXPRESSION;GESTATIONAL AGE;PROTEIN KINASE B;ALLELE;BREAST CANCER;DOTA;HUMAN CYTOMEGALOVIRUS;MONOCLONAL ANTIBODY;MUTATION;OVERWEIGHT;PROGRAMMED CELL DEATH;SEROLOGY;SOMATOSTATIN RECEPTOR;TACROLIMUS;VIRAL LOAD","16;11;10;9;9;8;8;6;6;6;6;5;5;5;5;5;5;5;5;5;5;5;5","HERPESVIRIDAE;RADIOIMMUNOTHERAPY;CANNABINOID RECEPTOR;ANTIRETROVIRAL THERAPY;FEBRILE NEUTROPENIA;PRIMARY ANGIOPLASTY;ABCIXIMAB;ANEUPLOIDY;ANTIGEN-PRESENTING CELL;BILIARY CIRRHOSIS;BRONCHOPULMONARY DYSPLASIA;CARDIAC RESYNCHRONIZATION THERAPY;CASPASE;CD40;CERVICAL INTRAEPITHELIAL NEOPLASIA;CYTOMEGALOVIRUS INFECTION;DEPHOSPHORYLATION;DIFFUSING CAPACITY;DRUG-ELUTING STENT;ESOPHAGITIS;FLUDARABINE;FOCUSED ASSESSMENT WITH SONOGRAPHY FOR TRAUMA;GENETIC HETEROGENEITY;GERD;GERMINAL CENTER;GRANZYME B;HBSAG;IMATINIB MESYLATE;INHIBITOR OF APOPTOSIS;INTERNATIONAL PROGNOSTIC INDEX;JURKAT CELLS;KARYOTYPE;LACUNAR STROKE;LAMIVUDINE;MERCAPTURIC ACID;MISSENSE MUTATION;NEUROPSYCHOLOGICAL ASSESSMENT;POLYCYSTIC OVARY;PROSTATECTOMY;PTEN;RASBURICASE;STROKE VOLUME;VINCRISTINE","7;5;4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","HUMANS;FEMALE;MALE;;MIDDLE AGED;ADULT;AGED;ITALY;TREATMENT OUTCOME;AGED, 80 AND OVER;ADOLESCENT;OBESITY;RISK FACTORS;TIME FACTORS;TOMOGRAPHY, X-RAY COMPUTED;FOLLOW-UP STUDIES;RETROSPECTIVE STUDIES;RADIOPHARMACEUTICALS;LIVER CIRRHOSIS;MYOCARDIAL INFARCTION","239;148;148;117;106;90;89;54;46;32;29;29;26;24;24;23;23;22;21;21","POSITRON EMISSION TOMOGRAPHY IMAGING IN ONCOLOGY;LYMPHOID NEOPLASMS;EPIDEMIOLOGY AND MANAGEMENT OF CYTOMEGALOVIRUS INFECTION;LIVER CIRRHOSIS AND ASSOCIATED COMPLICATIONS;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;DIAGNOSIS AND MANAGEMENT OF AORTIC DISEASES;EPIDEMIOLOGY AND MANAGEMENT OF NEUROENDOCRINE TUMORS;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;DIAGNOSIS AND MANAGEMENT OF ENDOMETRIOSIS;DIAGNOSIS AND MANAGEMENT OF GASTROESOPHAGEAL REFLUX DISEASE;HEPATITIS B INFECTION AND TREATMENT;HEPATOCELLULAR CARCINOMA;ORGAN TRANSPLANTATION AND REJECTION;PROVISION AND ASSESSMENT OF NUTRITION SUPPORT THERAPY;DIAGNOSIS AND MANAGEMENT OF PANCREATITIS;COMPOSITION AND HEALTH EFFECTS OF HUMAN MILK;ETHICAL AND MEDICAL ASPECTS OF ORGAN DONATION;GENOTOXICITY AND CARCINOGENESIS MECHANISMS;KIDNEY TRANSPLANTATION;LIVER TRANSPLANTATION AND GRAFT SURVIVAL ANALYSIS","13;10;8;8;7;7;7;6;6;6;6;6;6;6;5;4;4;4;4;4","PET/CT;TREATMENT;PET IMAGING;IMAGING;LIVER TRANSPLANTATION;CYTOMEGALOVIRUS;HEPATOCELLULAR CARCINOMA;TRANSPLANTATION;AORTIC DISSECTION;ECHOCARDIOGRAPHY;EVEROLIMUS;KIDNEY TRANSPLANTATION;LIVER CIRRHOSIS;CORONARY STENTS;DOTA;DRUG-ELUTING STENTS;HEART RATE VARIABILITY;IBRITUMOMAB TIUXETAN;IMMUNOSUPPRESSION;LIVER DISEASE","12;12;9;8;8;7;7;7;6;6;6;6;6;5;5;5;5;5;5;5","HEPATOCELLULAR CARCINOMA;ANIMAL PET;DE NOVO;LIVER TRANSPLANTATION;GASTROESOPHAGEAL REFLUX;HEART FAILURE;MYOCARDIAL INFARCTION;CORONARY ARTERY;IBRITUMOMAB TIUXETAN;INTESTINAL TRANSPLANTATION;LIVER CIRRHOSIS;PET IMAGES;RANDOMIZED TRIAL;TRANSPLANT RECIPIENTS;ACUTE LYMPHOBLASTIC;ARTERY DISEASE;ATRIAL FIBRILLATION;CLINICAL PRACTICE;CONTROLLED TRIAL;DRUG-ELUTING STENTS;HEART TRANSPLANT;LYMPHOBLASTIC LEUKEMIA;MYELOGENOUS LEUKEMIA;PRETERM INFANTS;RANDOMIZED CONTROLLED;STEM CELL;ACUTE AORTIC;ACUTE MYELOGENOUS;AKT INHIBITOR;AORTIC DISSECTION","10;7;7;7;6;6;6;5;5;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4;4;3;3;3;3","CONFIDENCE INTERVAL;CONTINUOUS USERS;DIABETIC PATIENTS;BOLOGNA ITALY;DI CARDIOLOGIA;ELEPHANT TRUNK;LYSIS SYNDROME;RISK FACTORS;SIGNIFICANTLY LOWER;TUMOR LYSIS;ACUTE MYELOID;CD CELLS;FROZEN ELEPHANT;MYELOID LEUKEMIA;ODDS RATIO;ABDOMINAL WALL;CMV INFECTION;GENE EXPRESSION;PERIPHERAL BLOOD;RATIO CONFIDENCE;SINUS RHYTHM;SLOW FREEZING;STABLE SINUS;STENT GRAFT;ACE INHIBITORS;APELIN RECEPTOR;BACTERIAL INFECTION;CELL DEATH;CELL LINES;ENDOMETRIOMA RECURRENCE","14;12;11;10;10;10;10;10;10;10;9;9;9;9;9;8;8;8;8;8;8;8;8;8;7;7;7;7;7;7",52,0.14,6,4,1,2.5,0,1,5,1,1,5,0,1,2.5,1,2,1.75,0,2,2.5,0,0,77.75,78.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,39,4.95,597.55,5.6,5,0.13,32.08,0,2,12,0,16,0,8,1,0,20,0,0,0,0,0,0,0,37,2,0,20,19,0,0,0,0,0,0,0,0,"United States;Italy;Germany;Japan","6;3;2;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3204 IMMUNOLOGY;42 HEALTH SCIENCES;31 BIOLOGICAL SCIENCES;3107 MICROBIOLOGY;3203 DENTISTRY;3207 MEDICAL MICROBIOLOGY;3208 MEDICAL PHYSIOLOGY;3210 NUTRITION AND DIETETICS;3212 OPHTHALMOLOGY AND OPTOMETRY;3213 PAEDIATRICS;3215 REPRODUCTIVE MEDICINE;34 CHEMICAL SCIENCES;3404 MEDICINAL AND BIOMOLECULAR CHEMISTRY;40 ENGINEERING;4003 BIOMEDICAL ENGINEERING;4203 HEALTH SERVICES AND SYSTEMS","34;15;9;5;3;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;DIGESTIVE DISEASES;PATIENT SAFETY;RARE DISEASES;CARDIOVASCULAR;HEART DISEASE;HEMATOLOGY;KIDNEY DISEASE;LIVER DISEASE;TRANSPLANTATION;EMERGING INFECTIOUS DISEASES;PREVENTION;ATHEROSCLEROSIS;BEHAVIORAL AND SOCIAL SCIENCE;BIOENGINEERING;BIOMEDICAL IMAGING;CHRONIC LIVER DISEASE AND CIRRHOSIS;CHRONIC PAIN","19;15;10;8;6;6;3;3;3;3;3;3;2;2;1;1;1;1;1;1","CANCER;CARDIOVASCULAR;ORAL AND GASTROINTESTINAL;INFECTION;RENAL AND UROGENITAL;EYE;INFLAMMATORY AND IMMUNE SYSTEM;METABOLIC AND ENDOCRINE;MUSCULOSKELETAL;RESPIRATORY;STROKE","8;5;5;2;2;1;1;1;1;1;1","6.1 PHARMACEUTICALS;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;5.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;6.4 SURGERY;7.3 MANAGEMENT AND DECISION MAKING","20;2;2;2;2;1","LEUKEMIA / LEUKAEMIA;LIVER CANCER;COLON AND RECTAL CANCER;LUNG CANCER;MYELOMA;NON-HODGKIN'S LYMPHOMA;HEAD AND NECK CANCER;HODGKIN'S DISEASE;LARYNGEAL CANCER;NOT SITE-SPECIFIC CANCER;ORAL CAVITY AND LIP CANCER;PHARYNGEAL CANCER;THYROID CANCER","4;4;2;2;2;2;1;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;2.1 EXOGENOUS FACTORS IN THE ORIGIN AND CAUSE OF CANCER;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;5.5 COMBINATIONS OF LOCALIZED AND SYSTEMIC THERAPIES;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","10;2;1;1;1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_SANTORSOLA",2009,368,9.95923913043478,3.72826086956522,0.510869565217391,0.418478260869565,0.668478260869565,1.828,1.36231884057971,1.57142857142857,1.55696202531646,0.388586956521739,10,194,76,36,37,0.53,0.21,0.1,0.1,39.45,0.8529220401149,NA,0.255434782608696,0.817934782608696,0.471,0.444,0.47,0.464,"GIOVANNI MARTINELLI;MICHELE BACCARANI;STEFANO FANTI;RAFFAELE PEZZILLI;DONATELLA SANTINI;SIMONA SOVERINI;GIAN LUCA GRAZI;GIANANTONIO ROSTI;GIUSEPPE SAGLIO;NICOLETTA TESTONI;ANTONIO DANIELE PINNA;FABRIZIO PANE;MARILINA AMABILE;FRANCESCA PALANDRI;PAOLO CASTELLUCCI;LUCA ANSALONI;FAUSTO CASTAGNETTI;ILARIA IACOBUCCI;TIZIANA LAZZAROTTO;MATTEO CESCON","26;23;17;15;15;13;12;12;12;12;11;11;11;10;10;10;10;10;9;9","ROBERTO MANFREDI;RAFFAELE PEZZILLI;TIZIANA LAZZAROTTO;ROBERTO DI BARTOLOMEO;STEFANO FANTI;RICCARDO CASADEI;GIOVANNI MARTINELLI;DONATELLA SANTINI;ANTONIO MARIA MORSELLI‐LABATE;ROSSELLA FATTORI;LUCA BOTTA;LUCA ANSALONI;ARRIGO F.G. CICERO;BENILDE COSMI;MICHELE BACCARANI;LUIGI BOLONDI;GIAN LUCA GRAZI;ANTONIO DANIELE PINNA;FAUSTO CATENA;RENATO SERACCHIOLI","4.83;4.76;2.73;2.11;1.8;1.63;1.61;1.58;1.47;1.4;1.38;1.37;1.37;1.31;1.29;1.24;1.23;1.19;1.17;1.17","GIOVANNI MARTINELLI;MICHELE BACCARANI;STEFANO FANTI;RAFFAELE PEZZILLI;DONATELLA SANTINI;SIMONA SOVERINI;GIAN LUCA GRAZI;GIANANTONIO ROSTI;NICOLETTA TESTONI;ANTONIO DANIELE PINNA;MARILINA AMABILE;FRANCESCA PALANDRI;PAOLO CASTELLUCCI;LUCA ANSALONI;FAUSTO CASTAGNETTI;ILARIA IACOBUCCI;TIZIANA LAZZAROTTO;MATTEO CESCON;ROBERTO DI BARTOLOMEO;RITA GOLFIERI","26;23;17;15;15;13;12;12;12;11;11;10;10;10;10;10;9;9;9;9","ROBERTO MANFREDI;RAFFAELE PEZZILLI;TIZIANA LAZZAROTTO;ROBERTO DI BARTOLOMEO;STEFANO FANTI;RICCARDO CASADEI;GIOVANNI MARTINELLI;DONATELLA SANTINI;ANTONIO MARIA MORSELLI‐LABATE;ROSSELLA FATTORI;LUCA BOTTA;LUCA ANSALONI;ARRIGO F.G. CICERO;BENILDE COSMI;MICHELE BACCARANI;LUIGI BOLONDI;GIAN LUCA GRAZI;ANTONIO DANIELE PINNA;FAUSTO CATENA;RENATO SERACCHIOLI","4.83;4.76;2.73;2.11;1.8;1.63;1.61;1.58;1.47;1.4;1.38;1.37;1.37;1.31;1.29;1.24;1.23;1.19;1.17;1.17","GIOVANNI BRANDI;ANNAMARIA PISI;ANNAÏG LAN;CHANTAL BRIDONNEAU;D. F. KELLY;EMELYNE LÉCUYER;GÉRARD EBERL;IMKE MULDER;JOHANNES SNEL;MARIANNE DE PAEPE;NADINE CERF‐BENSUSSAN;SABINE RAKOTOBÉ;VALÉRIE GABORIAU‐ROUTHIAU;VIOLAINE ROCHET;MICHELE BACCARANI;GIOVANNI MARTINELLI;FABRIZIO PANE;LUIGI BOLONDI;DONATELLA SANTINI;GIUSEPPE SAGLIO","1356;1336;1336;1336;1336;1336;1336;1336;1336;1336;1336;1336;1336;1336;1163;1043;775;732;723;706","GIOVANNI BRANDI;MICHELE BACCARANI;GIOVANNI MARTINELLI;CESARE ROSSI;CESARE CREMON;GIOVANNI BARBARA;ROBERTO DE GIORGIO;VINCENZO STANGHELLINI;NICOLETTA TESTONI;SIMONA SOVERINI;GIANANTONIO ROSTI;LUIGI BOLONDI;FRANCESCA PALANDRI;FAUSTO CASTAGNETTI;CATIA GIOVANNINI;LAURA GRAMANTIERI;PASQUALE CHIECO;STEFANO FANTI;ANTONIO MARIA MORSELLI‐LABATE;ROBERTO CORINALDESI","1356;1136;916;678;655;655;655;655;587;549;534;516;508;507;487;487;487;476;423;421","GIOVANNI MARTINELLI;MICHELE BACCARANI;ANTONIO DANIELE PINNA;DONATELLA SANTINI;STEFANO FANTI;FAUSTO CATENA;RAFFAELE PEZZILLI;SIMONA SOVERINI;GIANANTONIO ROSTI;LUCA ANSALONI;NICOLETTA TESTONI;ANDREA MARTONI;FAUSTO CASTAGNETTI;PIER LUIGI TAZZARI;RITA GOLFIERI;ROBERTO DI BARTOLOMEO;TIZIANA LAZZAROTTO;FRANCESCA PALANDRI;GIAN LUCA GRAZI;GIORGIO ERCOLANI","15;14;13;13;13;13;12;12;9;9;9;9;8;8;8;8;8;8;7;7","MEDICINE;BIOLOGY;PHYSICS;CHEMISTRY;COMPUTER SCIENCE;PSYCHOLOGY;ENGINEERING;MATERIALS SCIENCE;MATHEMATICS;POLITICAL SCIENCE;ECONOMICS;GEOLOGY;PHILOSOPHY;SOCIOLOGY;ENVIRONMENTAL SCIENCE;ART;BUSINESS;GEOGRAPHY","328;127;39;34;23;14;13;12;8;6;5;5;4;3;2;1;1;1","INTERNAL MEDICINE;SURGERY;GENETICS;PATHOLOGY;GASTROENTEROLOGY;IMMUNOLOGY;RADIOLOGY;ONCOLOGY;CANCER RESEARCH;CARDIOLOGY;ENDOCRINOLOGY;ENVIRONMENTAL HEALTH;BIOCHEMISTRY;OPTICS;PALEONTOLOGY;INTENSIVE CARE MEDICINE;GENERAL SURGERY;CELL BIOLOGY;NUCLEAR MEDICINE;QUANTUM MECHANICS","244;103;67;67;60;55;51;43;33;33;33;26;25;22;20;19;18;17;16;16","CANCER;GENE;DISEASE;CHEMOTHERAPY;POPULATION;TRANSPLANTATION;MYELOID LEUKEMIA;CIRRHOSIS;PREGNANCY;VIRUS;HEPATOCELLULAR CARCINOMA;RECEPTOR;ANTIBODY;CONFIDENCE INTERVAL;INCIDENCE (GEOMETRY);RANDOMIZED CONTROLLED TRIAL;STAGE (STRATIGRAPHY);CLINICAL TRIAL;DIABETES MELLITUS;MYOCARDIAL INFARCTION;STENT","53;45;39;26;24;24;21;18;18;16;15;15;14;13;13;13;13;12;12;12;12","IMATINIB;COLORECTAL CANCER;BREAST CANCER;MUTATION;LIVER TRANSPLANTATION;CHROMOSOME;CLINICAL ENDPOINT;EJECTION FRACTION;GENOTYPE;PERCUTANEOUS CORONARY INTERVENTION;VIRAL DISEASE;CERVICAL CANCER;FETUS;INFLAMMATORY BOWEL DISEASE;INSULIN RESISTANCE;AORTIC DISSECTION;CISPLATIN;DOCETAXEL;HAEMATOPOIESIS;HAZARD RATIO;HUMAN CYTOMEGALOVIRUS;METABOLIC SYNDROME;METASTASIS;PHENOTYPE;REFLUX;TYROSINE KINASE;TYROSINE-KINASE INHIBITOR;ULCERATIVE COLITIS","16;12;11;10;8;7;7;7;7;7;7;6;6;6;6;5;5;5;5;5;5;5;5;5;5;5;5;5","IMATINIB MESYLATE;HERPESVIRIDAE;NILOTINIB;CARDIAC RESYNCHRONIZATION THERAPY;CERVICAL INTRAEPITHELIAL NEOPLASIA;CETUXIMAB;DRUG-ELUTING STENT;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;SINGLE-NUCLEOTIDE POLYMORPHISM;ABL;ANTIRETROVIRAL THERAPY;CANNABINOID RECEPTOR;EXCESSIVE DAYTIME SLEEPINESS;KARYOTYPE;MACE;MISSENSE MUTATION;ADIPOKINE;ADIPONECTIN;BREAST CARCINOMA;COMPARATIVE GENOMIC HYBRIDIZATION;CYCLIN D1;DASATINIB;DOUBLE BLIND;EMBRYO CRYOPRESERVATION;EPWORTH SLEEPINESS SCALE;ESOPHAGITIS;GENOTYPING;INTRACYTOPLASMIC SPERM INJECTION;IRINOTECAN;ISCHEMIC CARDIOMYOPATHY;KRAS;METASTATIC BREAST CANCER;NEOADJUVANT THERAPY;OSWESTRY DISABILITY INDEX;PDGFRA;PLACENTA;POLYCYSTIC OVARY;PORTAL VENOUS PRESSURE;PRENATAL DIAGNOSIS;RADIOIMMUNOTHERAPY;RESPIRATORY RATE;RIBAVIRIN;RPTOR;VINCRISTINE","14;7;6;5;5;5;4;4;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","HUMANS;FEMALE;MALE;MIDDLE AGED;ADULT;AGED;;TREATMENT OUTCOME;ADOLESCENT;YOUNG ADULT;AGED, 80 AND OVER;ITALY;LIVER NEOPLASMS;RISK FACTORS;LIVER;RETROSPECTIVE STUDIES;FOLLOW-UP STUDIES;PANCREATIC NEOPLASMS;PROSPECTIVE STUDIES;TOMOGRAPHY, X-RAY COMPUTED","249;168;161;125;117;107;106;68;51;48;47;44;33;29;28;26;25;25;25;25","EFFICACY AND RESISTANCE IN CML TREATMENT;DIAGNOSIS AND MANAGEMENT OF PANCREATITIS;EPIDEMIOLOGY AND MANAGEMENT OF CYTOMEGALOVIRUS INFECTION;HEPATOCELLULAR CARCINOMA;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;LIVER CIRRHOSIS AND ASSOCIATED COMPLICATIONS;LYMPHOID NEOPLASMS;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;DIAGNOSIS AND MANAGEMENT OF AORTIC DISEASES;EPIDEMIOLOGY AND TREATMENT OF CHILDHOOD LEUKEMIA;HUMAN PAPILLOMAVIRUS AND CERVICAL CANCER EPIDEMIOLOGY;PANCREATIC CANCER RESEARCH AND TREATMENT;COLORECTAL CANCER RESEARCH AND TREATMENT;ENDOCANNABINOID SYSTEM AND ITS EFFECTS ON HEALTH;EPIDEMIOLOGY AND MANAGEMENT OF NEUROENDOCRINE TUMORS;GASTRIC CANCER RESEARCH AND TREATMENT;GLOBAL BURDEN OF CHRONIC PAIN;HEPATITIS C INFECTION AND TREATMENT;KIDNEY TRANSPLANTATION;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH","17;10;9;8;7;7;7;6;6;6;5;5;4;4;4;4;4;4;4;3","IMATINIB MESYLATE;IMATINIB;ETIOLOGY;TREATMENT;CLINICAL ENDPOINT;CYTOMEGALOVIRUS;DIAGNOSIS;HEPATOCELLULAR CARCINOMA;PANCREATIC DISEASE;TREATMENT OUTCOMES;ACUTE PANCREATITIS;AORTIC DISSECTION;CONCOMITANT;HEPATITIS C;METASTATIC PANCREATIC CANCER;DISCONTINUATION;DRUG-ELUTING STENTS;HEMATOLOGY;IMMUNOSUPPRESSION;LIVER BIOPSY","14;12;9;9;7;7;7;7;7;7;6;6;6;6;6;5;5;5;5;5","MYELOID LEUKEMIA;CHRONIC MYELOID;HEPATOCELLULAR CARCINOMA;PATIENTS TREATED;LEUKEMIA PATIENTS;ACUTE LYMPHOBLASTIC;LYMPHOBLASTIC LEUKEMIA;CANCER PATIENTS;ITALIAN SOCIETY;LEFT MAIN;LIVER TRANSPLANTATION;PHASE II;STEM CELL;CONTROLLED TRIAL;CORONARY ARTERY;DE NOVO;GIMEMA CML;IMATINIB IM;LEUKEMIA CML;MAIN CORONARY;ACUTE CHOLECYSTITIS;ACUTE PANCREATITIS;ADVANCED GASTRIC;BREAST CANCER;CELL CARCINOMA;CHRONIC PANCREATITIS;CHRONIC PHASE;CLINICAL FEATURES;CML PATIENTS;CONGENITALLY INFECTED","14;13;9;8;7;6;6;5;5;5;5;5;5;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3","PUBMED SCOPUS;CROSSREF PUBMED;GENET -CROSSREF;MENTAL RETARDATION;HUM GENET;DE NOVO;GERIATRIC UNIT;HR CI;GENET -ABSTRACT;MYELOID LEUKEMIA;CD PATIENTS;CONSECUTIVE PATIENTS;X-LINKED MENTAL;CELL LINES;CHRONIC MYELOID;CHRONIC PANCREATITIS;MAGNETIC RESONANCE;MEDIAN FOLLOW-UP;RISK FACTORS;BONE MARROW;FRYNS JP;HEPATOCELLULAR CARCINOMA;LIVER DISEASE;OBSTRUCTIVE SLEEP;PATIENTS UNDERWENT;SLEEP APNEA;SPEECH DELAY;X-INACTIVATION PATTERN;BILE DUCT;CLINICAL OUTCOME","37;26;20;17;15;14;12;12;11;11;10;10;10;9;9;9;9;9;9;8;8;8;8;8;8;8;8;8;7;7",70,0.19,6,2.75,1,1.25,0,1.5,5,1,1,3,0,1,2,1,1.75,1,1,1.75,2,0,0,68.75,76.75,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,43,5.65,421.56,6.3,9,0.21,38.33,1,1,11,1,13,0,6,10,0,29,3,0,0,0,0,0,0,34,7,2,31,11,0,1,0,0,0,0,0,0,"Italy;United States;Japan","12;5;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;42 HEALTH SCIENCES;3215 REPRODUCTIVE MEDICINE;51 PHYSICAL SCIENCES;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;3204 IMMUNOLOGY;3209 NEUROSCIENCES;3212 OPHTHALMOLOGY AND OPTOMETRY;37 EARTH SCIENCES;3704 GEOINFORMATICS;40 ENGINEERING;4003 BIOMEDICAL ENGINEERING;4201 ALLIED HEALTH AND REHABILITATION SCIENCE;4204 MIDWIFERY;4208 TRADITIONAL, COMPLEMENTARY AND INTEGRATIVE MEDICINE;44 HUMAN SOCIETY","41;17;16;13;5;4;3;2;2;1;1;1;1;1;1;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;RARE DISEASES;HEMATOLOGY;CARDIOVASCULAR;PREVENTION;DIGESTIVE DISEASES;HEART DISEASE;LIVER DISEASE;LYMPHOMA;TRANSPLANTATION;AGING;PATIENT SAFETY;PEDIATRIC;CHRONIC LIVER DISEASE AND CIRRHOSIS;HEPATITIS;INFECTIOUS DISEASES;LUNG;PAIN RESEARCH","33;22;15;13;8;7;7;5;5;5;5;5;4;4;4;3;3;3;3;3","CANCER;CARDIOVASCULAR;INFECTION;RESPIRATORY;BLOOD;REPRODUCTIVE HEALTH AND CHILDBIRTH;EYE;MENTAL HEALTH;MUSCULOSKELETAL;NEUROLOGICAL;ORAL AND GASTROINTESTINAL;RENAL AND UROGENITAL;STROKE","15;7;3;3;2;2;1;1;1;1;1;1;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES;5.2 CELLULAR AND GENE THERAPIES;6.7 PHYSICAL;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;2.2 FACTORS RELATING TO THE PHYSICAL ENVIRONMENT;2.4 SURVEILLANCE AND DISTRIBUTION;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;7.1 INDIVIDUAL CARE NEEDS;7.3 MANAGEMENT AND DECISION MAKING","21;5;3;3;2;2;1;1;1;1;1;1","NON-HODGKIN'S LYMPHOMA;HODGKIN'S DISEASE;HEAD AND NECK CANCER;LARYNGEAL CANCER;NOT SITE-SPECIFIC CANCER;ORAL CAVITY AND LIP CANCER;PHARYNGEAL CANCER;SALIVARY GLAND CANCER;LEUKEMIA / LEUKAEMIA;PROSTATE CANCER;BONE CANCER, OSTEOSARCOMA / MALIGNANT FIBROUS HISTIOCYTOMA;CERVICAL CANCER;EAR CANCER;ENDOMETRIAL CANCER;EYE CANCER;GENITAL SYSTEM, FEMALE;GENITAL SYSTEM, MALE;LIVER CANCER;LUNG CANCER;MYELOMA","7;4;3;3;3;3;3;3;2;2;1;1;1;1;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;5.5 COMBINATIONS OF LOCALIZED AND SYSTEMIC THERAPIES;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS","9;3;2;2;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_SANTORSOLA",2010,407,9.18181818181818,3.55528255528256,0.555282555282555,0.41031941031941,0.656019656019656,1.89515072083879,1.38650306748466,1.75789473684211,1.36923076923077,0.43980343980344,16,203,70,57,41,0.5,0.17,0.14,0.1,41.1,0.909497614553606,NA,0.243243243243243,0.771498771498772,0.502,0.437,0.445,0.434,"STEFANO FANTI;ANTONIO DANIELE PINNA;ROBERTO MANFREDI;CRISTINA NANNI;VALENTINA AMBROSINI;DONATELLA SANTINI;PAOLO CASTELLUCCI;VITTORIO SAMBRI;MICHELE BACCARANI;RAFFAELE PEZZILLI;GIAN LUCA GRAZI;FRANCESCA RICCI;FRANCESCA CAVRINI;GIACOMO FALDELLA;PIER LUIGI TAZZARI;PIER LUIGI ZINZANI;RENATO PASQUALI;GUALTIERO PALARETI;GIANANDREA PASQUINELLI;PAOLO GAIBANI","31;18;14;13;12;12;11;11;11;11;10;10;10;10;10;10;10;9;9;9","ROBERTO MANFREDI;SERGIO SABBATANI;STEFANO FANTI;RENATO PASQUALI;GIANANDREA PASQUINELLI;RAFFAELE PEZZILLI;MICHELE BACCARANI;CLAUDIO RAPEZZI;FEDERICA GUARALDI;SIRIO FIORINO;ANTONIO DANIELE PINNA;ANTONIO SANTORO;CLAUDIO BORGHI;VITTORIO SAMBRI;MARGHERITA NANNINI;FRANCESCA CAVRINI;ARRIGO F.G. CICERO;GIACOMO FALDELLA;ARIANNA ACETI;GUALTIERO PALARETI","8.42;3.92;3.58;2.49;2.26;2.15;2.07;2.05;2;1.91;1.84;1.61;1.61;1.61;1.56;1.51;1.48;1.42;1.38;1.35","STEFANO FANTI;ANTONIO DANIELE PINNA;ROBERTO MANFREDI;CRISTINA NANNI;VALENTINA AMBROSINI;DONATELLA SANTINI;PAOLO CASTELLUCCI;VITTORIO SAMBRI;MICHELE BACCARANI;RAFFAELE PEZZILLI;GIAN LUCA GRAZI;FRANCESCA RICCI;FRANCESCA CAVRINI;GIACOMO FALDELLA;PIER LUIGI TAZZARI;PIER LUIGI ZINZANI;RENATO PASQUALI;GUALTIERO PALARETI;GIANANDREA PASQUINELLI;PAOLO GAIBANI","31;18;14;13;12;12;11;11;11;11;10;10;10;10;10;10;10;9;9;9","ROBERTO MANFREDI;SERGIO SABBATANI;STEFANO FANTI;RENATO PASQUALI;GIANANDREA PASQUINELLI;RAFFAELE PEZZILLI;MICHELE BACCARANI;CLAUDIO RAPEZZI;FEDERICA GUARALDI;ANTONIO DANIELE PINNA;ANTONIO SANTORO;CLAUDIO BORGHI;VITTORIO SAMBRI;MARGHERITA NANNINI;FRANCESCA CAVRINI;ARRIGO F.G. CICERO;GIACOMO FALDELLA;ARIANNA ACETI;GUALTIERO PALARETI;DONATELLA SANTINI","8.42;3.92;3.58;2.49;2.26;2.15;2.07;2.05;2;1.84;1.61;1.61;1.61;1.56;1.51;1.48;1.42;1.38;1.35;1.3","STEFANO FANTI;VALENTINA AMBROSINI;CRISTINA NANNI;DONATELLA SANTINI;GIAN LUCA GRAZI;PAOLA TOMASSETTI;ANTONIO DANIELE PINNA;FABIO PISCAGLIA;VINCENZO ALLEGRI;UBERTO PAGOTTO;PASQUALE CHIECO;PAOLO CASTELLUCCI;ANTONIO GRIECO;DAVIDE CAMPANA;LUIGI BOLONDI;ARTURO CHITI;GIOVANNA PEPE;RICHARD P. BAUM;WIM J.G. OYEN;FAUSTO CATENA","1954;1525;1021;903;903;756;701;691;691;650;629;626;622;615;605;602;602;602;602;581","STEFANO FANTI;VALENTINA AMBROSINI;CRISTINA NANNI;PAOLA TOMASSETTI;VINCENZO ALLEGRI;DONATELLA SANTINI;FABIO PISCAGLIA;GIAN LUCA GRAZI;LUIGI BOLONDI;FAUSTO CATENA;PAOLO CASTELLUCCI;MARCO PASTORE-TROSSELLO;RITA GOLFIERI;FRANCESCA RICCI;PIER LUIGI TAZZARI;GIAN CARLO MONTINI;PASQUALE CHIECO;GUALTIERO PALARETI;DAVIDE CAMPANA;ANTONIO DANIELE PINNA","1665;1399;1002;756;691;683;673;668;588;581;545;543;539;536;536;476;451;450;447;431","STEFANO FANTI;ROBERTO MANFREDI;ANTONIO DANIELE PINNA;CRISTINA NANNI;VALENTINA AMBROSINI;FRANCESCA CAVRINI;DONATELLA SANTINI;PAOLO CASTELLUCCI;FRANCESCA RICCI;PIER LUIGI TAZZARI;FAUSTO CATENA;GUALTIERO PALARETI;CLAUDIO BORGHI;PAOLO GAIBANI;SERGIO SABBATANI;GIANANDREA PASQUINELLI;MAURIZIO ZOMPATORI;PIER LUIGI ZINZANI;GIAN CARLO MONTINI;PAOLA TOMASSETTI","25;12;12;11;11;10;10;10;10;10;9;9;9;9;9;8;8;8;7;7","MEDICINE;BIOLOGY;CHEMISTRY;COMPUTER SCIENCE;PHYSICS;MATHEMATICS;ENGINEERING;PSYCHOLOGY;SOCIOLOGY;HISTORY;MATERIALS SCIENCE;ECONOMICS;ART;PHILOSOPHY;GEOGRAPHY;POLITICAL SCIENCE;BUSINESS;ENVIRONMENTAL SCIENCE;GEOLOGY","356;154;38;34;32;17;16;12;9;8;8;6;5;5;3;3;2;2;2","INTERNAL MEDICINE;SURGERY;PATHOLOGY;GENETICS;RADIOLOGY;IMMUNOLOGY;BIOCHEMISTRY;CARDIOLOGY;GASTROENTEROLOGY;NUCLEAR MEDICINE;ENDOCRINOLOGY;ONCOLOGY;CANCER RESEARCH;VIROLOGY;INTENSIVE CARE MEDICINE;PEDIATRICS;CELL BIOLOGY;ENVIRONMENTAL HEALTH;PSYCHIATRY;OPTICS","268;112;77;71;67;60;50;46;42;37;35;35;31;28;26;26;25;25;18;17","CANCER;GENE;DISEASE;TRANSPLANTATION;RECEPTOR;VIRUS;POPULATION;POSITRON EMISSION TOMOGRAPHY;CHEMOTHERAPY;PREGNANCY;ANTIBODY;LYMPHOMA;ADVERSE EFFECT;CONFIDENCE INTERVAL;DIABETES MELLITUS;STEM CELL;COHORT;HEPATOCELLULAR CARCINOMA;IN VITRO;INCIDENCE (GEOMETRY);THROMBOSIS","61;52;38;29;24;24;22;21;20;19;18;18;16;16;16;15;14;13;13;12;12","LIVER TRANSPLANTATION;COLORECTAL CANCER;BREAST CANCER;FETUS;ADENOCARCINOMA;GENOTYPE;GESTATION;CYCLOPHOSPHAMIDE;METASTASIS;MONOCLONAL ANTIBODY;MUTATION;OVARIAN CANCER;VIRAL DISEASE;PI3K/AKT/MTOR PATHWAY;UNIVARIATE ANALYSIS;VENOUS THROMBOSIS;AORTIC DISSECTION;CHIKUNGUNYA;EJECTION FRACTION;FOLLICULAR LYMPHOMA;GIST;HAZARD RATIO;HUMAN CYTOMEGALOVIRUS;PET-CT;PROTEIN KINASE B;RITUXIMAB;RNA;SOMATOSTATIN RECEPTOR;VENOUS THROMBOEMBOLISM","15;14;12;11;9;9;8;7;7;7;7;7;7;6;6;6;5;5;5;5;5;5;5;5;5;5;5;5;5","HERPESVIRIDAE;RADIOIMMUNOTHERAPY;ANTIRETROVIRAL THERAPY;CANNABINOID RECEPTOR;DEBULKING;KARYOTYPE;MTORC1;PLASMODIUM VIVAX;PRENATAL DIAGNOSIS;SHIGA TOXIN;SINGLE-NUCLEOTIDE POLYMORPHISM;VINCRISTINE;AEDES ALBOPICTUS;AMPK;ANDROSTENEDIONE;AORTIC VALVULOPLASTY;AXILLA;CERVICAL INTRAEPITHELIAL NEOPLASIA;CONGENITAL SYPHILIS;CYTOREDUCTIVE SURGERY;DRUG-ELUTING STENT;ELEPHANT TRUNKS;ESTROGEN RECEPTOR;EXCESSIVE DAYTIME SLEEPINESS;FIRST TRIMESTER;FLUDARABINE;HMG-COA REDUCTASE;IDARUBICIN;IMATINIB MESYLATE;INTERNATIONAL PROGNOSTIC SCORING SYSTEM;MACE;MELANOPSIN;MONOCLONAL;NEOADJUVANT THERAPY;OXALIPLATIN;PDGFRA;PHILADELPHIA CHROMOSOME;POLYCYSTIC OVARY;POLYMORPHISM (COMPUTER SCIENCE);PROSTATECTOMY;RIBAVIRIN;RNA INTERFERENCE;SUBVENTRICULAR ZONE;TRANSIENT ELASTOGRAPHY;TRANSITIONAL CELL CARCINOMA;VECTOR (MOLECULAR BIOLOGY)","6;4;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","HUMANS;FEMALE;MALE;;MIDDLE AGED;AGED;ADULT;AGED, 80 AND OVER;ITALY;TREATMENT OUTCOME;POSITRON-EMISSION TOMOGRAPHY;LIVER NEOPLASMS;ADOLESCENT;RISK FACTORS;TOMOGRAPHY, X-RAY COMPUTED;PANCREATIC NEOPLASMS;RETROSPECTIVE STUDIES;YOUNG ADULT;PROSPECTIVE STUDIES;PROGNOSIS","273;179;165;122;114;109;105;54;53;53;41;40;34;33;32;30;29;29;28;26","LYMPHOID NEOPLASMS;EPIDEMIOLOGY AND MANAGEMENT OF NEUROENDOCRINE TUMORS;GLOBAL IMPACT OF ARBOVIRAL DISEASES;HEPATOCELLULAR CARCINOMA;POSITRON EMISSION TOMOGRAPHY IMAGING IN ONCOLOGY;PREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM;DIAGNOSIS AND MANAGEMENT OF AORTIC DISEASES;ACUTE MYELOID LEUKEMIA;PANCREATIC CANCER RESEARCH AND TREATMENT;DIAGNOSIS AND MANAGEMENT OF ENDOMETRIOSIS;DIAGNOSIS AND TREATMENT OF GASTROINTESTINAL STROMAL TUMORS;EPIDEMIOLOGY AND MANAGEMENT OF NAFLD;MANAGEMENT OF VALVULAR HEART DISEASE;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;CHRONIC KIDNEY DISEASE AND DIALYSIS TREATMENT;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;COMPOSITION AND HEALTH EFFECTS OF HUMAN MILK;EFFICACY AND RESISTANCE IN CML TREATMENT;EPIDEMIOLOGY AND MANAGEMENT OF CYTOMEGALOVIRUS INFECTION;EPIDEMIOLOGY AND TREATMENT OF CHILDHOOD LEUKEMIA","12;9;9;8;8;8;7;6;6;5;5;5;5;4;4;4;4;4;4;4","PET IMAGING;TREATMENT;LIVER TRANSPLANTATION;AORTIC DISSECTION;LIVER DISEASE;PANCREATIC NEUROENDOCRINE TUMORS;PET/CT;LIVER BIOPSY;REGIMEN;VENOUS THROMBOEMBOLISM;DIAGNOSIS;TRANSPLANTATION;TYPE B AORTIC DISSECTION;UNIVARIATE ANALYSIS;AORTIC ROOT REPLACEMENT;CYTOMEGALOVIRUS;DEEP VEIN THROMBOSIS;ECHOCARDIOGRAPHY;FETAL DNA ANALYSIS;FOLLICULAR LYMPHOMA","14;14;9;8;8;8;8;7;7;7;6;6;6;6;5;5;5;5;5;5","LIVER TRANSPLANTATION;HEPATOCELLULAR CARCINOMA;ACUTE LYMPHOBLASTIC;BREAST CANCER;GASTROINTESTINAL STROMAL;LYMPHOBLASTIC LEUKEMIA;MULTIPLE MYELOMA;PATIENTS TREATED;RISK FACTORS;AORTIC DISSECTION;CLINICAL PRACTICE;COLORECTAL CANCER;FOLLICULAR LYMPHOMA;LIVER DISEASE;MYELOID LEUKEMIA;PANCREATIC ENDOCRINE;STROMAL TUMORS;VENOUS THROMBOEMBOLISM;ACUTE MYELOID;AORTIC VALVE;CANCER CELLS;CANCER PATIENTS;CELL LYMPHOMA;CLINICAL OUTCOMES;CLINICAL TRIAL;COMPUTED TOMOGRAPHY;CORD BLOOD;ENDOCRINE TUMORS;FACTOR RECEPTOR;FDG PET","8;6;5;5;5;5;5;5;5;4;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3","PUBMED SCOPUS;CROSSREF PUBMED;COLORECTAL CANCER;GROWTH FACTOR;EPIDERMAL GROWTH;BOLOGNA ITALY;FACTOR RECEPTOR;CROSSREFGOOGLE SCHOLAR;HOSPITAL UNIVERSITY;CAR CRASHES;CLIN ONCOL;LIVER DISEASE;METASTATIC COLORECTAL;BOLOGNA BOLOGNA;INTERNAL MEDICINE;BAD SLEEP;CYTOGENETIC RESPONSE;RISK FACTORS;BREAST CANCER;LIVER TRANSPLANTATION;MAGNETIC RESONANCE;STEM CELL;TACROLIMUS BID;INCREASED RISK;SORSOLA-MALPIGHI HOSPITAL;STEM CELLS;BONE MARROW;DAYTIME SLEEPINESS;GENET -CROSSREF;LOGISTIC REGRESSION","60;56;34;34;25;24;24;23;20;19;17;16;15;14;14;13;13;13;12;12;12;12;12;11;11;11;10;10;10;10",67,0.16,5.54,2,1,1,7,7.75,3,1,1,2.5,0,1,2,1,1.25,1,1.5,1,1,0,0,90.5,92,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,37,5.11,939.18,5.47,7,0.19,44.08,0,0,13,0,11,0,5,8,0,23,6,0,0,0,0,0,0,34,3,0,28,8,0,1,0,0,0,0,0,0,"Italy;United States;Germany;Netherlands;Spain;Switzerland","8;5;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;42 HEALTH SCIENCES;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;3215 REPRODUCTIVE MEDICINE;3212 OPHTHALMOLOGY AND OPTOMETRY;4203 HEALTH SERVICES AND SYSTEMS;4205 NURSING;3204 IMMUNOLOGY;3206 MEDICAL BIOTECHNOLOGY;40 ENGINEERING;4003 BIOMEDICAL ENGINEERING;4204 MIDWIFERY;4206 PUBLIC HEALTH;44 HUMAN SOCIETY;4403 DEMOGRAPHY","34;18;10;5;4;3;3;2;2;2;1;1;1;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;RARE DISEASES;CARDIOVASCULAR;HEMATOLOGY;DIGESTIVE DISEASES;BIOENGINEERING;PATIENT SAFETY;PREVENTION;ASSISTIVE TECHNOLOGY;HEART DISEASE;KIDNEY DISEASE;NEUROSCIENCES;ORPHAN DRUG;PEDIATRIC;STEM CELL RESEARCH;TRANSPLANTATION;ATHEROSCLEROSIS;BIOMEDICAL IMAGING","28;16;11;11;7;7;5;4;4;4;3;3;3;3;3;3;3;3;2;2","CANCER;CARDIOVASCULAR;BLOOD;EYE;RENAL AND UROGENITAL;INFLAMMATORY AND IMMUNE SYSTEM;ORAL AND GASTROINTESTINAL;REPRODUCTIVE HEALTH AND CHILDBIRTH","10;5;2;2;2;1;1;1","6.1 PHARMACEUTICALS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.2 CELLULAR AND GENE THERAPIES;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;6.3 MEDICAL DEVICES;5.2 CELLULAR AND GENE THERAPIES;5.3 MEDICAL DEVICES;6.4 SURGERY;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES;7.1 INDIVIDUAL CARE NEEDS","17;5;3;2;2;2;1;1;1;1;1","LEUKEMIA / LEUKAEMIA;NON-HODGKIN'S LYMPHOMA;BREAST CANCER;COLON AND RECTAL CANCER;KIDNEY CANCER;LIVER CANCER;BLOOD CANCER;GASTROINTESTINAL TRACT;HODGKIN'S DISEASE;NOT SITE-SPECIFIC CANCER;PANCREATIC CANCER;PROSTATE CANCER;STOMACH CANCER","3;3;2;2;2;2;1;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;5.5 COMBINATIONS OF LOCALIZED AND SYSTEMIC THERAPIES","9;4;1;1",1,74657,74657,3,1,1,0,0,24885.6666666667,16.3547959334021,"POLICLINICO S.ORSOLA-MALPIGHI","1","BILL & MELINDA GATES FOUNDATION","1","COALITION S","1",NA,NA,"32 BIOMEDICAL AND CLINICAL SCIENCES;3207 MEDICAL MICROBIOLOGY","1;1",NA,NA,"INFECTION","1",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_SANTORSOLA",2011,449,10.1135857461024,3.57238307349666,0.505567928730512,0.434298440979955,0.570155902004454,1.89928909952607,1.31976744186047,1.72566371681416,1.31282051282051,0.429844097995546,10,246,89,46,36,0.55,0.2,0.1,0.08,39.62,0.93146391980252,NA,0.285077951002227,0.812917594654788,0.47,0.429,0.451,0.428,"STEFANO FANTI;G. PILU;T. GHI;STEFANO PILERI;PIER LUIGI ZINZANI;MICHELE BACCARANI;A. YOUSSEF;ANDREA PESSION;PIER PAOLO PICCALUGA;ANTONIO DANIELE PINNA;DONATELLA SANTINI;GIOVANNI MARTINELLI;TULLIO PALMERINI;RITA GOLFIERI;GUIDO BIASCO;NICOLA RIZZO;ANTONÍO MARZOCCHI;GUALTIERO PALARETI;E. MARONI;FABIO MUSSO","18;17;16;14;14;13;13;12;11;11;11;11;10;10;10;10;10;9;9;9","FEDERICA GUARALDI;RENATO PASQUALI;STEFANO FANTI;RAFFAELE PEZZILLI;G. PILU;CLAUDIO MARCHETTI;T. GHI;CLAUDIO RAPEZZI;TULLIO PALMERINI;A. YOUSSEF;GUALTIERO PALARETI;NICOLA RIZZO;GIACOMO FALDELLA;FRANCESCO AZZAROLI;ANTONIO SANTORO;RENATO SERACCHIOLI;ANDREA PESSION;GUIDO BIASCO;STEFANO PILERI;SERGIO SABBATANI","3;2.87;2.05;1.95;1.94;1.9;1.86;1.85;1.54;1.51;1.38;1.36;1.31;1.31;1.25;1.18;1.18;1.16;1.14;1.14","STEFANO FANTI;G. PILU;T. GHI;STEFANO PILERI;PIER LUIGI ZINZANI;MICHELE BACCARANI;A. YOUSSEF;ANDREA PESSION;PIER PAOLO PICCALUGA;ANTONIO DANIELE PINNA;DONATELLA SANTINI;GIOVANNI MARTINELLI;TULLIO PALMERINI;RITA GOLFIERI;GUIDO BIASCO;NICOLA RIZZO;ANTONÍO MARZOCCHI;GUALTIERO PALARETI;E. MARONI;FABIO MUSSO","18;17;16;14;14;13;13;12;11;11;11;11;10;10;10;10;10;9;9;9","FEDERICA GUARALDI;RENATO PASQUALI;STEFANO FANTI;RAFFAELE PEZZILLI;G. PILU;CLAUDIO MARCHETTI;T. GHI;CLAUDIO RAPEZZI;TULLIO PALMERINI;A. YOUSSEF;GUALTIERO PALARETI;NICOLA RIZZO;GIACOMO FALDELLA;FRANCESCO AZZAROLI;ANTONIO SANTORO;RENATO SERACCHIOLI;ANDREA PESSION;GUIDO BIASCO;STEFANO PILERI;SERGIO SABBATANI","3;2.87;2.05;1.95;1.94;1.9;1.86;1.85;1.54;1.51;1.38;1.36;1.31;1.31;1.25;1.18;1.18;1.16;1.14;1.14","MICHELE BACCARANI;FABIO PISCAGLIA;RITA GOLFIERI;MICHELE BERTOLOTTO;LIBERO BAROZZI;GIOVANNI MARTINELLI;PAUL S. SIDHU;D. TIMMERMAN;A IGNEE;ADRIAN SǍFTOIU;ANDREA KLAUSER;C. DIETRICH;CHRISTIAN NOLSØE;DAVID O. COSGROVE;DIRK‐ANDRÉ CLEVERT;E.M. JUNG;EDWARD LEEN;FRANCESCO MARIA DRUDI;G SEIDEL;G. MATHIS","2022;1393;1351;1236;1185;1182;1131;1022;1021;1021;1021;1021;1021;1021;1021;1021;1021;1021;1021;1021","MICHELE BACCARANI;LIBERO BAROZZI;GIOVANNI MARTINELLI;STEFANO FANTI;GIANANTONIO ROSTI;PAOLA FORTI;GUALTIERO PALARETI;ALBERTA CAPPELLI;FAUSTO CATENA;ANTONIO DANIELE PINNA;CINZIA PETTINATO;ANDREA BONTADINI;ILARIA IACOBUCCI;ORNELLA LEONE;SIMONA SOVERINI;ROBERTO M. LEMOLI;ANDREA PESSION;FIORENZA FRUET;STEFANIA PAOLINI;UMBERTO VOLTA","1815;1185;1011;848;822;747;652;615;578;526;486;464;435;432;428;417;416;373;370;366","STEFANO FANTI;T. GHI;G. PILU;A. YOUSSEF;N. RIZZO;STEFANO PILERI;MICHELE BACCARANI;ANTONIO DANIELE PINNA;FAUSTO CATENA;PIER PAOLO PICCALUGA;PIER LUIGI ZINZANI;ANDREA PESSION;GUALTIERO PALARETI;ANTONIO FARINA;FABIO MUSSO;NICOLA RIZZO;CRISTINA NANNI;DONATELLA SANTINI;E. MARONI;GUIDO BIASCO","16;15;15;12;12;12;11;11;10;10;10;9;9;9;9;9;8;8;8;8","MEDICINE;BIOLOGY;PHYSICS;COMPUTER SCIENCE;ENGINEERING;CHEMISTRY;MATHEMATICS;PSYCHOLOGY;SOCIOLOGY;HISTORY;POLITICAL SCIENCE;ECONOMICS;MATERIALS SCIENCE;PHILOSOPHY;BUSINESS;GEOGRAPHY;ART;GEOLOGY","421;155;32;28;27;25;20;15;11;10;10;5;5;5;4;4;2;2","INTERNAL MEDICINE;SURGERY;GENETICS;PATHOLOGY;RADIOLOGY;IMMUNOLOGY;GASTROENTEROLOGY;CARDIOLOGY;ONCOLOGY;ENVIRONMENTAL HEALTH;INTENSIVE CARE MEDICINE;BIOCHEMISTRY;OBSTETRICS;CANCER RESEARCH;NUCLEAR MEDICINE;PEDIATRICS;ANESTHESIA;ENDOCRINOLOGY;PSYCHIATRY;GYNECOLOGY","301;131;86;81;81;65;61;59;44;38;34;32;31;29;29;28;23;23;23;22","CANCER;GENE;DISEASE;POPULATION;PREGNANCY;TRANSPLANTATION;CHEMOTHERAPY;CONFIDENCE INTERVAL;LYMPHOMA;MYOCARDIAL INFARCTION;HEPATOCELLULAR CARCINOMA;MAGNETIC RESONANCE IMAGING;CLINICAL TRIAL;INCIDENCE (GEOMETRY);ANTIBODY;CIRRHOSIS;PROSPECTIVE COHORT STUDY;ULTRASOUND;VIRUS;LEUKEMIA;MYELOID LEUKEMIA;STEM CELL","51;47;39;39;33;29;23;23;21;21;18;18;17;17;16;16;16;16;16;15;15;15","LIVER TRANSPLANTATION;COLORECTAL CANCER;FETUS;BREAST CANCER;GESTATION;GENOTYPE;PERCUTANEOUS CORONARY INTERVENTION;HAZARD RATIO;IMATINIB;EJECTION FRACTION;MUTATION;RITUXIMAB;CLINICAL ENDPOINT;GENE EXPRESSION;UNIVARIATE ANALYSIS;BONE MINERAL;CYCLOPHOSPHAMIDE;CONVENTIONAL PCI;GESTATIONAL AGE;SEROLOGY;VENOUS THROMBOSIS","19;16;15;13;12;11;11;10;10;9;9;9;8;8;8;7;7;6;6;6;6","CARDIAC RESYNCHRONIZATION THERAPY;FLUDARABINE;COLONOSCOPY;DASATINIB;GENE EXPRESSION PROFILING;IMATINIB MESYLATE;NEOADJUVANT THERAPY;PRENATAL DIAGNOSIS;CETUXIMAB;ELEPHANT TRUNKS;HAPLOTYPE;MILAN CRITERIA;NILOTINIB;PERIPHERAL T-CELL LYMPHOMA;RADIOIMMUNOTHERAPY;TWIN PREGNANCY;UTERINE ARTERY;ACUTE LYMPHOCYTIC LEUKEMIA;ANEUPLOIDY;CANNABINOID RECEPTOR;CAPECITABINE;CLOFARABINE;COLPOSCOPY;CONGENITAL SYPHILIS;DISCOVERY AND DEVELOPMENT OF MTOR INHIBITORS;ENTEROBACTERIACEAE;ESTROGEN RECEPTOR;FIRST TRIMESTER;GENE MUTATION;GERMLINE MUTATION;HBSAG;HERPESVIRIDAE;HYDROPS FETALIS;INTERNATIONAL PROGNOSTIC INDEX;INTRAUTERINE GROWTH RESTRICTION;KARYOTYPE;KILLIP CLASS;KLEBSIELLA PNEUMONIAE;LAMIVUDINE;MACE;MISSENSE MUTATION;MTORC1;PANCREATIC DUCTAL ADENOCARCINOMA;PLACENTA;PLACENTAL GROWTH FACTOR;PRIMARY ANGIOPLASTY;RESPIRATORY RATE;SINGLE-NUCLEOTIDE POLYMORPHISM;TERIPARATIDE;TIMI;TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT","7;5;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","HUMANS;FEMALE;MALE;;MIDDLE AGED;AGED;ADULT;AGED, 80 AND OVER;ITALY;TREATMENT OUTCOME;YOUNG ADULT;ADOLESCENT;LIVER NEOPLASMS;RETROSPECTIVE STUDIES;CARCINOMA, HEPATOCELLULAR;RISK FACTORS;ANTINEOPLASTIC AGENTS;FOLLOW-UP STUDIES;PROSPECTIVE STUDIES;TOMOGRAPHY, X-RAY COMPUTED","292;205;182;148;146;127;125;62;61;57;51;47;45;43;42;39;35;34;33;33","LYMPHOID NEOPLASMS;PREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;HEPATOCELLULAR CARCINOMA;LIVER CIRRHOSIS AND ASSOCIATED COMPLICATIONS;EFFICACY AND RESISTANCE IN CML TREATMENT;HEPATITIS C INFECTION AND TREATMENT;PATHOPHYSIOLOGY AND MANAGEMENT OF PREECLAMPSIA;DIAGNOSIS AND MANAGEMENT OF AORTIC DISEASES;MANAGEMENT OF VALVULAR HEART DISEASE;OSTEOPOROSIS;ACUTE MYELOID LEUKEMIA;DIAGNOSIS AND TREATMENT OF GASTROINTESTINAL STROMAL TUMORS;EPIDEMIOLOGY AND MANAGEMENT OF CYTOMEGALOVIRUS INFECTION;EPIDEMIOLOGY AND MANAGEMENT OF NAFLD;MANAGEMENT OF ACUTE MYOCARDIAL INFARCTION;MECHANICAL VENTILATION IN RESPIRATORY FAILURE AND ARDS;CHRONIC KIDNEY DISEASE AND DIALYSIS TREATMENT;DIAGNOSIS AND MANAGEMENT OF CELIAC DISEASE;DIAGNOSIS AND MANAGEMENT OF ENDOMETRIOSIS","15;9;8;8;8;7;7;7;6;6;6;5;5;5;5;5;5;4;4;4","TREATMENT;DIAGNOSIS;LIVER BIOPSY;CLINICAL ENDPOINT;LIVER CIRRHOSIS;REGIMEN;TRANSCATHETER AORTIC-VALVE REPLACEMENT;UNIVARIATE ANALYSIS;LIVER DISEASE;LIVER TRANSPLANTATION;STROKE (ENGINE);AORTIC DISSECTION;AORTIC ROOT REPLACEMENT;CONCOMITANT;DIABETES;ECHOCARDIOGRAPHY;HEPATOCELLULAR CARCINOMA;LIVER CANCER;PROSTHETIC VALVES EVALUATION;CARDIAC IMAGING","14;11;10;8;8;8;8;8;7;7;7;6;6;6;6;6;6;6;6;5","LIVER TRANSPLANTATION;HEPATOCELLULAR CARCINOMA;MYELOID LEUKEMIA;STEM CELL;STEM CELLS;ACUTE LYMPHOBLASTIC;AORTIC VALVE;CLINICAL TRIAL;MYOCARDIAL INFARCTION;PERCUTANEOUS CORONARY;ACUTE MYELOID;GASTROINTESTINAL STROMAL;LYMPHOBLASTIC LEUKEMIA;MEDICAL PHILATELY;PILOT STUDY;ATRIAL FIBRILLATION;CELL TRANSPLANTATION;CORONARY ARTERY;ELEVATION ACUTE;FOLLICULAR LYMPHOMA;GENE EXPRESSION;HEMATOPOIETIC STEM;LIVER DISEASE;MESENCHYMAL STEM;MULTICENTER STUDY;OBSERVATIONAL STUDY;PATIENTS TREATED;PHASE II;PRIMARY PERCUTANEOUS;RANDOMIZED CLINICAL","14;13;7;7;7;6;6;6;6;6;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4","PUBMED SCOPUS;CONFIDENCE INTERVAL;CROSSREF PUBMED;ASCENDING AORTA;PATIENTS RECEIVED;RISK FACTORS;STEM CELLS;BACTERIAL INFECTIONS;HAZARD RATIO;ADVERSE EVENTS;POSITIVE HCCS;PRETERM INFANTS;TWIN PREGNANCIES;UNIVERSITY HOSPITAL;COMPUTED TOMOGRAPHY;INCREASED RISK;MULTIVARIATE ANALYSIS;REFERENCE INTERVALS;STRIPPED PLASMA;CB RECEPTOR;COMPLETE REMISSION;GESTATIONAL AGE;GROWTH FACTOR;INTERVAL CI;LIVER TRANSPLANTATION;MESENCHYMAL STEM;MYELOID LEUKEMIA;PATIENTS TREATED;PATIENTS UNDERGOING;ACUTE LYMPHOBLASTIC","20;19;16;12;12;12;12;11;11;10;10;10;10;10;9;9;9;9;9;8;8;8;8;8;8;8;8;8;8;7",103,0.23,6,3,1,1,0,4,2,0,1,3,0,1,3,1,2,1,1.5,2,1.5,0,0,100.5,100.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,43,5.58,1178.55,5.68,17,0.4,57.65,1,0,16,0,10,0,2,14,0,27,11,0,0,0,0,0,0,41,1,1,38,5,0,0,0,0,0,0,0,0,"United States;Italy;Canada;Japan;United Kingdom","7;4;2;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;40 ENGINEERING;42 HEALTH SCIENCES;31 BIOLOGICAL SCIENCES;3107 MICROBIOLOGY;3212 OPHTHALMOLOGY AND OPTOMETRY;3213 PAEDIATRICS;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;4003 BIOMEDICAL ENGINEERING;4007 CONTROL ENGINEERING, MECHATRONICS AND ROBOTICS;4203 HEALTH SERVICES AND SYSTEMS;52 PSYCHOLOGY;5203 CLINICAL AND HEALTH PSYCHOLOGY","41;19;17;12;2;2;1;1;1;1;1;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;RARE DISEASES;HEMATOLOGY;CARDIOVASCULAR;PATIENT SAFETY;DIGESTIVE DISEASES;HEART DISEASE;LYMPHOMA;ORPHAN DRUG;PREVENTION;GENETICS;HEART DISEASE - CORONARY HEART DISEASE;KIDNEY DISEASE;LIVER DISEASE;NEUROSCIENCES;ATHEROSCLEROSIS;BIOMEDICAL IMAGING;CHRONIC LIVER DISEASE AND CIRRHOSIS","31;21;19;18;11;9;9;8;7;5;5;4;3;3;3;3;3;2;2;2","CANCER;CARDIOVASCULAR;INFECTION;INFLAMMATORY AND IMMUNE SYSTEM;METABOLIC AND ENDOCRINE;ORAL AND GASTROINTESTINAL;REPRODUCTIVE HEALTH AND CHILDBIRTH;RESPIRATORY","16;9;2;1;1;1;1;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;5.1 PHARMACEUTICALS;6.3 MEDICAL DEVICES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;3.1 PRIMARY PREVENTION INTERVENTIONS TO MODIFY BEHAVIOURS OR PROMOTE WELLBEING;5.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES;6.4 SURGERY;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES;6.7 PHYSICAL","21;9;4;3;2;1;1;1;1;1;1","NON-HODGKIN'S LYMPHOMA;LIVER CANCER;MYELOMA;LEUKEMIA / LEUKAEMIA;THYROID CANCER;BLOOD CANCER;BRAIN TUMOR;COLON AND RECTAL CANCER;GALLBLADDER CANCER;HEAD AND NECK CANCER;NEUROBLASTOMA;NOT SITE-SPECIFIC CANCER;OVARIAN CANCER;PANCREATIC CANCER;SKIN CANCER","6;4;3;2;2;1;1;1;1;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;2.1 EXOGENOUS FACTORS IN THE ORIGIN AND CAUSE OF CANCER;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","16;1;1;1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,1,"PUBLIC LIBRARY OF SCIENCE","1","32 BIOMEDICAL AND CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY","2;1","HEMATOLOGY;REGENERATIVE MEDICINE;STEM CELL RESEARCH;STEM CELL RESEARCH - NONEMBRYONIC - NON-HUMAN","1;1;1;1","BLOOD;GENERIC HEALTH RELEVANCE","1;1","1.1 NORMAL BIOLOGICAL DEVELOPMENT AND FUNCTIONING;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS","1;1","BIOMEDICAL","1","BASIC SCIENCE","1","LEUKEMIA / LEUKAEMIA;NOT SITE-SPECIFIC CANCER","1;1",NA,NA
"IRCCS_SANTORSOLA",2012,520,10.5730769230769,3.45961538461538,0.503846153846154,0.401923076923077,0.686538461538462,2.11150234741784,1.49714285714286,1.83333333333333,1.60810810810811,0.380769230769231,11,266,105,45,56,0.51,0.2,0.09,0.11,33.73,0.807429842248478,5.84751598622727,0.253846153846154,0.801923076923077,0.486,0.453,0.454,0.456,"RAFFAELE PEZZILLI;STEFANO FANTI;DONATELLA SANTINI;RICCARDO CASADEI;FRANCESCO MINNI;MICHELE BACCARANI;MARIELDA D’AMBRA;CLAUDIO RICCI;CRISTINA NANNI;GIOVANNI TAFFURELLI;SALVATORE BUSCEMI;VALENTINA AMBROSINI;ANDREA PESSION;RITA GOLFIERI;GUIDO BIASCO;G. PILU;GIACOMO FALDELLA;T. GHI;GUALTIERO PALARETI;GIORGIO ERCOLANI","32;27;25;25;21;18;18;16;16;14;14;13;13;12;12;12;11;11;10;10","RAFFAELE PEZZILLI;MICHELE BACCARANI;MASSIMILIANO POLASTRI;STEFANO FANTI;RICCARDO CASADEI;DONATELLA SANTINI;PAOLO CASTELLUCCI;RENATO PASQUALI;FRANCESCO MINNI;CRISTINA NANNI;GIACOMO FALDELLA;MARIELDA D’AMBRA;CLAUDIO BORGHI;ALESSANDRA GAMBINERI;ANTONIO P. CIARDELLA;CLAUDIO RICCI;RITA GOLFIERI;VALENTINA AMBROSINI;ROBERTO DI BARTOLOMEO;STEFANO NAVA","6.18;3.86;3.83;3.08;2.55;2.36;2.07;1.84;1.84;1.75;1.63;1.61;1.5;1.47;1.42;1.41;1.39;1.34;1.33;1.33","RAFFAELE PEZZILLI;STEFANO FANTI;DONATELLA SANTINI;RICCARDO CASADEI;FRANCESCO MINNI;MICHELE BACCARANI;MARIELDA D’AMBRA;CLAUDIO RICCI;CRISTINA NANNI;GIOVANNI TAFFURELLI;SALVATORE BUSCEMI;VALENTINA AMBROSINI;ANDREA PESSION;RITA GOLFIERI;GUIDO BIASCO;G. PILU;GIACOMO FALDELLA;T. GHI;GUALTIERO PALARETI;GIORGIO ERCOLANI","32;27;25;25;21;18;18;16;16;14;14;13;13;12;12;12;11;11;10;10","RAFFAELE PEZZILLI;MICHELE BACCARANI;MASSIMILIANO POLASTRI;STEFANO FANTI;RICCARDO CASADEI;DONATELLA SANTINI;PAOLO CASTELLUCCI;RENATO PASQUALI;FRANCESCO MINNI;CRISTINA NANNI;GIACOMO FALDELLA;MARIELDA D’AMBRA;CLAUDIO BORGHI;ALESSANDRA GAMBINERI;ANTONIO P. CIARDELLA;CLAUDIO RICCI;RITA GOLFIERI;VALENTINA AMBROSINI;ROBERTO DI BARTOLOMEO;STEFANO NAVA","6.18;3.86;3.83;3.08;2.55;2.36;2.07;1.84;1.84;1.75;1.63;1.61;1.5;1.47;1.42;1.41;1.39;1.34;1.33;1.33","LUIGI BOLONDI;GUIDO GERKEN;PETER R. GALLE;STEFANO FANTI;DAVIDE PACINI;ARMANDO SANTORO;ANTONIO CRAXÌ;A. SANGIOVANNI;ANDREA NADEL;CAMILLO PORTA;D. VOLIOTIS;JEAN‐LUC RAOUL;JORDI BRUIX;JORGE A. MARRERO;JOSEP M. LLOVET;M. MOSCOVICI;MICHAEL SHAN;MICHEL BEAUGRAND;MORRIS SHERMAN;VINCENZO MAZZAFERRO","1419;1141;1141;916;868;796;777;773;773;773;773;773;773;773;773;773;773;773;773;773","LUIGI BOLONDI;DAVIDE PACINI;ROBERTO DI BARTOLOMEO;R. FATTORI;STEFANO FANTI;MICHELE BACCARANI;RITA GOLFIERI;GUALTIERO PALARETI;ANNAMARIA BRIOLI;MICHÈLE CAVO;ANTONÍO MARZOCCHI;MATTEO RENZULLI;ELENA ZAMAGNI;FRANCESCA RICCI;PIER LUIGI TAZZARI;FRANCESCA FORNARI;LAURA GRAMANTIERI;CRISTINA NANNI;EMANUELA GIAMPALMA;ELENA MANCINI","1315;868;707;643;583;581;479;453;421;421;416;408;406;405;405;400;400;381;380;368","STEFANO FANTI;RICCARDO CASADEI;RAFFAELE PEZZILLI;MICHELE BACCARANI;CRISTINA NANNI;VALENTINA AMBROSINI;RITA GOLFIERI;ANTONIO DANIELE PINNA;G. PILU;DONATELLA SANTINI;GUALTIERO PALARETI;T. GHI;FRANCO STELLA;ANTONIO P. CIARDELLA;A. YOUSSEF;ALESSANDRA GAMBINERI;GIORGIO ERCOLANI;MARIACHIARA MORARA;RICCARDO MASETTI;ANDREA DELL’AMORE","22;18;16;13;12;12;12;11;11;11;10;10;9;9;8;8;8;8;8;8","MEDICINE;BIOLOGY;PHYSICS;CHEMISTRY;ENGINEERING;COMPUTER SCIENCE;MATHEMATICS;PSYCHOLOGY;MATERIALS SCIENCE;ECONOMICS;HISTORY;POLITICAL SCIENCE;SOCIOLOGY;PHILOSOPHY;GEOGRAPHY;ART;BUSINESS;GEOLOGY","483;171;36;31;27;24;19;16;10;9;7;7;6;5;4;1;1;1","INTERNAL MEDICINE;SURGERY;PATHOLOGY;GENETICS;RADIOLOGY;GASTROENTEROLOGY;ONCOLOGY;CARDIOLOGY;IMMUNOLOGY;NUCLEAR MEDICINE;CANCER RESEARCH;BIOCHEMISTRY;PALEONTOLOGY;ENVIRONMENTAL HEALTH;INTENSIVE CARE MEDICINE;ENDOCRINOLOGY;PEDIATRICS;CELL BIOLOGY;OPTICS;ANESTHESIA","371;161;94;92;85;68;64;60;53;47;43;41;40;38;34;32;30;29;25;23","CANCER;GENE;DISEASE;POPULATION;CHEMOTHERAPY;PREGNANCY;TRANSPLANTATION;CONFIDENCE INTERVAL;ADVERSE EFFECT;MYOCARDIAL INFARCTION;MYELOID LEUKEMIA;RANDOMIZED CONTROLLED TRIAL;DIABETES MELLITUS;HEART FAILURE;POSITRON EMISSION TOMOGRAPHY;STAGE (STRATIGRAPHY);STEM CELL;ANTIBODY;CONTEXT (ARCHAEOLOGY);COHORT;INCIDENCE (GEOMETRY)","86;59;43;37;36;34;32;28;23;23;21;21;20;19;19;18;18;17;17;16;16","COLORECTAL CANCER;FETUS;ADENOCARCINOMA;HAZARD RATIO;PERCUTANEOUS CORONARY INTERVENTION;PET-CT;GENOTYPE;IMATINIB;MUTATION;PROSTATE CANCER;BREAST CANCER;INSULIN RESISTANCE;LIVER TRANSPLANTATION;EJECTION FRACTION;METASTASIS;OVARIAN CANCER;PANCREATIC CANCER;CLINICAL ENDPOINT;CONVENTIONAL PCI;GENE EXPRESSION;GESTATIONAL AGE","23;19;13;13;12;12;11;11;11;11;10;10;10;9;9;9;9;8;8;8;8","IMATINIB MESYLATE;KRAS;NILOTINIB;POLYCYSTIC OVARY;PROSTATECTOMY;CETUXIMAB;IRINOTECAN;ANTIRETROVIRAL THERAPY;DASATINIB;FERTILITY PRESERVATION;HERPESVIRIDAE;OXALIPLATIN;PDGFRA;SINGLE-NUCLEOTIDE POLYMORPHISM;BASILIXIMAB;CAPECITABINE;CONGENITAL DIAPHRAGMATIC HERNIA;CYTOREDUCTIVE SURGERY;DACLIZUMAB;DEBULKING;DUAL-ENERGY X-RAY ABSORPTIOMETRY;FLUDARABINE;GENOTYPING;IDARUBICIN;MEN1;PANCREATIC TUMOR;PHARMACOGENETICS;SANGER SEQUENCING;THYMOGLOBULIN","7;7;7;6;6;5;5;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3","HUMANS;FEMALE;MALE;;MIDDLE AGED;ADULT;AGED;TREATMENT OUTCOME;ITALY;AGED, 80 AND OVER;RETROSPECTIVE STUDIES;YOUNG ADULT;LIVER NEOPLASMS;PROSPECTIVE STUDIES;ADOLESCENT;RISK FACTORS;TOMOGRAPHY, X-RAY COMPUTED;TIME FACTORS;FOLLOW-UP STUDIES;ANTINEOPLASTIC AGENTS","306;231;201;198;145;124;123;81;70;62;50;44;43;39;37;37;36;35;34;32","PANCREATIC CANCER RESEARCH AND TREATMENT;EFFICACY AND RESISTANCE IN CML TREATMENT;HEPATOCELLULAR CARCINOMA;LYMPHOID NEOPLASMS;ACUTE MYELOID LEUKEMIA;EPIDEMIOLOGY AND MANAGEMENT OF CYTOMEGALOVIRUS INFECTION;MANAGEMENT OF VALVULAR HEART DISEASE;ORGAN TRANSPLANTATION AND REJECTION;POSITRON EMISSION TOMOGRAPHY IMAGING IN ONCOLOGY;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;DIAGNOSIS AND MANAGEMENT OF AORTIC DISEASES;DIAGNOSIS AND MANAGEMENT OF PANCREATITIS;DIAGNOSIS AND MANAGEMENT OF POLYCYSTIC OVARY SYNDROME;DIAGNOSIS AND TREATMENT OF GASTROINTESTINAL STROMAL TUMORS;EPIDEMIOLOGY AND MANAGEMENT OF NEUROENDOCRINE TUMORS;MECHANICAL VENTILATION IN RESPIRATORY FAILURE AND ARDS;MOLECULAR PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;DEVELOPMENT AND DISORDERS OF FETAL BRAIN;EPIDEMIOLOGY AND TREATMENT OF CHILDHOOD LEUKEMIA","20;11;11;11;7;7;7;7;7;6;6;6;6;6;6;6;6;5;5;5","TREATMENT;PET/CT;PET-CT;PANCREATIC CANCER;PANCREATIC NEUROENDOCRINE TUMORS;TRANSCATHETER AORTIC-VALVE REPLACEMENT;DIAGNOSIS;PANCREATIC DISEASE;PET IMAGING;STROKE (ENGINE);CARDIAC IMAGING;CLINICAL ENDPOINT;CONCOMITANT;IMATINIB MESYLATE;NONINVASIVE VENTILATION;FETAL MRI;METASTATIC PANCREATIC CANCER;PRENATAL DIAGNOSIS;PROSTHETIC VALVES EVALUATION;REGIMEN","18;15;12;11;11;11;10;9;9;9;7;7;7;7;7;6;6;6;6;6","MYELOID LEUKEMIA;CHRONIC MYELOID;HEPATOCELLULAR CARCINOMA;STEM CELLS;CANCER PATIENTS;PATIENTS TREATED;LEFT VENTRICULAR;MESENCHYMAL STEM;PROSTATE CANCER;COLORECTAL CANCER;FDG PETCT;GASTROINTESTINAL STROMAL;PATIENTS AFFECTED;PRELIMINARY RESULTS;AORTIC VALVE;BREAST CANCER;MAGNETIC RESONANCE;MITOCHONDRIAL DNA;MULTICENTER STUDY;PANCREATIC CANCER;PRETERM INFANTS;TRANSPLANT RECIPIENTS;TYPE DIABETES;ACUTE CORONARY;ACUTE LYMPHOBLASTIC;ACUTE MYELOID;BIOCHEMICAL RELAPSE;C-CHOLINE PETCT;CANCER CELLS;CARE UNIT","16;12;11;10;8;8;7;7;7;6;6;6;6;6;5;5;5;5;5;5;5;5;5;4;4;4;4;4;4;4","PUBMED SCOPUS;CROSSREF PUBMED;CELL LINES;TURCO MC;PANCREATIC CANCER;MITRAL VALVE;MULTIPLE SCLEROSIS;BAG EXPRESSION;CONFIDENCE INTERVAL;RESISTANT ACR;STEROID RESISTANT;TRANSPLANT RECIPIENTS;BOLOGNA ITALY;HEPATOCELLULAR CARCINOMA;RENAL FUNCTION;BAG PROTEIN;CELL CYCLE;CLINICAL PRACTICE;NEUROLOGY UNIT;ODDS RATIO;RISK FACTORS;VALVE REPLACEMENT;CANCER CELLS;CHEST WALL;EBV INFECTION;ELDERLY PATIENTS;MC LEONE;PATIENTS UNDERWENT;SCLEROSIS CENTER;STEM CELLS","92;67;28;26;25;24;24;23;23;16;16;16;15;15;15;14;14;14;14;14;14;13;12;12;12;12;12;12;12;12",143,0.28,3.25,3,1,1,1.75,1,3,1,1,4,0,1,3,1,1.25,1,1,2,2,0,0,65.5,66,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,38,5.32,1098.19,4.96,14,0.37,54.26,0,2,9,0,11,0,3,13,0,23,8,0,0,0,0,0,0,32,4,2,31,7,0,0,0,0,0,0,0,0,"United States;Italy;Austria;Germany","10;5;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3215 REPRODUCTIVE MEDICINE;3204 IMMUNOLOGY;3208 MEDICAL PHYSIOLOGY;3210 NUTRITION AND DIETETICS;3212 OPHTHALMOLOGY AND OPTOMETRY;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;40 ENGINEERING;4011 ENVIRONMENTAL ENGINEERING;52 PSYCHOLOGY","37;16;12;10;4;1;1;1;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;HEMATOLOGY;RARE DISEASES;DIGESTIVE DISEASES;LYMPHOMA;LIVER DISEASE;PREVENTION;CARDIOVASCULAR;CHRONIC LIVER DISEASE AND CIRRHOSIS;HEPATITIS;INFECTIOUS DISEASES;KIDNEY DISEASE;ORPHAN DRUG;PATIENT SAFETY;PEDIATRIC;BIOMEDICAL IMAGING;CHILDHOOD LEUKEMIA;COLO-RECTAL CANCER","29;20;14;11;11;7;6;5;5;4;4;3;3;3;3;3;3;2;2;2","CANCER;ORAL AND GASTROINTESTINAL;CARDIOVASCULAR;INFECTION;RENAL AND UROGENITAL;RESPIRATORY;BLOOD;METABOLIC AND ENDOCRINE","12;4;3;2;2;2;1;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;6.4 SURGERY;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;4.4 POPULATION SCREENING;5.1 PHARMACEUTICALS;5.2 CELLULAR AND GENE THERAPIES;7.1 INDIVIDUAL CARE NEEDS","21;5;2;1;1;1;1;1","NON-HODGKIN'S LYMPHOMA;LEUKEMIA / LEUKAEMIA;LIVER CANCER;COLON AND RECTAL CANCER;ENDOMETRIAL CANCER;MYELOMA;BREAST CANCER;KIDNEY CANCER;OVARIAN CANCER;PROSTATE CANCER;THYROID CANCER","7;5;4;2;2;2;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;2.1 EXOGENOUS FACTORS IN THE ORIGIN AND CAUSE OF CANCER;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;3.3 CHEMOPREVENTION","14;3;3;2;2;2;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,11,"PUBLIC LIBRARY OF SCIENCE","11","31 BIOLOGICAL SCIENCES;32 BIOMEDICAL AND CLINICAL SCIENCES;3103 ECOLOGY;34 CHEMICAL SCIENCES;37 EARTH SCIENCES;30 AGRICULTURAL, VETERINARY AND FOOD SCIENCES;3101 BIOCHEMISTRY AND CELL BIOLOGY;3102 BIOINFORMATICS AND COMPUTATIONAL BIOLOGY;3105 GENETICS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3202 CLINICAL SCIENCES;3207 MEDICAL MICROBIOLOGY;33 BUILT ENVIRONMENT AND DESIGN;3304 URBAN AND REGIONAL PLANNING;3401 ANALYTICAL CHEMISTRY;3702 CLIMATE CHANGE SCIENCE","12;5;2;2;2;1;1;1;1;1;1;1;1;1;1;1","CANCER;GENETICS;RARE DISEASES;BIOTECHNOLOGY;CHILDHOOD LEUKEMIA;HEMATOLOGY;INFECTIOUS DISEASES;PEDIATRIC;PEDIATRIC CANCER","2;2;2;1;1;1;1;1;1","CANCER;GENERIC HEALTH RELEVANCE;INFECTION","1;1;1","1.1 NORMAL BIOLOGICAL DEVELOPMENT AND FUNCTIONING;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS","1;1","BIOMEDICAL","2","BASIC SCIENCE;CLINICAL MEDICINE AND SCIENCE","2;1","LEUKEMIA / LEUKAEMIA;NOT SITE-SPECIFIC CANCER","2;1",NA,NA
"IRCCS_SANTORSOLA",2013,621,10.877616747182,3.57326892109501,0.468599033816425,0.383252818035427,0.557165861513688,2.08748824082785,1.34722222222222,1.8030303030303,1.41224489795918,0.466988727858293,14,327,130,74,41,0.53,0.21,0.12,0.07,36.18,1.03695342816554,5.6640625,0.326892109500805,0.871175523349436,0.505,0.465,0.468,0.467,"STEFANO FANTI;RICCARDO CASADEI;RAFFAELE PEZZILLI;RICCARDO SCHIAVINA;FABIO PISCAGLIA;MICHELE BACCARANI;ROBERTO DI BARTOLOMEO;EUGENIO BRUNOCILLA;GIUSEPPE MARTORANA;FRANCESCO MINNI;VITTORIO SAMBRI;RITA GOLFIERI;DONATELLA SANTINI;MARCO BORGHESI;CLAUDIO RICCI;CARMINE PINTO;CRISTINA NANNI;ANDREA PESSION;MARIELDA D’AMBRA;MARIA PAOLA LANDINI","24;22;21;20;19;18;18;18;18;17;17;15;15;14;14;13;13;13;13;12","RAFFAELE PEZZILLI;ROBERTO DI BARTOLOMEO;STEFANO FANTI;RICCARDO CASADEI;MASSIMILIANO POLASTRI;FABIO PISCAGLIA;MARCO DI EUSANIO;GIACOMO FALDELLA;RICCARDO SCHIAVINA;SERGIO SABBATANI;VITTORIO SAMBRI;EUGENIO BRUNOCILLA;GIUSEPPE MARTORANA;GIAMPAOLO UGOLINI;ALBERTO BAZZOCCHI;FRANCESCO MINNI;RITA GOLFIERI;ANTONIO SANTORO;ANTONIO DANIELE PINNA;MARCO BORGHESI","3.35;2.64;2.53;2.42;2.37;2.13;2.12;2.1;2.05;2;1.92;1.91;1.87;1.82;1.81;1.74;1.64;1.57;1.51;1.5","STEFANO FANTI;RICCARDO CASADEI;RAFFAELE PEZZILLI;RICCARDO SCHIAVINA;FABIO PISCAGLIA;MICHELE BACCARANI;ROBERTO DI BARTOLOMEO;EUGENIO BRUNOCILLA;GIUSEPPE MARTORANA;FRANCESCO MINNI;VITTORIO SAMBRI;RITA GOLFIERI;DONATELLA SANTINI;MARCO BORGHESI;CLAUDIO RICCI;CARMINE PINTO;CRISTINA NANNI;ANDREA PESSION;MARIELDA D’AMBRA;MARIA PAOLA LANDINI","24;22;21;20;19;18;18;18;18;17;17;15;15;14;14;13;13;13;13;12","RAFFAELE PEZZILLI;ROBERTO DI BARTOLOMEO;STEFANO FANTI;RICCARDO CASADEI;MASSIMILIANO POLASTRI;FABIO PISCAGLIA;MARCO DI EUSANIO;GIACOMO FALDELLA;RICCARDO SCHIAVINA;SERGIO SABBATANI;VITTORIO SAMBRI;EUGENIO BRUNOCILLA;GIUSEPPE MARTORANA;GIAMPAOLO UGOLINI;ALBERTO BAZZOCCHI;FRANCESCO MINNI;RITA GOLFIERI;ANTONIO SANTORO;ANTONIO DANIELE PINNA;MARCO BORGHESI","3.35;2.64;2.53;2.42;2.37;2.13;2.12;2.1;2.05;2;1.92;1.91;1.87;1.82;1.81;1.74;1.64;1.57;1.51;1.5","MARCO DOMENICALI;MAURO BERNARDI;JUAN CÓRDOBA;MARCO PAVESI;PAOLO ANGELI;PERE GINÈS;VICENTE ARROYO;STEFAN ZEUZEM;ALEXANDER GERBES;CARLO ALESSANDRIA;FAOUZI SALIBA;FRANÇOIS DURAND;JONEL TREBICKA;JULIA WENDON;RAJIV JALAN;RICHARD MOREAU;THIERRY GUSTOT;WIM LALEMAN;RENATO PASQUALI;CORRINE K. WELT","2750;2750;2748;2748;2748;2748;2748;2485;2467;2467;2467;2467;2467;2467;2467;2467;2467;2467;1711;1626","MARCO DOMENICALI;MAURO BERNARDI;RENATO PASQUALI;LUIGI BOLONDI;FABIO PISCAGLIA;DONATELLA SANTINI;CLAUDIO CECCARELLI;MARCO DI EUSANIO;RITA GOLFIERI;STEFANO FANTI;ANDREA PESSION;STEFANO PILERI;PIER PAOLO PICCALUGA;LUIGI LOVATO;MARIO TAFFURELLI;ALESSANDRO CUCCHETTI;RICCARDO SCHIAVINA;CRISTINA NANNI;MASSIMILIANO BONAFÉ;ROBERTO DI BARTOLOMEO","2750;2750;1644;861;731;686;677;670;575;569;545;541;537;523;505;475;475;474;469;447","STEFANO FANTI;RAFFAELE PEZZILLI;MICHELE BACCARANI;ROBERTO DI BARTOLOMEO;RICCARDO CASADEI;FRANCESCO MINNI;FABIO PISCAGLIA;CARMINE PINTO;RICCARDO SCHIAVINA;LUIGI BOLONDI;DONATELLA SANTINI;VITTORIO SAMBRI;CLAUDIO RICCI;CRISTINA NANNI;MARIELDA D’AMBRA;RITA GOLFIERI;ANDREA PESSION;ANTONIO DANIELE PINNA;TULLIO PALMERINI;MARCO DI EUSANIO","21;18;17;16;16;14;14;13;13;13;13;12;12;12;12;12;11;11;11;11","MEDICINE;BIOLOGY;PHYSICS;CHEMISTRY;COMPUTER SCIENCE;ENGINEERING;MATHEMATICS;ECONOMICS;PSYCHOLOGY;POLITICAL SCIENCE;SOCIOLOGY;MATERIALS SCIENCE;PHILOSOPHY;ART;GEOGRAPHY;GEOLOGY;HISTORY;BUSINESS;ENVIRONMENTAL SCIENCE","571;190;53;35;28;28;23;21;18;15;15;12;10;3;3;3;2;1;1","INTERNAL MEDICINE;SURGERY;GENETICS;PATHOLOGY;RADIOLOGY;CARDIOLOGY;GASTROENTEROLOGY;ONCOLOGY;IMMUNOLOGY;ENVIRONMENTAL HEALTH;BIOCHEMISTRY;INTENSIVE CARE MEDICINE;PEDIATRICS;CANCER RESEARCH;PALEONTOLOGY;ENDOCRINOLOGY;NUCLEAR MEDICINE;PSYCHIATRY;VIROLOGY;OPTICS","431;176;109;101;95;82;76;76;70;61;46;43;42;39;37;35;35;29;29;26","CANCER;GENE;POPULATION;DISEASE;CHEMOTHERAPY;MYOCARDIAL INFARCTION;TRANSPLANTATION;CONFIDENCE INTERVAL;PREGNANCY;VIRUS;HEART FAILURE;AORTA;COHORT;HEPATOCELLULAR CARCINOMA;ADVERSE EFFECT;ULTRASOUND;RANDOMIZED CONTROLLED TRIAL;INCIDENCE (GEOMETRY);MYELOID LEUKEMIA;ANTIBODY;MULTIVARIATE ANALYSIS","94;83;59;46;36;33;29;28;27;27;26;24;24;24;23;23;22;21;21;20;20","COLORECTAL CANCER;BREAST CANCER;PROSTATE CANCER;CLINICAL ENDPOINT;IMATINIB;GENOTYPE;PANCREATIC CANCER;MUTATION;PERCUTANEOUS CORONARY INTERVENTION;UNIVARIATE ANALYSIS;EJECTION FRACTION;FETUS;HAZARD RATIO;ADENOCARCINOMA;AORTIC DISSECTION;GENE EXPRESSION;HEMATOPOIETIC STEM CELL TRANSPLANTATION;PHENOTYPE;AORTIC ARCH;PROSTATE","26;17;16;15;15;14;14;13;13;13;12;11;11;10;10;10;10;10;9;9","IMATINIB MESYLATE;PROSTATECTOMY;NILOTINIB;CARDIAC RESYNCHRONIZATION THERAPY;CETUXIMAB;DASATINIB;ELEPHANT TRUNKS;OXALIPLATIN;SINGLE-NUCLEOTIDE POLYMORPHISM;TRANSIENT ELASTOGRAPHY;KRAS;METASTATIC BREAST CANCER;TRANSCRIPTOME;TRASTUZUMAB;ANTIRETROVIRAL THERAPY;CAPECITABINE;DUAL-ENERGY X-RAY ABSORPTIOMETRY;HERPESVIRIDAE;KLEBSIELLA PNEUMONIAE;PROSTATE-SPECIFIC ANTIGEN","10;9;8;7;6;6;6;6;6;6;5;5;5;5;4;4;4;4;4;4","HUMANS;FEMALE;MALE;;MIDDLE AGED;AGED;ADULT;ITALY;TREATMENT OUTCOME;AGED, 80 AND OVER;LIVER NEOPLASMS;ADOLESCENT;RETROSPECTIVE STUDIES;YOUNG ADULT;PROSPECTIVE STUDIES;RISK FACTORS;CHILD;CARCINOMA, HEPATOCELLULAR;PROSTATIC NEOPLASMS;TOMOGRAPHY, X-RAY COMPUTED","359;268;253;248;192;172;154;97;89;83;72;71;71;59;55;50;44;43;43;42","PANCREATIC CANCER RESEARCH AND TREATMENT;HEPATOCELLULAR CARCINOMA;DIAGNOSIS AND MANAGEMENT OF AORTIC DISEASES;EFFICACY AND RESISTANCE IN CML TREATMENT;EPIDEMIOLOGY AND MANAGEMENT OF NAFLD;MANAGEMENT OF VALVULAR HEART DISEASE;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;MECHANICAL VENTILATION IN RESPIRATORY FAILURE AND ARDS;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;GLOBAL IMPACT OF ARBOVIRAL DISEASES;ACUTE MYELOID LEUKEMIA;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;HEPATITIS C INFECTION AND TREATMENT;LIVER CIRRHOSIS AND ASSOCIATED COMPLICATIONS;LYMPHOID NEOPLASMS;MANAGEMENT OF ACUTE MYOCARDIAL INFARCTION;PROSTATE CANCER RESEARCH AND TREATMENT;ADVANCED CARDIAC IMAGING TECHNIQUES AND DIAGNOSTICS;DIAGNOSIS AND MANAGEMENT OF CELIAC DISEASE","22;19;17;17;10;10;9;8;8;7;7;6;6;6;6;6;6;6;5;5","TREATMENT;PANCREATIC CANCER;AORTIC DISSECTION;CLINICAL ENDPOINT;CARDIAC IMAGING;UNIVARIATE ANALYSIS;HEPATOCELLULAR CARCINOMA;TRANSCATHETER AORTIC-VALVE REPLACEMENT;DISCONTINUATION;AORTIC ROOT REPLACEMENT;CARDIOTHORACIC SURGERY;IMATINIB MESYLATE;METASTATIC PANCREATIC CANCER;CARDIOVASCULAR RISK ASSESSMENT;DIAGNOSIS;ECHOCARDIOGRAPHY;LIVER BIOPSY;PROSTHETIC VALVES EVALUATION;THORACIC AORTA;CARDIAC RESYNCHRONIZATION THERAPY","24;16;15;15;13;13;12;12;11;10;10;10;10;9;8;8;8;8;8;7","HEPATOCELLULAR CARCINOMA;MYELOID LEUKEMIA;CHRONIC MYELOID;PROSTATE CANCER;MYOCARDIAL INFARCTION;BREAST CANCER;ACUTE MYOCARDIAL;AORTIC DISSECTION;CELL TRANSPLANTATION;LEFT VENTRICULAR;MULTICENTRE STUDY;STEM CELL;ACUTE LYMPHOBLASTIC;AORTIC VALVE;CHRONIC HEPATITIS;COLORECTAL CANCER;LYMPHOBLASTIC LEUKEMIA;PANCREATIC CANCER;RESPIRATORY FAILURE;RISK FACTORS;STEM CELLS;ACUITY TRIAL;ACUTE MYELOID;C-CHOLINE PETCT;CANCER PATIENTS;CARDIAC RESYNCHRONIZATION;DIABETES MELLITUS;HEMATOPOIETIC STEM;ITALIAN SOCIETY;LUNG CANCER","18;16;11;11;10;9;8;7;7;7;7;7;6;6;6;6;6;6;6;6;6;5;5;5;5;5;5;5;5;5","MYOCARDIAL INFARCTION;RISK FACTORS;ADVERSE EVENTS;EUROSCORE II;COELIAC DISEASE;CONFIDENCE INTERVAL;CUMULATIVE PREGNANCY;OOCYTE CRYOPRESERVATION;PATIENTS TREATED;PATIENTS UNDERGOING;SINUS NODE;AORTIC DISSECTION;AV NODE;CYSTIC TUMOR;INCREASED RISK;STEM CELL;AORTIC ARCH;EMBRYO CRYOPRESERVATION;MULTIVARIATE ANALYSIS;NODE DYSFUNCTION;PATIENTS UNDERWENT;PREGNANCY RATE;SOFT PALATE;STEM CELLS;ACUTE AORTIC;CELL LINES;IN-HOSPITAL MORTALITY;LEFT VENTRICULAR;PROTEIN EXPRESSION;ACUTE MYOCARDIAL","26;26;19;18;16;16;15;15;14;14;14;13;13;13;13;13;12;12;12;12;12;12;12;12;11;11;11;11;11;10",180,0.29,5.26,5,2,1,1,2,3.5,0,1,6,1,1,4,1,2,1,2,3.75,1.5,0,0,85.25,85.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,50,5.89,1016.83,5.15,23,0.46,81.06,2,0,6,2,15,0,0,25,0,30,18,0,0,0,0,0,0,44,6,0,48,2,0,0,0,0,0,0,0,0,"United States;Italy;France;Germany;United Kingdom","15;13;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3213 PAEDIATRICS;42 HEALTH SCIENCES;4201 ALLIED HEALTH AND REHABILITATION SCIENCE;31 BIOLOGICAL SCIENCES;3107 MICROBIOLOGY;3204 IMMUNOLOGY;3212 OPHTHALMOLOGY AND OPTOMETRY;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;3215 REPRODUCTIVE MEDICINE;40 ENGINEERING;4003 BIOMEDICAL ENGINEERING;4012 FLUID MECHANICS AND THERMAL ENGINEERING;4203 HEALTH SERVICES AND SYSTEMS","50;23;20;10;5;4;2;1;1;1;1;1;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;RARE DISEASES;HEMATOLOGY;PEDIATRIC;BREAST CANCER;DIGESTIVE DISEASES;PATIENT SAFETY;CARDIOVASCULAR;LYMPHOMA;INFANT MORTALITY;LUNG;NUTRITION;PERINATAL PERIOD - CONDITIONS ORIGINATING IN PERINATAL PERIOD;PRETERM, LOW BIRTH WEIGHT AND HEALTH OF THE NEWBORN;ORPHAN DRUG;AGING;LUNG CANCER;NEUROSCIENCES","44;30;27;19;14;8;7;7;7;6;6;5;5;5;5;5;4;3;3;3","CANCER;REPRODUCTIVE HEALTH AND CHILDBIRTH;INFLAMMATORY AND IMMUNE SYSTEM;BLOOD;CARDIOVASCULAR;ORAL AND GASTROINTESTINAL;EYE;INFECTION;METABOLIC AND ENDOCRINE;MUSCULOSKELETAL;RESPIRATORY;STROKE","21;4;3;2;2;2;1;1;1;1;1;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;6.4 SURGERY;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;5.1 PHARMACEUTICALS;6.7 PHYSICAL;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;5.3 MEDICAL DEVICES;6.3 MEDICAL DEVICES;7.1 INDIVIDUAL CARE NEEDS","26;4;4;2;2;2;1;1;1;1","LEUKEMIA / LEUKAEMIA;BREAST CANCER;NON-HODGKIN'S LYMPHOMA;LUNG CANCER;OVARIAN CANCER;MELANOMA;SARCOMA;GENITAL SYSTEM, FEMALE;HODGKIN'S DISEASE;LIVER CANCER;MYELOMA;NOT SITE-SPECIFIC CANCER;STOMACH CANCER;THYROID CANCER","8;7;6;3;3;2;2;1;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;5.7 RESOURCES AND INFRASTRUCTURE RELATED TO TREATMENT AND THE PREVENTION OF RECURRENCE;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","24;2;1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,45,"PUBLIC LIBRARY OF SCIENCE;KARGER PUBLISHERS","44;1","32 BIOMEDICAL AND CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;42 HEALTH SCIENCES;30 AGRICULTURAL, VETERINARY AND FOOD SCIENCES;3105 GENETICS;3207 MEDICAL MICROBIOLOGY;4206 PUBLIC HEALTH;3008 HORTICULTURAL PRODUCTION;40 ENGINEERING;3202 CLINICAL SCIENCES;3101 BIOCHEMISTRY AND CELL BIOLOGY;3102 BIOINFORMATICS AND COMPUTATIONAL BIOLOGY;3210 NUTRITION AND DIETETICS;3211 ONCOLOGY AND CARCINOGENESIS;36 CREATIVE ARTS AND WRITING;4003 BIOMEDICAL ENGINEERING;46 INFORMATION AND COMPUTING SCIENCES;51 PHYSICAL SCIENCES;3103 ECOLOGY;3104 EVOLUTIONARY BIOLOGY","34;20;13;8;6;6;6;4;4;3;2;2;2;2;2;2;2;2;1;1","PREVENTION;CLINICAL RESEARCH;INFECTIOUS DISEASES;NUTRITION;VACCINE RELATED;BIODEFENSE;BIOTECHNOLOGY;EMERGING INFECTIOUS DISEASES;RARE DISEASES;VECTOR-BORNE DISEASES;CARDIOVASCULAR;GENETICS;OBESITY;STEM CELL RESEARCH;STEM CELL RESEARCH - NONEMBRYONIC - HUMAN;WEST NILE VIRUS;MENTAL HEALTH;REHABILITATION;ATHEROSCLEROSIS;BRAIN DISORDERS","11;5;5;5;5;4;4;4;4;4;3;3;3;3;3;3;2;2;1;1","INFECTION;CARDIOVASCULAR;CANCER;GENERIC HEALTH RELEVANCE;NEUROLOGICAL;ORAL AND GASTROINTESTINAL","5;2;1;1;1;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;5.2 CELLULAR AND GENE THERAPIES","5;1;1;1","BIOMEDICAL","4","CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE;PUBLIC HEALTH","10;6;3","BREAST CANCER;COLON AND RECTAL CANCER;NON-HODGKIN'S LYMPHOMA;NOT SITE-SPECIFIC CANCER","1;1;1;1","3 GOOD HEALTH AND WELL BEING","10"
"IRCCS_SANTORSOLA",2014,581,12.1858864027539,3.66265060240964,0.433734939759036,0.394148020654045,0.521514629948365,2.18032786885246,1.42372881355932,1.7890625,1.46376811594203,0.440619621342513,9,315,127,48,46,0.54,0.22,0.08,0.08,37.47,0.991575419851838,5.60928143712575,0.285714285714286,0.870912220309811,0.495,0.431,0.439,0.43,"G. PILU;STEFANO FANTI;T. GHI;ANTONIO DANIELE PINNA;RICCARDO SCHIAVINA;CARMINE PINTO;EUGENIO BRUNOCILLA;GIUSEPPE MARTORANA;A. YOUSSEF;MICHELE BACCARANI;MAURO BERNARDI;MARCO BORGHESI;ANDRÉA STELLA;GIORGIO ERCOLANI;PIER PAOLO PICCALUGA;STEFANO PILERI;RAFFAELE PEZZILLI;GIACOMO FALDELLA;ROBERTO DI BARTOLOMEO;N. RIZZO","25;23;21;17;17;16;16;16;15;14;14;13;13;12;12;12;12;12;11;11","RAFFAELE PEZZILLI;G. PILU;T. GHI;STEFANO FANTI;ANTONIO DANIELE PINNA;GIACOMO FALDELLA;FRANCESCO VASURI;LUIGI CORVAGLIA;A. YOUSSEF;MASSIMILIANO POLASTRI;MARIO LIMA;RICCARDO SCHIAVINA;ANDRÉA STELLA;ANNALISA PATRIZI;GIUSEPPE MARTORANA;STEFANO NAVA;ARRIGO F.G. CICERO;ROBERTO DI BARTOLOMEO;BAHJAT BARAKAT;N. RIZZO","4.95;3.1;2.63;2.13;2;1.91;1.89;1.8;1.78;1.75;1.5;1.49;1.49;1.45;1.44;1.44;1.42;1.42;1.37;1.36","G. PILU;STEFANO FANTI;T. GHI;ANTONIO DANIELE PINNA;RICCARDO SCHIAVINA;CARMINE PINTO;EUGENIO BRUNOCILLA;GIUSEPPE MARTORANA;A. YOUSSEF;MICHELE BACCARANI;MAURO BERNARDI;MARCO BORGHESI;ANDRÉA STELLA;GIORGIO ERCOLANI;PIER PAOLO PICCALUGA;STEFANO PILERI;RAFFAELE PEZZILLI;GIACOMO FALDELLA;ROBERTO DI BARTOLOMEO;N. RIZZO","25;23;21;17;17;16;16;16;15;14;14;13;13;12;12;12;12;12;11;11","RAFFAELE PEZZILLI;G. PILU;T. GHI;STEFANO FANTI;ANTONIO DANIELE PINNA;GIACOMO FALDELLA;FRANCESCO VASURI;LUIGI CORVAGLIA;A. YOUSSEF;MASSIMILIANO POLASTRI;MARIO LIMA;RICCARDO SCHIAVINA;ANDRÉA STELLA;ANNALISA PATRIZI;GIUSEPPE MARTORANA;STEFANO NAVA;ARRIGO F.G. CICERO;ROBERTO DI BARTOLOMEO;BAHJAT BARAKAT;N. RIZZO","4.95;3.1;2.63;2.13;2;1.91;1.89;1.8;1.78;1.75;1.5;1.49;1.49;1.45;1.44;1.44;1.42;1.42;1.37;1.36","MAURO BERNARDI;PAOLO CARACENI;CATERINA FANIZZA;GIANNI TOGNONI;LUCIANO GATTINONI;MARILENA ROMERO;PIETRO CAIRONI;ROBERTO FUMAGALLI;ROBERTO LATINI;SERGE MASSON;RITA GOLFIERI;MARCO PAVESI;PAOLO ANGELI;PERE GINÈS;VICENTE ARROYO;STEFAN ZEUZEM;STEFANO FAENZA;CARLO ALESSANDRIA;DIDIER SAMUEL;FAOUZI SALIBA","1745;1425;1286;1286;1286;1286;1286;1286;1286;1286;1227;1219;1219;1219;1219;1185;1136;1121;1121;1121","PAOLO CARACENI;MAURO BERNARDI;RITA GOLFIERI;STEFANO FAENZA;EMANUELA GIAMPALMA;STEFANO FANTI;GIUSEPPE BORIANI;FILIPPO MORANDO;STEFANO PILERI;LORIS PIRONI;MATTEO RENZULLI;PIER PAOLO PICCALUGA;CRISTINA MOSCONI;TIZIANA LAZZAROTTO;NICOLA RIZZO;LILIANA GABRIELLI;L. SAVELLI;BRUNELLA GUERRA;RICCARDO SCHIAVINA;STEFANO NAVA","1310;1211;1204;1136;931;830;817;813;755;735;629;612;552;526;509;472;461;449;449;443","G. PILU;T. GHI;STEFANO FANTI;ANTONIO DANIELE PINNA;RICCARDO SCHIAVINA;N. RIZZO;A. YOUSSEF;CARMINE PINTO;GIUSEPPE MARTORANA;MICHELE BACCARANI;EUGENIO BRUNOCILLA;RAFFAELE PEZZILLI;MARCO BORGHESI;STEFANO PILERI;GIACOMO FALDELLA;FEDERICA BELLUSSI;PIER PAOLO PICCALUGA;GIORGIO ERCOLANI;RITA GOLFIERI;STEFANO NAVA","25;21;21;19;16;15;15;14;13;13;12;12;11;10;10;10;10;9;9;9","MEDICINE;BIOLOGY;PHYSICS;CHEMISTRY;ENGINEERING;COMPUTER SCIENCE;MATHEMATICS;PSYCHOLOGY;SOCIOLOGY;ECONOMICS;GEOLOGY;PHILOSOPHY;POLITICAL SCIENCE;HISTORY;BUSINESS;MATERIALS SCIENCE;ART;GEOGRAPHY;ENVIRONMENTAL SCIENCE","546;209;44;40;30;26;19;17;15;11;8;7;6;5;4;4;3;3;1","INTERNAL MEDICINE;SURGERY;GENETICS;GASTROENTEROLOGY;PATHOLOGY;RADIOLOGY;IMMUNOLOGY;ONCOLOGY;CARDIOLOGY;PEDIATRICS;INTENSIVE CARE MEDICINE;ENVIRONMENTAL HEALTH;BIOCHEMISTRY;CANCER RESEARCH;ENDOCRINOLOGY;NUCLEAR MEDICINE;OPTICS;PALEONTOLOGY;ANESTHESIA;PSYCHIATRY","415;185;137;99;95;80;72;66;57;57;54;51;49;45;35;32;32;32;31;28","GENE;CANCER;POPULATION;PREGNANCY;DISEASE;CHEMOTHERAPY;TRANSPLANTATION;CONFIDENCE INTERVAL;RETROSPECTIVE COHORT STUDY;ADVERSE EFFECT;COHORT;INCIDENCE (GEOMETRY);VIRUS;PROSPECTIVE COHORT STUDY;RANDOMIZED CONTROLLED TRIAL;MYELOID LEUKEMIA;STAGE (STRATIGRAPHY);MYOCARDIAL INFARCTION;ULTRASOUND;HEPATOCELLULAR CARCINOMA;LEUKEMIA","91;88;48;45;40;38;37;36;32;27;27;27;27;25;25;23;22;21;21;20;20","FETUS;COLORECTAL CANCER;HAZARD RATIO;MUTATION;GENOTYPE;LIVER TRANSPLANTATION;CLINICAL ENDPOINT;IMATINIB;PHENOTYPE;UNIVARIATE ANALYSIS;GENE EXPRESSION;ALLELE;EJECTION FRACTION;GIST;PLACEBO;ESCHERICHIA COLI;HEPATITIS C VIRUS;PERCUTANEOUS CORONARY INTERVENTION;PROSTATE CANCER;AORTIC DISSECTION;GESTATIONAL AGE;HEMATOPOIETIC STEM CELL TRANSPLANTATION;MITOCHONDRIAL DNA;OVARIAN CANCER;TOLERABILITY","23;21;19;19;16;16;14;14;12;12;11;10;10;10;10;9;9;9;9;8;8;8;8;8;8","NILOTINIB;CETUXIMAB;DASATINIB;KLEBSIELLA PNEUMONIAE;KRAS;RIBAVIRIN;PDGFRA;PROSTATECTOMY;FETAL HEAD;HERPESVIRIDAE;IMATINIB MESYLATE;PRENATAL DIAGNOSIS;ANTIRETROVIRAL THERAPY;GENOTYPING;MISSENSE MUTATION;SINGLE-NUCLEOTIDE POLYMORPHISM;CARDIAC RESYNCHRONIZATION THERAPY;DNA METHYLATION;FERTILITY PRESERVATION;MILAN CRITERIA;SANGER SEQUENCING","9;8;8;8;8;8;7;7;6;6;6;6;5;5;5;5;4;4;4;4;4","HUMANS;FEMALE;MALE;MIDDLE AGED;;AGED;ADULT;ITALY;TREATMENT OUTCOME;AGED, 80 AND OVER;RETROSPECTIVE STUDIES;RISK FACTORS;PROSPECTIVE STUDIES;ADOLESCENT;YOUNG ADULT;LIVER NEOPLASMS;FOLLOW-UP STUDIES;CHILD;TIME FACTORS;POSTOPERATIVE COMPLICATIONS","386;300;277;192;186;179;153;119;87;80;74;65;64;57;55;52;48;46;46;41","HEPATOCELLULAR CARCINOMA;EFFICACY AND RESISTANCE IN CML TREATMENT;ACUTE MYELOID LEUKEMIA;DIAGNOSIS AND MANAGEMENT OF AORTIC DISEASES;LYMPHOID NEOPLASMS;HEPATITIS C INFECTION AND TREATMENT;ATRIAL FIBRILLATION;GLOBAL CHALLENGE OF ANTIBIOTIC RESISTANCE IN BACTERIA;MECHANICAL VENTILATION IN RESPIRATORY FAILURE AND ARDS;PANCREATIC CANCER RESEARCH AND TREATMENT;RENAL CELL CARCINOMA;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;EPIDEMIOLOGY AND MANAGEMENT OF NAFLD;LIVER CIRRHOSIS AND ASSOCIATED COMPLICATIONS;MANAGEMENT OF VALVULAR HEART DISEASE;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;DIAGNOSIS AND TREATMENT OF GASTROINTESTINAL STROMAL TUMORS;ADVANCEMENTS IN LUNG CANCER RESEARCH;DIAGNOSIS AND MANAGEMENT OF ENDOMETRIOSIS;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA","16;14;12;12;12;10;9;9;9;9;9;7;7;7;7;6;6;5;5;5","TREATMENT;CLINICAL ENDPOINT;DIAGNOSIS;AORTIC DISSECTION;HEPATOCELLULAR CARCINOMA;UNIVARIATE ANALYSIS;AORTIC ROOT REPLACEMENT;TRANSCATHETER AORTIC-VALVE REPLACEMENT;TYPE B AORTIC DISSECTION;REGIMEN;ATRIAL FIBRILLATION;DISCONTINUATION;LIVER BIOPSY;METASTATIC COLORECTAL CANCER;PONATINIB;ETIOLOGY;FETAL DNA ANALYSIS;HEPATITIS C;LIVER CANCER;PDGFRA","17;13;13;12;12;12;11;10;10;9;8;8;8;8;8;7;7;7;7;7","HEPATOCELLULAR CARCINOMA;MYELOID LEUKEMIA;ATRIAL FIBRILLATION;COLORECTAL CANCER;CANCER PATIENTS;CELL TRANSPLANTATION;KLEBSIELLA PNEUMONIAE;LUNG CANCER;AORTIC VALVE;BREAST CANCER;CHRONIC MYELOID;PATIENTS PTS;STEM CELL;ACUTE MYELOID;C-CHOLINE PETCT;CELL CARCINOMA;CHRONIC HEPATITIS;MYOCARDIAL INFARCTION;PROSPECTIVE MULTICENTER;ACUTE LYMPHOBLASTIC;AORTIC DISSECTION;COHORT STUDY;CONTROLLED TRIAL;KPC-PRODUCING KLEBSIELLA;LEUKEMIA PATIENTS;LONG-TERM FOLLOW-UP;LYMPHOBLASTIC LEUKEMIA;MULTICENTER STUDY;NONINVASIVE VENTILATION;OBSERVATIONAL STUDY","14;14;9;9;8;8;8;8;7;7;7;7;7;6;6;6;6;6;6;5;5;5;5;5;5;5;5;5;5;5","ODDS RATIO;RISK FACTORS;PATIENTS UNDERGOING;AORTIC VALVE;INDEPENDENT PREDICTORS;LOGISTIC REGRESSION;UNIVERSITY HOSPITAL;CMV INFECTION;CONFIDENCE INTERVAL;AORTIC DISSECTION;HR CI;MULTIVARIATE ANALYSIS;GENE EXPRESSION;INCREASED RISK;ORAL ANTICOAGULATION;CLINICAL NUTRITION;CONSECUTIVE PATIENTS;CORONARY ARTERY;LEFT VENTRICULAR;PATIENTS TREATED;PERCUTANEOUS CORONARY;VALVE REPLACEMENT;CLIF-C ACLFS;CORONARY INTERVENTION;ENDOCRINOLOGY DIABETES;HOSPITAL ZURICH;ISLET TRANSPLANTATION;NUTRITION UNIVERSITY;TRANSCATHETER AORTIC;VISCERAL ISCHEMIA","24;21;19;17;17;17;17;16;16;15;15;15;14;14;14;13;13;13;13;13;13;13;12;12;12;12;12;12;12;11",228,0.39,6.56,5,2,1,1,3.5,2.75,0,1.75,5,1,1,4,1.5,1.25,1,2,3,2,0,0,84.75,80.75,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,53,5.73,508.25,6.18,31,0.58,80.77,0,4,11,1,17,0,3,17,0,45,6,0,0,0,0,0,0,45,7,1,50,2,0,1,0,0,0,0,0,0,"United States;Italy;Belgium;Germany;Japan","17;14;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;42 HEALTH SCIENCES;31 BIOLOGICAL SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;3204 IMMUNOLOGY;3102 BIOINFORMATICS AND COMPUTATIONAL BIOLOGY;3107 MICROBIOLOGY;3215 REPRODUCTIVE MEDICINE;4206 PUBLIC HEALTH","51;27;22;7;5;3;3;2;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;RARE DISEASES;DIGESTIVE DISEASES;PATIENT SAFETY;HEMATOLOGY;BREAST CANCER;AUTOIMMUNE DISEASE;INFLAMMATORY BOWEL DISEASE;LIVER DISEASE;LUNG;ASSISTIVE TECHNOLOGY;BIOENGINEERING;NUTRITION;PREVENTION;BIOTECHNOLOGY;CARDIOVASCULAR;CHRONIC LIVER DISEASE AND CIRRHOSIS;GENETICS","45;34;27;19;16;14;12;6;5;5;5;5;4;4;4;4;3;3;3;3","CANCER;ORAL AND GASTROINTESTINAL;RESPIRATORY;CARDIOVASCULAR;INFECTION;RENAL AND UROGENITAL;STROKE;BLOOD;INFLAMMATORY AND IMMUNE SYSTEM","22;5;3;2;2;2;2;1;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS;6.4 SURGERY;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;6.3 MEDICAL DEVICES;7.1 INDIVIDUAL CARE NEEDS;3.1 PRIMARY PREVENTION INTERVENTIONS TO MODIFY BEHAVIOURS OR PROMOTE WELLBEING;6.7 PHYSICAL","35;7;5;4;3;2;2;2;1;1","LEUKEMIA / LEUKAEMIA;BREAST CANCER;NON-HODGKIN'S LYMPHOMA;COLON AND RECTAL CANCER;LIVER CANCER;MYELOMA;LUNG CANCER;OVARIAN CANCER;PROSTATE CANCER;ESOPHAGEAL / OESOPHAGEAL CANCER;GENITAL SYSTEM, FEMALE;HODGKIN'S DISEASE;NOT SITE-SPECIFIC CANCER;PANCREATIC CANCER;SARCOMA;STOMACH CANCER","9;6;6;3;3;3;2;2;2;1;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS;2.1 EXOGENOUS FACTORS IN THE ORIGIN AND CAUSE OF CANCER;3.3 CHEMOPREVENTION;4.2 TECHNOLOGY AND/OR MARKER EVALUATION WITH RESPECT TO FUNDAMENTAL PARAMETERS OF METHOD;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","28;2;2;1;1;1;1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,23,"PUBLIC LIBRARY OF SCIENCE","23","32 BIOMEDICAL AND CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;42 HEALTH SCIENCES;30 AGRICULTURAL, VETERINARY AND FOOD SCIENCES;3107 MICROBIOLOGY;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3215 REPRODUCTIVE MEDICINE;4206 PUBLIC HEALTH;49 MATHEMATICAL SCIENCES;4904 PURE MATHEMATICS;3006 FOOD SCIENCES;3009 VETERINARY SCIENCES;3103 ECOLOGY;3105 GENETICS;3204 IMMUNOLOGY;3208 MEDICAL PHYSIOLOGY;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;4202 EPIDEMIOLOGY","22;7;7;3;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1","CLINICAL RESEARCH;HEMATOLOGY;CANCER;PEDIATRIC;PREVENTION;AUTOIMMUNE DISEASE;CARDIOVASCULAR;DIGESTIVE DISEASES;NUTRITION;RARE DISEASES;TOBACCO;TOBACCO SMOKE AND HEALTH;BIOTECHNOLOGY;CANNABINOID RESEARCH;CHILDHOOD LEUKEMIA;COLO-RECTAL CANCER;CROHN'S DISEASE;GENETICS;HEART DISEASE;HUMAN GENOME","4;4;3;3;3;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1","ORAL AND GASTROINTESTINAL;RESPIRATORY;CARDIOVASCULAR;INFECTION;INFLAMMATORY AND IMMUNE SYSTEM;REPRODUCTIVE HEALTH AND CHILDBIRTH","2;2;1;1;1;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;1.1 NORMAL BIOLOGICAL DEVELOPMENT AND FUNCTIONING;2.2 FACTORS RELATING TO THE PHYSICAL ENVIRONMENT;3.1 PRIMARY PREVENTION INTERVENTIONS TO MODIFY BEHAVIOURS OR PROMOTE WELLBEING","7;1;1;1","BIOMEDICAL;POPULATION & SOCIETY;HEALTH SERVICES & SYSTEMS","3;2;1","CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE;PUBLIC HEALTH","6;2;2","LEUKEMIA / LEUKAEMIA;COLON AND RECTAL CANCER;LUNG CANCER;NON-HODGKIN'S LYMPHOMA;NOT SITE-SPECIFIC CANCER","3;1;1;1;1","3 GOOD HEALTH AND WELL BEING","2"
"IRCCS_SANTORSOLA",2015,609,12.3481116584565,3.38095238095238,0.433497536945813,0.394088669950739,0.527093596059113,2.02859960552268,1.3469387755102,1.6551724137931,1.36595744680851,0.489326765188834,5,317,139,62,51,0.52,0.23,0.1,0.08,34.35,0.92169051459649,5.53465679676986,0.339901477832512,0.89983579638752,0.473,0.443,0.419,0.448,"MICHÈLE CAVO;GIOVANNI MARTINELLI;SIMONA SOVERINI;STEFANO FANTI;GIUSEPPE BORIANI;CLAUDIO RAPEZZI;MICHELE BACCARANI;PIERLUIGI VIALE;G. PILU;GUIDO BIASCO;GIORGIO ERCOLANI;FABIO PISCAGLIA;RAFFAELE PEZZILLI;ANNALISA ASTOLFI;FRANCESCO SAIA;CLAUDIO BORGHI;DONATELLA SANTINI;GIOVANNI BRANDI;T. GHI;VINCENZO VALENTINI","23;20;17;17;17;15;15;15;15;13;12;12;12;12;12;11;11;11;11;10","RAFFAELE PEZZILLI;P ZUCCHELLI;MARCO DI EUSANIO;G. PILU;BAHJAT BARAKAT;ANTONIO SANTORO;GIUSEPPE BORIANI;PIERLUIGI VIALE;A. ZUCCAL�;STEFANO FANTI;CLAUDIO MARCHETTI;CLAUDIO BORGHI;CLAUDIO RAPEZZI;ROSSELLA GAGGI;MICHÈLE CAVO;DONATELLA SANTINI;GIACOMO FALDELLA;LUIGI CORVAGLIA;ANNALISA PATRIZI;GUIDO BIASCO","3.11;2.29;2;1.86;1.83;1.72;1.66;1.6;1.55;1.55;1.53;1.5;1.5;1.41;1.4;1.36;1.35;1.24;1.23;1.23","MICHÈLE CAVO;GIOVANNI MARTINELLI;SIMONA SOVERINI;STEFANO FANTI;GIUSEPPE BORIANI;CLAUDIO RAPEZZI;MICHELE BACCARANI;PIERLUIGI VIALE;G. PILU;GUIDO BIASCO;GIORGIO ERCOLANI;FABIO PISCAGLIA;RAFFAELE PEZZILLI;ANNALISA ASTOLFI;FRANCESCO SAIA;CLAUDIO BORGHI;DONATELLA SANTINI;GIOVANNI BRANDI;T. GHI;P ZUCCHELLI","23;20;17;17;17;15;15;15;15;13;12;12;12;12;12;11;11;11;11;10","RAFFAELE PEZZILLI;P ZUCCHELLI;MARCO DI EUSANIO;G. PILU;BAHJAT BARAKAT;ANTONIO SANTORO;GIUSEPPE BORIANI;PIERLUIGI VIALE;A. ZUCCAL�;STEFANO FANTI;CLAUDIO MARCHETTI;CLAUDIO BORGHI;CLAUDIO RAPEZZI;ROSSELLA GAGGI;MICHÈLE CAVO;DONATELLA SANTINI;GIACOMO FALDELLA;LUIGI CORVAGLIA;ANNALISA PATRIZI;GUIDO BIASCO","3.11;2.29;2;1.86;1.83;1.72;1.66;1.6;1.55;1.55;1.53;1.5;1.5;1.41;1.4;1.36;1.35;1.24;1.23;1.23","STEFANO FANTI;MARCO DI EUSANIO;ARTURO EVANGELISTA;CHRISTOPH NIENABER;DANIEL MONTGOMERY;EDUARDO BOSSONE;ELISE M. WOZNICKI;ERIC M. ISSELBACHER;KEVIN L. GREASON;KEVIN M. HARRIS;KIM A. EAGLE;LINDA PAPE;MAGNUS LARSEN;MAZEN AWAIS;PATRICK T. O’GARA;SANTI TRIMARCHI;TORU SUZUKI;TRULS MYRMEL;FABIO PISCAGLIA;PAOLO GARAGNANI","1609;1233;892;892;892;892;892;892;892;892;892;892;892;892;892;892;892;892;858;846","STEFANO FANTI;MARCO DI EUSANIO;PAOLO GARAGNANI;FABIO PISCAGLIA;SARA MARINELLI;PIERLUIGI VIALE;SIMONE AMBRETTI;MADDALENA GIANNELLA;MICHELE BARTOLETTI;SARA TEDESCHI;MARCO DOMENICALI;MAURO BERNARDI;PAOLO CARACENI;ROBERTO DI BARTOLOMEO;C. LANDOLFO;DANIEL BENTEN;VICENTE ARROYO;ANNA PECORELLI;JOSHUA JAMES MORIGI;TOMMASO PIPPUCCI","1448;1182;839;761;751;747;701;694;691;691;573;573;573;572;553;546;546;531;529;529","GIUSEPPE BORIANI;SIMONA SOVERINI;MICHÈLE CAVO;STEFANO FANTI;ANTONIO SANTORO;RAFFAELE PEZZILLI;ANTONIO DANIELE PINNA;DONATELLA SANTINI;CLAUDIO BORGHI;CLAUDIO RAPEZZI;GUIDO BIASCO;PIERLUIGI VIALE;RICCARDO SCHIAVINA;FRANCESCO SAIA;G. PILU;GIOVANNI BRANDI;ANDREA ARDIZZONI;FABIO PISCAGLIA;MICHELE BACCARANI;A.G. MORGANTI","17;14;14;14;14;12;12;11;10;10;10;10;10;10;9;9;9;9;9;8","MEDICINE;BIOLOGY;PHYSICS;CHEMISTRY;COMPUTER SCIENCE;ENGINEERING;MATHEMATICS;PSYCHOLOGY;SOCIOLOGY;ECONOMICS;PHILOSOPHY;MATERIALS SCIENCE;POLITICAL SCIENCE;HISTORY;ART;BUSINESS;GEOGRAPHY;ENVIRONMENTAL SCIENCE;GEOLOGY","552;211;57;39;34;29;21;20;15;14;14;9;9;7;4;4;4;2;2","INTERNAL MEDICINE;SURGERY;GENETICS;PATHOLOGY;ONCOLOGY;CARDIOLOGY;RADIOLOGY;GASTROENTEROLOGY;ENVIRONMENTAL HEALTH;IMMUNOLOGY;CANCER RESEARCH;BIOCHEMISTRY;PEDIATRICS;INTENSIVE CARE MEDICINE;NUCLEAR MEDICINE;PSYCHIATRY;PALEONTOLOGY;OPTICS;CELL BIOLOGY;ENDOCRINOLOGY","433;151;130;103;93;89;86;76;58;58;54;52;41;37;36;34;32;30;22;22","GENE;CANCER;DISEASE;POPULATION;CONFIDENCE INTERVAL;TRANSPLANTATION;CHEMOTHERAPY;MYELOID LEUKEMIA;PREGNANCY;COHORT;INCIDENCE (GEOMETRY);CLINICAL TRIAL;MYOCARDIAL INFARCTION;RETROSPECTIVE COHORT STUDY;BLOOD PRESSURE;RADIATION THERAPY;ADVERSE EFFECT;HEART FAILURE;PROSPECTIVE COHORT STUDY;RANDOMIZED CONTROLLED TRIAL","111;94;56;55;37;37;31;30;30;27;27;25;25;25;23;22;21;21;21;21","MUTATION;IMATINIB;CLINICAL ENDPOINT;COLORECTAL CANCER;PROSTATE CANCER;GENOTYPE;HAZARD RATIO;PHENOTYPE;FETUS;GENE EXPRESSION;BREAST CANCER;LIVER TRANSPLANTATION;METASTASIS;CHROMOSOME;EJECTION FRACTION;GESTATION;HEMATOPOIETIC STEM CELL TRANSPLANTATION;MICRORNA;UNIVARIATE ANALYSIS;ALLELE;AORTIC VALVE REPLACEMENT;CYCLOPHOSPHAMIDE;GIST","37;22;21;18;17;16;16;16;15;14;12;12;11;10;10;9;9;9;9;8;8;8;8","EXOME SEQUENCING;IMATINIB MESYLATE;NILOTINIB;DASATINIB;KRAS;SINGLE-NUCLEOTIDE POLYMORPHISM;DNA METHYLATION;MISSENSE MUTATION;PROSTATECTOMY;BUSULFAN;COLONOSCOPY;COPY-NUMBER VARIATION;CYTOGENETICS;GENOTYPING;PHILADELPHIA CHROMOSOME;PRENATAL DIAGNOSIS;PROSTATE-SPECIFIC ANTIGEN;VINCRISTINE;AORTIC VALVULOPLASTY;CARDIAC RESYNCHRONIZATION THERAPY;FLUORESCENCE IN SITU HYBRIDIZATION;GERMLINE MUTATION;HERPESVIRIDAE;INTERNATIONAL PROGNOSTIC SCORING SYSTEM;KARYOTYPE;LAMIVUDINE;OSTEOPENIA;OSTEOPOROTIC FRACTURE;PDGFRA;PTEN;TRASTUZUMAB","11;11;11;10;10;8;7;7;5;4;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3","HUMANS;FEMALE;MALE;;MIDDLE AGED;AGED;ADULT;ITALY;AGED, 80 AND OVER;RETROSPECTIVE STUDIES;TREATMENT OUTCOME;YOUNG ADULT;ADOLESCENT;LIVER NEOPLASMS;CARCINOMA, HEPATOCELLULAR;PROSPECTIVE STUDIES;FOLLOW-UP STUDIES;RISK FACTORS;LUNG NEOPLASMS;CHILD","375;267;263;225;183;173;170;93;81;77;63;61;59;57;46;46;44;44;43;41","EFFICACY AND RESISTANCE IN CML TREATMENT;HEPATOCELLULAR CARCINOMA;MANAGEMENT OF VALVULAR HEART DISEASE;ACUTE MYELOID LEUKEMIA;PANCREATIC CANCER RESEARCH AND TREATMENT;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;DIAGNOSIS AND TREATMENT OF GASTROINTESTINAL STROMAL TUMORS;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;CHOLANGIOCARCINOMA;DIAGNOSIS AND MANAGEMENT OF AORTIC DISEASES;LYMPHOID NEOPLASMS;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;EPIDEMIOLOGY AND MANAGEMENT OF NEUROENDOCRINE TUMORS;RADIOTHERAPY PHYSICS AND TECHNOLOGY;VIRAL-RELATED CANCERS IN IMMUNOCOMPROMISED PATIENTS;DIAGNOSIS AND TREATMENT OF LUNG CANCER;ORGAN TRANSPLANTATION AND REJECTION;EPIDEMIOLOGY AND TREATMENT OF CHILDHOOD LEUKEMIA;MECHANICAL VENTILATION IN RESPIRATORY FAILURE AND ARDS;","18;13;13;10;10;9;9;9;8;8;8;7;7;7;7;6;6;5;5;4","CLINICAL ENDPOINT;TREATMENT;TRANSCATHETER AORTIC-VALVE REPLACEMENT;AORTIC ROOT REPLACEMENT;PET IMAGING;HEPATOCELLULAR CARCINOMA;IMATINIB MESYLATE;REGIMEN;CARDIAC IMAGING;STROKE (ENGINE);DIAGNOSIS;HEMATOLOGY;PROSTHETIC VALVES EVALUATION;SURGICAL AORTIC-VALVE REPLACEMENT;UNIVARIATE ANALYSIS;AORTIC DISSECTION;ACUTE MYELOID LEUKEMIA;BREAST CANCER;CONCORDANCE;EXOME","21;17;14;13;13;12;11;11;10;10;9;9;9;9;9;8;7;7;7;7","HEPATOCELLULAR CARCINOMA;MYELOID LEUKEMIA;PROSTATE CANCER;CANCER PATIENTS;AORTIC VALVE;STEM CELL;ATRIAL FIBRILLATION;MULTIPLE MYELOMA;CHRONIC MYELOID;PATIENTS PTS;PATIENTS TREATED;ACUTE MYELOID;CELL TRANSPLANTATION;ELDERLY PATIENTS;RETROSPECTIVE STUDY;ACUTE LYMPHOBLASTIC;COHORT STUDY;GASTROINTESTINAL STROMAL;LOCALLY ADVANCED;LUNG CANCER;MAGNETIC RESONANCE;PANCREATIC CANCER;VALVE REPLACEMENT;ALLOGENEIC STEM;BREAST CANCER;CP-CML PATIENTS;EFSUMB GUIDELINES;EMERGENCY DEPARTMENT;INTERVENTIONAL ULTRASOUND;LIVER TRANSPLANTATION","15;14;14;12;11;10;9;9;8;8;8;7;7;7;7;6;6;6;6;6;6;6;6;5;5;5;5;5;5;5","BOLOGNA ITALY;BOLOGNA BOLOGNA;ITALY SEARCH;DI SCIENZE;DIPARTIMENTO DI;ATR ABS;RISK FACTORS;HR CI;CONFIDENCE INTERVAL;DI NEUROLOGIA;HEPATOCELLULAR CARCINOMA;MULTIVARIATE ANALYSIS;BREAST CANCER;DIBINEM UNIVERSITY;IRCCS ISTITUTO;NEUROLOGIA DIPARTIMENTO;NEUROMOTORIE DIBINEM;SCIENZE BIOMEDICHE;UNITA DI;AORTIC VALVE;HAZARD RATIO;STATISTICALLY SIGNIFICANT;CLINICAL PRACTICE;ITALY DEPARTMENT;ADVERSE EVENTS;CHIRURGICHE DIMEC;DELLE SCIENZE;DI BOLOGNA;DIMEC UNIVERSITY;GENE EXPRESSION","74;55;40;37;37;24;22;21;20;20;19;18;17;17;17;17;17;17;17;16;15;15;14;14;13;13;13;13;13;13",248,0.41,5.08,6,2,1,1,3,2,0,1,6,1,1,5,1,3.75,2,2,4,2,0,0,70.25,70.25,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,47,4.43,985.66,5.19,21,0.45,91.15,0,1,9,1,11,0,7,18,0,33,11,0,0,0,0,0,0,42,5,0,44,3,0,0,0,0,0,0,0,0,"United States;Italy;Japan;Canada;Germany;Netherlands","16;6;3;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3215 REPRODUCTIVE MEDICINE;42 HEALTH SCIENCES;30 AGRICULTURAL, VETERINARY AND FOOD SCIENCES;3006 FOOD SCIENCES;31 BIOLOGICAL SCIENCES;3105 GENETICS;3203 DENTISTRY;3207 MEDICAL MICROBIOLOGY;3210 NUTRITION AND DIETETICS;3212 OPHTHALMOLOGY AND OPTOMETRY;40 ENGINEERING;4003 BIOMEDICAL ENGINEERING;4203 HEALTH SERVICES AND SYSTEMS;48 LAW AND LEGAL STUDIES;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY","46;23;14;9;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;CARDIOVASCULAR;RARE DISEASES;HEART DISEASE;HEMATOLOGY;PATIENT SAFETY;DIGESTIVE DISEASES;PEDIATRIC;BIOMEDICAL IMAGING;LYMPHOMA;NUTRITION;BIOENGINEERING;ORPHAN DRUG;PEDIATRIC CANCER;PREVENTION;TRANSPLANTATION;AUTOIMMUNE DISEASE;BREAST CANCER","38;28;15;13;10;9;9;9;7;5;4;4;4;3;3;3;3;3;2;2","CANCER;CARDIOVASCULAR;ORAL AND GASTROINTESTINAL;BLOOD;EYE;INFECTION;METABOLIC AND ENDOCRINE;RESPIRATORY;STROKE","11;10;3;1;1;1;1;1;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS;2.4 SURVEILLANCE AND DISTRIBUTION;3.1 PRIMARY PREVENTION INTERVENTIONS TO MODIFY BEHAVIOURS OR PROMOTE WELLBEING;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;5.3 MEDICAL DEVICES;6.3 MEDICAL DEVICES","28;5;4;2;1;1;1;1;1","COLON AND RECTAL CANCER;NON-HODGKIN'S LYMPHOMA;LEUKEMIA / LEUKAEMIA;BREAST CANCER;ENDOMETRIAL CANCER;LUNG CANCER;NOT SITE-SPECIFIC CANCER;OVARIAN CANCER;BLOOD CANCER;GENITAL SYSTEM, FEMALE;LIVER CANCER;PROSTATE CANCER","4;4;3;2;2;2;2;2;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;4.4 RESOURCES AND INFRASTRUCTURE RELATED TO DETECTION, DIAGNOSIS, OR PROGNOSIS;2.1 EXOGENOUS FACTORS IN THE ORIGIN AND CAUSE OF CANCER;4.2 TECHNOLOGY AND/OR MARKER EVALUATION WITH RESPECT TO FUNDAMENTAL PARAMETERS OF METHOD","13;3;2;2;1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,24,"PUBLIC LIBRARY OF SCIENCE;AMERICAN ASSOCIATION FOR CANCER RESEARCH;TAYLOR & FRANCIS GROUP","22;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;42 HEALTH SCIENCES;3103 ECOLOGY;3105 GENETICS;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3102 BIOINFORMATICS AND COMPUTATIONAL BIOLOGY;3203 DENTISTRY;44 HUMAN SOCIETY;46 INFORMATION AND COMPUTING SCIENCES;3101 BIOCHEMISTRY AND CELL BIOLOGY;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3204 IMMUNOLOGY;3215 REPRODUCTIVE MEDICINE;4202 EPIDEMIOLOGY;4206 PUBLIC HEALTH;4403 DEMOGRAPHY;4601 APPLIED COMPUTING;48 LAW AND LEGAL STUDIES","21;20;5;4;4;3;3;2;2;2;2;1;1;1;1;1;1;1;1;1","GENETICS;BIOTECHNOLOGY;CANCER;CLINICAL RESEARCH;LUNG;NUTRITION;PREVENTION;CHRONIC OBSTRUCTIVE PULMONARY DISEASE;HEMATOLOGY;HUMAN GENOME;LUNG CANCER;OBESITY;PEDIATRIC;RARE DISEASES;ACQUIRED COGNITIVE IMPAIRMENT;AGING;ALZHEIMER'S DISEASE;ALZHEIMER'S DISEASE INCLUDING ALZHEIMER'S DISEASE RELATED DEMENTIAS (AD/ADRD);BRAIN DISORDERS;CHILDHOOD LEUKEMIA","5;4;4;4;4;3;3;2;2;2;2;2;2;2;1;1;1;1;1;1","CANCER;RESPIRATORY;METABOLIC AND ENDOCRINE","4;4;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;2.6 RESOURCES AND INFRASTRUCTURE (AETIOLOGY);5.1 PHARMACEUTICALS","7;1;1","BIOMEDICAL;CLINICAL","4;3","CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE;PUBLIC HEALTH","5;3;1","LUNG CANCER;NON-HODGKIN'S LYMPHOMA;LEUKEMIA / LEUKAEMIA","2;2;1","12 RESPONSIBLE CONSUMPTION AND PRODUCTION","1"
"IRCCS_SANTORSOLA",2016,747,13.425702811245,3.35073627844712,0.377510040160643,0.369477911646586,0.457831325301205,2.17841601392515,1.36893203883495,1.86486486486486,1.41908713692946,0.530120481927711,4,432,156,64,49,0.58,0.21,0.09,0.07,34.42,1.05951794066834,5.37099697885196,0.319946452476573,0.93574297188755,0.492,0.435,0.429,0.429,"A.G. MORGANTI;GABRIELLA MACCHIA;FRANCESCO DEODATO;ANDREA ARDIZZONI;SAVINO CILLA;VINCENZO VALENTINI;S. CAMMELLI;A. IANIRO;DONATELLA SANTINI;RAFFAELE PEZZILLI;G. PILU;PIERLUIGI VIALE;MICHÈLE CAVO;RITA GOLFIERI;STEFANO FANTI;ANDREA PESSION;GIUSEPPE BORIANI;RENATO SERACCHIOLI;GIOVANNI MARTINELLI;MAURO BIFFI","35;30;29;27;24;24;19;17;17;16;16;15;15;14;14;14;14;13;13;13","RAFFAELE PEZZILLI;A.G. MORGANTI;GABRIELLA MACCHIA;FRANCESCO DEODATO;G. PILU;ANDREA ARDIZZONI;RITA GOLFIERI;VINCENZO VALENTINI;SAVINO CILLA;DONATELLA SANTINI;RENATO SERACCHIOLI;A. YOUSSEF;BENILDE COSMI;ANDREA PESSION;FEDERICA BELLUSSI;GIACOMO FALDELLA;MASSIMILIANO POLASTRI;GIUSEPPE BORIANI;GIANANDREA PASQUINELLI;A. IANIRO","3.35;2.99;2.22;2.17;2.13;2.01;1.91;1.86;1.85;1.71;1.71;1.67;1.67;1.67;1.55;1.53;1.5;1.48;1.44;1.39","A.G. MORGANTI;GABRIELLA MACCHIA;FRANCESCO DEODATO;ANDREA ARDIZZONI;S. CAMMELLI;DONATELLA SANTINI;RAFFAELE PEZZILLI;G. PILU;PIERLUIGI VIALE;MICHÈLE CAVO;RITA GOLFIERI;STEFANO FANTI;ANDREA PESSION;GIUSEPPE BORIANI;RENATO SERACCHIOLI;GIOVANNI MARTINELLI;MAURO BIFFI;A. YOUSSEF;CLAUDIO RICCI;MICHELE BACCARANI","35;30;29;27;19;17;16;16;15;15;14;14;14;14;13;13;13;13;12;12","RAFFAELE PEZZILLI;A.G. MORGANTI;GABRIELLA MACCHIA;FRANCESCO DEODATO;G. PILU;ANDREA ARDIZZONI;RITA GOLFIERI;DONATELLA SANTINI;RENATO SERACCHIOLI;A. YOUSSEF;BENILDE COSMI;ANDREA PESSION;FEDERICA BELLUSSI;GIACOMO FALDELLA;MASSIMILIANO POLASTRI;GIUSEPPE BORIANI;GIANANDREA PASQUINELLI;STEFANO FANTI;MAURO BIFFI;CLAUDIO BORGHI","3.35;2.99;2.22;2.17;2.13;2.01;1.91;1.71;1.71;1.67;1.67;1.67;1.55;1.53;1.5;1.48;1.44;1.37;1.34;1.33","MASATOSHI KUDO;SHUKUI QIN;GIANLUCA MASI;ALESSANDRO GRANITO;ANNETTE BAUMHAUER;G. BODOKY;ISABELLE OLLIVIER‐HOURMAND;JORDI BRUIX;OLIVIER ROSMORDUC;OSAMU YOKOSUKA;PHILIPPE MERLE;RENÉ GÉROLAMI;TIANQIANG SONG;YI‐HSIANG HUANG;В. В. БРЕДЕР;GUOHONG HAN;PAUL J. ROSS;ANN‐LII CHENG;GEROLD MEINHARDT;JEAN-PIERRE BRONOWICKI","3220;3173;3156;3141;3141;3141;3141;3141;3141;3141;3141;3141;3141;3141;3141;3102;3102;3092;3092;3092","ALESSANDRO GRANITO;CLAUDIO RAPEZZI;PIERLUIGI GUIDALOTTI;ADAM CASTAÑO;ANDOR W. J. M. GLAUDEMANS;ANGELA DISPENZIERI;ASHUTOSH D. WECHALEKAR;BOUKE P. C. HAZENBERG;CANDIDA CRISTINA QUARTA;CAROL WHELAN;DAVID F. HUTT;EDWARD J. MILLER;FREDERICK L. RUBERG;FREDERICK W. VONBERG;GEOFFREY B. JOHNSON;GIAMPAOLO MERLINI;GIOVANNI PALLADINI;HELEN J. LACHMANN;JAMES MOON;JOHN L. BERK","3141;1743;1596;1566;1566;1566;1566;1566;1566;1566;1566;1566;1566;1566;1566;1566;1566;1566;1566;1566","A.G. MORGANTI;ANDREA ARDIZZONI;S. CAMMELLI;DONATELLA SANTINI;RAFFAELE PEZZILLI;MAURO BIFFI;RITA GOLFIERI;STEFANO FANTI;RICCARDO SCHIAVINA;PIERLUIGI VIALE;FEDERICA BELLUSSI;NICO PAGANO;GIUSEPPE BORIANI;CARLA SERRA;G. PILU;RENATO SERACCHIOLI;CLAUDIO RICCI;MARIACRISTINA DI MARCO;MARIO MARENGO;TIZIANA LAZZAROTTO","33;26;18;17;15;13;13;13;12;12;11;11;11;10;10;10;10;10;10;10","MEDICINE;BIOLOGY;PHYSICS;ENGINEERING;CHEMISTRY;COMPUTER SCIENCE;MATHEMATICS;PSYCHOLOGY;SOCIOLOGY;ECONOMICS;MATERIALS SCIENCE;POLITICAL SCIENCE;PHILOSOPHY;GEOGRAPHY;BUSINESS;GEOLOGY;ART;ENVIRONMENTAL SCIENCE;HISTORY","706;213;86;52;45;42;34;29;21;18;17;13;10;8;6;5;4;4;3","INTERNAL MEDICINE;SURGERY;PATHOLOGY;ONCOLOGY;RADIOLOGY;GENETICS;GASTROENTEROLOGY;CARDIOLOGY;IMMUNOLOGY;ENVIRONMENTAL HEALTH;BIOCHEMISTRY;NUCLEAR MEDICINE;PEDIATRICS;CANCER RESEARCH;OPTICS;ENDOCRINOLOGY;PSYCHIATRY;INTENSIVE CARE MEDICINE;MECHANICAL ENGINEERING;UROLOGY","538;219;139;133;117;108;98;87;74;71;54;49;49;45;43;42;40;35;31;27","CANCER;GENE;POPULATION;DISEASE;COHORT;CHEMOTHERAPY;CONFIDENCE INTERVAL;RADIATION THERAPY;INCIDENCE (GEOMETRY);RANDOMIZED CONTROLLED TRIAL;ADVERSE EFFECT;PREGNANCY;TRANSPLANTATION;CLINICAL TRIAL;RETROSPECTIVE COHORT STUDY;VIRUS;HEART FAILURE;HEPATOCELLULAR CARCINOMA;ALTERNATIVE MEDICINE;MULTIVARIATE ANALYSIS;ODDS RATIO;ULTRASOUND","164;81;71;62;54;49;46;40;35;35;32;32;31;29;29;27;26;26;25;25;25;25","COLORECTAL CANCER;BREAST CANCER;CLINICAL ENDPOINT;HAZARD RATIO;PROSTATE CANCER;FETUS;UNIVARIATE ANALYSIS;PANCREATIC CANCER;GENOTYPE;IMATINIB;MUTATION;GENE EXPRESSION;HEMATOPOIETIC STEM CELL TRANSPLANTATION;PHASES OF CLINICAL RESEARCH;PHENOTYPE;EJECTION FRACTION;IMMUNOTHERAPY;METASTASIS;PROSTATE;ALLELE;PERCUTANEOUS CORONARY INTERVENTION;PLACEBO;VIRAL LOAD","44;25;24;24;23;16;16;15;13;13;13;12;12;12;12;11;11;11;11;10;10;10;10","TRASTUZUMAB;PROSTATECTOMY;ANTIRETROVIRAL THERAPY;CARDIAC RESYNCHRONIZATION THERAPY;CETUXIMAB;DASATINIB;KRAS;METASTATIC BREAST CANCER;COLONOSCOPY;DNA METHYLATION;IMATINIB MESYLATE;NIVOLUMAB;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;RIBAVIRIN;SINGLE-NUCLEOTIDE POLYMORPHISM;CHROMOPHOBE CELL;FERTILITY PRESERVATION;HERPESVIRIDAE;NILOTINIB;CARBOPLATIN;ENDOVASCULAR ANEURYSM REPAIR;GENOTYPING;INTERNATIONAL PROGNOSTIC SCORING SYSTEM;IRINOTECAN;OXALIPLATIN;PAZOPANIB;REGORAFENIB","10;9;8;8;8;8;8;7;6;6;6;6;6;6;6;5;5;5;5;4;4;4;4;4;4;4;4","HUMANS;FEMALE;MALE;;MIDDLE AGED;AGED;ADULT;ITALY;RETROSPECTIVE STUDIES;AGED, 80 AND OVER;TREATMENT OUTCOME;PROSPECTIVE STUDIES;RISK FACTORS;YOUNG ADULT;ADOLESCENT;PROSTATIC NEOPLASMS;CHILD;LIVER NEOPLASMS;POSTOPERATIVE COMPLICATIONS;PANCREATIC NEOPLASMS","446;322;300;290;238;211;171;129;98;97;94;67;66;61;55;50;49;49;49;43","PANCREATIC CANCER RESEARCH AND TREATMENT;RADIOTHERAPY PHYSICS AND TECHNOLOGY;HEPATITIS C INFECTION AND TREATMENT;ACUTE MYELOID LEUKEMIA;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;EFFICACY AND RESISTANCE IN CML TREATMENT;MANAGEMENT OF VALVULAR HEART DISEASE;RENAL CELL CARCINOMA;COLORECTAL CANCER RESEARCH AND TREATMENT;HEPATOCELLULAR CARCINOMA;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;ATRIAL FIBRILLATION;CANCER IMMUNOTHERAPY;DIAGNOSIS AND MANAGEMENT OF AORTIC DISEASES;EPIDEMIOLOGY AND MANAGEMENT OF NEUROENDOCRINE TUMORS;MOLECULAR PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;EPIDEMIOLOGY AND MANAGEMENT OF SEXUAL DYSFUNCTION;GLOBAL CHALLENGE OF ANTIBIOTIC RESISTANCE IN BACTERIA","16;14;12;11;11;10;10;10;10;9;9;8;8;8;8;8;8;7;7;7","CLINICAL ENDPOINT;TREATMENT;STROKE (ENGINE);REGIMEN;RADIOTHERAPY;UNIVARIATE ANALYSIS;TRANSCATHETER AORTIC-VALVE REPLACEMENT;METASTATIC COLORECTAL CANCER;PROSTATE CANCER;INTENSITY-MODULATED RADIOTHERAPY;HEPATOCELLULAR CARCINOMA;PANCREATIC NEUROENDOCRINE TUMORS;PROSTHETIC VALVES EVALUATION;BREAST CANCER;CONCOMITANT;PROGRESSION-FREE SURVIVAL;AORTIC ROOT REPLACEMENT;ATRIAL FIBRILLATION;IMAGE-GUIDED RADIOTHERAPY;PANCREATIC CANCER","25;24;22;17;16;16;15;14;14;11;10;10;10;9;9;9;8;8;8;8","HEPATOCELLULAR CARCINOMA;PROSTATE CANCER;COLORECTAL CANCER;BREAST CANCER;MYELOID LEUKEMIA;ATRIAL FIBRILLATION;PHASE II;CANCER PATIENTS;PANCREATIC CANCER;RISK FACTORS;STEM CELL;AORTIC VALVE;METASTATIC COLORECTAL;PROSPECTIVE STUDY;RETROSPECTIVE ANALYSIS;CELL TRANSPLANTATION;CHRONIC MYELOID;COHORT STUDY;OBSERVATIONAL STUDY;PATIENTS TREATED;ACUTE MYELOID;ELDERLY PATIENTS;II STUDY;ITALIAN MULTICENTER;LEUKEMIA PATIENTS;PATIENTS PTS;PHASE III;RANDOMIZED PHASE;BONE METASTASES;CHRONIC HEPATITIS","19;19;15;14;14;12;12;10;10;10;10;9;9;9;9;8;8;8;8;8;7;7;7;7;7;7;7;7;6;6","PUBMED SCOPUS;CROSSREF PUBMED;PANCREATIC CANCER;CONFIDENCE INTERVAL;ADVERSE EVENTS;MULTIVARIATE ANALYSIS;ITALY DEPARTMENT;ALLERGY CLIN;PROSTATE CANCER;HR CI;MEDIAN AGE;CLIN IMMUNOL;UNIVERSITY HOSPITAL;CLINICAL PRACTICE;IMMUNOL -ABSTRACT;MEDIAN FOLLOW-UP;RISK FACTORS;PATIENTS TREATED;PATIENTS UNDERGOING;BOLOGNA ITALY;CLINICAL TRIALS;PLACEBO-CONTROLLED TRIAL;PUBLIC HEALTH;STEM CELL;DOUBLE-BLIND PLACEBO-CONTROLLED;PRIMARY ENDPOINT;STATISTICALLY SIGNIFICANT;USA DEPARTMENT;PATIENTS PTS;PRIMARY PREVENTION","106;56;53;40;38;38;36;34;34;33;33;32;30;28;27;27;27;25;25;24;23;23;23;23;22;22;22;22;21;21",291,0.39,6.75,6,2,2,2,7,2,0,2,6.5,1,1,6,1,3,2,3,5,3,0,0,68,68,1,1,0,1,0,0,0,0,0,0,0,0,2,0,0,1,5,0.4,3,0,2,2,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"BORIANI STEFANO;DE LUCA MARCO;DE OTO LUCIANO;GIROLAMI MAURO;NUCCI MARIA CONCETTA","2;2;2;2;2","AUTOMOBILI LAMBORGHINI SPA;ISTITUTO ORTOPEDICO RIZZOLI;AZIENDA OSPEDALIERO UNIVERSITARIA DI BOLOGNA POLICLINICO S ORSOLA MALPIGHI;AZIENDA OSPEDALIERO-UNIVERSITARIA DI BOLOGNA POLICLINICO S ORSOLA - MALPIGHI","2;2;1;1","31 BIOLOGICAL SCIENCES;33 BUILT ENVIRONMENT AND DESIGN;3303 DESIGN","2;2;2",NA,NA,NA,NA,"A61B17/62;A61B17/64","2;2","A61B17/62;A61B17/6441;A61B17/645","2;2;2",62,4.58,437.81,6.07,34,0.55,75.76,2,3,13,1,21,0,0,22,0,52,10,0,0,0,0,0,0,56,6,0,61,0,0,1,0,0,0,0,0,0,"United States;Italy;Japan;Belgium;France;Germany","20;13;6;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3204 IMMUNOLOGY;3210 NUTRITION AND DIETETICS;3213 PAEDIATRICS;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;3215 REPRODUCTIVE MEDICINE;42 HEALTH SCIENCES;30 AGRICULTURAL, VETERINARY AND FOOD SCIENCES;3006 FOOD SCIENCES;3207 MEDICAL MICROBIOLOGY;3212 OPHTHALMOLOGY AND OPTOMETRY;40 ENGINEERING;4003 BIOMEDICAL ENGINEERING;4203 HEALTH SERVICES AND SYSTEMS;50 PHILOSOPHY AND RELIGIOUS STUDIES;5002 HISTORY AND PHILOSOPHY OF SPECIFIC FIELDS;52 PSYCHOLOGY","61;27;20;8;5;4;2;2;2;2;1;1;1;1;1;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;RARE DISEASES;HEMATOLOGY;DIGESTIVE DISEASES;PREVENTION;PATIENT SAFETY;PEDIATRIC;LUNG;CARDIOVASCULAR;NUTRITION;ORPHAN DRUG;AUTOIMMUNE DISEASE;BREAST CANCER;KIDNEY DISEASE;LYMPHOMA;NEUROSCIENCES;STEM CELL RESEARCH;TRANSPLANTATION","59;43;33;24;16;11;10;9;9;7;5;5;5;4;4;4;4;4;4;4","CANCER;CARDIOVASCULAR;RESPIRATORY;ORAL AND GASTROINTESTINAL;INFECTION;INFLAMMATORY AND IMMUNE SYSTEM;RENAL AND UROGENITAL;REPRODUCTIVE HEALTH AND CHILDBIRTH","24;4;4;3;2;2;2;2","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;5.1 PHARMACEUTICALS;3.3 NUTRITION AND CHEMOPREVENTION;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;5.2 CELLULAR AND GENE THERAPIES;5.3 MEDICAL DEVICES;6.3 MEDICAL DEVICES;6.4 SURGERY;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES;7.2 END OF LIFE CARE;7.3 MANAGEMENT AND DECISION MAKING;8.1 ORGANISATION AND DELIVERY OF SERVICES","43;10;6;2;2;1;1;1;1;1;1;1;1;1","LEUKEMIA / LEUKAEMIA;MYELOMA;BREAST CANCER;COLON AND RECTAL CANCER;NON-HODGKIN'S LYMPHOMA;LUNG CANCER;GENITAL SYSTEM, FEMALE;KIDNEY CANCER;OVARIAN CANCER;ENDOMETRIAL CANCER;HODGKIN'S DISEASE;NOT SITE-SPECIFIC CANCER;SARCOMA","9;7;4;4;4;3;2;2;2;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS;5.5 COMBINATIONS OF LOCALIZED AND SYSTEMIC THERAPIES;5.7 RESOURCES AND INFRASTRUCTURE RELATED TO TREATMENT AND THE PREVENTION OF RECURRENCE;6.6 END-OF-LIFE CARE","24;3;3;1;1;1;1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,18,"PUBLIC LIBRARY OF SCIENCE;SPRINGER NATURE;KARGER PUBLISHERS","12;5;1","31 BIOLOGICAL SCIENCES;32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3105 GENETICS;3102 BIOINFORMATICS AND COMPUTATIONAL BIOLOGY;3101 BIOCHEMISTRY AND CELL BIOLOGY;3107 MICROBIOLOGY;3213 PAEDIATRICS;40 ENGINEERING;4003 BIOMEDICAL ENGINEERING;47 LANGUAGE, COMMUNICATION AND CULTURE","17;13;5;4;2;1;1;1;1;1;1","AGING;BRAIN DISORDERS;CLINICAL RESEARCH;DEPRESSION;GENETICS;MENTAL HEALTH;NEURODEGENERATIVE;NEUROSCIENCES;NUTRITION;PARKINSON'S DISEASE;PEDIATRIC;PREVENTION","1;1;1;1;1;1;1;1;1;1;1;1","CANCER;INFLAMMATORY AND IMMUNE SYSTEM;NEUROLOGICAL","1;1;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;6.1 PHARMACEUTICALS;7.1 INDIVIDUAL CARE NEEDS","3;1;1","CLINICAL;BIOMEDICAL","2;1","CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE","4;2","NOT SITE-SPECIFIC CANCER;CERVICAL CANCER","3;1",NA,NA
"IRCCS_SANTORSOLA",2017,717,14.5509065550907,3.41422594142259,0.373779637377964,0.354253835425384,0.444909344490934,2.21739130434783,1.34673366834171,1.76388888888889,1.44343891402715,0.578800557880056,7,401,167,65,41,0.56,0.23,0.09,0.06,25.82,0.875998640990599,5.60569218016026,0.337517433751743,0.923291492329149,0.513,0.473,0.425,0.463,"ANDREA ARDIZZONI;MICHÈLE CAVO;GIOVANNI MARTINELLI;MAURO BIFFI;A. YOUSSEF;GUIDO BIASCO;GIUSEPPE BORIANI;STEFANO FANTI;RAFFAELE PEZZILLI;FRANCESCO MASSARI;CLAUDIO RAPEZZI;G. PILU;MARIA LETIZIA BACCHI REGGIANI;MAURO GARGIULO;CLAUDIO ZAMAGNI;GIOVANNI BRANDI;MARCELLO TISEO;MATTEO ZIACCHI;MICHELANGELO FIORENTINO;FAUSTO CASTAGNETTI","23;23;21;20;20;19;19;18;17;17;16;16;15;14;13;13;13;13;12;12","RAFFAELE PEZZILLI;A. YOUSSEF;G. PILU;CRISTINA NANNI;STEFANO NAVA;CLAUDIO ZAMAGNI;FRANCESCO MASSARI;MASSIMILIANO POLASTRI;GUIDO BIASCO;GIORGIO GALLINELLA;ELISA MONTAGUTI;MAURO BIFFI;MAURO GARGIULO;CLAUDIO RAPEZZI;GIUSEPPE BORIANI;ANDREA ARDIZZONI;MICHÈLE CAVO;FEDERICA BELLUSSI;STEFANO FANTI;I. CATANEO","4.2;3.35;3.03;2.42;1.96;1.95;1.94;1.75;1.7;1.7;1.69;1.67;1.6;1.58;1.53;1.52;1.5;1.49;1.47;1.41","ANDREA ARDIZZONI;MICHÈLE CAVO;GIOVANNI MARTINELLI;MAURO BIFFI;A. YOUSSEF;GUIDO BIASCO;GIUSEPPE BORIANI;STEFANO FANTI;RAFFAELE PEZZILLI;FRANCESCO MASSARI;CLAUDIO RAPEZZI;G. PILU;MARIA LETIZIA BACCHI REGGIANI;MAURO GARGIULO;CLAUDIO ZAMAGNI;GIOVANNI BRANDI;MATTEO ZIACCHI;MICHELANGELO FIORENTINO;FAUSTO CASTAGNETTI;PIERLUIGI VIALE","23;23;21;20;20;19;19;18;17;17;16;16;15;14;13;13;13;12;12;12","RAFFAELE PEZZILLI;A. YOUSSEF;G. PILU;CRISTINA NANNI;STEFANO NAVA;CLAUDIO ZAMAGNI;FRANCESCO MASSARI;MASSIMILIANO POLASTRI;GUIDO BIASCO;GIORGIO GALLINELLA;ELISA MONTAGUTI;MAURO BIFFI;MAURO GARGIULO;CLAUDIO RAPEZZI;GIUSEPPE BORIANI;ANDREA ARDIZZONI;MICHÈLE CAVO;FEDERICA BELLUSSI;STEFANO FANTI;I. CATANEO","4.2;3.35;3.03;2.42;1.96;1.95;1.94;1.75;1.7;1.7;1.69;1.67;1.6;1.58;1.53;1.52;1.5;1.49;1.47;1.41","FABIO PISCAGLIA;STEFANO FANTI;DAVID O. COSGROVE;VITO CANTISANI;ADRIAN SǍFTOIU;ANNALISA BERZIGOTTI;BOGDAN PROCOPEȚ;GIOVANNA FERRAIOLI;IOAN SPOREA;JEFFREY C. BAMBER;LAURENT CASTÉRA;MAJA THIELE;MIREEN FRIEDRICH‐RUST;ODD HELGE GILJA;PAUL S. SIDHU;ROBERT J. DE KNEGT;RUEDIGER S. GOERTZ;SIMONA BOTA;THOMAS KARLAS;VICTOR DE LÉDINGHEN","1464;1252;1045;988;932;932;932;932;932;932;932;932;932;932;932;932;932;932;932;932","FABIO PISCAGLIA;STEFANO FANTI;PIERLUIGI VIALE;MASSIMILIANO BONAFÉ;CLAUDIA SAVINI;CLAUDIO RAPEZZI;MONICA CRICCA;ANDREA ARDIZZONI;MICHÈLE CAVO;VERONICA SALVATORE;CANDIDA CRISTINA QUARTA;ORNELLA LEONE;RICCARDO CASADEI;MAURO GARGIULO;FRANCESCA PALANDRI;MARIACRISTINA DI MARCO;MICHELANGELO FIORENTINO;FRANCESCO TOVOLI;AGNESE MILANDRI;CHRISTIAN GAGLIARDI","1385;1252;759;722;707;654;582;515;469;463;442;426;399;392;379;377;366;336;321;321","ANDREA ARDIZZONI;MAURO BIFFI;STEFANO FANTI;FRANCESCO MASSARI;RAFFAELE PEZZILLI;GUIDO BIASCO;CLAUDIO RAPEZZI;A. YOUSSEF;MATTEO ZIACCHI;MAURO GARGIULO;CLAUDIO ZAMAGNI;G. PILU;GIOVANNI BRANDI;MICHÈLE CAVO;MICHELANGELO FIORENTINO;MARIA LETIZIA BACCHI REGGIANI;ANDREA PESSION;CRISTINA NANNI;FRANCESCO SAIA;GIANANTONIO ROSTI","23;19;18;17;17;15;14;14;13;13;13;12;12;12;11;11;11;11;10;10","MEDICINE;BIOLOGY;PHYSICS;CHEMISTRY;ENGINEERING;MATHEMATICS;COMPUTER SCIENCE;PSYCHOLOGY;SOCIOLOGY;ECONOMICS;MATERIALS SCIENCE;POLITICAL SCIENCE;GEOLOGY;HISTORY;PHILOSOPHY;BUSINESS;ART;GEOGRAPHY","677;215;56;38;35;33;32;28;26;14;11;10;6;5;5;4;3;2","INTERNAL MEDICINE;SURGERY;ONCOLOGY;PATHOLOGY;GASTROENTEROLOGY;RADIOLOGY;GENETICS;CARDIOLOGY;IMMUNOLOGY;ENVIRONMENTAL HEALTH;CANCER RESEARCH;BIOCHEMISTRY;PEDIATRICS;INTENSIVE CARE MEDICINE;OPTICS;PALEONTOLOGY;PSYCHIATRY;ENDOCRINOLOGY;NUCLEAR MEDICINE;FAMILY MEDICINE;VIROLOGY","539;181;155;133;113;106;105;96;80;67;66;60;54;44;39;39;33;31;29;28;28","CANCER;GENE;DISEASE;POPULATION;CHEMOTHERAPY;ADVERSE EFFECT;COHORT;RANDOMIZED CONTROLLED TRIAL;TRANSPLANTATION;RETROSPECTIVE COHORT STUDY;PREGNANCY;CONFIDENCE INTERVAL;INCIDENCE (GEOMETRY);HEPATOCELLULAR CARCINOMA;MYELOID LEUKEMIA;CLINICAL TRIAL;VIRUS;LUNG CANCER;MYOCARDIAL INFARCTION;ULTRASOUND","147;80;68;66;51;43;43;42;41;38;36;35;35;31;31;30;29;27;26;25","BREAST CANCER;CLINICAL ENDPOINT;COLORECTAL CANCER;IMMUNOTHERAPY;HAZARD RATIO;PROSTATE CANCER;GENOTYPE;GENE EXPRESSION;METASTASIS;MUTATION;PLACEBO;SORAFENIB;IMATINIB;EJECTION FRACTION;HEMATOPOIETIC STEM CELL TRANSPLANTATION;PANCREATIC CANCER;ADENOCARCINOMA;COMMON TERMINOLOGY CRITERIA FOR ADVERSE EVENTS;PROSTATE;SEROLOGY;UNIVARIATE ANALYSIS","30;27;25;24;23;21;17;16;16;16;15;15;14;13;13;12;11;11;11;11;11","NIVOLUMAB;CARDIAC RESYNCHRONIZATION THERAPY;CEPHALIC PRESENTATION;DNA METHYLATION;METASTATIC BREAST CANCER;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;KRAS;ANTIRETROVIRAL THERAPY;ENDOVASCULAR ANEURYSM REPAIR;INTERNATIONAL PROGNOSTIC SCORING SYSTEM;REGORAFENIB;TRASTUZUMAB;DASATINIB;GENOTYPING;IMATINIB MESYLATE;NILOTINIB;RIBAVIRIN;RUXOLITINIB;EICOSAPENTAENOIC ACID;GERMLINE MUTATION;HBSAG;HERPESVIRIDAE;PDGFRA;PROBAND;SINGLE-NUCLEOTIDE POLYMORPHISM","18;9;9;9;8;8;7;6;6;6;6;6;5;5;5;5;5;5;4;4;4;4;4;4;4","HUMANS;;FEMALE;MALE;MIDDLE AGED;AGED;ADULT;ITALY;AGED, 80 AND OVER;RETROSPECTIVE STUDIES;TREATMENT OUTCOME;ADOLESCENT;YOUNG ADULT;LIVER NEOPLASMS;RISK FACTORS;PROSPECTIVE STUDIES;CHILD;CARCINOMA, HEPATOCELLULAR;POSTOPERATIVE COMPLICATIONS;TIME FACTORS","391;317;305;288;219;199;157;142;92;92;80;76;68;59;59;54;49;48;42;42","CANCER IMMUNOTHERAPY;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;EFFICACY AND RESISTANCE IN CML TREATMENT;HEPATOCELLULAR CARCINOMA;PANCREATIC CANCER RESEARCH AND TREATMENT;ACUTE MYELOID LEUKEMIA;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;MANAGEMENT OF VALVULAR HEART DISEASE;RENAL CELL CARCINOMA;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;EPIDEMIOLOGY AND MANAGEMENT OF NAFLD;HEMATOPOIETIC STEM CELL BIOLOGY;MANAGEMENT AND PATHOPHYSIOLOGY OF ABDOMINAL AORTIC ANEURYSMS;MOLECULAR PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS;HEPATITIS C INFECTION AND TREATMENT;GENOMIC LANDSCAPE OF CANCER AND MUTATIONAL SIGNATURES;GLOBAL CHALLENGE OF ANTIBIOTIC RESISTANCE IN BACTERIA;MATERNAL AND NEONATAL OUTCOMES OF CESAREAN SECTION;SARCOMA RESEARCH AND TREATMENT;ADVANCEMENTS IN LUNG CANCER RESEARCH","18;18;14;14;14;11;11;11;11;10;10;10;10;10;8;7;7;7;7;6","TREATMENT;CLINICAL ENDPOINT;REGIMEN;BREAST CANCER;DISCONTINUATION;TRANSCATHETER AORTIC-VALVE REPLACEMENT;STROKE (ENGINE);CARDIAC RESYNCHRONIZATION THERAPY;CONCORDANCE;HEPATOCELLULAR CARCINOMA;TUMOR MICROENVIRONMENT;UNIVARIATE ANALYSIS;EXPANDED ACCESS;HEMATOLOGY;PET/CT;PROGRESSION-FREE SURVIVAL;PROSTATE CANCER;BIOMARKERS FOR IMMUNOTHERAPY;CEPHALIC PRESENTATION;CUMULATIVE INCIDENCE","36;27;15;14;13;13;12;11;11;11;11;11;10;10;10;10;10;9;9;9","HEPATOCELLULAR CARCINOMA;MYELOID LEUKEMIA;BREAST CANCER;PATIENTS TREATED;LUNG CANCER;CELL CARCINOMA;PROSTATE CANCER;CHRONIC MYELOID;EXPANDED ACCESS;CELL LUNG;CLINICAL PRACTICE;MULTIPLE MYELOMA;ATRIAL FIBRILLATION;CELL TRANSPLANTATION;ITALIAN SOCIETY;PANCREATIC CANCER;RENAL CELL;RETROSPECTIVE ANALYSIS;ACUTE MYELOID;COHORT STUDY;OBSERVATIONAL STUDY;STEM CELL;AORTIC VALVE;CARDIAC RESYNCHRONIZATION;ELDERLY PATIENTS;INTRADUCTAL PAPILLARY;PAPILLARY MUCINOUS;PATIENTS PTS;PERCUTANEOUS CORONARY;PHASE III","22;18;17;14;13;12;12;11;11;10;10;10;9;9;9;9;9;9;8;8;8;8;7;7;7;7;7;7;7;7","METABOLIC ACIDOSIS;SERUM BICARBONATE;ADVERSE EVENTS;PUBMED SCOPUS;CONFIDENCE INTERVAL;BREAST CANCER;KIDNEY DISEASE;CHRONIC KIDNEY;HR CI;STATISTICALLY SIGNIFICANT;MEDIAN FOLLOW-UP;RESPONSE RATE;BOLOGNA ITALY;CLINICAL PRACTICE;CROSSREF PUBMED;RETROSPECTIVE STUDY;PATIENTS TREATED;HAZARD RATIO;MULTIVARIATE ANALYSIS;MYELOID LEUKEMIA;NULLIPAROUS WOMEN;RISK FACTORS;PATIENTS UNDERGOING;SIGNIFICANT DIFFERENCE;MEDIAN AGE;VISUAL FEEDBACK;PELVIC FLOOR;BRISTOL-MYERS SQUIBB;CARDIAC LEIOMYOMA;LUNG CANCER","58;52;50;43;35;34;34;33;32;32;30;30;29;27;27;26;25;24;23;23;22;22;21;21;20;20;19;18;18;18",291,0.41,5.6,6,1,1,1,6,1.5,1,1,7,1,1,6,2.75,2.25,2,3,4,3,0,0,64,64,1,0,2,1,1,0,0,0,0,0,0,0,3,0,1,0,5,0.82,3.5,0,4,4,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,2,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"BORIANI STEFANO;DE LUCA MARCO;DE OTO LUCIANO;GIROLAMI MAURO;NUCCI MARIA CONCETTA","4;4;4;4;4","AUTOMOBILI LAMBORGHINI SPA;ST ORTOPEDICO RIZZOLI;AZIENDA OSPEDALIERO-UNIVERSITARIA DI BOLOGNA POLICLINICO S ORSOLA - MALPIGHI;ISTITUTO ORTOPEDICO RIZZOLI;AZIENDA OSPEDALIERO UNIV DI BOLOGNA POLICLINICO S ORSOLA MALPIGHI;AZIENDA OSPEDALIERO-UNIVERSITARIA DI BOLOGNA POLICLINICO S ORSOLA-MALPIGHI","4;4;2;2;1;1","31 BIOLOGICAL SCIENCES;33 BUILT ENVIRONMENT AND DESIGN;3303 DESIGN;3107 MICROBIOLOGY;32 BIOMEDICAL AND CLINICAL SCIENCES;3203 DENTISTRY;51 PHYSICAL SCIENCES","4;2;2;1;1;1;1",NA,NA,NA,NA,"A61B17/62;A61B17/64","4;4","A61B17/62;A61B17/6441;A61B17/645","4;4;4",77,5.39,551.23,7.87,33,0.43,81.96,6,3,13,0,27,0,1,27,0,62,10,0,0,0,0,0,0,72,4,1,70,5,0,2,0,0,0,0,0,0,"United States;Italy;Japan;Germany;Switzerland;Turkey;Australia;Austria;Belgium;France;Netherlands;United Kingdom","29;18;7;5;2;2;1;1;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;42 HEALTH SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;4203 HEALTH SERVICES AND SYSTEMS;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY;40 ENGINEERING;4003 BIOMEDICAL ENGINEERING;51 PHYSICAL SCIENCES;3210 NUTRITION AND DIETETICS;30 AGRICULTURAL, VETERINARY AND FOOD SCIENCES;3009 VETERINARY SCIENCES;31 BIOLOGICAL SCIENCES;3107 MICROBIOLOGY;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;4201 ALLIED HEALTH AND REHABILITATION SCIENCE;4205 NURSING;46 INFORMATION AND COMPUTING SCIENCES","72;37;27;8;7;5;4;4;3;3;3;2;1;1;1;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;RARE DISEASES;DIGESTIVE DISEASES;PATIENT SAFETY;HEMATOLOGY;CARDIOVASCULAR;HEART DISEASE;LIVER DISEASE;PREVENTION;PEDIATRIC;CHRONIC LIVER DISEASE AND CIRRHOSIS;BIOENGINEERING;HEPATITIS;ORPHAN DRUG;ASSISTIVE TECHNOLOGY;AUTOIMMUNE DISEASE;EMERGING INFECTIOUS DISEASES;INFECTIOUS DISEASES","65;46;32;28;17;15;14;9;8;8;8;7;6;5;5;5;4;4;4;4","CANCER;CARDIOVASCULAR;ORAL AND GASTROINTESTINAL;INFECTION;INFLAMMATORY AND IMMUNE SYSTEM;MENTAL HEALTH;NEUROLOGICAL;RESPIRATORY;STROKE","21;9;7;6;2;1;1;1;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS;7.1 INDIVIDUAL CARE NEEDS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;6.3 MEDICAL DEVICES","54;8;3;3;2;1;1","LIVER CANCER;MYELOMA;NON-HODGKIN'S LYMPHOMA;LEUKEMIA / LEUKAEMIA;LUNG CANCER;BREAST CANCER;BLOOD CANCER;NOT SITE-SPECIFIC CANCER;OVARIAN CANCER;BRAIN TUMOR;ESOPHAGEAL / OESOPHAGEAL CANCER;HEAD AND NECK CANCER;ORAL CAVITY AND LIP CANCER;PANCREATIC CANCER;PHARYNGEAL CANCER;PROSTATE CANCER;SALIVARY GLAND CANCER","8;6;6;5;4;3;2;2;2;1;1;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;2.1 EXOGENOUS FACTORS IN THE ORIGIN AND CAUSE OF CANCER;3.3 CHEMOPREVENTION;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;4.4 RESOURCES AND INFRASTRUCTURE RELATED TO DETECTION, DIAGNOSIS, OR PROGNOSIS;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS","28;3;2;2;2;2;1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,49,"PUBLIC LIBRARY OF SCIENCE;SPRINGER NATURE;KARGER PUBLISHERS;TAYLOR & FRANCIS GROUP;AMERICAN ASSOCIATION FOR CANCER RESEARCH","37;7;2;2;1","32 BIOMEDICAL AND CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;3202 CLINICAL SCIENCES;3105 GENETICS;30 AGRICULTURAL, VETERINARY AND FOOD SCIENCES;3207 MEDICAL MICROBIOLOGY;3009 VETERINARY SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3211 ONCOLOGY AND CARCINOGENESIS;3215 REPRODUCTIVE MEDICINE;35 COMMERCE, MANAGEMENT, TOURISM AND SERVICES;3101 BIOCHEMISTRY AND CELL BIOLOGY;3102 BIOINFORMATICS AND COMPUTATIONAL BIOLOGY;3107 MICROBIOLOGY;3108 PLANT BIOLOGY;3203 DENTISTRY;3204 IMMUNOLOGY;3213 PAEDIATRICS;37 EARTH SCIENCES;3703 GEOCHEMISTRY","47;19;13;5;3;3;2;2;2;2;2;1;1;1;1;1;1;1;1;1","CLINICAL RESEARCH;GENETICS;PREVENTION;RARE DISEASES;ANTIMICROBIAL RESISTANCE;BRAIN DISORDERS;CANCER;EMERGING INFECTIOUS DISEASES;INFECTIOUS DISEASES;STEM CELL RESEARCH;VACCINE RELATED;AGING;ATHEROSCLEROSIS;BIODEFENSE;BIOTECHNOLOGY;CARDIOVASCULAR;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CONTRACEPTION/REPRODUCTION;DIGESTIVE DISEASES;ESTROGEN","4;3;3;3;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1","INFECTION;CARDIOVASCULAR;BLOOD;CANCER;MUSCULOSKELETAL;RENAL AND UROGENITAL;STROKE","7;2;1;1;1;1;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.1 PHARMACEUTICALS;2.2 FACTORS RELATING TO THE PHYSICAL ENVIRONMENT;5.1 PHARMACEUTICALS;1.1 NORMAL BIOLOGICAL DEVELOPMENT AND FUNCTIONING;5.2 CELLULAR AND GENE THERAPIES;7.3 MANAGEMENT AND DECISION MAKING","4;3;3;3;2;2;1;1;1","CLINICAL;BIOMEDICAL","9;4","CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE;HEALTH SERVICES RESEARCH;PUBLIC HEALTH","18;10;1;1","NOT SITE-SPECIFIC CANCER;LEUKEMIA / LEUKAEMIA;KIDNEY CANCER;LIVER CANCER;OVARIAN CANCER;SKIN CANCER","5;2;1;1;1;1","3 GOOD HEALTH AND WELL BEING","3"
"IRCCS_SANTORSOLA",2018,742,14.9353099730458,3.43126684636119,0.342318059299191,0.334231805929919,0.539083557951482,2.38166510757718,1.46820809248555,1.984,1.61290322580645,0.56199460916442,6,417,161,64,44,0.56,0.22,0.09,0.06,25.95,0.850726418572402,5.45784662265107,0.382749326145553,0.94743935309973,0.516,0.438,0.446,0.462,"MICHÈLE CAVO;MAURO BIFFI;SAVINO CILLA;ANDREA ARDIZZONI;A.G. MORGANTI;STEFANO FANTI;GABRIELLA MACCHIA;FRANCESCO DEODATO;GIUSEPPE BORIANI;MILLY BUWENGE;S. CAMMELLI;FRANCESCO MASSARI;FRANCESCA PALANDRI;MATTEO ZIACCHI;MARIA A. PANTALEO;NICOLA VIANELLI;VINCENZO VALENTINI;GIUSEPPE GIANNACCARE;MICHELANGELO FIORENTINO;RICCARDO CASADEI","32;28;23;23;23;23;23;21;20;19;19;19;17;17;16;16;15;15;15;15","MASSIMILIANO POLASTRI;STEFANO FANTI;A. YOUSSEF;CLAUDIO BORGHI;GIUSEPPE GIANNACCARE;MAURO BIFFI;EMILIO C. CAMPOS;GABRIELLA MACCHIA;MICHÈLE CAVO;GIUSEPPE BORIANI;A.G. MORGANTI;RICCARDO CASADEI;ANDREA ARDIZZONI;FRANCESCO MASSARI;SAVINO CILLA;MICHELANGELO FIORENTINO;FRANCESCO MINNI;FRANCESCO DEODATO;CLAUDIO RICCI;CARLO ALBERTO PACILIO","2.9;2.72;2.59;2.47;2.45;2.33;2.05;1.94;1.93;1.91;1.88;1.88;1.85;1.84;1.82;1.82;1.73;1.69;1.66;1.54","MICHÈLE CAVO;MAURO BIFFI;ANDREA ARDIZZONI;A.G. MORGANTI;STEFANO FANTI;GABRIELLA MACCHIA;GIUSEPPE BORIANI;MILLY BUWENGE;S. CAMMELLI;FRANCESCO MASSARI;FRANCESCA PALANDRI;MATTEO ZIACCHI;MARIA A. PANTALEO;NICOLA VIANELLI;GIUSEPPE GIANNACCARE;MICHELANGELO FIORENTINO;RICCARDO CASADEI;GIOVANNI MARTINELLI;FRANCESCO MINNI;PIERLUIGI VIALE","32;28;23;23;23;23;20;19;19;19;17;17;16;16;15;15;15;15;14;14","MASSIMILIANO POLASTRI;STEFANO FANTI;A. YOUSSEF;CLAUDIO BORGHI;GIUSEPPE GIANNACCARE;MAURO BIFFI;EMILIO C. CAMPOS;GABRIELLA MACCHIA;MICHÈLE CAVO;GIUSEPPE BORIANI;A.G. MORGANTI;RICCARDO CASADEI;ANDREA ARDIZZONI;FRANCESCO MASSARI;MICHELANGELO FIORENTINO;FRANCESCO MINNI;CLAUDIO RICCI;CARLO ALBERTO PACILIO;MARIA CRISTINA MERIGGIOLA;RUSSELL E. LEWIS","2.9;2.72;2.59;2.47;2.45;2.33;2.05;1.94;1.93;1.91;1.88;1.88;1.85;1.84;1.82;1.73;1.66;1.54;1.51;1.51","MARIA A. PANTALEO;ANGELO PAOLO DEI TOS;PAOLO G. CASALI;ALESSANDRO GRONCHI;JAVIER MARTÍN‐BROTO;GIOVANNI GRIGNANI;SILVIA GASPERONI;SILVIA STACCHIOTTI;A. BASSIM HASSAN;AKMAL SAFWAT;ANDREA FERRARI;ANGELA BUONADONNA;ANNA MARIA FREZZA;ANTONIO LÓPEZ–POUSA;AXEL LE CESNE;BERND KASPER;DAGMAR ADÁMKOVÁ KRÁKOROVÁ;ENRIQUE DE ÁLAVA;EVA WARDELMANN;FRITS VAN COEVORDEN","2742;2598;2593;2582;2558;2555;2555;2551;2525;2525;2525;2525;2525;2525;2525;2525;2525;2525;2525;2525","MARIA A. PANTALEO;RUSSELL E. LEWIS;MARIO MARENGO;G. CICORIA;MAURO BIFFI;LUIGI BOLONDI;A. YOUSSEF;STEFANO FANTI;IGOR DIEMBERGER;SIMONE AMBRETTI;DAVIDE PACINI;MATTEO ZIACCHI;ALESSANDRO GRANITO;TOMMASO PIPPUCCI;CLAUDIO RAPEZZI;CLAUDIO ZAMAGNI;MARIA CRISTINA MORELLI;LAURA GRAMANTIERI;MADDALENA GIANNELLA;MICHELE BARTOLETTI","2681;1519;585;562;472;461;425;412;374;374;365;353;349;346;339;320;318;312;309;302","MAURO BIFFI;A.G. MORGANTI;STEFANO FANTI;ANDREA ARDIZZONI;MILLY BUWENGE;FRANCESCO MASSARI;MATTEO ZIACCHI;S. CAMMELLI;NICOLA VIANELLI;DONATELLA SANTINI;FRANCESCA PALANDRI;MICHELANGELO FIORENTINO;MICHÈLE CAVO;FRANCESCA BONIFAZI;ANDRÉA STELLA;ENRICO GALLITTO;GIOVANNI BRANDI;MAURO GARGIULO;ANTONIO DANIELE PINNA;GIUSEPPE GIANNACCARE","27;22;22;20;18;17;17;17;15;14;14;13;13;12;12;12;12;12;12;12","MEDICINE;BIOLOGY;PHYSICS;COMPUTER SCIENCE;CHEMISTRY;ENGINEERING;MATHEMATICS;PSYCHOLOGY;ECONOMICS;SOCIOLOGY;MATERIALS SCIENCE;PHILOSOPHY;POLITICAL SCIENCE;GEOLOGY;GEOGRAPHY;ART;ENVIRONMENTAL SCIENCE;HISTORY;BUSINESS","695;207;67;54;47;32;31;28;16;14;13;11;8;5;3;2;2;2;1","INTERNAL MEDICINE;SURGERY;ONCOLOGY;GENETICS;PATHOLOGY;GASTROENTEROLOGY;RADIOLOGY;CARDIOLOGY;ENVIRONMENTAL HEALTH;IMMUNOLOGY;BIOCHEMISTRY;CANCER RESEARCH;INTENSIVE CARE MEDICINE;PEDIATRICS;NUCLEAR MEDICINE;PALEONTOLOGY;OPTICS;PSYCHIATRY;ENDOCRINOLOGY;NURSING","534;217;144;116;114;111;105;91;72;59;54;54;45;45;43;38;36;34;32;29","CANCER;GENE;POPULATION;DISEASE;COHORT;CHEMOTHERAPY;RANDOMIZED CONTROLLED TRIAL;TRANSPLANTATION;CONFIDENCE INTERVAL;RETROSPECTIVE COHORT STUDY;ADVERSE EFFECT;HEPATOCELLULAR CARCINOMA;RADIATION THERAPY;CLINICAL TRIAL;INCIDENCE (GEOMETRY);HEART FAILURE;PREGNANCY;BONE MARROW;MULTIVARIATE ANALYSIS;QUALITY OF LIFE (HEALTHCARE);STAGE (STRATIGRAPHY)","150;92;70;57;53;43;40;40;39;38;30;30;29;28;28;27;27;22;22;22;22","COLORECTAL CANCER;MUTATION;CLINICAL ENDPOINT;BREAST CANCER;HAZARD RATIO;IMMUNOTHERAPY;PROSTATE CANCER;EJECTION FRACTION;GENOTYPE;HEMATOPOIETIC STEM CELL TRANSPLANTATION;METASTASIS;PLACEBO;FETUS;GENE EXPRESSION;PHENOTYPE;PROSTATE;SORAFENIB;UNIVARIATE ANALYSIS;LIVER TRANSPLANTATION;MYELOFIBROSIS;TOLERABILITY","31;31;29;27;21;20;19;15;14;14;14;14;13;13;13;13;13;13;12;12;12","NIVOLUMAB;CARDIAC RESYNCHRONIZATION THERAPY;PROSTATECTOMY;RUXOLITINIB;EXOME SEQUENCING;DNA METHYLATION;TAMOXIFEN;ENDOVASCULAR ANEURYSM REPAIR;IMATINIB MESYLATE;INTERNATIONAL PROGNOSTIC SCORING SYSTEM;KARYOTYPE;KLEBSIELLA PNEUMONIAE;KRAS;SINGLE-NUCLEOTIDE POLYMORPHISM;BUSULFAN;COLONOSCOPY;GERMLINE MUTATION;METASTATIC BREAST CANCER;MISSENSE MUTATION;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;TRANSCRIPTOME;TRASTUZUMAB","15;9;9;9;8;7;7;6;6;6;6;6;6;6;5;5;5;5;5;5;5;5","HUMANS;FEMALE;;MALE;MIDDLE AGED;AGED;ADULT;ITALY;TREATMENT OUTCOME;RETROSPECTIVE STUDIES;AGED, 80 AND OVER;ADOLESCENT;YOUNG ADULT;RISK FACTORS;PROSPECTIVE STUDIES;LIVER NEOPLASMS;CHILD;LUNG NEOPLASMS;CARCINOMA, HEPATOCELLULAR;FOLLOW-UP STUDIES","420;320;310;300;227;201;185;110;108;100;94;62;62;57;51;48;46;45;43;43","CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;PANCREATIC CANCER RESEARCH AND TREATMENT;MOLECULAR PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS;CANCER IMMUNOTHERAPY;HEPATOCELLULAR CARCINOMA;ACUTE MYELOID LEUKEMIA;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;RADIOTHERAPY PHYSICS AND TECHNOLOGY;ATRIAL FIBRILLATION;EPIDEMIOLOGY AND MANAGEMENT OF NEUROENDOCRINE TUMORS;MANAGEMENT AND PATHOPHYSIOLOGY OF ABDOMINAL AORTIC ANEURYSMS;MANAGEMENT OF VALVULAR HEART DISEASE;RENAL CELL CARCINOMA;DIAGNOSIS AND TREATMENT OF GASTROINTESTINAL STROMAL TUMORS;GLOBAL CHALLENGE OF ANTIBIOTIC RESISTANCE IN BACTERIA;CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS IN BREAST CANCER;DEVELOPMENT AND APPLICATIONS OF RADIOPHARMACEUTICALS;DIAGNOSIS AND MANAGEMENT OF AORTIC DISEASES;DIAGNOSIS AND MANAGEMENT OF FUNGAL INFECTIONS;EPIDEMIOLOGY AND MANAGEMENT OF NAFLD","20;20;16;15;15;13;13;11;10;10;10;10;9;8;8;7;7;7;7;7","CLINICAL ENDPOINT;TREATMENT;DISCONTINUATION;IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR;REGIMEN;UNIVARIATE ANALYSIS;RADIOTHERAPY;TOLERABILITY;HEMATOPOIETIC CELL TRANSPLANTATION;TRANSCATHETER AORTIC-VALVE REPLACEMENT;CARDIAC RESYNCHRONIZATION THERAPY;CONCOMITANT;ETIOLOGY;HEPATOCELLULAR CARCINOMA;INTENSITY-MODULATED RADIOTHERAPY;INTERQUARTILE RANGE;METASTATIC PROSTATE CANCER;MYELOFIBROSIS;PANCREATIC NEUROENDOCRINE TUMORS;PROSTATE CANCER","29;23;18;16;15;13;12;12;11;11;10;10;10;10;10;10;10;10;10;10","HEPATOCELLULAR CARCINOMA;BREAST CANCER;CELL CARCINOMA;PROSTATE CANCER;LUNG CANCER;MYELOID LEUKEMIA;PRELIMINARY RESULTS;ATRIAL FIBRILLATION;PATIENTS PTS;STEM CELL;PHASE II;RENAL CELL;CELL TRANSPLANTATION;PHASE III;RISK FACTORS;CLINICAL PRACTICE;MULTICENTER STUDY;NEUROENDOCRINE TUMORS;PANCREATIC CANCER;ACUTE MYELOID;CARDIAC RESYNCHRONIZATION;GROWTH FACTOR;PATIENTS TREATED;RETROSPECTIVE STUDY;TRANSPLANT RECIPIENTS;ADVANCED BREAST;ADVANCED HEPATOCELLULAR;CELL LUNG;COHORT STUDY;GASTROINTESTINAL STROMAL","22;18;17;17;12;12;12;11;11;11;10;10;9;9;9;8;8;8;8;7;7;7;7;7;7;6;6;6;6;6","PUBMED SCOPUS;ADVISORY COMMITTEES;ENTITYS BOARD;HONORARIA MEMBERSHIP;CROSSREF PUBMED;SPEAKERS BUREAU;RESEARCH FUNDING;HR CI;PATIENTS TREATED;ADVISORY BOARD;GASTROINTESTINAL STROMAL;MEDIAN AGE;AORTIC ARCH;CONFIDENCE INTERVAL;SURVIVAL OS;FUNDING SPEAKERS;ONCOL -CROSSREF;NOVARTIS PFIZER;CLIN ONCOL;HAZARD RATIO;RISK FACTORS;COMMITTEES RESEARCH;SOFT TISSUE;ADVERSE EVENTS;PROGRESSION-FREE SURVIVAL;STEM CELL;COMPUTED TOMOGRAPHY;ADVISORY ROLE;CELL CARCINOMA;MULTIVARIATE ANALYSIS","176;155;155;128;113;113;75;51;48;43;37;37;35;35;34;33;32;31;30;30;30;29;27;26;26;26;25;24;23;23",293,0.39,5.6,7,2,1,1,2,2,0,1,8,1,1,7,0,1.5,1,4,4,4,0,0,62,62,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,5,0.39,3.5,0,2,2,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"BORIANI STEFANO;DE LUCA MARCO;DE OTO LUCIANO;GIROLAMI MAURO;LUCIANO DE OTO;MARCO DE LUCA;MARIA CONCETTA NUCCI;MAURO GIROLAMI;NUCCI MARIA CONCETTA;STEFANO BORIANI","1;1;1;1;1;1;1;1;1;1","AUTOMOBILI LAMBORGHINI SPA;AZIENDA OSPEDALIERO UNIV DI BOLOGNA POLICLINICO S ORSOLA MALPIGHI;ST ORTOPEDICO RIZZOLI;ISTITUTO ORTOPEDICO RIZZOLI","2;2;2;1","31 BIOLOGICAL SCIENCES;33 BUILT ENVIRONMENT AND DESIGN;3303 DESIGN;34 CHEMICAL SCIENCES;3403 MACROMOLECULAR AND MATERIALS CHEMISTRY","2;1;1;1;1",NA,NA,NA,NA,"A61B17/62;A61B17/64","2;2","A61B17/62;A61B17/6441;A61B17/645","2;2;2",85,4.59,686.35,8.75,38,0.45,83.49,2,5,14,2,26,0,3,32,1,62,20,0,0,0,0,0,0,79,6,0,80,3,1,1,0,0,0,0,0,0,"Italy;United States;Japan;United Kingdom;Germany;Netherlands;Spain;Belgium;France","21;18;8;5;4;2;2;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY;42 HEALTH SCIENCES;3204 IMMUNOLOGY;3213 PAEDIATRICS;4203 HEALTH SERVICES AND SYSTEMS;3215 REPRODUCTIVE MEDICINE;40 ENGINEERING;31 BIOLOGICAL SCIENCES;3210 NUTRITION AND DIETETICS;3212 OPHTHALMOLOGY AND OPTOMETRY;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;4003 BIOMEDICAL ENGINEERING","84;45;27;19;7;5;4;3;3;3;2;2;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;RARE DISEASES;HEMATOLOGY;PEDIATRIC;PATIENT SAFETY;DIGESTIVE DISEASES;PREVENTION;CARDIOVASCULAR;AUTOIMMUNE DISEASE;PEDIATRIC CANCER;INFLAMMATORY BOWEL DISEASE;LYMPHOMA;CHILDHOOD LEUKEMIA;HEART DISEASE;LUNG;NUTRITION;BREAST CANCER;GENETICS","78;52;35;28;19;17;16;15;14;13;9;8;7;7;6;6;6;6;5;5","CANCER;CARDIOVASCULAR;ORAL AND GASTROINTESTINAL;INFECTION;REPRODUCTIVE HEALTH AND CHILDBIRTH;RENAL AND UROGENITAL;BLOOD;INFLAMMATORY AND IMMUNE SYSTEM;EYE;RESPIRATORY;SKIN","24;11;7;4;4;3;2;2;1;1;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS;6.3 MEDICAL DEVICES;6.4 SURGERY;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;2.4 SURVEILLANCE AND DISTRIBUTION;5.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES;6.6 PSYCHOLOGICAL AND BEHAVIOURAL;7.1 INDIVIDUAL CARE NEEDS;8.1 ORGANISATION AND DELIVERY OF SERVICES","47;11;5;4;3;3;1;1;1;1;1;1;1","LEUKEMIA / LEUKAEMIA;NON-HODGKIN'S LYMPHOMA;BREAST CANCER;LIVER CANCER;SARCOMA;BONE CANCER, OSTEOSARCOMA / MALIGNANT FIBROUS HISTIOCYTOMA;COLON AND RECTAL CANCER;ENDOMETRIAL CANCER;KIDNEY CANCER;LUNG CANCER;NOT SITE-SPECIFIC CANCER;CERVICAL CANCER;LARYNGEAL CANCER;MELANOMA;OVARIAN CANCER;PANCREATIC CANCER;SALIVARY GLAND CANCER;STOMACH CANCER","10;6;5;4;4;3;3;2;2;2;2;1;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS;4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;2.2 ENDOGENOUS FACTORS IN THE ORIGIN AND CAUSE OF CANCER","26;4;4;3;2;2;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,35,"PUBLIC LIBRARY OF SCIENCE;FRONTIERS;TAYLOR & FRANCIS GROUP","27;7;1","32 BIOMEDICAL AND CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;3202 CLINICAL SCIENCES;34 CHEMICAL SCIENCES;30 AGRICULTURAL, VETERINARY AND FOOD SCIENCES;3105 GENETICS;3107 MICROBIOLOGY;3211 ONCOLOGY AND CARCINOGENESIS;3210 NUTRITION AND DIETETICS;3401 ANALYTICAL CHEMISTRY;38 ECONOMICS;49 MATHEMATICAL SCIENCES;3009 VETERINARY SCIENCES;3103 ECOLOGY;3207 MEDICAL MICROBIOLOGY;3801 APPLIED ECONOMICS;4901 APPLIED MATHEMATICS;3006 FOOD SCIENCES;3205 MEDICAL BIOCHEMISTRY AND METABOLOMICS;3208 MEDICAL PHYSIOLOGY","40;19;9;7;5;5;4;4;3;3;3;3;2;2;2;2;2;1;1;1","NEUROSCIENCES;NUTRITION;PREVENTION;CANCER;PEDIATRIC;AGING;CLINICAL RESEARCH;COMPLEMENTARY AND INTEGRATIVE HEALTH;DIGESTIVE DISEASES;LUNG;PERINATAL PERIOD - CONDITIONS ORIGINATING IN PERINATAL PERIOD;PNEUMONIA;PNEUMONIA & INFLUENZA;PROSTATE CANCER;UROLOGIC DISEASES;AUTOIMMUNE DISEASE;BIOTECHNOLOGY;INFECTIOUS DISEASES;PAIN RESEARCH;BIOMEDICAL IMAGING","5;5;5;4;4;3;3;3;3;3;3;3;3;3;3;2;2;2;2;1","INFECTION;ORAL AND GASTROINTESTINAL;METABOLIC AND ENDOCRINE;CANCER;EYE;GENERIC HEALTH RELEVANCE","3;3;2;1;1;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;3.3 NUTRITION AND CHEMOPREVENTION;2.2 FACTORS RELATING TO THE PHYSICAL ENVIRONMENT;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;6.1 PHARMACEUTICALS;6.4 SURGERY","5;4;3;2;1;1;1","CLINICAL;BIOMEDICAL;HEALTH SERVICES & SYSTEMS","5;3;1","CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE","4;3","PROSTATE CANCER;COLON AND RECTAL CANCER","4;1","3 GOOD HEALTH AND WELL BEING","1"
"IRCCS_SANTORSOLA",2019,831,15.0336943441637,3.16004813477737,0.342960288808664,0.346570397111913,0.441636582430806,2.52015355086372,1.425,1.93288590604027,1.41698841698842,0.594464500601685,6,398,183,96,65,0.48,0.22,0.12,0.08,20.46,0.841526179576952,5.59589041095891,0.368231046931408,0.930204572803851,0.504,0.486,0.44,0.497,"MICHÈLE CAVO;MAURO GARGIULO;STEFANO FANTI;ANDREA ARDIZZONI;A.G. MORGANTI;MAURO BIFFI;FRANCESCA PALANDRI;GIANLUCA FAGGIOLI;MASSIMILIANO BONIFACIO;GIUSEPPE GIANNACCARE;NICOLA VIANELLI;ALESSANDRA IURLO;ANDREA PESSION;FRANCESCO MASSARI;RODOLFO PINI;FRANCESCO DEODATO;GIULIA BENEVOLO;PIERLUIGI VIALE;SAVINO CILLA;DONATELLA SANTINI","32;27;27;26;24;23;21;21;21;20;20;19;19;18;18;17;17;17;16;16","MAURO GARGIULO;STEFANO FANTI;GIUSEPPE GIANNACCARE;GIANLUCA FAGGIOLI;G. PILU;MICHÈLE CAVO;MARCO PELLEGRINI;RODOLFO PINI;A. YOUSSEF;PIERA VERSURA;STEFANO NAVA;ANDREA ARDIZZONI;ROCCO TRISOLINI;SIMONE AMBRETTI;MAURO BIFFI;A.G. MORGANTI;CHIARA MASCOLI;ENRICO GALLITTO;EMILIO C. CAMPOS;FRANCESCO MASSARI","3.37;3.27;2.9;2.57;2.33;2.27;2.18;2.18;2.14;2.1;2.01;1.94;1.87;1.83;1.82;1.8;1.75;1.75;1.72;1.7","MICHÈLE CAVO;MAURO GARGIULO;STEFANO FANTI;ANDREA ARDIZZONI;A.G. MORGANTI;MAURO BIFFI;FRANCESCA PALANDRI;GIANLUCA FAGGIOLI;GIUSEPPE GIANNACCARE;NICOLA VIANELLI;ANDREA PESSION;FRANCESCO MASSARI;RODOLFO PINI;PIERLUIGI VIALE;DONATELLA SANTINI;CHIARA MASCOLI;ENRICO GALLITTO;ANTONIO DANIELE PINNA;MARCO PELLEGRINI;G. PILU","32;27;27;26;24;23;21;21;20;20;19;18;18;17;16;16;15;15;15;15","MAURO GARGIULO;STEFANO FANTI;GIUSEPPE GIANNACCARE;GIANLUCA FAGGIOLI;G. PILU;MICHÈLE CAVO;MARCO PELLEGRINI;RODOLFO PINI;A. YOUSSEF;PIERA VERSURA;STEFANO NAVA;ANDREA ARDIZZONI;ROCCO TRISOLINI;SIMONE AMBRETTI;MAURO BIFFI;A.G. MORGANTI;CHIARA MASCOLI;ENRICO GALLITTO;EMILIO C. CAMPOS;FRANCESCO MASSARI","3.37;3.27;2.9;2.57;2.33;2.27;2.18;2.18;2.14;2.1;2.01;1.94;1.87;1.83;1.82;1.8;1.75;1.75;1.72;1.7","GIOVANNI BRANDI;MASATOSHI KUDO;RICHARD S. FINN;ANDREW X. ZHU;BRUNO DANIELE;CHIA‐JUI YEN;CHRISTOPHE BORG;DONG BOK SHIN;ERIC ASSÉNAT;GUIDO GERKEN;HO YEONG LIM;IZUMI OHNO;JEAN‐BAPTISTE HIRIART;JOSEP M. LLOVET;KENTA MOTOMURA;KUN‐MING RAU;MANABU MORIMOTO;MARC PRACHT;P. ABADA;PETER R. GALLE","1494;1460;1352;1331;1331;1331;1331;1331;1331;1331;1331;1331;1331;1331;1331;1331;1331;1331;1331;1331","GIOVANNI BRANDI;STEFANO FANTI;TOMMASO PIPPUCCI;CRISTINA NANNI;STEFANO NAVA;NICOLA VIANELLI;MAURO BIFFI;LARA PISANI;FRANCESCA BONIFAZI;ANDREA ARDIZZONI;FRANCESCA PALANDRI;ANDREA PESSION;A.G. MORGANTI;CLAUDIO BORGHI;LORIS PIRONI;SIMONE AMBRETTI;ARRIGO F.G. CICERO;GIUSEPPE GIANNACCARE;ANTONIETTA D’ANTUONO;VALERIA GASPARI","1494;938;522;485;422;397;395;364;348;340;331;322;316;300;299;299;298;284;282;282","STEFANO FANTI;MAURO GARGIULO;ANDREA ARDIZZONI;MAURO BIFFI;FRANCESCA PALANDRI;GIANLUCA FAGGIOLI;NICOLA VIANELLI;MICHÈLE CAVO;A.G. MORGANTI;FRANCESCO MASSARI;RODOLFO PINI;CHIARA MASCOLI;DONATELLA SANTINI;GIUSEPPE GIANNACCARE;ENRICO GALLITTO;G. PILU;ANDREA PESSION;PIERLUIGI VIALE;MATTEO ZIACCHI;A. YOUSSEF","26;26;25;23;21;20;20;19;19;18;17;16;16;15;15;15;14;14;13;13","MEDICINE;BIOLOGY;PHYSICS;COMPUTER SCIENCE;CHEMISTRY;ENGINEERING;MATHEMATICS;PSYCHOLOGY;ECONOMICS;SOCIOLOGY;PHILOSOPHY;POLITICAL SCIENCE;MATERIALS SCIENCE;GEOLOGY;HISTORY;ART;BUSINESS;GEOGRAPHY;ENVIRONMENTAL SCIENCE","784;244;78;47;45;29;25;20;16;15;12;12;9;8;6;5;5;4;1","INTERNAL MEDICINE;SURGERY;ONCOLOGY;PATHOLOGY;GENETICS;RADIOLOGY;GASTROENTEROLOGY;IMMUNOLOGY;CARDIOLOGY;CANCER RESEARCH;ENVIRONMENTAL HEALTH;INTENSIVE CARE MEDICINE;BIOCHEMISTRY;PEDIATRICS;NUCLEAR MEDICINE;ENDOCRINOLOGY;OPTICS;ANESTHESIA;PALEONTOLOGY;MICROBIOLOGY","599;246;165;148;145;127;107;81;80;76;66;61;58;56;48;39;36;33;31;29","CANCER;GENE;DISEASE;POPULATION;RETROSPECTIVE COHORT STUDY;COHORT;CHEMOTHERAPY;TRANSPLANTATION;CONFIDENCE INTERVAL;PREGNANCY;RANDOMIZED CONTROLLED TRIAL;CLINICAL TRIAL;ULTRASOUND;ADVERSE EFFECT;MULTIVARIATE ANALYSIS;BONE MARROW;RADIATION THERAPY;PROSPECTIVE COHORT STUDY;HEART FAILURE;LUNG CANCER","165;102;93;62;55;45;42;40;37;37;36;35;33;31;31;30;29;28;27;27","BREAST CANCER;CLINICAL ENDPOINT;PROSTATE CANCER;COLORECTAL CANCER;IMMUNOTHERAPY;HAZARD RATIO;MYELOFIBROSIS;MUTATION;FETUS;GENE EXPRESSION;PROSTATE;UNIVARIATE ANALYSIS;ABDOMINAL AORTIC ANEURYSM;EJECTION FRACTION;GENOTYPE;HEMATOPOIETIC STEM CELL TRANSPLANTATION;PHENOTYPE;PLACEBO;AORTIC ANEURYSM;GESTATIONAL AGE","26;26;26;25;22;20;19;18;15;15;15;15;14;14;14;14;13;13;12;12","NIVOLUMAB;ENDOVASCULAR ANEURYSM REPAIR;RUXOLITINIB;CARDIAC RESYNCHRONIZATION THERAPY;INTERNATIONAL PROGNOSTIC SCORING SYSTEM;CANAKINUMAB;EXOME SEQUENCING;KLEBSIELLA PNEUMONIAE;SINGLE-NUCLEOTIDE POLYMORPHISM;COLONOSCOPY;DNA METHYLATION;METASTATIC BREAST CANCER;CRITICAL LIMB ISCHEMIA;CYSTECTOMY;DASATINIB;PRENATAL DIAGNOSIS;DARATUMUMAB;FETAL HEAD;FLUDARABINE;KRAS;MISSENSE MUTATION;MYELOPROLIFERATIVE NEOPLASM;PANCREATIC DUCTAL ADENOCARCINOMA;PDGFRA;POMALIDOMIDE;PROSTATE-SPECIFIC ANTIGEN;PROSTATECTOMY;TRASTUZUMAB;VITAMIN K ANTAGONIST","13;11;10;9;8;7;7;7;7;6;6;6;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4;4;4","HUMANS;;FEMALE;MALE;MIDDLE AGED;AGED;ADULT;ITALY;RETROSPECTIVE STUDIES;TREATMENT OUTCOME;AGED, 80 AND OVER;ADOLESCENT;PROSPECTIVE STUDIES;CHILD;YOUNG ADULT;POSTOPERATIVE COMPLICATIONS;LIVER NEOPLASMS;TIME FACTORS;PROGNOSIS;RISK FACTORS","434;389;326;310;216;202;167;150;120;82;81;65;62;61;60;58;52;49;45;43","MOLECULAR PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;MANAGEMENT AND PATHOPHYSIOLOGY OF ABDOMINAL AORTIC ANEURYSMS;PANCREATIC CANCER RESEARCH AND TREATMENT;CANCER IMMUNOTHERAPY;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;LYMPHOID NEOPLASMS;DIAGNOSIS AND MANAGEMENT OF DRY EYE DISEASE;DIAGNOSIS AND TREATMENT OF GASTROINTESTINAL STROMAL TUMORS;MECHANICAL VENTILATION IN RESPIRATORY FAILURE AND ARDS;ACUTE MYELOID LEUKEMIA;HEPATOCELLULAR CARCINOMA;CHOLANGIOCARCINOMA;DIAGNOSIS AND MANAGEMENT OF FUNGAL INFECTIONS;DIAGNOSIS AND TREATMENT OF BLADDER CANCER;EFFICACY AND RESISTANCE IN CML TREATMENT;RENAL CELL CARCINOMA;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;GENOMIC STUDIES AND TREATMENT OF OVARIAN CARCINOMA;RADIOMICS IN MEDICAL IMAGING ANALYSIS","23;21;17;14;13;12;12;11;11;11;10;10;9;9;9;9;9;8;8;7","CLINICAL ENDPOINT;TREATMENT;INTERQUARTILE RANGE;MYELOFIBROSIS;REFRACTORY (PLANETARY SCIENCE);TUMOR MICROENVIRONMENT;UNIVARIATE ANALYSIS;CARDIAC RESYNCHRONIZATION THERAPY;ENDOVASCULAR REPAIR;PROSTATE CANCER;DISCONTINUATION;ENDOVASCULAR ANEURYSM REPAIR;PET IMAGING;REGIMEN;CANCER IMAGING;NONINVASIVE VENTILATION;RUXOLITINIB;RUXOLITINIB THERAPY;ANEURYSM SCREENING;BREAST CANCER","26;25;19;15;15;15;15;14;12;12;11;11;11;11;10;10;10;10;9;9","PROSTATE CANCER;CELL CARCINOMA;MULTICENTER STUDY;MYELOID LEUKEMIA;BREAST CANCER;HEPATOCELLULAR CARCINOMA;LUNG CANCER;MULTIPLE MYELOMA;CANCER PATIENTS;OBSERVATIONAL STUDY;PHASE II;ACUTE MYELOID;COHORT STUDY;RENAL CELL;RETROSPECTIVE STUDY;CELL LUNG;LEFT VENTRICULAR;MINIMALLY INVASIVE;PATIENTS PTS;PATIENTS TREATED;CELL TRANSPLANTATION;CHRONIC MYELOID;COLORECTAL CANCER;DRY EYE;MULTICENTER RETROSPECTIVE;NEWLY DIAGNOSED;PATIENTS AFFECTED;PHASE III;SQUAMOUS CELL;ATRIAL FIBRILLATION","19;17;17;16;13;13;12;12;11;11;11;10;10;10;10;9;9;8;8;8;7;7;7;7;7;7;7;7;7;6","ADVISORY COMMITTEES;ENTITYS BOARD;SPEAKERS BUREAU;RESEARCH FUNDING;ADVISORY CONSULTANCY;CONSULTANCY HONORARIA;HONORARIA MEMBERSHIP;COMMITTEES SPEAKERS;PATIENTS TREATED;BUREAU EXPERT;EXPERT TESTIMONY;PUBMED SCOPUS;SPEAKER BUREAU;HR CI;NOVARTIS HONORARIA;PROSTATE CANCER;RISK FACTORS;ADVERSE EVENTS;HONORARIA RESEARCH;MEDIAN AGE;CONSULTANCY SPEAKER;MULTIVARIATE ANALYSIS;PATIENTS UNDERGOING;CROSSREF PUBMED;LYMPH NODE;CONSULTANCY SPEAKERS;LUNG CANCER;ACCOMMODATION EXPENSES;CONSULTANCY MEMBERSHIP;SURVIVAL OS","250;250;189;158;98;96;96;92;64;58;58;58;58;57;54;49;49;47;45;43;39;39;37;35;32;31;30;28;28;28",342,0.41,7.39,8,2,1,1,4,1,1,1,9,1.5,1,7.75,1,1.75,2,4,6,4,0,0,53.75,53,2,0,0,2,0,1,0,1,0,0,0,0,1,2,1,0,5.5,0.84,3.25,0,4,4,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"BORIANI STEFANO;DE LUCA MARCO;DE OTO LUCIANO;GIROLAMI MAURO;NUCCI MARIA CONCETTA;BARBARA GIOVANNI;BARBARO MARIA RAFFAELLA;CREMON CESARE;MASTROROBERTO MARIANNA;MORSELLI-LABATE ANTONIO MARIA","3;3;3;3;3;1;1;1;1;1","ISTITUTO ORTOPEDICO RIZZOLI;AUTOMOBILI LAMBORGHINI SPA;AZIENDA OSPEDALIERO UNIV DI BOLOGNA POLICLINICO S ORSOLA MALPIGHI;AUTOMOBILI LAMBORGHINI S.P.A.;AZIENDA OSPEDALIERO-UNIVERSITARIA DI BOLOGNA POLICLINICO S ORSOLA - MALPIGHI;AZIENDA OSPEDALIERO-UNIVERSITARIA DI BOLOGNA POLICLINICO S ORSOLA-MALPIGHI;AZIENDA OSPEDALIERO-UNIVERSITARIA DI BOLOGNA POLICLINICO S. ORSOLA - MALPIGHI;ST ORTOPEDICO RIZZOLI;UNIV BOLOGNA ALMA MATER STUDIORUM","3;2;2;1;1;1;1;1;1","33 BUILT ENVIRONMENT AND DESIGN;30 AGRICULTURAL, VETERINARY AND FOOD SCIENCES;3303 DESIGN;3006 FOOD SCIENCES;51 PHYSICAL SCIENCES","3;2;2;1;1",NA,NA,NA,NA,"A61B17/62;A61B17/64;G16H50/30","3;3;1","A61B17/62;A61B17/6441;A61B17/645;G06N7/01;G16H10/20;G16H10/40;G16H10/60;G16H50/20;G16H50/30;G16H50/70","3;3;3;1;1;1;1;1;1;1",77,3.96,843.51,8.28,39,0.51,82.44,2,5,16,1,21,0,1,31,0,57,19,0,0,0,0,0,0,69,6,2,75,1,0,1,0,0,0,0,0,0,"United States;Italy;Netherlands;United Kingdom;Japan;Germany;Belgium;Switzerland;Brazil;China;France;Indonesia;Norway;Portugal;South Korea;Spain;Turkey","21;19;7;6;5;4;3;2;1;1;1;1;1;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY;3213 PAEDIATRICS;3215 REPRODUCTIVE MEDICINE;4206 PUBLIC HEALTH;31 BIOLOGICAL SCIENCES;3107 MICROBIOLOGY;3204 IMMUNOLOGY;40 ENGINEERING;4003 BIOMEDICAL ENGINEERING;4201 ALLIED HEALTH AND REHABILITATION SCIENCE","75;42;32;14;7;4;3;3;2;2;2;1;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;RARE DISEASES;HEMATOLOGY;DIGESTIVE DISEASES;PATIENT SAFETY;LYMPHOMA;CARDIOVASCULAR;LUNG;HEART DISEASE;PEDIATRIC;PREVENTION;AGING;LIVER DISEASE;AUTOIMMUNE DISEASE;BIOENGINEERING;BREAST CANCER;LUNG CANCER;NUTRITION","72;51;47;31;23;17;15;11;9;9;8;7;7;6;6;4;4;4;4;4","CANCER;CARDIOVASCULAR;ORAL AND GASTROINTESTINAL;BLOOD;INFECTION;RENAL AND UROGENITAL;STROKE;REPRODUCTIVE HEALTH AND CHILDBIRTH;RESPIRATORY;SKIN","30;11;8;2;2;2;2;1;1;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;5.1 PHARMACEUTICALS;6.4 SURGERY;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;7.1 INDIVIDUAL CARE NEEDS;2.6 RESOURCES AND INFRASTRUCTURE (AETIOLOGY);4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;6.3 MEDICAL DEVICES","52;12;8;4;3;2;1;1;1","NON-HODGKIN'S LYMPHOMA;LEUKEMIA / LEUKAEMIA;BREAST CANCER;LUNG CANCER;COLON AND RECTAL CANCER;LIVER CANCER;MYELOMA;PROSTATE CANCER;ENDOMETRIAL CANCER;NOT SITE-SPECIFIC CANCER;STOMACH CANCER;BLOOD CANCER;ESOPHAGEAL / OESOPHAGEAL CANCER;GALLBLADDER CANCER;HODGKIN'S DISEASE;KIDNEY CANCER;OVARIAN CANCER;PANCREATIC CANCER;SARCOMA","11;8;4;4;3;3;3;3;2;2;2;1;1;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;4.4 RESOURCES AND INFRASTRUCTURE RELATED TO DETECTION, DIAGNOSIS, OR PROGNOSIS;6.2 SURVEILLANCE","32;5;4;1;1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,37,"PUBLIC LIBRARY OF SCIENCE;FRONTIERS;SCIELO JOURNALS;AMERICAN ASSOCIATION FOR CANCER RESEARCH;KARGER PUBLISHERS;TAYLOR & FRANCIS GROUP","18;14;2;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;3202 CLINICAL SCIENCES;49 MATHEMATICAL SCIENCES;3105 GENETICS;3211 ONCOLOGY AND CARCINOGENESIS;3212 OPHTHALMOLOGY AND OPTOMETRY;3213 PAEDIATRICS;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;3204 IMMUNOLOGY;3101 BIOCHEMISTRY AND CELL BIOLOGY;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3215 REPRODUCTIVE MEDICINE;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;44 HUMAN SOCIETY;4901 APPLIED MATHEMATICS;4904 PURE MATHEMATICS;4905 STATISTICS","56;12;10;6;5;4;3;3;3;2;1;1;1;1;1;1;1;1;1","CLINICAL RESEARCH;PEDIATRIC;GENETICS;CANCER;PREVENTION;BIOTECHNOLOGY;GENETIC TESTING;HUMAN GENOME;NEUROSCIENCES;INFECTIOUS DISEASES;BREAST CANCER;HEADACHES;MIGRAINES;PAIN RESEARCH;SEXUALLY TRANSMITTED INFECTIONS;BIOMEDICAL IMAGING;CERVICAL CANCER;HEMATOLOGY;KIDNEY DISEASE;BRAIN DISORDERS","18;11;9;6;6;5;5;5;5;4;3;3;3;3;3;2;2;2;2;1","INFLAMMATORY AND IMMUNE SYSTEM;CANCER;NEUROLOGICAL;INFECTION;RENAL AND UROGENITAL;CARDIOVASCULAR;EYE;METABOLIC AND ENDOCRINE","8;5;4;3;2;1;1;1","4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;2.4 SURVEILLANCE AND DISTRIBUTION;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;2.2 FACTORS RELATING TO THE PHYSICAL ENVIRONMENT;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.1 PHARMACEUTICALS;8.1 ORGANISATION AND DELIVERY OF SERVICES","8;4;3;1;1;1;1","CLINICAL;BIOMEDICAL;POPULATION & SOCIETY","10;6;1","CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE;PUBLIC HEALTH","24;2;2","BREAST CANCER;CERVICAL CANCER;LEUKEMIA / LEUKAEMIA;NON-HODGKIN'S LYMPHOMA","3;2;2;1","3 GOOD HEALTH AND WELL BEING","2"
"IRCCS_SANTORSOLA",2020,950,16.8789473684211,3.39789473684211,0.330526315789474,0.306315789473684,0.403157894736842,2.76995708154506,1.46728971962617,2.02083333333333,1.49027237354086,0.622105263157895,7,492,242,64,46,0.52,0.25,0.07,0.05,21.77,0.864126013120629,6.39337349397588,0.36421052631579,0.933684210526316,0.536,0.462,0.427,0.459,"GIOVANNI BRANDI;FRANCESCO MASSARI;RITA GOLFIERI;ANDREA ARDIZZONI;NAZZARENO GALIÈ;MAURO BIFFI;MATTEO CESCON;A.G. MORGANTI;STEFANO FANTI;ALESSANDRO RIZZO;FRANCESCO SAIA;PIERANDREA DE IACO;CLAUDIO ZAMAGNI;MATTEO RAVAIOLI;ANNA MYRIAM PERRONE;DONATELLA SANTINI;MICHÈLE CAVO;G. PILU;MAURO GARGIULO;MARIA CARLA RE","27;26;24;23;23;23;22;21;21;20;20;20;19;19;18;18;18;18;16;16","G. PILU;A. YOUSSEF;ELENA MANCINI;GIOVANNI BRANDI;FRANCESCO MASSARI;ALESSANDRO RIZZO;E. BRUNELLI;RITA GOLFIERI;ANDREA ARDIZZONI;MARIA CARLA RE;STEFANO FANTI;A.G. MORGANTI;MAURO GARGIULO;CRISTINA NANNI;SERGIO SABBATANI;SIMONE AMBRETTI;NAZZARENO GALIÈ;GIUSEPPE GIANNACCARE;MAURO BIFFI;VERONICA MOLLICA","3.25;3.07;2.8;2.6;2.53;2.43;2.38;2.34;2.28;2.21;1.87;1.8;1.79;1.77;1.75;1.7;1.69;1.64;1.61;1.58","GIOVANNI BRANDI;FRANCESCO MASSARI;RITA GOLFIERI;ANDREA ARDIZZONI;NAZZARENO GALIÈ;MAURO BIFFI;MATTEO CESCON;A.G. MORGANTI;STEFANO FANTI;ALESSANDRO RIZZO;FRANCESCO SAIA;PIERANDREA DE IACO;CLAUDIO ZAMAGNI;MATTEO RAVAIOLI;ANNA MYRIAM PERRONE;DONATELLA SANTINI;MICHÈLE CAVO;G. PILU;MAURO GARGIULO;MARIA CARLA RE","27;26;24;23;23;23;22;21;21;20;20;20;19;19;18;18;18;18;16;16","G. PILU;A. YOUSSEF;ELENA MANCINI;GIOVANNI BRANDI;FRANCESCO MASSARI;ALESSANDRO RIZZO;E. BRUNELLI;RITA GOLFIERI;ANDREA ARDIZZONI;MARIA CARLA RE;STEFANO FANTI;A.G. MORGANTI;MAURO GARGIULO;CRISTINA NANNI;SERGIO SABBATANI;SIMONE AMBRETTI;NAZZARENO GALIÈ;GIUSEPPE GIANNACCARE;MAURO BIFFI;VERONICA MOLLICA","3.25;3.07;2.8;2.6;2.53;2.43;2.38;2.34;2.28;2.21;1.87;1.8;1.79;1.77;1.75;1.7;1.69;1.64;1.61;1.58","V. MARCO RANIERI;STEFANO NAVA;TOMMASO TONETTI;GIACINTO PIZZILLI;MASSIMO GIRARDIS;CARLO FINELLI;VALERIA SANTINI;CRISTINA BASSO;MICHAEL R. SAVONA;PETER L. GREENBERG;PIERRE FENAUX;UWE PLATZBECKER;LIONEL ADÈS;EVA HELLSTRÖM-LINDBERG;MARIO CAZZOLA;ULRICH GERMING;ANTONIO ARTIGAS;GIACOMO BELLANI;RUSSELL E. LEWIS;PIERLUIGI VIALE","1705;1589;1267;1263;922;902;896;893;876;876;876;876;869;868;868;868;833;833;809;780","V. MARCO RANIERI;STEFANO NAVA;TOMMASO TONETTI;GIACINTO PIZZILLI;CARLO FINELLI;RUSSELL E. LEWIS;STEFANO FANTI;ANNA MYRIAM PERRONE;PIERLUIGI VIALE;MADDALENA GIANNELLA;MICHELE BARTOLETTI;FABIO PISCAGLIA;LINDA BUSSINI;MATTEO RINALDI;RENATO PASCALE;ORNELLA LEONE;FRANCESCO SAIA;SIMONE AMBRETTI;MARIA CRISTINA MORELLI;LUCIANO ATTARD","1547;1342;1144;1101;902;777;746;701;671;653;634;605;596;569;564;550;518;510;503;501","FRANCESCO MASSARI;GIOVANNI BRANDI;MAURO BIFFI;CLAUDIO ZAMAGNI;ANDREA ARDIZZONI;PIERANDREA DE IACO;FRANCESCO SAIA;RITA GOLFIERI;ANNA MYRIAM PERRONE;G. PILU;A.G. MORGANTI;STEFANO FANTI;DONATELLA SANTINI;A. YOUSSEF;ALESSANDRO RIZZO;NAZZARENO GALIÈ;ANTONIO CURTI;LORENZO FUCCIO;MATTEO RAVAIOLI;MAURO GARGIULO","25;24;22;20;20;20;19;19;18;18;18;17;17;16;16;16;15;15;15;15","MEDICINE;BIOLOGY;PHYSICS;COMPUTER SCIENCE;CHEMISTRY;ENGINEERING;PSYCHOLOGY;MATHEMATICS;ECONOMICS;POLITICAL SCIENCE;SOCIOLOGY;PHILOSOPHY;BUSINESS;MATERIALS SCIENCE;HISTORY;GEOGRAPHY;GEOLOGY;ART;ENVIRONMENTAL SCIENCE","920;245;71;57;49;47;36;31;29;24;22;18;11;10;6;5;4;2;2","INTERNAL MEDICINE;SURGERY;ONCOLOGY;PATHOLOGY;GASTROENTEROLOGY;GENETICS;RADIOLOGY;CARDIOLOGY;ENVIRONMENTAL HEALTH;INTENSIVE CARE MEDICINE;IMMUNOLOGY;PEDIATRICS;PALEONTOLOGY;CANCER RESEARCH;ENDOCRINOLOGY;BIOCHEMISTRY;VIROLOGY;PSYCHIATRY;ANESTHESIA;NUCLEAR MEDICINE","730;295;190;172;140;135;127;108;90;84;74;70;59;58;54;49;48;45;40;39","CANCER;DISEASE;GENE;POPULATION;COHORT;RETROSPECTIVE COHORT STUDY;CHEMOTHERAPY;RANDOMIZED CONTROLLED TRIAL;CONFIDENCE INTERVAL;TRANSPLANTATION;ADVERSE EFFECT;CLINICAL TRIAL;HEART FAILURE;OUTBREAK;PROSPECTIVE COHORT STUDY;PREGNANCY;MULTIVARIATE ANALYSIS;HEPATOCELLULAR CARCINOMA;ALTERNATIVE MEDICINE;INCIDENCE (GEOMETRY);KIDNEY;RADIATION THERAPY","201;143;97;88;70;66;62;57;53;53;48;46;44;44;38;37;35;33;32;32;32;32","INFECTIOUS DISEASE (MEDICAL SPECIALTY);CLINICAL ENDPOINT;COLORECTAL CANCER;HAZARD RATIO;2019-20 CORONAVIRUS OUTBREAK;BREAST CANCER;IMMUNOTHERAPY;MUTATION;LIVER TRANSPLANTATION;UNIVARIATE ANALYSIS;EJECTION FRACTION;PROSTATE CANCER;GENE EXPRESSION;PHENOTYPE;METASTASIS;MULTICENTER STUDY;PANCREATIC CANCER;HEMATOPOIETIC STEM CELL TRANSPLANTATION;NEUTROPENIA;SORAFENIB","70;51;40;38;34;34;34;31;25;25;22;22;19;16;15;15;14;13;12;12","CORONAVIRUS DISEASE 2019 (COVID-19);COLONOSCOPY;NIVOLUMAB;CARDIAC RESYNCHRONIZATION THERAPY;DNA METHYLATION;EXOME SEQUENCING;GERMLINE MUTATION;PEMBROLIZUMAB;OXALIPLATIN;PRIMARY TUMOR;BONE METASTASIS;ENDOVASCULAR ANEURYSM REPAIR;INTERNATIONAL PROGNOSTIC SCORING SYSTEM;IRINOTECAN;KRAS;METASTATIC BREAST CANCER;PDGFRA;POLY ADP RIBOSE POLYMERASE;TRASTUZUMAB;ANDROGEN RECEPTOR;AXITINIB;CAPECITABINE;DASATINIB;FETAL HEAD;GENE EXPRESSION PROFILING;GLUTAMATE CARBOXYPEPTIDASE II;IMATINIB MESYLATE;MACHINE PERFUSION;MICROSATELLITE;MISSENSE MUTATION;NILOTINIB;NON-SMALL CELL LUNG CANCER (NSCLC);PROSTATECTOMY;PTEN;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;RUXOLITINIB;SINGLE-NUCLEOTIDE POLYMORPHISM;TAMOXIFEN","70;16;15;11;11;10;9;8;6;6;5;5;5;5;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4",";HUMANS;FEMALE;MALE;MIDDLE AGED;AGED;ADULT;ITALY;RETROSPECTIVE STUDIES;AGED, 80 AND OVER;TREATMENT OUTCOME;COVID-19;PROSPECTIVE STUDIES;CHILD;LIVER NEOPLASMS;POSTOPERATIVE COMPLICATIONS;NEOPLASM RECURRENCE, LOCAL;ADOLESCENT;BLOOD VESSEL PROSTHESIS IMPLANTATION;RISK FACTORS","547;400;248;239;162;157;128;128;112;77;68;58;57;55;52;52;50;46;44;44","CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;HEPATOCELLULAR CARCINOMA;MANAGEMENT OF VALVULAR HEART DISEASE;ACUTE MYELOID LEUKEMIA;IMPACT OF COVID-19 ON CANCER PATIENTS AND CARE;RENAL CELL CARCINOMA;CANCER IMMUNOTHERAPY;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;CORONAVIRUS DISEASE 2019;MECHANICAL VENTILATION IN RESPIRATORY FAILURE AND ARDS;CHOLANGIOCARCINOMA;PANCREATIC CANCER RESEARCH AND TREATMENT;MANAGEMENT AND PATHOPHYSIOLOGY OF ABDOMINAL AORTIC ANEURYSMS;SARCOMA RESEARCH AND TREATMENT;DIAGNOSIS AND TREATMENT OF GASTROINTESTINAL STROMAL TUMORS;GYNECOLOGIC ONCOLOGY;ADVANCEMENTS IN LUNG CANCER RESEARCH;DIAGNOSIS AND MANAGEMENT OF AORTIC DISEASES;EFFICACY AND RESISTANCE IN CML TREATMENT;EPIDEMIOLOGY AND MANAGEMENT OF NAFLD","23;23;22;20;18;16;15;14;14;14;13;13;11;11;10;10;9;9;9;9","CLINICAL ENDPOINT;PANDEMIC;TREATMENT;2019-20 CORONAVIRUS OUTBREAK;UNIVARIATE ANALYSIS;TRANSCATHETER AORTIC-VALVE REPLACEMENT;CARDIAC IMAGING;IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR;INTERQUARTILE RANGE;REGIMEN;STROKE (ENGINE);CONCOMITANT;REFRACTORY (PLANETARY SCIENCE);BREAST CANCER;PROSTHETIC VALVES EVALUATION;BIOMARKERS FOR IMMUNOTHERAPY;ECHOCARDIOGRAPHY;HEMATOLOGY;CARDIAC RESYNCHRONIZATION THERAPY;DISCONTINUATION","53;38;33;29;27;23;18;17;17;17;16;15;14;13;13;12;12;12;11;11","HEPATOCELLULAR CARCINOMA;CELL CARCINOMA;BREAST CANCER;PATIENTS TREATED;MYELOID LEUKEMIA;RENAL CELL;ACUTE MYELOID;COVID- PANDEMIC;LUNG CANCER;MULTICENTER STUDY;CANCER PATIENTS;PROSTATE CANCER;OBSERVATIONAL STUDY;CELL LUNG;LIVER TRANSPLANTATION;METASTATIC RENAL;PATIENTS UNDERGOING;PROGNOSTIC FACTORS;RISK FACTORS;AORTIC VALVE;COHORT STUDY;CORONAVIRUS DISEASE;PANCREATIC CANCER;PILOT STUDY;MYELODYSPLASTIC SYNDROMES;PHASE II;RETROSPECTIVE STUDY;STEM CELL;MULTIPLE MYELOMA;NEWLY DIAGNOSED","21;20;19;19;18;17;14;14;14;14;13;13;12;11;11;11;11;11;11;10;10;10;10;10;9;9;9;9;8;8","RESEARCH FUNDING;ENTITYS BOARD;ADVISORY COMMITTEES;SPEAKERS BUREAU;CONSULTANCY HONORARIA;HR CI;PATIENTS TREATED;ADVERSE EVENTS;MEDIAN AGE;COMMITTEES SPEAKERS;PROSTATE CANCER;RISK FACTORS;CONSULTANCY MEMBERSHIP;HONORARIA MEMBERSHIP;HONORARIA RESEARCH;MULTIVARIATE ANALYSIS;DAY MORTALITY;SURVIVAL OS;COVID- PANDEMIC;MEDIAN FOLLOW-UP;PROGRESSION-FREE SURVIVAL;PUBMED SCOPUS;CURRENT EMPLOYMENT;CONSECUTIVE PATIENTS;HAZARD RATIO;PATIENTS UNDERGOING;UNIVERSITY HOSPITAL;CLINICAL TRIALS;CONFIDENCE INTERVAL;CORONAVIRUS DISEASE","283;216;200;137;126;87;76;62;61;54;54;54;52;51;50;50;40;40;39;38;37;37;35;33;33;33;33;32;31;31",441,0.46,8.05,9,2,1,0,2,2,1,1,10,1,1,8.75,1,1,2,4,7,5,0,0,46,46,1,1,0,0,1,0,0,0,0,0,0,0,2,0,0,0,7,0.43,2,0,2,2,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"BARBARA GIOVANNI;BARBARO MARIA RAFFAELLA;CREMON CESARE;MASTROROBERTO MARIANNA;MORSELLI-LABATE ANTONIO MARIA;STANGHELLINI VINCENZO;VOLTA UMBERTO","2;2;2;2;2;2;2","AZIENDA OSPEDALIERO-UNIVERSITARIA DI BOLOGNA POLICLINICO S ORSOLA - MALPIGHI;ALMA MATER STUDIORUM UNIVERSITA DL BOLOGNA;UNIVERSITA DI BOLOGNA","2;1;1","30 AGRICULTURAL, VETERINARY AND FOOD SCIENCES;3006 FOOD SCIENCES","4;2",NA,NA,NA,NA,"G16H50/30;G06N7/00;G16H10/20;G16H10/40;G16H10/60;G16H50/20;G16H50/70","2;1;1;1;1;1;1","G06N7/01;G16H10/20;G16H10/40;G16H10/60;G16H50/20;G16H50/30;G16H50/70;Y02A90/10;G06N7/005","2;2;2;2;2;2;2;2;1",73,3.6,654.1,7.24,49,0.67,87.34,2,5,16,1,23,0,2,24,0,54,19,0,0,0,0,0,0,67,6,0,72,0,0,1,0,0,0,0,0,0,"Italy;United States;Netherlands;Germany;Japan;Switzerland;United Kingdom;France;Sweden;Austria;Belgium;Czechia;Denmark;Finland;Poland;Spain","12;10;8;5;5;5;5;3;2;1;1;1;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;3204 IMMUNOLOGY;3212 OPHTHALMOLOGY AND OPTOMETRY;52 PSYCHOLOGY;40 ENGINEERING;4003 BIOMEDICAL ENGINEERING;5202 BIOLOGICAL PSYCHOLOGY;3207 MEDICAL MICROBIOLOGY;3209 NEUROSCIENCES;3213 PAEDIATRICS;3215 REPRODUCTIVE MEDICINE;41 ENVIRONMENTAL SCIENCES;4102 ECOLOGICAL APPLICATIONS;4208 TRADITIONAL, COMPLEMENTARY AND INTEGRATIVE MEDICINE;44 HUMAN SOCIETY","73;40;25;9;5;4;3;3;3;2;2;2;1;1;1;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;RARE DISEASES;PATIENT SAFETY;HEMATOLOGY;LUNG;DIGESTIVE DISEASES;PEDIATRIC;PREVENTION;LYMPHOMA;ORPHAN DRUG;INFECTIOUS DISEASES;BIOMEDICAL IMAGING;CARDIOVASCULAR;PEDIATRIC CANCER;ACUTE RESPIRATORY DISTRESS SYNDROME;AUTOIMMUNE DISEASE;BIOTECHNOLOGY;BREAST CANCER","70;46;35;35;19;18;14;12;9;8;7;7;6;5;5;5;3;3;3;3","CANCER;CARDIOVASCULAR;RESPIRATORY;EYE;ORAL AND GASTROINTESTINAL;INFECTION;RENAL AND UROGENITAL;REPRODUCTIVE HEALTH AND CHILDBIRTH;SKIN","25;4;4;3;3;2;2;1;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;5.1 PHARMACEUTICALS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;3.3 NUTRITION AND CHEMOPREVENTION;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.3 MEDICAL DEVICES;6.4 SURGERY;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES;8.1 ORGANISATION AND DELIVERY OF SERVICES","53;10;4;4;2;1;1;1;1;1;1","LEUKEMIA / LEUKAEMIA;NON-HODGKIN'S LYMPHOMA;BREAST CANCER;LUNG CANCER;OVARIAN CANCER;LIVER CANCER;PANCREATIC CANCER;COLON AND RECTAL CANCER;MYELOMA;SARCOMA;BLOOD CANCER;CERVICAL CANCER;ESOPHAGEAL / OESOPHAGEAL CANCER;KIDNEY CANCER;STOMACH CANCER","10;8;4;4;4;3;3;2;2;2;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;4.2 TECHNOLOGY AND/OR MARKER EVALUATION WITH RESPECT TO FUNDAMENTAL PARAMETERS OF METHOD;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;3.3 CHEMOPREVENTION;4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS;6.2 SURVEILLANCE","24;3;2;2;1;1;1;1",3,0,0,4,1,1,0,4,0,0,"POLICLINICO S.ORSOLA-MALPIGHI","3","ITALIAN ASSOCIATION FOR CANCER RESEARCH","3","ICRP - INTERNATIONAL CANCER RESEARCH PARTNERSHIP","3",NA,NA,"32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;31 BIOLOGICAL SCIENCES;3101 BIOCHEMISTRY AND CELL BIOLOGY;3202 CLINICAL SCIENCES;3204 IMMUNOLOGY;51 PHYSICAL SCIENCES","3;3;1;1;1;1;1","CANCER;RARE DISEASES;CLINICAL RESEARCH;HEMATOLOGY;PEDIATRIC;BIOENGINEERING;BIOTECHNOLOGY;CHILDHOOD LEUKEMIA;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;DIGESTIVE DISEASES;GENETICS;LIVER CANCER;LIVER DISEASE;ORPHAN DRUG;PEDIATRIC CANCER;PEDIATRIC RESEARCH INITIATIVE;STEM CELL RESEARCH;STEM CELL RESEARCH - NONEMBRYONIC - HUMAN","3;3;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1","CANCER;INFLAMMATORY AND IMMUNE SYSTEM","3;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS","1;1;1","LEUKEMIA / LEUKAEMIA;LIVER CANCER","2;1","5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;1.4 CANCER PROGRESSION AND METASTASIS;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS","2;1;1;1","A01 CLINICAL MEDICINE","3",NA,NA,21,"PUBLIC LIBRARY OF SCIENCE;FRONTIERS;SPRINGER NATURE;KARGER PUBLISHERS;TAYLOR & FRANCIS GROUP;AMERICAN CHEMICAL SOCIETY;THE CAMBRIDGE STRUCTURAL DATABASE","9;3;3;2;2;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;3202 CLINICAL SCIENCES;34 CHEMICAL SCIENCES;3107 MICROBIOLOGY;3211 ONCOLOGY AND CARCINOGENESIS;30 AGRICULTURAL, VETERINARY AND FOOD SCIENCES;3105 GENETICS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3404 MEDICINAL AND BIOMOLECULAR CHEMISTRY;3006 FOOD SCIENCES;3102 BIOINFORMATICS AND COMPUTATIONAL BIOLOGY;3204 IMMUNOLOGY;3210 NUTRITION AND DIETETICS;3407 THEORETICAL AND COMPUTATIONAL CHEMISTRY;40 ENGINEERING;42 HEALTH SCIENCES;43 HISTORY, HERITAGE AND ARCHAEOLOGY;4303 HISTORICAL STUDIES;46 INFORMATION AND COMPUTING SCIENCES","20;12;6;4;3;3;2;2;2;2;1;1;1;1;1;1;1;1;1;1","CLINICAL RESEARCH;GENETICS;CANCER;DIGESTIVE DISEASES;AGING;BIOMEDICAL IMAGING;CARDIOVASCULAR;CHRONIC PAIN;DENTAL/ORAL AND CRANIOFACIAL DISEASE;FIBROMYALGIA;HEADACHES;HEART DISEASE;HIV/AIDS;HUMAN GENOME;INFECTIOUS DISEASES;KIDNEY DISEASE;LUNG;NEUROSCIENCES;PAIN RESEARCH;PATIENT SAFETY","7;4;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CANCER;CARDIOVASCULAR;INFECTION;ORAL AND GASTROINTESTINAL;RENAL AND UROGENITAL","3;1;1;1;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;2.2 FACTORS RELATING TO THE PHYSICAL ENVIRONMENT;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES","5;3;1;1","CLINICAL;BIOMEDICAL","5;3","CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE","8;2","NON-HODGKIN'S LYMPHOMA;COLON AND RECTAL CANCER;LEUKEMIA / LEUKAEMIA;LUNG CANCER;NOT SITE-SPECIFIC CANCER","2;1;1;1;1",NA,NA
"IRCCS_SANTORSOLA",2021,703,17.4423897581792,2.98435277382646,0.297297297297297,0.294452347083926,0.365576102418208,2.44807467911319,1.3841059602649,1.93457943925234,1.35978835978836,0.665718349928876,5,321,160,78,29,0.46,0.23,0.11,0.04,12.99,0.842191863563745,6.781453362256,0.362731152204836,0.935988620199147,0.52,0.486,0.478,0.487,"NAZZARENO GALIÈ;MAURO BIFFI;MATTEO ZIACCHI;ANDREA ARDIZZONI;FRANCESCO SAIA;MAURO GARGIULO;GIOVANNI BRANDI;MATTEO CESCON;ANNALISA PATRIZI;ALESSANDRO RIZZO;CARMINE PIZZI;ALBERTO FOÀ;PIERLUIGI VIALE;FRANCESCO ANGELI;PASQUALE PAOLISSO;ENRICO GALLITTO;GIANLUCA FAGGIOLI;RODOLFO PINI;MICHELE FABRIZIO;ANGELO SANSONETTI","33;30;23;21;21;20;20;18;18;16;16;16;16;16;16;15;15;15;15;14","ALESSANDRO RIZZO;GIOVANNI BRANDI;NAZZARENO GALIÈ;FRANCESCO SAIA;ANNALISA PATRIZI;MAURO BIFFI;G. PILU;ANGELA DALIA RICCI;ANDREA ARDIZZONI;MAURO GARGIULO;MATTEO ZIACCHI;IRIA NERI;RODOLFO PINI;BIANCA MARIA PIRACCINI;COSTANZA FILOMENA;GIANLUCA FAGGIOLI;ENRICO GALLITTO;SIMONE AMBRETTI;COSIMO MISCIALI;STEFANO FANTI","5.36;3;2.72;2.67;2.42;2.37;2.1;1.86;1.81;1.81;1.75;1.56;1.54;1.53;1.5;1.5;1.48;1.42;1.38;1.33","NAZZARENO GALIÈ;MAURO BIFFI;MATTEO ZIACCHI;ANDREA ARDIZZONI;FRANCESCO SAIA;MAURO GARGIULO;GIOVANNI BRANDI;MATTEO CESCON;ANNALISA PATRIZI;ALESSANDRO RIZZO;CARMINE PIZZI;ALBERTO FOÀ;PIERLUIGI VIALE;FRANCESCO ANGELI;PASQUALE PAOLISSO;ENRICO GALLITTO;GIANLUCA FAGGIOLI;RODOLFO PINI;MICHELE FABRIZIO;ANGELO SANSONETTI","33;30;23;21;21;20;20;18;18;16;16;16;16;16;16;15;15;15;15;14","ALESSANDRO RIZZO;GIOVANNI BRANDI;NAZZARENO GALIÈ;FRANCESCO SAIA;ANNALISA PATRIZI;MAURO BIFFI;G. PILU;ANGELA DALIA RICCI;ANDREA ARDIZZONI;MAURO GARGIULO;MATTEO ZIACCHI;IRIA NERI;RODOLFO PINI;BIANCA MARIA PIRACCINI;COSTANZA FILOMENA;GIANLUCA FAGGIOLI;ENRICO GALLITTO;SIMONE AMBRETTI;COSIMO MISCIALI;STEFANO FANTI","5.36;3;2.72;2.67;2.42;2.37;2.1;1.86;1.81;1.81;1.75;1.56;1.54;1.53;1.5;1.5;1.48;1.42;1.38;1.33","TOMMASO TONETTI;PIERLUIGI VIALE;MICHELE BARTOLETTI;MASSIMO ANTONELLI;V. MARCO RANIERI;GENNARO DE PASCALE;SALVATORE LUCIO CUTULI;MASSIMO GIRARDIS;ANTONELLA POTALIVO;CARLO ALBERTO VOLTA;SAVINO SPADARO;EMANUELA BIAGIONI;IRENE COLORETTI;GIULIA FALÒ;JONATHAN MONTOMOLI;ANDREA GORI;MARIA GRAZIA BOCCI;GIORGIO CONTI;DOMENICO LUCA GRIECO;MATTEO BASSETTI","894;790;764;659;655;651;651;472;466;466;466;420;420;408;408;395;380;362;358;356","MICHELE BARTOLETTI;PIERLUIGI VIALE;V. MARCO RANIERI;TOMMASO TONETTI;LINDA BUSSINI;MADDALENA GIANNELLA;GIOVANNI BRANDI;GIACOMO FORNARO;MAURO GARGIULO;ELENA BIAGINI;FABRIZIO GIOSTRA;GABRIELE FARINA;MATTEO RINALDI;RUSSELL E. LEWIS;MATTEO CESCON;SIMONE AMBRETTI;ENRICO GALLITTO;RENATO PASCALE;LUCA SANTI;STEFANO NAVA","707;692;539;477;320;310;287;264;242;240;227;227;226;220;207;207;199;189;186;186","NAZZARENO GALIÈ;MAURO BIFFI;MATTEO ZIACCHI;FRANCESCO SAIA;GIOVANNI BRANDI;ANNALISA PATRIZI;MAURO GARGIULO;ANDREA ARDIZZONI;ALBERTO FOÀ;PASQUALE PAOLISSO;FRANCESCO ANGELI;MATTEO CESCON;CARMINE PIZZI;MICHELE FABRIZIO;ANGELO SANSONETTI;MATTEO ARMILLOTTA;ENRICO GALLITTO;GIANLUCA FAGGIOLI;ANDREA STEFANIZZI;LUCA BERGAMASCHI","30;29;22;21;19;18;18;17;16;16;16;16;15;15;14;14;14;14;13;13","MEDICINE;BIOLOGY;PHYSICS;COMPUTER SCIENCE;PSYCHOLOGY;ENGINEERING;MATHEMATICS;ECONOMICS;CHEMISTRY;POLITICAL SCIENCE;SOCIOLOGY;PHILOSOPHY;BUSINESS;HISTORY;MATERIALS SCIENCE;GEOLOGY;GEOGRAPHY","677;179;48;37;36;30;26;24;22;21;15;10;9;7;7;6;5","INTERNAL MEDICINE;SURGERY;CARDIOLOGY;ONCOLOGY;PATHOLOGY;GENETICS;GASTROENTEROLOGY;RADIOLOGY;ENVIRONMENTAL HEALTH;INTENSIVE CARE MEDICINE;PEDIATRICS;IMMUNOLOGY;DERMATOLOGY;PSYCHIATRY;PALEONTOLOGY;MICROBIOLOGY;OPTICS;FAMILY MEDICINE;BIOCHEMISTRY;ENDOCRINOLOGY;VIROLOGY","540;228;119;112;109;103;80;79;77;62;55;51;47;46;35;32;32;31;30;30;30","CANCER;DISEASE;POPULATION;GENE;COHORT;HEART FAILURE;RETROSPECTIVE COHORT STUDY;CONFIDENCE INTERVAL;RANDOMIZED CONTROLLED TRIAL;TRANSPLANTATION;PROSPECTIVE COHORT STUDY;CHEMOTHERAPY;PREGNANCY;ADVERSE EFFECT;INCIDENCE (GEOMETRY);OUTBREAK;CLINICAL TRIAL;HEPATOCELLULAR CARCINOMA;MYOCARDIAL INFARCTION;ANTIBIOTICS;STENOSIS","121;114;75;64;54;53;53;52;44;38;36;33;32;29;28;27;26;26;25;24;24","INFECTIOUS DISEASE (MEDICAL SPECIALTY);HAZARD RATIO;BREAST CANCER;EJECTION FRACTION;CLINICAL ENDPOINT;2019-20 CORONAVIRUS OUTBREAK;LIVER TRANSPLANTATION;UNIVARIATE ANALYSIS;PHENOTYPE;FETUS;CARDIOMYOPATHY;COLORECTAL CANCER;MUTATION;GEMCITABINE;GENOTYPE;IMMUNOTHERAPY;AORTIC VALVE REPLACEMENT;GENE EXPRESSION;METASTASIS;PERCUTANEOUS CORONARY INTERVENTION;PHASES OF CLINICAL RESEARCH;VALVE REPLACEMENT","56;30;28;27;25;23;16;16;15;14;13;13;13;11;10;10;9;9;9;9;9;9","CORONAVIRUS DISEASE 2019 (COVID-19);CARDIAC RESYNCHRONIZATION THERAPY;BILIARY TRACT CANCER;ENDOVASCULAR ANEURYSM REPAIR;METASTATIC BREAST CANCER;DNA METHYLATION;NON-SMALL CELL LUNG CANCER (NSCLC);ACINETOBACTER BAUMANNII;CANAKINUMAB;ENTEROBACTERIACEAE;PEMBROLIZUMAB;PLACENTA;PROBAND;RUXOLITINIB;TRASTUZUMAB;DIFFUSING CAPACITY;ESTROGEN RECEPTOR;GOSERELIN;INFLAMMATORY BOWEL DISEASES;MACE;MILAN CRITERIA;NILOTINIB;NIVOLUMAB;PTEN;SINGLE-NUCLEOTIDE POLYMORPHISM;TAMOXIFEN","56;11;7;6;6;5;5;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3",";HUMANS;FEMALE;MALE;RETROSPECTIVE STUDIES;ADULT;ITALY;MIDDLE AGED;AGED;COVID-19;TREATMENT OUTCOME;POSTOPERATIVE COMPLICATIONS;PROSPECTIVE STUDIES;CHILD;RISK FACTORS;AGED, 80 AND OVER;ENDOVASCULAR PROCEDURES;AORTIC ANEURYSM, THORACIC;ADOLESCENT;LIVER NEOPLASMS","374;325;142;118;98;77;73;73;72;72;59;43;40;39;39;37;30;29;27;27","CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;HEPATOCELLULAR CARCINOMA;CHOLANGIOCARCINOMA;PANCREATIC CANCER RESEARCH AND TREATMENT;MANAGEMENT OF VALVULAR HEART DISEASE;IMPACT OF COVID-19 ON CANCER PATIENTS AND CARE;MANAGEMENT AND PATHOPHYSIOLOGY OF ABDOMINAL AORTIC ANEURYSMS;ATRIAL FIBRILLATION;MECHANICAL VENTILATION IN RESPIRATORY FAILURE AND ARDS;MOLECULAR PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS;ACUTE MYELOID LEUKEMIA;ADVANCEMENTS IN LUNG CANCER RESEARCH;CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS IN BREAST CANCER;EFFICACY AND RESISTANCE IN CML TREATMENT;CANCER IMMUNOTHERAPY;DIAGNOSIS AND MANAGEMENT OF HYPERTROPHIC CARDIOMYOPATHY;EPIDEMIOLOGY AND MANAGEMENT OF NEUROENDOCRINE TUMORS;EPIDEMIOLOGY AND MANAGEMENT OF NAFLD;GYNECOLOGIC ONCOLOGY;MOLECULAR BIOLOGY OF STEROIDOGENESIS AND DISORDERS","25;25;16;16;15;13;13;9;9;9;8;8;8;8;7;7;7;6;6;6","PANDEMIC;TREATMENT;CARDIAC IMAGING;CLINICAL ENDPOINT;2019-20 CORONAVIRUS OUTBREAK;UNIVARIATE ANALYSIS;HEPATOCELLULAR CARCINOMA;TRANSCATHETER AORTIC-VALVE REPLACEMENT;IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR;PROSTHETIC VALVES EVALUATION;INTERQUARTILE RANGE;BILIARY TRACT CANCER;CARDIOVASCULAR RISK ASSESSMENT;CONCOMITANT;DISCONTINUATION;BREAST CANCER;CARDIAC RESYNCHRONIZATION THERAPY;ENDOVASCULAR REPAIR;STROKE (ENGINE);ATRIAL FIBRILLATION","29;26;25;25;20;17;16;16;15;14;13;12;12;12;12;11;11;11;10;9","HEPATOCELLULAR CARCINOMA;COHORT STUDY;BREAST CANCER;LUNG CANCER;COVID- PANDEMIC;ATRIAL FIBRILLATION;CANCER PATIENTS;CELL LUNG;AORTIC VALVE;BILIARY TRACT;COVID- PATIENTS;MYOCARDIAL INFARCTION;NON-SMALL CELL;RANDOMIZED CONTROLLED;CELL CARCINOMA;INTENSIVE CARE;LIVER TRANSPLANTATION;MULTICENTER STUDY;TRACT CANCER;CONTROLLED TRIAL;ENDOVASCULAR REPAIR;HYPERTROPHIC CARDIOMYOPATHY;ITALIAN SOCIETY;RETROSPECTIVE STUDY;STEM CELL;TRANSCATHETER AORTIC;ACUTE MYOCARDIAL;CHRONIC MYELOID;CLINICAL OUTCOMES;CLINICAL PRACTICE","22;18;15;14;12;11;10;10;9;9;9;9;9;9;8;8;8;8;8;7;7;7;7;7;7;7;6;6;6;6","RESEARCH FUNDING;ADVISORY COMMITTEES;ENTITYS BOARD;HR CI;SPEAKERS BUREAU;CONSULTANCY HONORARIA;PATIENTS TREATED;COMMITTEES SPEAKERS;RISK FACTORS;MEDIAN AGE;ADVERSE EVENTS;HONORARIA MEMBERSHIP;CONFIDENCE INTERVAL;COVID- PANDEMIC;CONSECUTIVE PATIENTS;ODDS RATIO;AORTIC VALVE;MEDIAN FOLLOW-UP;STATISTICALLY SIGNIFICANT;CLINICAL PRACTICE;HEART FAILURE;FUNDING SOURCES;MYOCARDIAL INFARCTION;COHORT STUDY;PATIENTS UNDERGOING;ATRIAL FIBRILLATION;HAZARD RATIO;INTENSIVE CARE;PATIENTS UNDERWENT;INSTITUTIONAL SPONSORFUNDING","166;150;150;95;90;55;50;47;42;41;40;40;35;34;33;33;30;30;30;29;29;28;28;27;27;26;26;26;26;25",311,0.44,10.3,9.5,1,1,0,2,0,0,1.25,11,1,0,9,1,4,2,4,6,5,0,0,32,31.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,76,4.47,729.4,10.07,39,0.51,79.57,3,5,13,1,25,0,1,28,0,55,20,0,0,0,0,0,0,72,3,1,72,1,0,3,0,0,0,0,0,0,"Italy;United States;Switzerland;Belgium;France;Germany;Brazil;Japan;United Kingdom;Netherlands;Poland;Portugal;Russia;Spain;Thailand","18;13;4;3;3;3;2;2;2;1;1;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY;42 HEALTH SCIENCES;3204 IMMUNOLOGY;3207 MEDICAL MICROBIOLOGY;31 BIOLOGICAL SCIENCES;3105 GENETICS;3210 NUTRITION AND DIETETICS;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;3215 REPRODUCTIVE MEDICINE;35 COMMERCE, MANAGEMENT, TOURISM AND SERVICES;3505 HUMAN RESOURCES AND INDUSTRIAL RELATIONS;4203 HEALTH SERVICES AND SYSTEMS;4205 NURSING;4206 PUBLIC HEALTH","75;40;27;14;6;6;3;2;2;1;1;1;1;1;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;RARE DISEASES;HEMATOLOGY;PATIENT SAFETY;CARDIOVASCULAR;PREVENTION;HEART DISEASE;PEDIATRIC;DIGESTIVE DISEASES;LYMPHOMA;PEDIATRIC CANCER;ORPHAN DRUG;CHILDHOOD LEUKEMIA;LUNG;STEM CELL RESEARCH;INFECTIOUS DISEASES;TRANSPLANTATION;ASSISTIVE TECHNOLOGY","69;49;36;33;24;18;12;11;10;10;9;7;7;6;5;5;5;4;4;3","CANCER;CARDIOVASCULAR;INFECTION;INFLAMMATORY AND IMMUNE SYSTEM;METABOLIC AND ENDOCRINE;ORAL AND GASTROINTESTINAL;RENAL AND UROGENITAL;RESPIRATORY;BLOOD;GENERIC HEALTH RELEVANCE","29;10;3;2;2;2;2;2;1;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;5.1 PHARMACEUTICALS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;2.2 FACTORS RELATING TO THE PHYSICAL ENVIRONMENT;2.4 SURVEILLANCE AND DISTRIBUTION;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;5.2 CELLULAR AND GENE THERAPIES;5.3 MEDICAL DEVICES;6.3 MEDICAL DEVICES;6.4 SURGERY;7.1 INDIVIDUAL CARE NEEDS;7.3 MANAGEMENT AND DECISION MAKING","51;10;4;4;2;1;1;1;1;1;1;1;1;1","LEUKEMIA / LEUKAEMIA;NON-HODGKIN'S LYMPHOMA;MYELOMA;BREAST CANCER;HODGKIN'S DISEASE;BONE CANCER, OSTEOSARCOMA / MALIGNANT FIBROUS HISTIOCYTOMA;LUNG CANCER;SARCOMA;BLOOD CANCER;COLON AND RECTAL CANCER;ENDOMETRIAL CANCER;ESOPHAGEAL / OESOPHAGEAL CANCER;LIVER CANCER;NOT SITE-SPECIFIC CANCER;OVARIAN CANCER;PANCREATIC CANCER;PROSTATE CANCER;STOMACH CANCER","12;8;7;3;3;2;2;2;1;1;1;1;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;2.1 EXOGENOUS FACTORS IN THE ORIGIN AND CAUSE OF CANCER;4.4 RESOURCES AND INFRASTRUCTURE RELATED TO DETECTION, DIAGNOSIS, OR PROGNOSIS;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS;5.5 COMBINATIONS OF LOCALIZED AND SYSTEMIC THERAPIES;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","31;3;2;1;1;1;1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,31,"FRONTIERS;ZENODO;PUBLIC LIBRARY OF SCIENCE;SCIELO JOURNALS;TAYLOR & FRANCIS GROUP","22;4;3;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;52 PSYCHOLOGY;3105 GENETICS;3202 CLINICAL SCIENCES;42 HEALTH SCIENCES;5202 BIOLOGICAL PSYCHOLOGY;3211 ONCOLOGY AND CARCINOGENESIS;3101 BIOCHEMISTRY AND CELL BIOLOGY;3204 IMMUNOLOGY;3207 MEDICAL MICROBIOLOGY;38 ECONOMICS;4202 EPIDEMIOLOGY;47 LANGUAGE, COMMUNICATION AND CULTURE;51 PHYSICAL SCIENCES;3107 MICROBIOLOGY;3212 OPHTHALMOLOGY AND OPTOMETRY;3213 PAEDIATRICS;3801 APPLIED ECONOMICS;4201 ALLIED HEALTH AND REHABILITATION SCIENCE","35;30;16;12;10;7;7;4;2;2;2;2;2;2;2;1;1;1;1;1","GENETICS;HUMAN GENOME;AGING;BRAIN DISORDERS;CANCER;CLINICAL RESEARCH;NEUROSCIENCES;RARE DISEASES;ACQUIRED COGNITIVE IMPAIRMENT;ALZHEIMER'S DISEASE;ALZHEIMER'S DISEASE INCLUDING ALZHEIMER'S DISEASE RELATED DEMENTIAS (AD/ADRD);DEMENTIA;NEURODEGENERATIVE;PEDIATRIC;BIOTECHNOLOGY;PREVENTION;DIGESTIVE DISEASES;INFECTIOUS DISEASES;LUNG;ANTIMICROBIAL RESISTANCE","17;10;8;8;8;8;8;8;7;7;7;7;7;6;4;4;3;3;3;2","NEUROLOGICAL;CANCER;INFECTION;CONGENITAL;METABOLIC AND ENDOCRINE;GENERIC HEALTH RELEVANCE;REPRODUCTIVE HEALTH AND CHILDBIRTH","8;6;3;2;2;1;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;1.1 NORMAL BIOLOGICAL DEVELOPMENT AND FUNCTIONING;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES","13;2;1","BIOMEDICAL;CLINICAL;HEALTH SERVICES & SYSTEMS","10;5;1","CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE","14;9","NOT SITE-SPECIFIC CANCER;LIVER CANCER;BREAST CANCER;LEUKEMIA / LEUKAEMIA;COLON AND RECTAL CANCER;LARYNGEAL CANCER;LUNG CANCER;ORAL CAVITY AND LIP CANCER;PHARYNGEAL CANCER;SALIVARY GLAND CANCER","6;3;2;2;1;1;1;1;1;1","3 GOOD HEALTH AND WELL BEING;4 QUALITY EDUCATION","2;1"
"IRCCS_SANTORSOLA",2022,561,17.729055258467,3.27629233511586,0.290552584670232,0.331550802139037,0.340463458110517,2.32953105196451,1.25384615384615,1.80582524271845,1.27333333333333,0.730837789661319,5,264,115,63,18,0.47,0.2,0.11,0.03,6.28,0.70368261547649,6.19665122907022,0.381461675579323,0.912655971479501,0.505,0.491,0.5,0.471,"NAZZARENO GALIÈ;MAURO BIFFI;CARMINE PIZZI;PIERLUIGI VIALE;MATTEO ZIACCHI;ALBERTO FOÀ;LUCA BERGAMASCHI;ANGELO SANSONETTI;MATTEO ARMILLOTTA;SARA AMICONE;ANDREA IMPELLIZZERI;MAURO GARGIULO;FRANCESCO ANGELI;FRANCESCO SAIA;ANDREA STEFANIZZI;ENRICO GALLITTO;LUCIANO POTENA;ANDREA RINALDI;PASQUALE PAOLISSO;IGOR DIEMBERGER","47;27;20;19;19;18;18;18;18;17;16;15;15;15;15;13;13;13;13;12","NAZZARENO GALIÈ;CLAUDIO BORGHI;ENRICO GALLITTO;MAURO BIFFI;MAURO GARGIULO;LORENZO FUCCIO;GIOVANNI BRANDI;CARMINE PIZZI;MATTEO ZIACCHI;ANNALISA PATRIZI;FEDERICO BARDAZZI;PIERLUIGI VIALE;DAVIDE PACINI;FRANCESCO SAIA;MARIA LETIZIA PETRONI;GIULIO MARCHESINI;LUIGI LOVATO;BARBARA CORTI;LUCIANO POTENA;LUCA BERGAMASCHI","4;2.32;2.13;1.87;1.66;1.51;1.4;1.38;1.37;1.33;1.27;1.24;1.23;1.22;1.19;1.19;1.19;1.18;1.18;1.18","NAZZARENO GALIÈ;MAURO BIFFI;CARMINE PIZZI;PIERLUIGI VIALE;MATTEO ZIACCHI;ALBERTO FOÀ;LUCA BERGAMASCHI;ANGELO SANSONETTI;MATTEO ARMILLOTTA;SARA AMICONE;ANDREA IMPELLIZZERI;MAURO GARGIULO;FRANCESCO ANGELI;FRANCESCO SAIA;ANDREA STEFANIZZI;ENRICO GALLITTO;LUCIANO POTENA;ANDREA RINALDI;PASQUALE PAOLISSO;IGOR DIEMBERGER","47;27;20;19;19;18;18;18;18;17;16;15;15;15;15;13;13;13;13;12","NAZZARENO GALIÈ;CLAUDIO BORGHI;ENRICO GALLITTO;MAURO BIFFI;MAURO GARGIULO;LORENZO FUCCIO;GIOVANNI BRANDI;CARMINE PIZZI;MATTEO ZIACCHI;ANNALISA PATRIZI;FEDERICO BARDAZZI;PIERLUIGI VIALE;DAVIDE PACINI;FRANCESCO SAIA;MARIA LETIZIA PETRONI;GIULIO MARCHESINI;LUIGI LOVATO;BARBARA CORTI;LUCIANO POTENA;LUCA BERGAMASCHI","4;2.32;2.13;1.87;1.66;1.51;1.4;1.38;1.37;1.33;1.27;1.24;1.23;1.22;1.19;1.19;1.19;1.18;1.18;1.18","GIOVANNI SCAMBIA;PIERLUIGI VIALE;ANNA MYRIAM PERRONE;FRANCESCO RASPAGLIESI;FABIO GHEZZI;GIORGIO BOGANI;VIOLANTE DI DONATO;LORENZO FUCCIO;MARIO MALZONI;DIEGO RAIMONDO;NICOLETTA BIGLIA;LUCA BONI;PAOLO BRUZZI;RENATO SERACCHIOLI;MICHELE BARTOLETTI;FRANCESCO SAIA;STEFANO NAVA;MAURO BIFFI;ALANNA EBIGBO;HALIM AWADIE","232;191;147;147;141;141;141;137;137;135;123;121;121;119;113;109;105;103;102;102","PIERLUIGI VIALE;ANNA MYRIAM PERRONE;LORENZO FUCCIO;FRANCESCO SAIA;PIERANDREA DE IACO;MICHELE BARTOLETTI;MAURO BIFFI;DIEGO RAIMONDO;ANTONIO RAFFONE;MARIO TAFFURELLI;RUSSELL E. LEWIS;NAZZARENO GALIÈ;IGOR DIEMBERGER;MAURO GARGIULO;ANGELO SANSONETTI;CLAUDIO BORGHI;LUCA BERGAMASCHI;ALBERTO FOÀ;ANDREA IMPELLIZZERI;CARMINE PIZZI","153;147;137;107;96;94;91;90;88;84;83;82;78;77;75;75;75;74;74;74","NAZZARENO GALIÈ;MAURO BIFFI;CARMINE PIZZI;ALBERTO FOÀ;MATTEO ARMILLOTTA;ANGELO SANSONETTI;LUCA BERGAMASCHI;MATTEO ZIACCHI;SARA AMICONE;PIERLUIGI VIALE;ANDREA IMPELLIZZERI;ANDREA STEFANIZZI;FRANCESCO ANGELI;MAURO GARGIULO;ENRICO GALLITTO;IGOR DIEMBERGER;FRANCESCO SAIA;ANDREA RINALDI;FRANCESCO PIO TATTILO;PASQUALE PAOLISSO","39;25;20;18;18;18;18;18;17;17;16;15;15;15;13;13;13;13;12;11","MEDICINE;BIOLOGY;PHYSICS;COMPUTER SCIENCE;ENGINEERING;PSYCHOLOGY;CHEMISTRY;MATHEMATICS;POLITICAL SCIENCE;ECONOMICS;SOCIOLOGY;PHILOSOPHY;MATERIALS SCIENCE;BUSINESS;GEOLOGY;ART;ENVIRONMENTAL SCIENCE;HISTORY","538;124;42;31;27;27;25;18;13;11;10;9;8;6;4;2;2;2","INTERNAL MEDICINE;SURGERY;CARDIOLOGY;PATHOLOGY;RADIOLOGY;GENETICS;GASTROENTEROLOGY;ENVIRONMENTAL HEALTH;INTENSIVE CARE MEDICINE;ONCOLOGY;PEDIATRICS;IMMUNOLOGY;PSYCHIATRY;BIOCHEMISTRY;DERMATOLOGY;ENDOCRINOLOGY;CANCER RESEARCH;NURSING;EMERGENCY MEDICINE;OPTICS;PHYSICAL THERAPY","425;174;124;83;78;66;65;55;54;54;45;43;36;34;34;26;25;25;24;22;22","DISEASE;CANCER;COHORT;POPULATION;HEART FAILURE;GENE;RETROSPECTIVE COHORT STUDY;MYOCARDIAL INFARCTION;CONFIDENCE INTERVAL;TRANSPLANTATION;CLINICAL TRIAL;RANDOMIZED CONTROLLED TRIAL;PROSPECTIVE COHORT STUDY;CHEMOTHERAPY;ADVERSE EFFECT;BLOOD PRESSURE;IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR;INCIDENCE (GEOMETRY);OBSERVATIONAL STUDY;ATRIAL FIBRILLATION;PREGNANCY;PROPORTIONAL HAZARDS MODEL","85;81;65;53;48;44;43;41;34;30;25;24;22;21;20;20;20;20;20;19;19;19","INFECTIOUS DISEASE (MEDICAL SPECIALTY);EJECTION FRACTION;CLINICAL ENDPOINT;HAZARD RATIO;IMMUNOTHERAPY;PERCUTANEOUS CORONARY INTERVENTION;ACUTE CORONARY SYNDROME;BREAST CANCER;FETUS;GENE EXPRESSION;COLORECTAL CANCER;HEART TRANSPLANTATION;MUTATION;UNIVARIATE ANALYSIS;CARDIOMYOPATHY;CONVENTIONAL PCI;2019-20 CORONAVIRUS OUTBREAK;ABDOMINAL AORTIC ANEURYSM;CARDIOGENIC SHOCK;LIVER TRANSPLANTATION;MYELOFIBROSIS;PHENOTYPE;PSORIATIC ARTHRITIS;TROPONIN","37;25;22;18;16;14;12;12;12;12;11;11;11;10;9;9;8;8;7;7;7;7;7;7","CORONAVIRUS DISEASE 2019 (COVID-19);CARDIAC RESYNCHRONIZATION THERAPY;COLONOSCOPY;MACE;DNA METHYLATION;ENDOVASCULAR ANEURYSM REPAIR;NIVOLUMAB;RADICAL HYSTERECTOMY;RIGHT CORONARY ARTERY;RUXOLITINIB;SECUKINUMAB;ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA;GENETIC HETEROGENEITY;MISSENSE MUTATION;PEMBROLIZUMAB;POLY ADP RIBOSE POLYMERASE;PRENATAL DIAGNOSIS;UROTHELIAL CARCINOMA;USTEKINUMAB;UTERINE ARTERY","37;8;7;7;6;5;5;4;4;4;4;3;3;3;3;3;3;3;3;3","HUMANS;;RETROSPECTIVE STUDIES;FEMALE;TREATMENT OUTCOME;COVID-19;MALE;ATRIAL FIBRILLATION;AGED;ADULT;CHILD;PROSPECTIVE STUDIES;RISK FACTORS;AORTIC ANEURYSM, ABDOMINAL;LIVER NEOPLASMS;HEART FAILURE;ITALY;MIDDLE AGED;NEOPLASMS;STROKE","284;270;88;66;62;59;49;33;31;30;30;28;26;25;25;22;22;21;21;21","CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;MANAGEMENT OF VALVULAR HEART DISEASE;ATRIAL FIBRILLATION;CANCER IMMUNOTHERAPY;HEPATOCELLULAR CARCINOMA;MANAGEMENT AND PATHOPHYSIOLOGY OF ABDOMINAL AORTIC ANEURYSMS;ORGAN TRANSPLANTATION AND REJECTION;DIAGNOSIS AND TREATMENT OF PULMONARY HYPERTENSION;MECHANICAL CIRCULATORY SUPPORT SYSTEMS;RECIPROCAL DEVELOPMENT OF TH17 AND TREG CELLS;DIAGNOSIS AND MANAGEMENT OF ENDOMETRIOSIS;GLOBAL TRENDS IN COLORECTAL CANCER RESEARCH;GYNECOLOGIC ONCOLOGY;MECHANICAL VENTILATION IN RESPIRATORY FAILURE AND ARDS;MOLECULAR PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS;PANCREATIC CANCER RESEARCH AND TREATMENT;ADVANCED CARDIAC IMAGING TECHNIQUES AND DIAGNOSTICS;CORONAVIRUS DISEASE 2019 RESEARCH;DIAGNOSIS AND MANAGEMENT OF AORTIC DISEASES;DIAGNOSIS AND TREATMENT OF CAROTID ARTERY DISEASE","23;14;9;9;9;9;9;8;8;8;7;7;7;7;7;7;6;6;6;5","CLINICAL ENDPOINT;IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR;CARDIAC IMAGING;INTERQUARTILE RANGE;PANDEMIC;TRANSCATHETER AORTIC-VALVE REPLACEMENT;CARDIOVASCULAR RISK ASSESSMENT;STROKE (ENGINE);TREATMENT;PROSTHETIC VALVES EVALUATION;ECHOCARDIOGRAPHY;SINGLE CENTER;UNIVARIATE ANALYSIS;ATRIAL FIBRILLATION;PULMONARY HYPERTENSION;REGIMEN;TUMOR MICROENVIRONMENT;2019-20 CORONAVIRUS OUTBREAK;AORTIC DISSECTION;CARDIAC RESYNCHRONIZATION THERAPY","22;18;17;16;16;14;13;13;13;12;11;10;10;9;9;8;8;7;7;7","ATRIAL FIBRILLATION;MYOCARDIAL INFARCTION;OBSERVATIONAL STUDY;ITALIAN SOCIETY;COHORT STUDY;HEART FAILURE;AORTIC VALVE;MAGNETIC RESONANCE;TRANSCATHETER AORTIC;ARTERIAL HYPERTENSION;CARDIAC MAGNETIC;HEPATOCELLULAR CARCINOMA;PULMONARY ARTERIAL;RETROSPECTIVE STUDY;COVID- PANDEMIC;LEFT VENTRICULAR;PATIENTS TREATED;PILOT STUDY;PROGNOSTIC ROLE;RISK FACTORS;SINGLE CENTER;ACUTE RESPIRATORY;COVID- PATIENTS;INTENSIVE CARE;MULTICENTER RETROSPECTIVE;TRANSPLANT RECIPIENTS;VALVE IMPLANTATION;ATOPIC DERMATITIS;CARDIOGENIC SHOCK;CORONARY ARTERY","15;12;12;11;10;10;9;9;9;8;8;8;8;8;7;7;7;7;7;7;7;6;6;6;6;6;6;5;5;5","HR CI;HEART FAILURE;RISK FACTORS;MYOCARDIAL INFARCTION;MEDIAN AGE;ADVERSE EVENTS;LEFT VENTRICULAR;PATIENTS TREATED;FUNDING SOURCES;MEDIAN FOLLOW-UP;PATIENTS UNDERGOING;CLINICAL PRACTICE;CORONARY ARTERY;EJECTION FRACTION;INTENSIVE CARE;SIGNIFICANTLY LOWER;CORONARY ANGIOGRAPHY;DAY MORTALITY;IN-HOSPITAL MORTALITY;ACKNOWLEDGEMENT TYPE;FUNDING ACKNOWLEDGEMENT;LOGISTIC REGRESSION;ACUTE MYOCARDIAL;ATRIAL FIBRILLATION;CONSECUTIVE PATIENTS;HAZARD RATIO;SIGNIFICANT DIFFERENCE;COHORT STUDY;HEART TRANSPLANTATION;SIGNIFICANT DIFFERENCES","58;50;46;39;36;33;31;31;29;27;27;26;26;25;25;25;23;23;23;22;22;22;21;21;21;21;21;20;20;20",240,0.43,8.32,9,1,1,0,1.5,0,1,4,10,1,1,9,1,1,2,5,5.5,4,0,0,16.25,16.25,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,44,3.31,1961.92,6.34,24,0.55,96.07,1,1,7,1,15,0,0,19,0,27,15,0,0,0,0,0,0,41,3,0,42,2,0,0,0,0,0,0,0,0,"United States;Italy;Germany;Australia;Japan","12;8;3;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;42 HEALTH SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;4203 HEALTH SERVICES AND SYSTEMS;30 AGRICULTURAL, VETERINARY AND FOOD SCIENCES;31 BIOLOGICAL SCIENCES;3215 REPRODUCTIVE MEDICINE;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY;3005 FISHERIES SCIENCES;3009 VETERINARY SCIENCES;3101 BIOCHEMISTRY AND CELL BIOLOGY;3107 MICROBIOLOGY;3207 MEDICAL MICROBIOLOGY;40 ENGINEERING;4003 BIOMEDICAL ENGINEERING","44;21;11;5;3;3;2;2;2;2;2;1;1;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;RARE DISEASES;CARDIOVASCULAR;HEMATOLOGY;PATIENT SAFETY;AUTOIMMUNE DISEASE;HEART DISEASE;KIDNEY DISEASE;PREVENTION;AGING;COMPLEMENTARY AND INTEGRATIVE HEALTH;DIGESTIVE DISEASES;INFLAMMATORY BOWEL DISEASE;PEDIATRIC;BREAST CANCER;UROLOGIC DISEASES;ASSISTIVE TECHNOLOGY;ATHEROSCLEROSIS","38;26;16;12;10;7;7;6;5;5;5;4;4;4;4;4;3;3;2;2","CANCER;CARDIOVASCULAR;ORAL AND GASTROINTESTINAL;RENAL AND UROGENITAL;INFLAMMATORY AND IMMUNE SYSTEM;GENERIC HEALTH RELEVANCE;INFECTION;REPRODUCTIVE HEALTH AND CHILDBIRTH","14;8;3;3;2;1;1;1","6.1 PHARMACEUTICALS;5.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;2.4 SURVEILLANCE AND DISTRIBUTION;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;5.2 CELLULAR AND GENE THERAPIES;6.4 SURGERY;7.3 MANAGEMENT AND DECISION MAKING","27;5;4;3;2;1;1;1;1;1","LEUKEMIA / LEUKAEMIA;MYELOMA;BREAST CANCER;NON-HODGKIN'S LYMPHOMA;BLADDER CANCER;LUNG CANCER;KIDNEY CANCER;LIVER CANCER;NOT SITE-SPECIFIC CANCER;VULVA CANCER","4;4;3;3;2;2;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING","11;5;3",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,32,"FRONTIERS;AMERICAN ASSOCIATION FOR CANCER RESEARCH;KARGER PUBLISHERS;ZENODO;SPRINGER NATURE","23;3;3;2;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3215 REPRODUCTIVE MEDICINE;31 BIOLOGICAL SCIENCES;42 HEALTH SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3105 GENETICS;4202 EPIDEMIOLOGY;4203 HEALTH SERVICES AND SYSTEMS;3107 MICROBIOLOGY;4206 PUBLIC HEALTH","59;15;10;9;7;5;4;2;2;1;1","CLINICAL RESEARCH;GENETICS;BRAIN DISORDERS;DOWN SYNDROME;INTELLECTUAL AND DEVELOPMENTAL DISABILITIES (IDD);MENTAL HEALTH;CANCER;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;PATIENT SAFETY;PREVENTION;RARE DISEASES;AUTOIMMUNE DISEASE;COLO-RECTAL CANCER;DIGESTIVE DISEASES;GENETIC TESTING;PSORIASIS;ANTIMICROBIAL RESISTANCE;ASSISTIVE TECHNOLOGY;BIOENGINEERING;EMERGING INFECTIOUS DISEASES","23;21;16;15;15;15;8;3;3;3;3;2;2;2;2;2;1;1;1;1","CONGENITAL;CANCER;INFECTION","15;6;2","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;6.1 PHARMACEUTICALS;2.2 FACTORS RELATING TO THE PHYSICAL ENVIRONMENT;2.4 SURVEILLANCE AND DISTRIBUTION","15;3;1;1","CLINICAL","5","CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE;PUBLIC HEALTH","9;3;2","LEUKEMIA / LEUKAEMIA;LUNG CANCER;COLON AND RECTAL CANCER","5;3;2",NA,NA
"IRCCS_SANTORSOLA",2023,449,19.2984409799555,2.87082405345212,0.200445434298441,0.240534521158129,0.242761692650334,1.80532212885154,1.26760563380282,1.86206896551724,1.28235294117647,0.737193763919822,2,211,77,36,25,0.47,0.17,0.08,0.06,3.41,0.778452454565087,5.7405395935529,0.43652561247216,0.953229398663697,0.578,0.486,0.515,0.492,"MAURO BIFFI;MAURO GARGIULO;MATTEO ZIACCHI;FRANCESCO SAIA;IGOR DIEMBERGER;NAZZARENO GALIÈ;ENRICO GALLITTO;BIANCA MARIA PIRACCINI;MATTEO CESCON;A SPADOTTO;GIANLUCA FAGGIOLI;FEDERICO BARDAZZI;GIUSEPPE TARANTINI;ANTONIO DELLO RUSSO;GIULIA MASSARO;ELENA BIAGINI;ANTONIO D’ONOFRIO;PIETRO PALMISANO;GABRIELLA FABBROCINI;CARMINE PIZZI","24;22;21;17;15;15;14;12;12;12;12;12;11;11;10;10;10;9;9;9","MAURO GARGIULO;MAURO BIFFI;CLAUDIO BORGHI;BIANCA MARIA PIRACCINI;MATTEO ZIACCHI;ENRICO GALLITTO;A. YOUSSEF;ARRIGO F.G. CICERO;MICHELA STARACE;IGOR DIEMBERGER;MARIO LIMA;A SPADOTTO;GIANLUCA FAGGIOLI;FRANCESCO SAIA;NAZZARENO GALIÈ;FEDERICO BARDAZZI;GIULIA MASSARO;GIOVANNI PARENTE;LORENZO NISSEN;ANDREA GIANOTTI","1.97;1.83;1.7;1.69;1.64;1.3;1.25;1.25;1.24;1.23;1.18;1.13;1.11;1.09;1.08;0.96;0.94;0.9;0.87;0.87","MAURO BIFFI;MAURO GARGIULO;MATTEO ZIACCHI;FRANCESCO SAIA;IGOR DIEMBERGER;NAZZARENO GALIÈ;ENRICO GALLITTO;BIANCA MARIA PIRACCINI;MATTEO CESCON;A SPADOTTO;GIANLUCA FAGGIOLI;FEDERICO BARDAZZI;GIULIA MASSARO;ELENA BIAGINI;CARMINE PIZZI;MATTEO SERENARI;MICHELA STARACE;MARIO LIMA;LUCA BERGAMASCHI;FEDERICO BARONIO","24;22;21;17;15;15;14;12;12;12;12;12;10;10;9;9;9;8;8;8","MAURO GARGIULO;MAURO BIFFI;CLAUDIO BORGHI;BIANCA MARIA PIRACCINI;MATTEO ZIACCHI;ENRICO GALLITTO;A. YOUSSEF;ARRIGO F.G. CICERO;MICHELA STARACE;IGOR DIEMBERGER;MARIO LIMA;A SPADOTTO;GIANLUCA FAGGIOLI;FRANCESCO SAIA;NAZZARENO GALIÈ;FEDERICO BARDAZZI;GIULIA MASSARO;GIOVANNI PARENTE;LORENZO NISSEN;ANDREA GIANOTTI","1.97;1.83;1.7;1.69;1.64;1.3;1.25;1.25;1.24;1.23;1.18;1.13;1.11;1.09;1.08;0.96;0.94;0.9;0.87;0.87","PIERLUIGI VIALE;MAURO GARGIULO;ANNA MYRIAM PERRONE;PIERANDREA DE IACO;GIOVANNI SCAMBIA;MOHAMMED ABU HILAL;FEDERICO BARDAZZI;ALESSANDRO ZERBI;SIMONE FERRERO;BAS GROOT KOERKAMP;BERGÞÓR BJÖRNSSON;UGO BOGGI;CIRO PINELLI;ENRICO VIZZA;FABIO GHEZZI;FABRIZIO DI BENEDETTO;FRANCESCO PLOTTI;FRANCESCO RASPAGLIESI;GABRIELLA FABBROCINI;GIORGIO BOGANI","84;75;73;73;70;70;68;67;66;65;65;65;64;64;64;64;64;64;64;64","PIERLUIGI VIALE;MAURO GARGIULO;ANNA MYRIAM PERRONE;PIERANDREA DE IACO;MAURO BIFFI;MATTEO ZIACCHI;FEDERICO BARDAZZI;FRANCESCO SAIA;ENRICO GALLITTO;IGOR DIEMBERGER;MATTEO CESCON;ARRIGO F.G. CICERO;MADDALENA GIANNELLA;STEFANO FANTI;ELIO JOVINE;MATTEO SERENARI;FEDERICO BARONIO;RICCARDO CASADEI;YLENIA BARTOLACELLI;ALESSANDRO CILLI","84;75;73;73;61;56;53;51;48;48;48;43;41;41;36;36;32;32;30;29","MAURO BIFFI;MATTEO ZIACCHI;MAURO GARGIULO;FRANCESCO SAIA;IGOR DIEMBERGER;NAZZARENO GALIÈ;A SPADOTTO;ENRICO GALLITTO;MATTEO CESCON;BIANCA MARIA PIRACCINI;FEDERICO BARDAZZI;GIANLUCA FAGGIOLI;CARMINE PIZZI;ELENA BIAGINI;MICHELA STARACE;MATTEO SERENARI;STEFANO FANTI;MARIO LIMA;RODOLFO PINI;ALBERTO FOÀ","23;21;21;16;15;12;12;11;11;11;10;10;9;9;9;9;8;8;7;7","MEDICINE;BIOLOGY;COMPUTER SCIENCE;PHYSICS;MATHEMATICS;ENGINEERING;PSYCHOLOGY;CHEMISTRY;ECONOMICS;POLITICAL SCIENCE;SOCIOLOGY;PHILOSOPHY;MATERIALS SCIENCE;GEOLOGY;BUSINESS;ENVIRONMENTAL SCIENCE;GEOGRAPHY;HISTORY","431;86;37;35;25;23;22;16;13;11;10;8;6;2;1;1;1;1","INTERNAL MEDICINE;SURGERY;CARDIOLOGY;RADIOLOGY;ONCOLOGY;GASTROENTEROLOGY;GENETICS;PATHOLOGY;PEDIATRICS;ENVIRONMENTAL HEALTH;INTENSIVE CARE MEDICINE;DERMATOLOGY;IMMUNOLOGY;PSYCHIATRY;NURSING;BIOCHEMISTRY;FAMILY MEDICINE;OPTICS;PHYSICAL THERAPY;ENDOCRINOLOGY","340;157;96;70;60;49;49;44;40;38;37;27;25;24;23;20;19;19;18;17","CANCER;COHORT;DISEASE;HEART FAILURE;RETROSPECTIVE COHORT STUDY;POPULATION;CONFIDENCE INTERVAL;GENE;CHEMOTHERAPY;RANDOMIZED CONTROLLED TRIAL;ADVERSE EFFECT;PROSPECTIVE COHORT STUDY;MYOCARDIAL INFARCTION;INCIDENCE (GEOMETRY);PREGNANCY;OBSERVATIONAL STUDY;LOGISTIC REGRESSION;CLINICAL TRIAL;IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR;ATRIAL FIBRILLATION;TRANSPLANTATION","71;52;51;44;37;36;35;34;26;26;25;23;21;19;19;18;17;16;16;15;15","HAZARD RATIO;EJECTION FRACTION;CLINICAL ENDPOINT;INFECTIOUS DISEASE (MEDICAL SPECIALTY);COLORECTAL CANCER;IMMUNOTHERAPY;BREAST CANCER;PANCREATIC CANCER;BEVACIZUMAB;GESTATIONAL AGE;HEART RATE;HEART TRANSPLANTATION;LIVER TRANSPLANTATION;PERCUTANEOUS CORONARY INTERVENTION;AORTIC DISSECTION;FETUS;GENE EXPRESSION;IMATINIB;PSORIASIS AREA AND SEVERITY INDEX;REVASCULARIZATION;UNIVARIATE ANALYSIS","25;23;21;16;15;15;12;9;8;8;7;7;7;7;6;6;6;6;6;6;6","CORONAVIRUS DISEASE 2019 (COVID-19);NIVOLUMAB;CARDIAC RESYNCHRONIZATION THERAPY;PEMBROLIZUMAB;COLONOSCOPY;DNA METHYLATION;ENDOVASCULAR ANEURYSM REPAIR;LENVATINIB;ANTIRETROVIRAL THERAPY;CARFILZOMIB;CHIMERIC ANTIGEN RECEPTOR;DARATUMUMAB;IPILIMUMAB;MACE;NEOADJUVANT THERAPY;NILOTINIB;OXALIPLATIN;POMALIDOMIDE;BRCA MUTATION;CAPECITABINE;CRITICAL LIMB ISCHEMIA;CYSTECTOMY;DASATINIB;FAMILIAL ADENOMATOUS POLYPOSIS;GENE EXPRESSION PROFILING;ISCHEMIC CARDIOMYOPATHY;LUCIFERASE;MEGAKARYOCYTE;MESALAZINE;PKD1;POLY ADP RIBOSE POLYMERASE;PROSTATECTOMY;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;SECUKINUMAB;SENTINEL LYMPH NODE;SENTINEL NODE","16;10;7;6;5;5;4;4;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2",";HUMANS;RETROSPECTIVE STUDIES;FEMALE;MALE;TREATMENT OUTCOME;ADULT;COVID-19;MIDDLE AGED;POSTOPERATIVE COMPLICATIONS;AGED;PROSPECTIVE STUDIES;CHILD;LIVER NEOPLASMS;ITALY;AORTIC ANEURYSM, THORACIC;DEFIBRILLATORS, IMPLANTABLE;ENDOVASCULAR PROCEDURES;RISK FACTORS;HEART FAILURE","247;196;57;54;48;45;31;28;25;23;21;20;19;18;17;16;16;16;16;15","CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;MANAGEMENT AND PATHOPHYSIOLOGY OF ABDOMINAL AORTIC ANEURYSMS;MANAGEMENT OF VALVULAR HEART DISEASE;PANCREATIC CANCER RESEARCH AND TREATMENT;RECIPROCAL DEVELOPMENT OF TH17 AND TREG CELLS;CHOLANGIOCARCINOMA;HEPATOCELLULAR CARCINOMA;MOLECULAR MECHANISMS OF AMYLOIDOSIS;ATRIAL FIBRILLATION;DIAGNOSIS AND MANAGEMENT OF AORTIC DISEASES;EFFICACY AND RESISTANCE IN CML TREATMENT;LIVER CIRRHOSIS AND ASSOCIATED COMPLICATIONS;MOLECULAR BIOLOGY OF STEROIDOGENESIS AND DISORDERS;MOLECULAR CHARACTERIZATION OF COLORECTAL CANCER;MOLECULAR PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;EPIDEMIOLOGY AND MANAGEMENT OF NAFLD;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;GENOMIC STUDIES AND TREATMENT OF OVARIAN CARCINOMA;LYMPHOID NEOPLASMS","24;11;10;10;8;7;7;7;5;5;5;5;5;5;5;4;4;4;4;4","CLINICAL ENDPOINT;IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR;CARDIAC IMAGING;TREATMENT;ECHOCARDIOGRAPHY;INTERQUARTILE RANGE;ENDOVASCULAR REPAIR;METASTATIC PANCREATIC CANCER;STROKE (ENGINE);TRANSCATHETER AORTIC-VALVE REPLACEMENT;ANEURYSM SCREENING;CARDIOVASCULAR RISK ASSESSMENT;ATEZOLIZUMAB;DIAGNOSIS;HEPATOCELLULAR CARCINOMA;PROSTHETIC VALVES EVALUATION;AORTIC DISSECTION;CONCOMITANT;CONCORDANCE;PANCREATIC CANCER","21;19;18;17;15;12;10;10;10;10;9;9;8;8;8;8;7;7;7;7","HEPATOCELLULAR CARCINOMA;MINIMALLY INVASIVE;MULTICENTER STUDY;COHORT STUDY;HEART FAILURE;AORTIC REPAIR;AORTIC VALVE;CANCER PATIENTS;ENDOVASCULAR AORTIC;IMPLANTABLE DEFIBRILLATOR;INTERNATIONAL REGISTRY;OVARIAN CANCER;CELL CARCINOMA;LEFT VENTRICULAR;PANCREATIC CANCER;PATIENTS TREATED;RETROSPECTIVE STUDY;VALVE IMPLANTATION;DISTAL PANCREATECTOMY;IMPLANTABLE ELECTRONIC;ITALIAN SOCIETY;MULTICENTER RETROSPECTIVE;MULTIPLE MYELOMA;MYELOID LEUKEMIA;MYOCARDIAL INFARCTION;PROSPECTIVE STUDY;RETROSPECTIVE MULTICENTER;SUBCUTANEOUS IMPLANTABLE;TRANSCATHETER AORTIC;TRANSPLANT RECIPIENTS","11;11;11;10;10;9;8;8;8;7;7;7;6;6;6;6;6;6;5;5;5;5;5;5;5;5;5;5;5;5","HR CI;PATIENTS TREATED;MEDIAN AGE;INDEX THV;AORTIC VALVE;CLINICAL PRACTICE;CONSECUTIVE PATIENTS;HEART FAILURE;PATIENTS UNDERGOING;MEDIAN FOLLOW-UP;PRIMARY ENDPOINT;MULTIVARIATE ANALYSIS;STATISTICALLY SIGNIFICANT;ADVERSE EVENTS;HAZARD RATIO;SIGNIFICANT DIFFERENCES;RISK FACTORS;LEFT VENTRICULAR;OBSERVATIONAL STUDY;EJECTION FRACTION;FUNDING SOURCES;PUBMED SCOPUS;ADULT PATIENTS;ATRIAL FIBRILLATION;LOGISTIC REGRESSION;ABSTRACT FUNDING;ACKNOWLEDGEMENTS TYPE;FUNDING ACKNOWLEDGEMENTS;MINIMALLY INVASIVE;PATIENTS RECEIVED","46;40;38;35;31;31;28;28;28;27;26;24;24;23;23;23;22;21;21;20;19;19;18;18;18;17;17;17;17;17",160,0.36,7.56,11.25,1,2,0,10,0,1,1,13,2.75,0,11,1,1,2,3,8,5.25,0,0,8,8,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,18,4.83,748.06,2.71,4,0.22,102.11,1,0,4,1,6,0,0,6,0,13,5,0,0,0,0,0,0,17,0,1,18,0,0,0,0,0,0,0,0,0,"Italy;United States;Belgium;Denmark;Germany;Switzerland","4;3;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY;31 BIOLOGICAL SCIENCES;3105 GENETICS;42 HEALTH SCIENCES;4201 ALLIED HEALTH AND REHABILITATION SCIENCE","17;12;5;3;2;2;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;RARE DISEASES;CARDIOVASCULAR;HEMATOLOGY;PATIENT SAFETY;BIOMEDICAL IMAGING;DIGESTIVE DISEASES;HEART DISEASE;TRANSPLANTATION;AGING;AUTOIMMUNE DISEASE;CHRONIC PAIN;GENETICS;LUNG;LYMPHOMA;NEUROSCIENCES;ORPHAN DRUG;PAIN RESEARCH","17;12;8;6;5;4;4;3;3;3;3;2;2;2;2;2;2;2;2;2","CANCER;CARDIOVASCULAR","8;3","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;2.4 SURVEILLANCE AND DISTRIBUTION;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS;5.3 MEDICAL DEVICES;6.3 MEDICAL DEVICES;6.4 SURGERY;7.1 INDIVIDUAL CARE NEEDS","11;3;2;1;1;1;1;1;1;1;1","MYELOMA;NON-HODGKIN'S LYMPHOMA;HODGKIN'S DISEASE;LEUKEMIA / LEUKAEMIA;LIVER CANCER;LUNG CANCER;PROSTATE CANCER","2;2;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS;5.5 COMBINATIONS OF LOCALIZED AND SYSTEMIC THERAPIES","7;1;1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,14,"FRONTIERS;ZENODO;FUTURE SCIENCE GROUP","8;4;2","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;31 BIOLOGICAL SCIENCES;3105 GENETICS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3204 IMMUNOLOGY","26;9;3;2;2;2;2","CLINICAL RESEARCH;CANCER;RARE DISEASES;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;DIGESTIVE DISEASES;HEMATOLOGY;CARDIOVASCULAR;HEART DISEASE;HEART DISEASE - CORONARY HEART DISEASE;PATIENT SAFETY;PREVENTION;AUTOIMMUNE DISEASE;BRAIN DISORDERS;DIGESTIVE DISEASES - (GALLBLADDER);KIDNEY DISEASE;LIVER DISEASE;ORGAN TRANSPLANTATION;PSORIASIS;TRANSPLANTATION","7;6;4;3;3;3;2;2;2;2;2;1;1;1;1;1;1;1;1","CANCER;CARDIOVASCULAR;SKIN","3;2;1","6.1 PHARMACEUTICALS;6.4 SURGERY","5;1","CLINICAL","8","CLINICAL MEDICINE AND SCIENCE","10","LEUKEMIA / LEUKAEMIA;KIDNEY CANCER;LIVER CANCER","3;2;1","3 GOOD HEALTH AND WELL BEING","4"
"IRCCS_SANTORSOLA",2024,320,20.878125,2.578125,0.221875,0.2375,0.278125,1.71670190274841,1.12903225806452,1.82926829268293,1.11392405063291,0.5375,1,172,50,26,16,0.54,0.16,0.08,0.05,0.8,0.840348638062153,4.56072449952337,0.41875,0.95,0.472,0.446,0.476,0.509,"MAURO GARGIULO;ENRICO GALLITTO;GIANLUCA FAGGIOLI;FRANCESCO SAIA;MATTEO CESCON;NAZZARENO GALIÈ;LORENZO FUCCIO;BIANCA MARIA PIRACCINI;LUCIANO POTENA;FEDERICO BARDAZZI;MATTEO SERENARI;DAVIDE PACINI;RODOLFO PINI;EMI DIKA;ANNA MYRIAM PERRONE;LEONARDO FRAZZONI;GERMANO MELISSANO;VALENTINA DINI;ELENA BIAGINI;FABIO DARDI","24;17;14;14;11;11;10;9;9;9;9;8;8;7;7;7;7;7;7;6","MAURO GARGIULO;BIANCA MARIA PIRACCINI;ENRICO GALLITTO;LORENZO FUCCIO;NAZZARENO GALIÈ;GIANLUCA FAGGIOLI;CARLOTTA ZANETTI;FEDERICO BARDAZZI;COSIMO MISCIALI;RODOLFO PINI;DAVIDE PACINI;ANDREA BOCCATONDA;GIACOMO CLARIZIO;EMI DIKA;LUIGI LOVATO;FERNANDO RIZZELLO;CARLA SERRA;BARBARA CORTI;FABIO DARDI;ALESSANDRA MANES","1.75;1.17;1.17;1.15;1.06;1.04;1;0.99;0.98;0.85;0.79;0.78;0.77;0.7;0.68;0.62;0.61;0.58;0.57;0.57","MAURO GARGIULO;ENRICO GALLITTO;GIANLUCA FAGGIOLI;FRANCESCO SAIA;MATTEO CESCON;NAZZARENO GALIÈ;LORENZO FUCCIO;BIANCA MARIA PIRACCINI;LUCIANO POTENA;FEDERICO BARDAZZI;MATTEO SERENARI;DAVIDE PACINI;RODOLFO PINI;EMI DIKA;ANNA MYRIAM PERRONE;LEONARDO FRAZZONI;GERMANO MELISSANO;ELENA BIAGINI;FABIO DARDI;FRANCESCA PALANDRI","24;17;14;14;11;11;10;9;9;9;9;8;8;7;7;7;7;7;6;6","MAURO GARGIULO;BIANCA MARIA PIRACCINI;ENRICO GALLITTO;LORENZO FUCCIO;NAZZARENO GALIÈ;GIANLUCA FAGGIOLI;CARLOTTA ZANETTI;FEDERICO BARDAZZI;COSIMO MISCIALI;RODOLFO PINI;DAVIDE PACINI;ANDREA BOCCATONDA;GIACOMO CLARIZIO;EMI DIKA;LUIGI LOVATO;FERNANDO RIZZELLO;CARLA SERRA;BARBARA CORTI;FABIO DARDI;ALESSANDRA MANES","1.75;1.17;1.17;1.15;1.06;1.04;1;0.99;0.98;0.85;0.79;0.78;0.77;0.7;0.68;0.62;0.61;0.58;0.57;0.57","MAURO GARGIULO;FRANCESCO SAIA;ÁNGELA CANO;VALENTINA DINI;ANGELO VALERIO MARZANO;ANNA BALATO;CLAUDIO GUARNERI;FEDERICO BARDAZZI;GIAMPIERO GIROLOMONI;MARTINA BURLANDO;MATTEO MEGNA;PAOLO DAPAVO;ALESSANDRA NARCISI;ANTONIO COSTANZO;CARLO GIOVANNI CARRERA;CLAUDIA LASAGNI;ENRICO GALLITTO;FRANCESCA MARIA GAIANI;FRANCESCO LOCONSOLE;GIANLUCA FAGGIOLI","27;25;22;20;19;18;18;18;18;18;18;18;17;17;17;17;17;17;17;17","MAURO GARGIULO;FRANCESCO SAIA;FEDERICO BARDAZZI;PIERLUIGI VIALE;ENRICO GALLITTO;GIANLUCA FAGGIOLI;ANNA MYRIAM PERRONE;PIERANDREA DE IACO;MARIA PAOLA LANDINI;ALESSANDRO MAZZAPICCHI;CIARDELLA ANTONIO PASQUALE;ALESSANDRO COMIS;EDUJE THOMAS;MARIO LIMA;EMI DIKA;ANDREA VACIRCA;BENILDE COSMI;DIEGO RAIMONDO;MATTEO SERENARI;RODOLFO PINI","27;21;18;16;13;13;12;12;11;10;10;9;9;8;7;6;6;6;6;6","MAURO GARGIULO;ENRICO GALLITTO;FRANCESCO SAIA;MATTEO CESCON;GIANLUCA FAGGIOLI;FEDERICO BARDAZZI;MATTEO SERENARI;NAZZARENO GALIÈ;RODOLFO PINI;BIANCA MARIA PIRACCINI;ANNA MYRIAM PERRONE;DAVIDE PACINI;MAURO BIFFI;FRANCESCA PALANDRI;M. SABATINO;ELENA BIAGINI;EMI DIKA;MARIO TAFFURELLI;MICHELA STARACE;STEPHANO CEDIRIAN","23;13;12;10;10;9;9;8;7;7;6;6;6;6;6;5;5;5;5;5","MEDICINE;BIOLOGY;PHYSICS;COMPUTER SCIENCE;ENGINEERING;POLITICAL SCIENCE;CHEMISTRY;ECONOMICS;MATHEMATICS;PSYCHOLOGY;SOCIOLOGY;MATERIALS SCIENCE;PHILOSOPHY;GEOLOGY;BUSINESS;GEOGRAPHY;HISTORY","308;57;27;25;23;17;13;8;8;8;7;6;5;3;2;1;1","INTERNAL MEDICINE;SURGERY;CARDIOLOGY;INTENSIVE CARE MEDICINE;RADIOLOGY;PATHOLOGY;GENETICS;ONCOLOGY;DERMATOLOGY;GASTROENTEROLOGY;GENERAL SURGERY;BIOCHEMISTRY;PEDIATRICS;PSYCHIATRY;ENVIRONMENTAL HEALTH;FAMILY MEDICINE;LAW;CANCER RESEARCH;ENDOCRINOLOGY;IMMUNOLOGY;OPTICS","213;105;63;51;49;43;31;30;26;26;20;17;17;17;16;15;15;13;13;13;13","CANCER;DISEASE;RANDOMIZED CONTROLLED TRIAL;RETROSPECTIVE COHORT STUDY;GENE;ANEURYSM;COHORT;PROSPECTIVE COHORT STUDY;HEART FAILURE;ULTRASOUND;OBSERVATIONAL STUDY;POPULATION;PREGNANCY;TRANSPLANTATION;ADVERSE EFFECT;CONFIDENCE INTERVAL;AORTA;INCIDENCE (GEOMETRY);MYOCARDIAL INFARCTION;PSORIASIS;STENOSIS","50;32;29;24;19;18;16;14;12;12;11;11;11;11;10;10;9;9;9;9;9","MULTICENTER STUDY;AORTIC ANEURYSM;BREAST CANCER;CLINICAL ENDPOINT;COLORECTAL CANCER;LIVER TRANSPLANTATION;ABDOMINAL AORTIC ANEURYSM;HAZARD RATIO;EJECTION FRACTION;INFECTIOUS DISEASE (MEDICAL SPECIALTY);AORTIC REPAIR;ENDOVASCULAR TREATMENT;METASTASIS;TOLERABILITY;ESOPHAGEAL CANCER;FABRY DISEASE;FETUS;MICRORNA;MYELOFIBROSIS;PHENOTYPE;VIRAL LOAD","13;11;11;10;10;10;8;7;6;6;5;5;5;5;4;4;4;4;4;4;4","COLONOSCOPY;CORONAVIRUS DISEASE 2019 (COVID-19);ENDOVASCULAR ANEURYSM REPAIR;ANTIRETROVIRAL THERAPY;ESOPHAGECTOMY;CARDIAC RESYNCHRONIZATION THERAPY;OBETICHOLIC ACID;RUXOLITINIB;SYSTEMIC THERAPY;COLECTOMY;CYSTECTOMY;DNA METHYLATION;HYPERTRIGLYCERIDEMIA;MASTECTOMY;MILAN CRITERIA;SECUKINUMAB;SENTINEL LYMPH NODE;TWIN TWIN TRANSFUSION SYNDROME;ACINETOBACTER BAUMANNII;ALCOHOLIC HEPATITIS;AMYLOID FIBRIL;ATYPICAL HEMOLYTIC UREMIC SYNDROME;AZOOSPERMIA;BARE METAL;BREAST RECONSTRUCTION;BREAST SURGERY;BRONCHOPULMONARY DYSPLASIA;CANCER-ASSOCIATED FIBROBLASTS;CARBOPLATIN;CARFILZOMIB;CAROTID STENTING;COMPOUND HETEROZYGOSITY;CRIZOTINIB;CYTOMEGALOVIRUS INFECTION;DARATUMUMAB;DESMOPLASIA;DIRECT BILIRUBIN;DOPPLER ECHOCARDIOGRAPHY;DOUBLE BLIND;EDINBURGH POSTNATAL DEPRESSION SCALE;ELLAGIC ACID;EMBOLIC STROKE;ENTEROBACTERIACEAE;ENTHESITIS;ESOPHAGEAL MOTILITY DISORDER;ESOPHAGEAL SPHINCTER;ESOPHAGEAL VARICES;EVANS SYNDROME;EXOME SEQUENCING;FABRY'S DISEASE;FAMILIAL ADENOMATOUS POLYPOSIS;FECAL BACTERIOTHERAPY;FLAVONOLS;FRACTIONAL FLOW RESERVE;FRONTOTEMPORAL DEMENTIA;GLOBAL DEVELOPMENTAL DELAY;HBSAG;HERPESVIRIDAE;HIGH RESOLUTION MANOMETRY;HISTONE DEACETYLASE;IMMUNE CHECKPOINT;INTRAVENTRICULAR HEMORRHAGE;INVASIVE CANDIDIASIS;JANUS KINASE INHIBITOR;JOINT INFECTIONS;KRAS;LAMIVUDINE;LEYDIG CELL;MACE;MACHINE PERFUSION;MAMMOGRAPHY;MERKEL CELL;MISSENSE MUTATION;MITOCHONDRIAL DISEASE;MITOCHONDRIAL PERMEABILITY TRANSITION PORE;MODEL FOR END-STAGE LIVER DISEASE;MOLECULARLY IMPRINTED POLYMER;MYELOPROLIFERATIVE NEOPLASM;NAIL MATRIX;NARINGENIN;NEOADJUVANT THERAPY;NORWOOD PROCEDURE;OMPHALOCELE;ONCOGENE;PD-L1;PEMBROLIZUMAB;PENETRANCE;PERIVENTRICULAR LEUKOMALACIA;PNEUMOCYSTIS CARINII;POMALIDOMIDE;PROBAND;PROCTOCOLECTOMY;PROSTATE BIOPSY;RETINOPATHY OF PREMATURITY;SANGER SEQUENCING;SENTINEL NODE;SLEEP RESTRICTION;SODIUM HYDROSULFIDE;SPLENIUM;STAPHYLOCOCCUS;STEATOHEPATITIS;SUBACUTE THYROIDITIS;SURFACTANT THERAPY;SYSTEMIC VASCULITIS;TELEDERMATOLOGY;THORACIC AORTIC ANEURYSM;TRANSCRIPTOME;TRINUCLEOTIDE REPEAT EXPANSION;TWIN-TO-TWIN TRANSFUSION SYNDROME;ULTRASOUND ELASTOGRAPHY;UROTHELIAL CANCER;VINCRISTINE","7;5;5;4;4;3;3;3;3;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1",";HUMANS;FEMALE;MALE;MIDDLE AGED;AGED;TREATMENT OUTCOME;RETROSPECTIVE STUDIES;ADULT;ITALY;RISK FACTORS;AGED, 80 AND OVER;PROSPECTIVE STUDIES;CHILD;INFANT;REGISTRIES;ADOLESCENT;CHILD, PRESCHOOL;POSTOPERATIVE COMPLICATIONS;TIME FACTORS","223;96;59;52;33;29;29;27;25;19;17;12;10;9;9;8;7;7;7;7","MANAGEMENT AND PATHOPHYSIOLOGY OF ABDOMINAL AORTIC ANEURYSMS;MANAGEMENT OF VALVULAR HEART DISEASE;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;EPIDEMIOLOGY AND MANAGEMENT OF NAFLD;GLOBAL TRENDS IN COLORECTAL CANCER RESEARCH;MELANOMA;DIAGNOSIS AND TREATMENT OF PULMONARY HYPERTENSION;GYNECOLOGIC ONCOLOGY;CHOLANGIOCARCINOMA;LIVER CIRRHOSIS AND ASSOCIATED COMPLICATIONS;MOLECULAR MECHANISMS OF AMYLOIDOSIS;MOLECULAR PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS;MOLECULAR RESEARCH ON BREAST CANCER;MULTIPOTENT MESENCHYMAL STEM CELLS;RECIPROCAL DEVELOPMENT OF TH17 AND TREG CELLS;ROLE OF LUNG ULTRASOUND IN CRITICAL CARE;DIAGNOSIS AND MANAGEMENT OF AORTIC DISEASES;DIAGNOSIS AND TREATMENT OF CAROTID ARTERY DISEASE;GENOMIC STUDIES AND TREATMENT OF OVARIAN CARCINOMA;IMPACT OF HIV INFECTION ON CARDIOVASCULAR HEALTH","16;16;9;7;6;6;5;5;4;4;4;4;4;4;4;4;3;3;3;3","ENDOVASCULAR REPAIR;TRANSCATHETER AORTIC-VALVE REPLACEMENT;CLINICAL ENDPOINT;AORTIC ROOT REPLACEMENT;PROSTHETIC VALVES EVALUATION;ANEURYSM SCREENING;CLINICAL PRACTICE;DIAGNOSIS;STROKE (ENGINE);TREATMENT;CARDIAC IMAGING;THORACIC AORTIC ANEURYSMS;ANEURYSM RUPTURE;AORTIC ANEURYSMS;COLONOSCOPY;IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR;LIVER BIOPSY;MELANOMA;AORTIC DISSECTION;AORTIC REPAIR","12;12;10;9;9;8;8;8;8;8;7;7;6;6;6;6;6;6;5;5","COHORT STUDY;AORTIC ANEURYSMS;AORTIC VALVE;ENDOVASCULAR AORTIC;ENDOVASCULAR REPAIR;HEPATOCELLULAR CARCINOMA;INTERNATIONAL CONSORTIUM;MULTICENTRE STUDY;OBSERVATIONAL STUDY;PRIMARY GRAFT;TRANSCATHETER AORTIC;VALVE IMPLANTATION;AORTIC REPAIR;ARTERIAL HYPERTENSION;GRAFT DYSFUNCTION;HEART FAILURE;PULMONARY ARTERIAL;RETROSPECTIVE STUDY;ANDERSON-FABRY DISEASE;CHRONIC KIDNEY;CLINICAL PRACTICE;ITALIAN SOCIETY;MINIMALLY INVASIVE;PATIENTS UNDERGOING;SCORING SYSTEM;ADHESION MOLECULES;ADULT PATIENTS;AORTIC ANEURYSM;BILIARY CHOLANGITIS;BREAST CANCER","8;7;7;7;7;6;6;6;6;6;6;6;5;5;5;5;5;5;4;4;4;4;4;4;4;3;3;3;3;3","CMV COLITIS;HR CI;MENTAL HEALTH;PATIENTS TREATED;RISK FACTORS;HEART FAILURE;ADVERSE EVENTS;INTENSIVE CARE;CLINICAL PRACTICE;HEALTHCARE WORKERS;CONSECUTIVE PATIENTS;PATIENTS UNDERGOING;STATISTICALLY SIGNIFICANT;CL GEL;COHORT STUDY;EV ICD;LEFT VENTRICULAR;ASI PATIENTS;FILTRATION RATE;GLOMERULAR FILTRATION;IN-HOSPITAL MORTALITY;INCREASED RISK;MULTIVARIABLE ANALYSIS;S-ICD RECIPIENTS;SIGNIFICANT DIFFERENCES;SURGICAL DEROOFING;ALL-CAUSE DEATH;AORTIC VALVE;CKD STAGE;DAY MORTALITY","20;19;19;16;16;14;13;13;11;11;10;10;10;9;9;9;9;8;8;8;8;8;8;8;8;8;7;7;7;7",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,4,1,431.25,0.92,1,0.25,38,0,0,1,0,1,0,0,2,0,2,2,0,0,0,0,0,0,4,0,0,4,0,0,0,0,0,0,0,0,0,"Germany;Italy","2;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;42 HEALTH SCIENCES;4205 NURSING","3;3;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CARDIOVASCULAR;HEMATOLOGY;CANCER;DIABETES;KIDNEY DISEASE;LYMPHOMA;PATIENT SAFETY;RARE DISEASES","4;3;2;2;1;1;1;1;1;1","CARDIOVASCULAR;BLOOD;METABOLIC AND ENDOCRINE;RENAL AND UROGENITAL","2;1;1;1","6.1 PHARMACEUTICALS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES","3;1","NON-HODGKIN'S LYMPHOMA","1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS","1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
